Pantothenamides as antibacterials:  mode of action tudies and Improvement of their potency by structural modification by Barnard, Leanne
PANTOTHENAMIDES AS ANTIBACTERIALS:
MODE OF ACTION STUDIES AND IMPROVEMENT
OF THEIR POTENCY BY STRUCTURAL
MODIFICATION 
Leanne Barnard 
Dissertation presented for the degree of Doctor of 
Philosophy (Chemistry) in the  
Faculty of Natural Sciences at  
Stellenbosch University 
Supervisor: Prof. Erick Strauss 
Department of Biochemistry, Stellenbosch University 
Co-supervisor: Prof. Willem A. L. van Otterlo 
Department of Chemistry, Stellenbosch University 
December 2015 





By submitting this thesis/dissertation electronically, I declare that the entirety of the work contained 
therein is my own, original work, that I am the sole author thereof (save to the extent explicitly 
otherwise stated), that reproduction and publication thereof by Stellenbosch University will not 
infringe any third party rights and that I have not previously in its entirety or in part submitted it for 

















Copyright © 2015 Stellenbosch University 
All rights reserved 
Stellenbosch University  https://scholar.sun.ac.za





The emergence of multidrug-resistant organisms is one of the main driving forces for the 
continuous development of new antimicrobial chemotherapies. Previous research established that 
Coenzyme A (CoA), biosynthesized from pantothenic acid, promotes the growth of various 
disease-causing pathogens, including Staphylococcus aureus and Plasmodium falciparum. 
Selective inhibition of CoA biosynthesis in pathogens might be accomplished with selected small 
molecule inhibitors due to the high level of structural and mechanistic divergence between the 
prokaryotic and eukaryotic enzymes. Consequently, the CoA biosynthetic pathway is seen as a 
prospective target for such chemotherapies and therefore specific analogues of pantothenic acid 
have been used in the search for new antimicrobials in various studies.  
 
One particular class of analogues, named N-substituted pantothenamides, has shown potential as 
inhibitors of CoA biosynthesis and utilization in S. aureus. However, our poor understanding of 
their mechanism of action has hampered their development as clinically relevant agents. 
Consequently, in this study we set out to elucidate the mode of action of pantothenamides by 
designing a compound that can only act as an inhibitor of S. aureus pantothenate kinase (SaPanK-
II) (the first enzyme in the CoA biosynthesis pathway) and not as a substrate. We were able to 
confirm that the mode of action of bacterial pantothenamide inhibition is determined by the PanK 
type of the targeted organism. Specifically, we show that in S. aureus growth inhibition is as a 
result of at least two factors working in combination: 1) by the formation of inactive acyl carrier 
proteins (ACPs) and CoA antimetabolites and 2) by the reduction of CoA levels through the 
inhibition of SaPanK-II. 
 
Although pantothenamides act as potent inhibitors of S. aureus in vitro, this promising antimicrobial 
activity is lost when such tests are performed in vivo due to enzymatic degradation of the 
pantothenamides by pantetheinase enzymes. This also translates to their inhibition of the malaria-
causing parasite, P. falciparum, since pantetheinase enzymes are present in plasma and serum. 
Therefore, the second part of this study focused on the design and synthesis of new potent 
inhibitors that are resistant to pantetheinase-mediated degradation. N-Heptyl pantothenamide (N7-
Pan) and N-phenethyl pantothenamide (N-PE-PanAm) were used as scaffolds, since these 
pantothenamides were previously shown to have excellent potential as inhibitors of S. aureus and 
P. falciparum proliferation, respectively. Structural modifications were made to the 
pantothenamides to protect the scissile amide bond from hydrolysis. Specifically, these 
modifications were chosen to increase the steric bulk around the amide bond, by replacing it with a 
bioisostere moiety that should withstand pantetheinase degradation, or by preventing the  
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compound from being recognized as a substrate. Ten N7-Pan analogues were successfully 
synthesized and fully characterized as inhibitors of SaPanK-II and S. aureus, while nine N-PE-
PanAm analogues were successfully synthesized and partially characterized as inhibitors of P. 
falciparum. Our results show that while modifications do result in imparting pantetheinase 
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Die verskyning van weerstandbiedende organismes is een van die belangrikste dryfkragte vir die 
voordurende ontwikkeling van nuwe antimikrobiese middels. Vorige navorsing het vasgestel dat 
koënsiem A (KoA), wat gebiosintesitieer word vanaf pantoteensuur, die groei van verskeie siekte-
veroorsakende patogene, insluitend Staphylococcus aureus en Plasmodium falciparum, bevorder. 
Weens die strukturele en meganistiese verskille tussen die prokariotiese en eukariotiese ensieme 
in die KoA-padweg is dit moontlik om die patogeniese ensieme selektief te inhibeer met spesifieke 
klein molekuul-inhibitore. Die KoA biosintese padweg word dus beskou as 'n voornemende teiken 
vir sulke inhibitore, en gevolglik was spesifieke analoë van pantoteensuur gebruik in die soektog 
na nuwe antimikrobiese middels in verskeie studies. 
 
Een spesifieke klas van hierdie analoë, naamlik die N-gesubstitueerde pantoteenamiede, is 
potensieel goeie inhibitore van KoA biosintese en KoA gebruik in S. aureus. Ongelukkig, weens 
ons swak begrip van hul meganisme van aksie, word hul ontwikkeling as klienies relevante middels 
beperk. Die fokus van die eerste deel van hierdie studie was om die aksiemodus van werking van 
pantoteenamiede te bepaal deur ‘n verbinding te ontwerp wat slegs kan optree as 'n inhibitor van 
S. aureus pantoteensuurkinase (SaPanK-II) (die eerste ensiem in die KoA biosintese padweg). Die 
resultate wys dat die meganisme van aksiemodus van die pantoteenamiede in bakterië bepaal 
word deur die tipe PanK wat die organisme van belang bevat. Ons toon spesifiek dat in S. aureus 
groei-inhibisie veroorsaak word deur ‘n kombinasie van twee faktore: 1) die vorming van onaktiewe 
asieldraerproteïene en KoA antimetaboliete en 2 ) die vermindering van die KoA vlakke deur die 
direkte inhibering van die SaPanK-II ensiem. 
 
Alhoewel pantoteenamiede optree as kragtige inhibitore van S. aureus in vitro, word hierdie 
belowende antimikrobiese aktiwiteit verloor in vivo weens ensiematiese afbraak deur pantetiënase 
ensieme teenwoordig in plasma en serum. Hierdie effek is ook waargeneem in studies met P. 
falciparum. Die tweede deel van hierdie studie het dus gefokus op die ontwerp en sintese van 
inhibitore wat bestand is teen hidrolise deur pantetiënase-ensieme. Die ontwerp van hierdie 
inhibitore is gebaseer op die N-heptiel pantoteenamied (N7-Pan) en N-fenetiel pantoteenamied (N-
PE-PanAm) raamwerk, aangesien verskeie studies reeds bewys het dat hierdie pantoteenamiede 
uitstekende inhibitore van onderskeidelik S. aureus en P. falciparum is. Strukturele veranderinge 
was gemaak om die geteikende amiedbinding in die pantoteenamiede teen hidrolise te beskerm. 
Hierdie veranderinge sluit in: 1) toevoeging van steriese hindernis rondom die geteikende 
amiedbinding; 2) vervanging met 'n bioisosteer-groep wat hidrolise deur pantetiënase-ensieme sal 
weerstaan; of 3) strukturele veranderings wat verhoed dat die verbinding erken word as 'n  
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substraat vir pantetiënase-ensieme. Tien N7-Pan-analoë is suksesvol gesintetiseer en ten volle 
gekarakteriseer as inhibitore van SaPanK-II en S. aureus, terwyl nege N-PE-PanAm-analoë 
suksesvol gesintetiseer en gedeeltelik gekarakteriseer is as inhibitore van P. falciparum. Ons 
resultate wys dat alhoewel die strukturele veranderinge tot toenemende weerstand teen 























Stellenbosch University  https://scholar.sun.ac.za















The financial assistance of the National Research Foundation (NRF) towards this research is 
hereby acknowledged. Opinions expressed and conclusions arrived at, are those of the author and 











Stellenbosch University  https://scholar.sun.ac.za





I cannot believe that all the frustrations and hard work has finally come to an end; regardless of the 
long hours and many disappointments of lab work over the last four years, I’ve had lots of fun and 
laughter, and given the choice, I would do it all over again. However, if it weren’t for my massive 
support structure I would not have been able to complete my PhD and I am grateful to one and all. 
 
First and foremost I would like to thank my supervisor Prof. Erick Strauss for allowing me to stay on 
in his lab after my honours project and for letting me continue with my love for chemistry. I truly 
appreciate all your help and guidance as well as your infinite patience during these past four years. 
I thoroughly enjoyed our coffee time discussions regarding research and life, as well as many other 
interesting topics. I will definitely have to start training a new minion next year to take over the 
“koffie kaptein” responsibility.  
 
Secondly, I would also like to thank my co-supervisor, Prof. Willem van Otterlo, for all his help and 
guidance throughout the course of this project and for making a bench available in his laboratory in 
order to conduct my research. How can I forget - thank you for the torturous problem sets at 8am 
on a Friday morning – it definitely made me a better organic chemist. 
  
Then I would also like to thank all of the Strauss lab members who always supported and willingly 
helped me, specifically when it came to biologically related research and for the coffee time chats 
and lab outings. Lizbé and Ilse – who would’ve thought that we would become such great friends 
when Sporty Spice first walked into the lab. Thank you for always being there for me, whether it 
was to celebrate my success or drown my sorrows with cheese cake. Furthermore, I would like to 
thank Lizbé for all the help with my biological experiments, my upgrade proposal and for acting as 
a sounding board when I wasn’t sure on how to do experiments. To the rest of the lab, Bertus, 
Sunette, René, Dirk, Albert, Ndivhu, Tanya, Cristiano, Riyad, Dave, Melisse, Gordon and Andrea, I 
am really thankful for all your contributions. To Marianne, it was nice to finally meet you after two 
and a half years – thank you for sharing first authorship in our article and for acting as the first line 
of editorial defence during the write up of this thesis. Additionally, I would also like to thank my 
extended lab family at chemistry. I am really thankful to Dewald, Lesotho, Jonny, Anton, Monica, 
Alet, Tanya and Ronel, for all of your help and thank you for letting me feel a part of the chemistry 
group. 
 
Last but not least, I also wish to thank my family and friends for their constant love and support. 
Especially to my Mom and Dad, for giving me the opportunity to study at Maties and for your  
 
Stellenbosch University  https://scholar.sun.ac.za
~ ix ~ 
 
unconditional love, encouragement and support, even though you don’t always understand what I 
do. Hopefully one day I can repay your confidence in me. Thank you to oom Johan and tannie 
Judy for accompanying my parents during their visits, thereby making it extra special. From the 
moment I set foot in Stellenbosch Shelyn and Arno, you both have always been there for me. I am 
grateful for all that you have done, including sharing the Meerlust wine; you’ve definitely turned me 
into a wine snob. I would also like to thank oom Sakkie and tannie Poenie for making time to see 
their “hanskind” during their visits and for all the home cooked meals. Thank you Jade for all the 
crazy fun times and for trying to understand what I’m doing on a daily basis as well as explaining to 
your mom with enthusiasm what my research is about. Roelien, if it wasn’t for you I would definitely 
not be where I am today – thank you for all the class notes and for all the fun times we’ve had over 
the years. On a final note Daniëlle, thank you for your friendship over the years – Stellenbosch is 
not the same without you. 
 
In conclusion I would like to thank my latest addition of friends, Niël, Barry, Gail and Annie – I really 
enjoyed busting clays with you guys on a Saturday. It kept me grounded the past year and a half of 














Stellenbosch University  https://scholar.sun.ac.za





 Stellenbosch University and Prof. Erick Strauss for the opportunity to study at this 
institution.  
 Stellenbosch University, the National Research Foundation (NRF), and the H.B. Thom trust 
as well as Prof. Erick Strauss for financial support. 
 The Department of Chemistry, specifically the GOMOC group, for accommodating me in 
the laboratory during my studies. 
 Prof. Jacky Snoep from the Department of Biochemistry for all his help in establishing a 
working kinetic model. 
 Dr. Marietjie Stander of the Central Analytical Facility of Stellenbosch University for HRMS 
analyses. 
 Mrs. Elsa Malherbe and Dr. Jaco Brand of the Central Analytical Facility of Stellenbosch 













Stellenbosch University  https://scholar.sun.ac.za









~ In loving memory of Ouma and Tannie Rita – I wish you were here to celebrate 












Stellenbosch University  https://scholar.sun.ac.za
~ xii ~ 
 
 
Table of Contents 
 
 
Declaration .................................................................................................................................... ii 
Abstract ........................................................................................................................................ iii 
Opsomming ................................................................................................................................... v 
Acknowledgements ................................................................................................................... viii 
Additional Acknowledgements .................................................................................................... x 
Table of Contents ........................................................................................................................ xii 
Outputs ..................................................................................................................................... xviii 
List of Abbreviations .................................................................................................................. xx 
 
Chapter 1 
Coenzyme A: Biosynthesis, Potential Drug Targets and Small Molecule Inhibitors 
1.1 Increase in drug resistance is a global health threat ....................................................... 1 
1.2 Antibiotic development is declining ................................................................................. 2 
1.3 Bacteria use a variety of molecular mechanisms to become drug-resistant ................. 4 
1.3.1 Bypassing of the antibiotic target ................................................................................... 5 
1.3.2 Preventing antibiotic access to the targets .................................................................... 6 
1.3.3 Enzymatic inactivation of antibiotic structures ................................................................ 8 
1.3.4 Changes in antibiotic targets by mutation ...................................................................... 9 
1.4 Coenzyme A biosynthesis and CoA utilization as prospective drug targets ............... 10 
1.5 CoA metabolism in S. aureus .......................................................................................... 11 
1.5.1 CoA biosynthesis from pantothenic acid ...................................................................... 11 
1.5.1.1 Pantothenate kinase (PanK; CoaA) ....................................................................... 12 
1.5.1.2 Enzymes completing the CoA biosynthetic pathway (CoaBCDE) ........................... 14 
1.5.2 CoA-dependent processes in metabolism ................................................................... 14 
1.5.3 The biosynthesis and utilization of CoA as an antimicrobial drug target ....................... 15 
Stellenbosch University  https://scholar.sun.ac.za
~ xiii ~ 
 
1.6 CoA metabolism in Plasmodium falciparum .................................................................. 17 
1.6.1 Pantothenic acid and CoA biosynthesis in P. falciparum-infected erythrocytes ............ 17 
1.6.1.1 Pantothenate kinase (PanK; CoaA) as characterized from parasite lysates ........... 19 
1.6.1.2 Enzymes completing the CoA biosynthetic pathway (CoaBCDE) ........................... 20 
1.6.2 CoA utilization processes in metabolism ..................................................................... 20 
1.6.3 CoA biosynthesis and utilization as an antimalarial drug target ................................... 21 
1.7 Pantothenic acid analogues as potential small molecule inhibitors ............................ 24 
1.7.1 Pantothenic acid analogues tested on S. aureus ......................................................... 25 
1.7.1.1 Overview of pantothenic acid analogues tested on S. aureus ................................ 25 
1.7.1.2 N-substituted pantothenamides tested on S. aureus. ............................................. 26 
1.7.2 Pantothenic acid analogues tested on Plasmodium ..................................................... 29 
1.7.2.1 Overview of pantothenic acid analogues tested on Plasmodium ............................ 29 
1.7.2.2 N-substituted pantothenamides tested on P. falciparum ........................................ 31 
1.8 N-substituted pantothenamides are susceptible to enzyme-mediated hydrolysis ...... 32 
1.9 Problem statement ........................................................................................................... 36 
i) Mode of action of the pantothenamides in S. aureus ................................................... 36 
ii) Developing antimicrobial pantothenamides that are resistant to pantetheinase-mediated 
degradation ................................................................................................................. 37 
1.10 References ........................................................................................................................ 39 
 
Chapter 2 
FEBS manuscript - Variation In Pantothenate Kinase Type Determines The Mode of Action In 
Bacteria............................................................................................................................................46 
 
Chapter 2 (continued) 
Variation In Pantothenate Kinase Type Determines The Mode of Action In Bacteria 
(Additional information) 
2.1 Additional kinetic parameters ......................................................................................... 70 
2.1.1 N7-Pan: pantothenic acid mixed kinetics with SaPanK-II ............................................. 70 
2.2 Synthetic strategies for the production of 4’-deoxy-N-pentyl pantothenamide (2.9) ... 71 
 
Stellenbosch University  https://scholar.sun.ac.za
~ xiv ~ 
 
2.2.1 Synthesis of (R/S)-4’-deoxy-N-pentyl pantothenamide [(R/S)-2.9] ............................... 72 
2.2.2 Synthesis of (R)-4’-deoxy-N-pentyl pantothenamide [(R)-2.9] ...................................... 75 
2.3 Conclusion ........................................................................................................................ 80 
2.4 Experimental section ....................................................................................................... 80 
2.4.1 Materials and methods ................................................................................................ 80 
2.4.2 Synthetic preparation of 4’-deoxy N5-Pan (2.9) ........................................................... 81 
2.5 References ........................................................................................................................ 86 
 
Chapter 3 
Developing PanK Inhibitors That Are Resistant To Pantetheinase-Mediated Degradation 
3.1 Introduction ...................................................................................................................... 87 
3.2 Study design and strategy ............................................................................................... 88 
3.3 Physicochemical properties of the proposed N7-Pan analogues ................................. 91 
3.4 Synthesis of pantetheinase-resistant N7-Pan analogues .............................................. 96 
3.4.1 Increasing steric bulk surrounding the N7-Pan scissile amide bond ............................ 96 
3.4.1.1 N-Heptyl α-methyl pantothenamide (3.7) and N-heptyl β-methyl pantothenamide 
(3.8) ....................................................................................................................... 96 
3.4.1.2 N-Methyl N-heptyl pantothenamide (3.11) .............................................................. 97 
3.4.1.3 (E)-N-Heptyl CJ pantothenamide ((E)-3.27) ......................................................... 100 
3.4.2 Preparation of bioisosteres of N7-Pan ....................................................................... 102 
3.4.2.1 N-Hexyl pantothenhydrazide (3.33) ...................................................................... 102 
3.4.2.2 N-Heptyl pantothenthioamide (3.36) .................................................................... 104 
3.4.2.3 N-Heptyl pantoyltauramide (3.44) ........................................................................ 105 
3.4.3 Removal of 4’-OH group from N7-Pan ....................................................................... 107 
3.4.3.1 (R/S)-4’-Deoxy-N-heptyl pantothenamide (3.49) .................................................. 107 
3.4.3.2 (R/S)-4’-Amino-N-heptyl pantothenamide (3.56) .................................................. 108 
3.4.3.3 4’-Phospho-N-heptyl pantothenamide (3.74) ........................................................ 115 
3.5 Biological evaluation of N7-Pan analogues .................................................................. 116 
3.5.1 Kinetic characterization of S. aureus pantothenate kinase (SaPanK-II) using the N7-Pan 
analogues as alternate substrates ............................................................................. 116 
Stellenbosch University  https://scholar.sun.ac.za
~ xv ~ 
 
3.5.2 Cell growth inhibition of S. aureus RN4220 by the N7-Pan analogues ....................... 121 
3.5.3 Pantetheinase resistance of the N7-Pan analogues .................................................. 123 
3.6 Rationalizing the poor inhibition observed for the N7-Pan analogues ....................... 123 
3.7 Conclusion ...................................................................................................................... 125 
3.8 Experimental section ..................................................................................................... 126 
3.8.1 Material and methods ................................................................................................ 126 
3.8.2 Synthetic preparation of the N7-Pan analogues ........................................................ 127 
3.8.3 Characterization of the N7-Pan analogues ................................................................ 147 
3.8.3.1 Bacterial growth inhibition studies of the N7-Pan analogues in minimal media..... 147 
3.8.3.2 Bacterial growth inhibition studies of the N7-Pan analogues in tryptone broth ..... 147 
3.8.3.3 Construction of SaPanK-II, protein expression and purification ............................ 148 
3.8.3.4 PanK steady state kinetic analysis ....................................................................... 148 
3.8.3.5 Data and statistical analysis ................................................................................. 148 
3.9 References ...................................................................................................................... 150 
 
Chapter 4 
Developing P. falciparum Inhibitors That Are Resistant To Pantetheinase-Mediated 
Degradation 
4.1 Introduction .................................................................................................................... 156 
4.1.1 Transmission and life cycle of the malaria parasite .................................................... 156 
4.1.2 Pantothenamides as potential small molecule inhibitors of the malaria parasite ........ 157 
4.2 Study design and strategy ............................................................................................. 158 
4.3 Physicochemical properties of the proposed N-Phenethyl pantothenamide analogues  
............................................................................................................................................ 160 
4.4 Synthesis of pantetheinase-resistant N-phenethyl pantothen-amide analogues ...... 162 
4.4.1 Introducing steric bulk to N-phenethyl pantothenamide ............................................. 162 
4.4.1.1 α-Methyl-N-phenethyl pantothenamide (4.3) and β-methyl-N-phenethyl pantothen-
amide (4.4) .......................................................................................................... 162 
4.4.1.2 N-Methyl N-phenethyl pantothenamide (4.6) ........................................................ 163 
4.4.1.3 (E)-N-Phenethyl CJ-pantothenamide ((E)-4.9) ..................................................... 164 
 
Stellenbosch University  https://scholar.sun.ac.za
~ xvi ~ 
 
4.4.2 Bioisostere replacement of the scissile amide in N-phenethyl pantothenamide ......... 165 
4.4.2.1 N-Benzyl pantothenhydrazide (4.12) .................................................................... 165 
4.4.2.2 N-Phenethyl pantothenthioamide (4.16) ............................................................... 166 
4.4.3 Removal of the 4’-OH group from N-phenethyl pantothenamide ................................ 167 
4.4.3.1 (R/S)-4’-Deoxy-N-phenethyl pantothenamide (4.19) ............................................ 167 
4.4.3.2 (R/S)-4’-Amino-N-phenethyl pantothenamide (4.21) ............................................ 168 
4.4.3.3 4’-Phospho-N-phenethyl pantothenamide (4.23) .................................................. 169 
4.5 Determination of the antiplasmodial activity of the N-phenethyl-pantothenamide 
analogues against P. falciparum ................................................................................... 170 
4.5.1 Biological testing of the methylated and deoxy N-PE-PanAm analogues ................... 171 
4.6 Conclusion ...................................................................................................................... 172 
4.7 Experimental section ..................................................................................................... 172 
4.7.1 Material and methods ................................................................................................ 172 
4.7.2 Synthetic preparation of the N-phenethyl pantothenamide analogues ....................... 173 
4.8 References ...................................................................................................................... 183 
 
Chapter 5 
Conclusion and Future Research Possibilities  
5.1 Summary of results achieved ........................................................................................ 186 
5.2.1 Elucidating the role of PanK in the mode of action of inhibitory pantothenamides in S. 
aureus ....................................................................................................................... 186 
5.2.2 Developing antimicrobial pantothenamides that are resistant to pantetheinase-mediated 
degradation ............................................................................................................... 188 
5.2 Future research possibilities ......................................................................................... 190 
5.3.1 Elucidating the role of PanK in the mode of action of inhibitory pantothenamides in S. 
aureus ....................................................................................................................... 190 
5.3.2 Developing antimicrobial pantothenamides that are resistant to pantetheinase-mediated 
degradation ............................................................................................................... 190 
5.3 Final remarks .................................................................................................................. 192 
5.4 References ...................................................................................................................... 193 
  
Stellenbosch University  https://scholar.sun.ac.za
~ xvii ~ 
 
Addendum   
Antimicrobial Agents & Chemotherapy manuscript – A Pantetheinase-Resistant Pantothenamide 























Stellenbosch University  https://scholar.sun.ac.za





The work reported in this thesis has contributed to the following outputs: 
 
Papers: 
1. De Villiers, M.,‡ Barnard, L.,‡ Koekemoer, L., Snoep, J. And Strauss, E. Variation in 
pantothenate kinase type determines the pantothenamide mode of action and impacts on 
coenzyme A salvage biosynthesis. FEBS Journal 2014, 281, 4731-4753. 
doi:10.1111/febs.13013. [‡Denotes equal contribution]. 
 
2. Macuamule, C. J., Tjhin, E. T., Jana, C. E., Barnard, L., Koekemoer, L., de Villiers, M., 
Saliba, K. J. and Strauss, E. A pantetheinase-resistant pantothenamide with potent, on 
target, and selective antiplasmodial activity. Antimicrobial Agents and Chemotherapy 2015, 
59, 3666-3668. doi.org/10.1128/AAC.04970-14.  
 
3. Macuamule, C. J., de Villiers, M., Wells, G., Barnard, L., Saliba, K. J. and Strauss, E. 
Pantothenate kinase as gateway to activate pantothenamides as potent antimalarials 




1. “Validating Staphylococcus aureus pantothenate kinase a drug target”. MSc progress 
lecture presented at the Department of Biochemistry, Faculty of Science, Stellenbosch 
University. May 2013. 
 
2. “Pantothenamides as antibacterials: mode of action studies and improvement of their 
potency by structural modifications”. MSc upgrade lecture presented at the Department of 
Biochemistry, Faculty of Science, Stellenbosch University. October 2013. 
 
3. “Developing degradation-resistant antimicrobials”. Lecture presented at the Biochemistry 40 
year symposium at the Department of Biochemistry, Faculty of Science, Stellenbosch 
University. January 2015. 
 
 
Stellenbosch University  https://scholar.sun.ac.za




1. De Villiers, M., Barnard, L., Koekemoer, L., Snoep, J. and Strauss, E. “Studies on the mode 
of action of the pantothenamide antibacterials reveals the importance of pantothenate 
kinase variation”. Poster presented by Dr. M. de Villiers at the Coenzyme A and its 
derivatives in cellular metabolism and disease conference, London. March 2014. 
 
2. Barnard, L., van Otterlo, W.A.L. and Strauss, E. “Design and synthesis of 
antistaphylococcal pantetheinase-resistant inhibitors”. Poster presented at the SACI-ACS 
bi-national organic chemistry conference, Stellenbosch. December 2014.  
 
3. De Villiers, M., Barnard, L., Koekemoer, L., Snoep, J. and Strauss, E. “Studies on the mode 
of action of the pantothenamide antibacterials reveals the importance of pantothenate 
kinase variation”. Poster presented by Dr. M. de Villiers at the SACI-ACS bi-national 
























Stellenbosch University  https://scholar.sun.ac.za
~ xx ~ 
 
 
List of Abbreviations 
 
ACP   Acyl carrier protein 
ADP   Adenosine 5’-diphosphate 
Ala   Alanine 
Arg   Arginine 
ATP   Adenosine 5’-triphosphate 
BiCl3   Bismuth (III) chloride  
BSA   Bovine serum albumin 
Cbz   Carbobenzoxy 
CAF   Central Analytical Facility  
CDC   Center for Disease Control and Prevention 
CH3I   Methyliodide 
CoA   Coenzyme A 
CoADR  Coenzyme A disulphide reductase 
CTAB   Cetyltrimethylammonium bromide 
CSA   10-Camphorsulfonic acid 
CsOH    Cesium hydroxide 
Cs2CO3  Cesium carbonate 
Cu   Copper 
CuCl   Copper (I) chloride 
Cys   Cysteine 
DAST   (Diethylamino)sulphur trifluoride 
DCE   1,2-Dichloroethane 
DCM   Dichloromethane 
Stellenbosch University  https://scholar.sun.ac.za
~ xxi ~ 
 
DCP   Dicumyl peroxide 
DEPC   Diethyl cyanophosphonate 
DIC   N, N-Diisopropyl carbodiimide 
DIPEA   N, N-Diisopropylethylamine 
DMAP   N, N-Dimethyl aminopyridine 
DMBNH2  Dimethoxybenzyl protected amine 
DMF   N, N-Dimethylformamide 
DMSO   Dimethyl sulfoxide 
DPPA   Diphenyl phosphorylazide 
E. coli   Escherichia coli (also Ec) 
EcPanK  Escherichia coli pantothenate kinase 
EDC   N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride  
equiv.    Equivalents 
ESBL   Extended-spectrum β-lactamase 
EtOH   Ethanol 
EtOAc   Ethyl acetate 
FCC   Flash column chromatography  
FDA   Food and Drug Administration 
Fmoc   9-Fluorenylmethyl carbamate 
Fsp3   Fraction of sp3 carbons 
Glu   Glutamic acid 
h   Hours 
H-bond  Hydrogen bond 
H2O   Water 
HBr   Hydrobromic acid 
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His   Histidine 
HIV   Human Immunodeficiency Virus 
HOBt   N-Hydroxybenzotriazole 
HRMS   High Resolution Mass Spectroscopy 
IC50   Concentration required for 50% inhibition 
IMAC   Immobilized Metal Affinity Chromatography 
IPM   Isopropenyl methyl ether 
IPTG   Isopropyl β-D-1-thiogalactopyranoside 
KCl   Potassium chloride 
K2CO3   Potassium carbonate 
kcat   Turnover number 
Ki   Inhibition constant 
KM   Michaelis-Menten constant 
KMnO4  Potassium permanganate  
tBuOK   Potassium tert-butoxide 
LB   Luria Bertani 
LDH   Lactate dehydrogenase 
LogD7.4  Distribution coefficient at pH 7.4 
LogP   Partition coefficient 
cLogP   Calculated partition coefficient  
Lys   Lysine 
CH3CN  Acetonitrile 
MeOH   Methanol 
MgCl2   Magnesium chloride 
MgSO4  Magnesium sulphate 
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MIC   Minimum inhibitory concentration needed to kill the organism 
MIC80   Minimum inhibitory concentration needed to kill 80% of the organism 
min   Minute 
MRSA   Multidrug-resistant Staphylococcus aureus 
NaBH4   Sodium borohydride 
NaBH3CN  Sodium cyanoborohydride 
NaCl   Sodium chloride / salt / brine 
NADH   Nicotinamide adenine dinucleotide (reduced) 
NaN3   Sodium azide  
Na2SO4  Sodium sulphate 
NaHCO3  Sodium bicarbonate 
NaOH   Sodium hydroxide 
Et3N   Triethylamine 
NH3   Ammonia 
NH4Cl   Ammonium chloride 
NH4OAc  Ammonium acetate 
Ni2+   Nickel 
NMR   Nuclear Magnetic Resonance Spectroscopy 
NPPs   New permeability pathways 
NRotBs  Number of rotatable bonds 
MsCl   Methylsulfonyl chloride 
OD   Optical density 
P   Partition 
Pan/PanCOOH Pantothenic acid 
PanK/CoaA  Pantothenate kinase 
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PantSH  Pantetheine 
Pd   Palladium 
Pd/C   Palladium on activated carbon 
PDB   Protein data bank 
PEP   Phosphoenolpyruvate 
PK   Pyruvate kinase 
PMB   p-Methoxybenzylidene 
PPAT/CoaD   Phosphopantetheine adenylytransferase 
PPCS/CoaB   Phosphopantothenoylcysteine synthetase 
PPCDC/CoaC  Phosphopantothenoylcysteine decarboxylase 
PPTS   Pyridinium p-toluenesulfonate 
PSA   Polar surface area 
p-TsOH  p-Toluenesulfonic acid 
RND   Tripartite resistance-nodulation-cell division 
rt   Room temperature 
S. aureus   Staphylococcus aureus (also Sa) 
SaPanK  Staphylococcus aureus pantothenate kinase 
SEM   Standard error of the mean 
Ser   Serine 
SPE   Solid Phase Extraction 
TBSCl   tert-Butyldimethylsilyl chloride 
TFA   Trifluoroacetic acid 
THF   Tetrahydrofuran 
TIPBSCl  2,4,6-Triisopropyl-benzenesulfonyl chloride 
TLC   Thin Layer Chromatography 
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TRIS-HCl  Tris(hydroxymethyl)aminomethane-HCl 
Trp   Tryptophan 
TsCl   4-Toluenesulfonyl chloride 
Tyr   Tyrosine 
U   Units (enzyme concentration) 
Vmax   Maximal velocity 
Vit. B5   Vitamin B5 also known as pantothenate/pantothenic acid 
VNN   Vanin 
WDI   World Drug Index 
XDR   Extensively drug resistant 
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Chapter 1 
Coenzyme A: Biosynthesis, Potential Drug Targets 
and Small Molecule Inhibitors 
1.1 Increase in drug resistance is a global health threat  
Antibiotics are seen as the original wonder drugs since their first discovery in 1940; since then they 
have been regarded as one of the most valuable forms of therapy in medicine [1-4]. To this day 
antibiotics still underpin modern medicine and it is central to healthcare facilities where it is used 
for treatments such as cancer chemotherapy to prevent patients from developing an infection when 
their white blood cell count is low, for complex surgical procedures to prevent surgical site 
infections, and for dialysis for end-stage renal failure given that patients who undergo dialysis 
treatment are more likely to get bloodstream infections. Additionally, antibiotics also lead to a major 
increase in life expectancy and a decrease in child mortality [5-6]. However, there has been a 
dramatic increase in morbidity and mortality worldwide over the last decade due to bacteria 
becoming increasingly drug resistant [3-4, 7]. According to the World Health Organization (WHO) 
emerging microbial resistance is most evident in bacteria that cause human diseases. In 2013 a 
national threat assessment was released by the Center for Disease Control and Prevention (CDC) 
in which the potential of a fatal infection becoming a reality as a result of increasing multidrug 
resistant (MDR) bacteria worldwide was highlighted [1, 5, 8]. Consequently, this threat has also 
been identified as a core medical challenge in most healthcare facilities [9].  
 
This global increase in drug-resistant pathogens is believed to be the result of repeated intensive 
and improper use of antibiotics in the agricultural sector and the human and veterinary medicinal 
sections [10], with the CDC estimating that at least 50% of all prescriptions for antibiotics are not 
necessary [11]. In fact, MDR bacteria is so prevalent, that the CDC and the European Center for 
Disease Control and Prevention (ECDC) standardized terminology to facilitate grading of various 
antimicrobial resistance profiles and reporting of comparable statistics internationally. Antibiotic 
resistance has been classified into three groups using this system, these being: 1) MDR, which is 
defined as “having acquired non-susceptibility to at least one agent in three or more antimicrobial 
categories”; 2) extensively drug-resistant (XDR), which is defined as “non-susceptibility to at least 
one agent in all but two or fewer antimicrobial categories”; 3) and pandrug-resistant (PDR), which 
is defined as “non-susceptibility to all agents in all antimicrobial categories” [9].  
 
Drug-resistant pathogens include, but are not limited to, methicillin- and MDR Staphylococcus 
aureus (MRSA), extended-spectrum β-lactamase (ESBL)-producing Escherichia coli, vancomycin-
resistant enterococci (VRE), MDR and XDR Mycobacterium tuberculosis and penicillin- and 
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macrolide-resistant pneumococci [12-13]. The current arsenal of available antibiotics is being 
rendered ineffective due to bacteria becoming increasingly insensitive to these compounds, 
leading to treatment failure [3, 14]. The majority of antibiotic classes that are currently being used 
to treat diseases were discovered during the ‘Golden Age’ of antibiotic discovery (from 1940-1960), 
which lead to the ‘Golden Age’ of antibiotic medicinal chemistry (from 1960 to present) (Figure 1.1) 
[15]. However, there has been a great innovation gap from 1960 to 2000 where no new antibiotic 
molecular entities were discovered. Moreover, none of the new antibiotic classes that were 
introduced from 2000 have made a noteworthy impact [15-16]. Consequently, we are losing the 
battle against the rapid emergence and spread of MDR bacteria, since we have not been 
successful at providing a continuous pipeline of novel antibiotics [9]. 
 
 
Figure 1.1. Timeline illustrating the 'Golden Age' of antibiotic discovery from 1940 to 1960, the 'Golden Age' of 
medicinal chemistry from 1960 to present and the big Innovation Gap for antibiotic discovery from 1960 to 2000. 
Reproduced from Ref. [15]. 
1.2 Antibiotic development is declining  
In addition to bacteria becoming antibiotic-resistant, many pharmaceutical companies have cut 
down on their development of new antimicrobials [3]. Figure 1.2 shows the rapid decrease in the 
approval of new antimicrobial agents by the Food and Drug Administration (FDA) over the last 30 
years, with only two new antibiotic molecular entities being introduced between 2008 and 2012, 
compared to the 16 that was introduced between 1983 and 1987 [3-4]. This is almost a 90% 
decrease in the number of new FDA approved antibiotics over the last 30 years [17].  
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Figure 1.2. Number of new antibiotic molecular entities approved by the FDA in five year periods from 1983 to 
2012 [3-4]. 
 
This decrease in the development of new antibiotic molecular entities is attributable to three main 
factors. First, the ‘Golden Ages’ of antibiotic discovery and antibiotic medicinal chemistry already 
provided us with more than 140 antibiotics globally. This limits the discovery and development of 
novel molecular entities due to the scientific challenge of identifying new targets and scaffolds that 
have not been utilized previously [17]. Second, and possibly the main reason, is the low return on 
investment in research and development. As is the case with all drugs, antibiotics are 
tremendously expensive and time-consuming to develop. However, when compared to chronic 
medicine (where a patient takes the medicine everyday for the rest of their lives) as well as lifestyle 
drugs (medicines that treat conditions associated with lifestyle such as drugs to treat smoking, 
weight loss and baldness to name but a few), antibiotics are normally used for short periods of time 
and the predominant market is patients from developing countries with a low income that cannot 
afford to pay inflated prices [4]. Figure 1.3 shows a typical drug discovery and development 
flowchart that illustrates that it takes a minimum of 12 years and a staggering $1.3 billion to 
develop a new antibiotic [4, 15, 17]. Additionally, sales of a new antibiotic can also be significantly 
hampered by antibiotic stewardship principles that demand that its use be limited. The London 
School of Economics used an advanced economic model to estimate the net present value of a 
new intravenous antibiotic to a company at the point of discovery; the prediction gave a value of 
minus $50 million [17]. 







Total # of new antimicrobial agents 
Period 
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Figure 1.3. Flowchart showing the timeline for the discovery and development of a new antibiotic. Reproduced 
from Ref. [15]. 
 
The third and final factor is the re-evaluation of how clinical trials for a new antibiotic should be 
conducted by the Office of Antimicrobials from the FDA over the past decade. Originally, this re-
evaluation was based on legitimate statistical and scientific concerns regarding conventional 
clinical trials; however, the concerns have been driven to irrational extremes based exclusively on 
statistical considerations, at the expense of feasibility trial conduct and clinical relevance of studies. 
Consequently, this re-evaluation has lead to a major increase in expenses, the clinical trials have 
become more time-consuming and the likelihood of a new antibiotic being approved decreased 
dramatically compared to previous years [17]. Therefore, it is not as profitable for pharmaceutical 
companies to invest in the research and development of new antimicrobial agents compared to 
chronic medicine and lifestyle drugs. However, with the rapid increase in drug-resistant and MDR 
pathogens globally, it has become a key medical challenge in most healthcare settings and 
extensive research worldwide will be crucial to reduce its consequences for patients and society [9, 
18].            
1.3 Bacteria use a variety of molecular mechanisms to become drug-
resistant  
To date, four molecular mechanisms for resistance have been described: 1) bypassing of the 
antibiotic targets, 2) preventing antibiotic access to the targets, 3) enzymatic inactivation of 
antibiotic structures, and 4) changes in antibiotic targets by mutation [2, 5, 19-20]. All of these 
molecular mechanisms are clinically important and the majority of antibiotics are subject to more 
than one mechanism [20]. Each of the four molecular mechanisms will be discussed in more detail 
below. 
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1.3.1 Bypassing of the antibiotic target  
Bacteria have developed mechanisms by which they evade antibiotic action by bypassing their 
molecular targets, and by utilizing alternate pathways that are not susceptible to the action of the 
antibiotic in question [20]. An example of such a mechanism is resistance to glycopeptide 
antibiotics such as vancomycin, a fermentation product from Streptomycetes [19-20]. Vancomycin 
has a unique mode of action that inhibits peptidoglycan crosslinking by binding to the acyl-D-
Alanyl-D-Alanine (acyl-D-Ala-D-Ala) terminus of the lipid-linked disaccharide pentapeptide, a 
precursor of cell wall peptidoglycan [5, 19-20]. Since vancomycin is an inhibitor of peptidoglycan 
crosslinking, it is mainly effective against Gram-positive bacteria by allowing vancomycin access to 
the lipid-linked disaccharide pentapeptide in the periplasm due to a lack of an outer membrane [5]. 
It was widely believed that antibiotic resistance would be impossible as a result of this unique 
mechanism; however, vancomycin resistance is now common among enterococci. Additionally, 
treatment of vancomycin-resistant enterococci is even more difficult, because they are naturally 
resistant to other antibiotics such as macrolides, aminoglycosides, tetracycline and β-lactams [19].  
 
Vancomycin exhibits its antimicrobial action by binding to the acyl-D-Ala-D-Ala terminus of the lipid-
linked disaccharide pentapeptide through five hydrogen bonds (H-bonds) to form a non-covalent 
complex (Figure 1.4). However, when vancomycin-resistance develops the acyl-D-Ala-D-Ala 
terminus is substituted with an isosteric depsipeptide acyl-D-Alanyl-D-Lactic acid (acyl-D-Ala-D-
Lac). This substitution leads to the replacement of an amide bond with an ester bond (indicated in 
red in Figure 1.4), resulting in the loss of an H-bond donor, in addition to the acquisition of 
electronic repulsion. Consequently, these changes prevent efficient binding of vancomycin to the 
lipid-linked disaccharide pentapeptide, leading to antibiotic resistance. This resistance mechanism 
necessitates the participation of seven genes, namely VanR, VanS, VanH, VanA, VanX, VanY and 
VanZ [19-21].  
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Figure 1.4. Vancomycin binds to the acyl-D-Ala-D-Ala terminus of the lipid-linked disaccharide pentapeptide 
through five H-bonds to form a non-covalent complex. Resistance develops when the acyl-D-Ala-D-Ala terminus 
is substituted with an isosteric depsipeptide acyl-D-Ala-D-Lac, resulting in the loss of an H-bond and the 
acquisition of electronic repulsion (replacement of amide bond with an ester bond). Adapted from Ref. [20]. 
 
1.3.2 Preventing antibiotic access to the targets  
Bacteria have the ability to prevent antibiotic access to the targets through one of three methods: 
1) drug access can be reduced locally, 2) access can be reduced by an active efflux process or 3) 
access can be reduced by decreasing the influx across an outer membrane barrier. The latter can 
only occur in Gram-negative bacteria.  
1.3.2.1 Local inhibition of drug access  
The access of antibiotics to their specific targets can be reduced locally in Gram-positive bacteria 
by ribosomal protection proteins such as Tet(M) or Tet(S) that are encoded by the tet(M) and tet(S) 
genes. [19]. These proteins affect the mode of action of tetracyclines, a broad-spectrum antibiotic 
that prevents protein synthesis by inhibiting the binding of aminoacyl-tRNA to the ribosomal 
acceptor (A) site [22]. Proteins Tet(M) and Tet(S) prevents the recognition of tetracyclines to 
ribosomes by binding with high affinity to the ribosomes, which subsequently triggers a 
conformational change [19, 22].  Another example of a class of broad-spectrum antibiotics that is 
effective against both Gram-positive and Gram-negative bacteria is the fluoroquinolones. 
Fluoroquinolones are the only known direct inhibitors of DNA synthesis; their mode of action entails 
either binding to the DNA-topoisomerases complex or the DNA-gyrase complex and in this manner 
they stabilize the DNA strand breaks created by DNA gyrase and topoisomerase IV [23]. It is 
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believed that DNA topoisomerases are protected from fluoroquinolones by plasmid-mediated 
quinolone resistance genes (Qnr) that encode Qnr proteins [19]. 
1.3.2.2 Active drug-specific efflux pumps 
Efflux pumps are also utilized by bacteria to actively remove antibiotics from within the cell. There 
are two groups of efflux pumps: 1) high substrate-specificity efflux pumps such as the Tet pumps 
that only transport a selective number of substrates and 2) MDR efflux pumps that transport a wide 
variety of substrates [2, 5, 20]. The best characterized of the clinically relevant MDR efflux 
transporters is the tripartite resistance-nodulation-cell division (RND) class found in Gram-negative 
bacteria. Some of the most studied RND class examples include the multidrug efflux pump AcrAB-
TolC in E. coli and MexAB-OprM in Pseudomonas aeruginosa. Efflux pumps, such as AcrB, occurs 
as a homotrimer and is found in the inner membrane where it forms a tripartite complex with the 
outer-membrane channel (TolC or OprM) and the periplasmic adaptor protein (AcrA and MexA) [5, 
20]. Additionally, P. aeruginosa also contains a MexXY multidrug efflux pump that is responsible 
for aminoglycoside resistance [2]. Furthermore, tetracycline is another antibiotic that is rendered 
ineffective by the efflux pumps – TetA, a well known tetracycline resistant protein, catalyzes the 
removal of a tetracycline-Magnesium (Mg2+) complex via proton-motive-force-dependent pumping 
toward the outside of the cell [19]. 
1.3.2.3 Decreasing membrane permeability 
Additionally, antibiotic access can also be decreased by reducing the outer membrane permeability 
[2, 5, 19-20]. Gram-negative bacteria are inherently less permeable to antibiotics than Gram-
positive bacteria due to the presence of an outer-membrane that forms a permeability barrier. 
Hydrophobic antibiotics utilize outer-membrane porin proteins to diffuse across the outer 
membrane; bacteria such as E. coli have OmpC and OmpF outer-membrane proteins that function 
as non-specific channels that can be targeted by such antibiotics. Bacteria have developed an 
antibiotic resistance mechanism by replacing the porins with more selective ones or by down 
regulating the porins which leads to a reduction in the outer-membrane permeability, thereby 
reducing antibiotic entry into the bacteria. For example Pseudomonas spp. and Acinetobacter spp. 
resistance to carbapenem and cephalosporin antibiotics were believed to be only as a result of 
enzymatic degradation; however, recent studies have shown that the reduction in porin expression 
also contributes extensively to the observed antibiotic resistance. Additionally, Klebsiella 
pneumoniae has also caused worldwide infections through clonal lineages that developed by 
means of expression of modified porins [5].  
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1.3.3 Enzymatic inactivation of antibiotic structures 
The type of antibiotics that are most affected by enzyme-catalyzed inactivation are those that were 
developed from natural products such as the aminoglycosides (tobramycin, kanamycin and 
amikacin) and the β-lactams (penicillins, carbapenems, monobactams and cephalosporins) [19-
20]. Aminoglycosides, a class of broad-spectrum antibiotics that inhibit protein synthesis by binding 
to the 30S ribosomal sub-unit leading to inaccurate mRNA translation, are inactivated by various 
enzymes that modify their structures in a variety of ways. These enzymes include aminoglycoside 
adenyltranferase or nucleotidyltransferase (inactivation through adenylation), aminoglycoside 
phosphoryl transferase (APH, inactivation through phosphorylation) and aminoglycoside 
acetyltransferase (AAC, inactivation through acetylation). The modifications inactivate the 
aminoglycosides by lowering the net positive charges on these polycationic antibiotics, resulting in 
their inactivation [19, 24].  
 
β-lactams, a class of broad-spectrum antibiotics that inhibit the biosynthesis of cell walls [2], are 
inactivated in the periplasm by β-lactamases. These β-lactamases are among the most 
widespread and clinically important resistance enzymes. To date, two distinct chemical 
mechanisms of β-lactamases have been described: 1) those that use metal-activation to increase 
the nucleophilicity of the water molecule that leads to bond cleavage; or 2) the formation of a 
covalent enzyme-complex followed by hydrolysis (Figure 1.5). The first mechanism occurs through 
1-2 active site zinc (Zn2+) atoms that activate a water molecule for direct nucleophilic attack on the 
electrophilic carbonyl carbon of the β-lactam centre resulting in an inactive antibiotic. The second 
mechanism is functionally analogous to Serine (Ser) proteinases where Ser acts as the nucleophile 
– the hydroxyl group of Ser launches a nucleophilic attack on the electrophilic carbonyl carbon of 
the β-lactam ring to form a covalent enzyme-complex that is subsequently hydrolysed,  leading to 
an inactive antibiotic. The covalent enzyme complex imitates the modification to the antibiotic 
targets, peptidoglycan transpeptidases [20].    
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Figure 1.5. General mechanism for Ser- and metallo-β-lactamases. In the Ser-β-lactamase mechanism the 
hydroxyl group of Ser makes a nucleophilic attack on the β-lactam ring followed by hydrolysis. In the metallo-β-
lactamase mechanism water is first activated as a nucleophile by 1-2 active site Zn
2+
 atoms, followed by a direct 
nucleophilic attack on the β-lactam ring. Adapted from Ref. [20].  
 
1.3.4 Changes in antibiotic targets by mutation 
Additionally, bacteria also have the ability to develop antibiotic resistance either by obtaining new 
foreign genes or by mutating their own genes to modify their expression and function [5, 10, 19, 
25-26]. To illustrate, S. aureus has the ability to use both of these mechanisms to develop 
antibiotic resistance. MRSA developed due to the acquisition of foreign DNA that encodes for the 
resistance mec regulon and by mutations in the pbp and abc genes. The mec regulon contains 
numerous genes of which the mecA gene—encoding the 76 kDa penicillin binding proteins (PBP 2’ 
or PBP 2a) that has a low affinity for β-lactams—is a prerequisite for methicillin-resistance [5, 26]. 
Penicillin-resistant S. aureus strains have modified their gene expression to produce narrow 
spectrum β-lactamase, an enzyme that hydrolyzes penicillins, thus rendering them ineffective [25-
26].  
 
Another example of target mutation is against the fluoroquinolone antibiotics that bind to the DNA-
enzyme complex resulting in the stabilization of DNA strand breaks created by DNA gyrase and 
topoisomerase IV. Even a single mutation to the gyrA gene, for example a mutation of Ser to a 
bulkier amino acid side chain such as isoleucine (Ile), tryptophan (Trp), leucine (Leu)) at position 
83 or a mutation of aspartic acid (Asp) to asparagine (Asn), tyrosine (Tyr) or glycine (Gly) at 
position 87 leads to a high level of resistance. These minor alternations to the amino acid 
sequences change the protein’s structure enough to inhibit antibiotic binding and action [19-20].  
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Since most bacteria make use of at least one mechanism to develop antibiotic resistance and most 
antibiotics are subject to several mechanisms, new antimicrobials with novel modes of action are 
needed as this will decrease the prospect of resistance across different classes of antibiotics 
(cross-resistance) [20]. 
1.4 Coenzyme A biosynthesis and CoA utilization as prospective drug 
targets 
One set of potential novel targets that is currently being investigated for antimicrobial 
chemotherapy development is the coenzyme A (CoA) biosynthetic pathway, or the enzymes that 
subsequently utilize CoA. The value of this pathway as a drug target lies in CoA being an essential 
cofactor that needs to be synthesized de novo in all living organisms with an estimation that ~9% 
of all enzymes reported in the BRENDA database utilize CoA, or a CoA thioester as co-substrate in 
one way or another [12, 27]. This ubiquitous cofactor is involved in various reactions within the cell, 
for example ester-, thioester- and amide-bond formation reactions, in addition to Claisen 
condensation reactions. Furthermore, CoA also plays a major role in the biosynthesis of 
nonribosomal peptides and polyketides as well as fatty acid metabolism and the citric acid cycle 
(tricarboxylic acid cycle; TCA) [28-29].   
 
The vital importance of the CoA biosynthetic pathway (which has been shown to be universal in all 
organisms) was further confirmed in various microorganisms given that attempts to disrupt genes 
encoding the enzymes of the CoA biosynthetic pathway consistently failed or resulted in lethal 
phenotypes [27]. It is important to note that even though the CoA biosynthetic pathway seems to 
be conserved across plants, microorganisms and mammals, there are several differences between 
the prokaryotic and eukaryotic pathways. For example, some of the prokaryotic enzymes show low 
sequence homology when compared to their human counterparts. They also show differences in 
regulation; these factors should allow for the selective targeting of the pathway in the pathogens 
without affecting the human host [30]. In S. aureus, CoA biosynthesis is an even more attractive 
target due to the accumulation of milimolar quantities of CoA in the organism. Moreover, CoA is 
involved in maintaining the redox balance in S. aureus through a unique CoA/CoA disulphide 
reductase (CoADR) redox system [12]. Taken together, these factors highlight the potential to 
develop high specificity inhibitors of bacterial CoA enzymes as new antimicrobial agents. 
 
This study focussed on the CoA biosynthetic pathway as a prospective target for the development 
of new antibiotics in two pathogens that both have been shown to cause MDR, namely S. aureus 
and Plasmodium falciparum. CoA-based targets in S. aureus and P. falciparum have both been  
exploited through the use of pantothenic acid analogues as potential drug candidates. 
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Consequently, to put this study into perspective, the CoA metabolism in these two organisms is 
discussed below. 
1.5 CoA metabolism in S. aureus  
1.5.1 CoA biosynthesis from pantothenic acid 
CoA is synthesized through a five-step universal pathway using pantothenic acid (also known as 
Vitamin B5 or, when ionized, as pantothenate) as substrate (Scheme 1.1A). The first step entails 
the adenosine triphosphate (ATP)-dependent phosphorylation of pantothenic acid by pantothenate 
kinase (PanK; CoaA) to form 4’-phosphopantothenic acid. This is followed by the coupling of L-
cysteine to 4’-phosphopantothenic acid by 4’-phosphopantothenoylcysteine synthetase (PPCS; 
CoaB) to form 4’-phosphopantothenoyl-cysteine. Subsequently, 4’-phosphopantothenoylcysteine is 
decarboxylated by 4’-phosphopantothenoylcysteine decarboxylase (PPCDC; CoaC) to yield 4’-
phosphopantetheine. Dephospho-CoA is formed by phosphopantetheine adenylyltransferase 
(PPAT; CoaD), which couples an adenosine monophosphate (AMP) moiety from ATP to the 
phosphate of 4’-phosphopantetheine (step 4), with the concomitant formation of inorganic 
pyrophosphate. In the final step, the 3’-hydroxy group of the adenosine moiety is phosphorylated 
by dephospho-CoA kinase (DPCK; CoaE) to yield CoA.  
 
Additionally, CoA can also be synthesized via the three step CoA salvage pathway using 
pantetheine (PantSH, a breakdown product of CoA) as an alternative substrate (Scheme1.1B). 
This pathway bypasses PPCS and PPCDC and only consists of three enzymes, i.e. PanK, PPAT 
and DPCK [12, 27, 31]. The universal five-step pathway and its shortened salvage route utilize four 
and three equivalents of ATP respectively, one of which provides the adenosine moiety of CoA 
during the PPAT-catalyzed reaction.  
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Scheme 1.1. The CoA biosynthetic pathway. (A) Biosynthesis of CoA from pantothenic acid in the universal five-
step pathway catalyzed by pantothenate kinase (PanK), phosphopantothenoylcysteine synthetase (PPCS), 
phosphopantothenoylcysteine decarboxylase (PPCDC), phosphopantetheine adenylyltransferase (PPAT) and 
dephospho-CoA kinase (DPCK). (B) Biosynthesis of CoA from pantetheine (PantSH) in the CoA salvage pathway 
catalyzed by PanK, PPAT and DPCK. 
 
1.5.1.1 Pantothenate kinase (PanK; CoaA) 
The first enzyme in the pathway, PanK, can be distinguished as belonging to one of three distinct 
types based on sequence homology, enzyme structure, kinetic parameters and feedback inhibition. 
For ease of distinction they are labelled as type I (PanK-I), type II (PanK-II) and type III (PanK-III) 
[32-34]. Moreover, eukaryotic type II PanKs frequently occur as different isoforms within the same 
organism. To distinguish between PanK types and PanK isoforms, Roman numbers are used to 
denote PanK types while Latin numbers are used to denote PanK isoforms. The term “PanK 
isoforms” implies that the same protein is either expressed from different initiating exons (for  
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example human PanK1α and PanK1β) [35], or that the same enzyme is expressed in different 
tissues or is found in different cellular locations (for example human PanK2 and PanK3 are 
restricted to the mitochondria and the cytosol, respectively) [36]. 
 
Type I PanKs are classified as a P-loop kinase containing a Walker A motif, while both, the type II 
and type III PanKs have an actin-like fold and therefore belong to the ribonuclease H-like kinase 
group and are part of the acetate and sugar kinase/heat-shock protein 70/actin (ASKHA) 
superfamily [32-33, 37]. All known PanKs are homodimers with two identical subunits, each of 
which contains a single nucleotide binding site [38]. Although PanK-IIs and PanK-IIIs share the 
same conserved fold and key catalytic residues, they differ considerably in how the dimer 
interaction surface is formed, as well as in the architecture of substrate (ATP and pantothenic acid) 
binding sites [33]. PanK-IIs bind pantothenic acid in an open pocket, while the PanK-IIIs have a 
fully enclosed binding pocket. Conversely, ATP is tightly bound by PanK-II in a cavity that displays 
a classical P-loop architecture combined with very specific interactions to the adenine moiety, while 
structural analysis of the PanK-III from Termotoga maritima indicates a low binding affinity for ATP 
due to the enzyme making few contacts with any part of the ATP molecule apart from its 
phosphate groups [32]. 
   
S. aureus is the only bacterium that is known to have an active, albeit atypical, PanK-II enzyme, 
with most other PanK-IIs mainly being found in eukaryotes. Previous phylogenetic studies have 
shown that the primary sequence of S. aureus-like PanK proteins are distantly related to the 
eukaryotic PanK proteins, for example the cell division protein fumble from Drosophila. Even 
though these proteins are distantly related, there are numerous amino acid deletions and insertions 
that undoubtedly differentiate eukaryotic PanK-IIs from prokaryotic PanK-II [29-31]. Given that S. 
aureus is the only known bacterium with an active type II PanK enzyme, it is suggested that the 
staphylococcal coaA gene was horizontally transferred from eukaryotes to bacteria [30].  
 
The kinetic mechanism of S. aureus PanK-II (SaPanK-II) has been proposed as being an ordered 
bisubstrate (Bi-Bi) mechanism (two substrates and the formation of two products), which entails the 
formation of a ternary complex before the chemical step occurs [30, 39]. SaPanK-II binds first to 
ATP in a highly cooperative manner, followed by the binding of pantothenic acid. After catalysis 4’-
phosphopantothenic acid is released first, followed by adenosine diphosphate (ADP) [30]. 
Structural analysis of the SaPanK-II structure with a non-hydrolyzable ATP analogue bound to the 
active site shows that it has two solvent exposed openings to the active site, indicating that it could 
also operate by a non-sequential mechanism, since ATP and pantothenic acid can enter from 
either side of the active site [32]. However, no kinetic data obtained to date provides any evidence  
of this. 
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The activity of the type I and type II PanKs are regulated via feedback inhibition by CoA and/or its 
thioesters which is responsible for the regulation of the flux through the pathway [29, 32, 37]. On 
the contrary, SaPanK-II as well as prokaryotic PanK-IIIs is refractory to feedback inhibition by CoA 
and/or its thioesters. Metabolic labeling of S. aureus confirmed that CoA levels are not controlled 
by CoA or at steps downstream from CoA, due to the lack of pathway intermediates accumulating 
in either intra- or extracellular compartments [31-32, 40]. Furthermore, when the structure of 
SaPanK-II was compared to human PanK3, a structural basis was found for this lack of feedback 
inhibition – two mutations (Ala to Tyr and Trp to arginine (Arg)) were found in the putative acetyl-
CoA binding pocket [36]. This lack of regulation allows the accumulation of milimolar quantities of 
CoA in the organism which is the major intracellular thiol in S. aureus [32, 40]. This observation is 
consistent with the physiology of S. aureus which lacks the low molecular weight thiol glutathione, 
and consequently depends on the CoA/CoA disulfide reductase (CoADR) redox system (that 
reduces CoA-disulfides to CoA in a nicotinamide adenine dinucleotide (NADH)-dependent manner) 
for protection from oxidative damage [29, 34]. Furthermore, it is also suggested that the CoA levels 
in S. aureus is likely to be limited by the supply of pantothenic acid, which is synthesized by the 
biosynthetic pathway encoded by the panB-E genes [29].  
1.5.1.2 Enzymes completing the CoA biosynthetic pathway (CoaBCDE)  
Given that this study will primarily focus on PanK, the remainder of the enzymes in the CoA 
biosynthetic pathway will not be discussed in detail. However, CoaB (PPCS), CoaC (PPCDC), 
CoaD (PPAT) and CoaE (DPCK) have all been identified and fully characterized in various 
organisms and a full summary of these enzymes are available in reviews by Strauss [41] and 
Leonardi et al. [31].      
1.5.2 CoA-dependent processes in metabolism 
CoA serves as the primary acyl group carrier in metabolism, especially in processes involved in 
energy metabolism, such as fatty acid biosynthesis and degradation, as well as the citric acid 
cycle. These energy metabolism processes either utilize CoA independently or in combination with 
acyl carrier proteins (ACPs) which are small acidic proteins that interact with more than twelve 
other proteins to play a central role in fatty acid biosynthesis [42]. CoA functions as the source of 
the 4’-phosphopantetheine moiety of ACPs in a reaction catalyzed by phosphopantetheinyl 
transferase (PPTase) enzymes that transfer the moiety to apo-ACP (inactive) to convert it to its 
holo-ACP (active) form. The 4’-phosphopantetheine group is covalently bound to Ser-36 of the 
ACP, thereby activating it for the synthesis of growing acyl chains carried as thioesters of the 
terminal sulfhydryl group of the prosthetic group. Previous studies have characterized the PPTase 
in E. coli (ACP synthase; AcpS) and have shown it to be essential [27, 43]. Since the  
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characterization of AcpS, numerous other PPTases have been identified as E. coli acpS homologs 
in various prokaryotes. These PPTases have also been shown to be essential for survival, as a 
result of the essential role of ACPs in fatty acid biosynthesis and degradation [27, 42-43]. 
 
Since various processes involve the acyl functionality, many other enzymes depend on CoA as 
acyl carrier. These include HMG-CoA reductase (involved in cholesterol biosynthesis), 3-hydroxy-
acyl-CoA dehydrogenase, 2-enoyl-CoA reductase, enoyl-CoA hydratase, 3-hydroxybutyryl-CoA 
epimerase, acyl-CoA oxidase, acyl-CoA dehydrogenases, and stearoyl-CoA desaturase (all 
involved in various fatty acid metabolic pathways), benzoyl-CoA reductase, and 4-chlorobenzoyl-
CoA dehalogenase (involved in xenobiotic degradation), and methylmalonyl-CoA mutase (involved 
in several degradation pathways) [41].  
1.5.3 The biosynthesis and utilization of CoA as an antimicrobial drug target  
It has been hypothesized that selective inhibition of CoA biosynthesis in pathogens might be 
accomplished with selected small molecule inhibitors due to the high level of structural and 
mechanistic divergence between the prokaryotic and eukaryotic PanKs [12, 27]. There are four 
potential targets in the biosynthesis and utilization of CoA that these small molecule inhibitors can 
act upon, shown schematically in Figure 1.6. The first target (Figure 1.6, Target 1) entails the 
inhibition of pantothenic acid uptake. However, since S. aureus (as most prokaryotes) has the 
ability to synthesize pantothenic acid de novo and is able to transport pantothenic acid into the cell, 
this is not regarded a tractable target. The second target is CoA biosynthesis (Figure 1.6, Target 
2), with the inhibition of the first enzyme (PanK) showing particular promise as PanK inhibition will 
decrease the amount of 4’-phosphopantothenic acid that forms and will consequently lead to a 
decrease in CoA levels, resulting in an overall decrease in the activity of CoA-dependent metabolic 
processes [44-46]. Coudhry et al. [30] have established that this is a viable drug target after they 
identified a series of low molecular weight compounds that inhibit SaPanK-II activity [30]. 
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Figure 1.6. The four major biological targets of pantothenic acid analogues such as N-pentyl pantothenamide 
(N5-Pan) used here as an example: 1) Pantothenic acid uptake 2) PanK, as the first CoA biosynthetic enzyme, 3) 
CoA-dependent enzymes, after transformation of the analogue into the corresponding CoA antimetabolite, and 
4) fatty acid biosynthesis, when the CoA antimetabolite serves as substrate for AcpS to form a crypto-ACP 
instead of the catalytically active holo-ACP. Holo- and crypto-ACP are recycled back to apo-ACP by AcpH. 
Modified from Ref. [47]. 
 
The third possible target is inhibition of CoA-dependent enzymes (Figure 1.6, Target 3). 
Compounds with this particular mode of action are usually pantothenic acid analogues that can be 
phosphorylated by PanK, and which are transformed by the remaining CoA biosynthetic machinery 
to the corresponding CoA antimetabolites. Since the essential terminal sulfhydryl group has been 
replaced by inactive moieties in these antimetabolites, this will adversely affect all CoA-dependent 
processes relying on this functional group. One specific process relying on CoA is fatty acid 
biosynthesis and is therefore seen as the fourth target of inhibition (Figure 1.6, Target 4). Fatty acid 
biosynthesis is dependent on ACPs to obtain the phosphopantetheine prosthetic group from the 
cofactor. If CoA is replaced by antimetabolites, it will lead to the synthesis of inactive ACPs due to 
the lack of the terminal sulfhydryl group needed for fatty acid biosynthesis [44-46]. This process 
has been validated as a potential drug target after Leonardi et al. discovered that low molecular 
weight compounds such as N-pentyl pantothenamide (N5-Pan) and N-heptyl pantothenamide (N7- 
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Pan) acts as substrates for SaPanK-II and is subsequently converted to the inactive ethyldethia-
CoA analogue (when N5-Pan is the substrate) or the inactive butyldethia-CoA analogue (when N7-
Pan is the substrate), which is also incorporated into ACPs leading to the formation of crypto-ACP 
instead of the catalytically active holo-ACP [29]. These crypto-ACPs do not have the requisite thiol 
group and are therefore unable to act as acyl carriers.  
 
However, it is important to note that previous studies have shown that some bacteria (especially 
some Gram-positives) have the ability to suppress fatty acid biosynthesis when exogenous fatty 
acids are present. This strict biochemical regulation of fatty acid biosynthesis by exogenous fatty 
acids means that these organisms are refractory to fatty acid biosynthesis inhibitors [48]. These 
implications will have to be considered for the development of antimicrobials that solely target fatty 
acid biosynthesis. 
1.6 CoA metabolism in Plasmodium falciparum 
1.6.1 Pantothenic acid and CoA biosynthesis in P. falciparum-infected 
erythrocytes  
Pantothenic acid is one of only a handful of low molecular weight compounds and the only water 
soluble vitamin shown to be an absolute requirement for growth of the intracellular blood-stage P. 
falciparum parasites [27]. A study by Saliba et al. [49], demonstrated that pantothenic acid is 
rapidly taken up by P. falciparum infected erythrocytes and that this uptake is facilitated by “new 
permeability pathways” (NPPs) which is induced by the maturing parasite in the erythrocyte 
membranes [49]. These NPPs have a broad specificity and provide the host cell with an increased 
permeability to various low molecular weight compounds, including several nutrients, inorganic 
salts and metabolic wastes [27]. Pantothenic acid uptake occurs rapidly in P. falciparum-infected 
erythrocytes and this rapid uptake was also observed for intact isolated P. falciparum parasites 
(Scheme 1.2) [50].  
 
It is believed that pantothenic acid enters the parasitophorous vacuole (a vacuole that forms when 
the parasite invades the erythrocyte via an endocytosis-like mechanism and in which the parasite 
remains enclosed) from the erythrocyte cytosol by diffusion through the vacuole membrane via low 
selectivity channels. Once it enters the vacuole, it is transported across the parasite’s membrane 
into the parasite where it gets phosphorylated by PanK [27]. The transporter (PfPAT) responsible 
for the transport of pantothenic acid in P. falciparum was identified in 2013 and it is localized to the 
parasite plasma membrane [51]. Transport across the parasite’s membrane occurs via an 
H+:pantothenic acid symport mechanism with a 1:1 stoichiometry (Scheme 1.2). This symport  
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mechanism couples the transport of one proton (H+) to the transport of one pantothenic acid 
molecule down an electrochemical gradient. To date no candidate genes encoding the enzymes of 
the pantothenic acid biosynthetic pathway have been identified in the parasite’s genome; this is 
consistent with studies on the P. falciparum parasite needing pantothenic acid for growth [27].  
 
 
Scheme 1.2. Pantothenic acid uptake and metabolism in P. falciparum infected erythrocytes. Pantothenic acid 
enters the erythrocyte through NPPs and is then believed to diffuse from the cytosol across the 
parasitophorous vacuole membrane into the parasitophorous vacuole. Subsequently, pantothenic acid is taken 
up by the parasite via an H
+
:pantothenic acid symporter, after which it is converted to dephospho-CoA by the 
PanK, PPCS, PPCDC and PPAT enzymes located in the parasite cytosol. Dephospho-CoA enters the apicoplast 
via an unknown mechanism and the enzyme DPCK converts dephospho-CoA to CoA which is then used in CoA-
dependent processes. Adapted from ref. [27, 46]. 
 
There is a significant difference in pantothenic acid uptake between healthy erythrocytes and P. 
falciparum-infected erythrocytes. It was initially thought that pantothenic acid uptake in healthy 
erythrocytes is negligible due to the fact that they do not have NPPs in their membranes, in 
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addition to no scientific evidence supporting the existence of a functional transporter. However, in 
2009 Spry et al. [50] showed that pantothenic acid uptake by healthy erythrocytes does indeed 
occur (albeit at a very slow rate) and these healthy erythrocytes do have the ability to metabolize 
pantothenic acid to form CoA. The mechanism by which healthy erythrocytes take up pantothenic 
acid remains to be established. Although pantothenic acid and CoA were detected in healthy 
erythrocytes, no other intermediates of the CoA pathway were detected. Conversely, CoA 
biosynthesis in P. falciparum-infected erythrocytes is considerably higher [50]. This is consistent 
with other published results on the increased permeability of P. falciparum infected erythrocytes to 
pantothenic acid [49]. These results suggest that CoA biosynthesis is regulated differently by P. 
falciparum and erythrocytes, and the rate of pantothenic acid phosphorylation by PanK does not 
determine the rate at which P. falciparum produces CoA [50]. 
1.6.1.1 Pantothenate kinase (PanK; CoaA) as characterized from parasite lysates  
PanK, expressed by P. falciparum (PfPanK), is predicted to localize to the P. falciparum cytosol 
and has a significantly higher affinity for pantothenic acid compared to mammalian PanKs, with 
PfPanK binding pantothenic acid with >10-fold higher affinity (based on KM) compared to the 
mammalian PanKs described to date. This increase in affinity allows PfPanK to trap pantothenic 
acid within the parasite cytosol in its phosphorylated form [27, 52]. Spry et al. [50] illustrated that 
although 4’-phoshopantothenic acid accumulates in P. falciparum-infected erythrocytes and 
isolated parasites, it does not accumulate in uninfected erythrocytes. This observation suggests 1) 
that the regulation of CoA biosynthesis by erythrocytes and P. falciparum is markedly different and 
2) that unlike other organisms, the rate of pantothenic acid phosphorylation by P. falciparum does 
not determine the rate of CoA biosynthesis. However, PanK activity in P. falciparum lysates is 
inhibited by CoA with an IC50 (the half maximal inhibitory concentration) of ~200 µM and is 
consequently not refractory to feedback inhibition (similar to what is shown for SaPanK-II) [50].  
 
Even though PanK activity has been observed in lysates for years, thus far no one has 
successfully overexpressed, purified and characterized the PanK enzyme from the organism or a 
heterologous expression system [27]. This lack of expression and purification could be attributable 
to the P. falciparum genome being adenine and thymine (AT)-rich, which requires the use of longer 
primers for polymerase chain reactions (PCR), while additionally exhibiting a codon bias with a 
heavy emphasis on AT-rich codons. Furthermore, P. falciparum proteins are often expressed in E. 
coli in insoluble inclusion bodies and it is not unusual for P. falciparum genes to contain start sites 
that are cryptic for E. coli, leading to the formation of numerous truncated products. Finally, there is 
also increasing evidence that P. falciparum proteins may bind the DNA and RNA which codes for 
them, thereby creating a regulatory mechanism which would impede attempts to overexpress the 
protein [53].   
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1.6.1.2 Enzymes completing the CoA biosynthetic pathway (CoaBCDE)  
Very limited information regarding the last four enzymes of the CoA biosynthetic pathway in P. 
falciparum is available. The genes predicted to code for the five enzymes share a sequence 
similarity with the genes coding for the human CoA biosynthetic enzymes; however, no soluble 
expression, purification and characterization has been achieved to date [27]. Spry et al. [50], 
however, have suggested that 4’-phosphopantothenoylcysteine synthetase (PPCS; CoaB), which 
catalyzes the condensation of L-cysteine to 4’-phosphopantothenic acid to form 4’-phospho-
pantothenoylcysteine (Scheme 1.1, Step 2), is the rate-limiting step in P. falciparum CoA 
biosynthesis due to the accumulation of 4’-phosphopantothenic acid in the parasite. Previously, 
similar results were found in perfused rat hearts in which PanK was stimulated, but this was due to 
an insufficient supply of L-cysteine. Therefore, at this stage it still remains unclear whether the 
accumulation of 4’-phosphopantothenic acid in P. falciparum is due to a lack of available L-cysteine 
or whether it is due to regulation of PPCS [50].  
 
From the predicted gene sequences phosphopantetheine adenylyltransferase (PPAT; CoaD) 
shows the lowest sequence similarity to its human counterpart. Interestingly, in P. falciparum it is 
predicted that separate genes code for PPAT and dephospho-CoA kinase (DPCK; CoaE) 
compared to the human genes that code for a bifunctional enzyme. It is predicted that enzymes 
two to four (i.e. PPCS, PPCDC and PPAT) are localized to the P. falciparum cytosol, while the fifth 
enzyme, DPCK, is localized to the apicoplast, a non-photosynthetic, relict plastid found in most 
apicomplexan parasites. The apicoplast is the site of fatty acid biosynthesis and the localization of 
DPCK to the apicoplast would allow for CoA biosynthesis to take place in the same organelle were 
the CoA-utilizing enzymes and ACPs are localized. This phenomenon has been reported 
previously for the human bifunctional PPAT/DPCK enzyme (also known as COASY or CoA 
synthase) that is localized to the mitochondrial outer membrane [27]. Furthermore, if DPCK is 
localized to the apicoplast, an uptake mechanism of dephospho-CoA by the apicoplast would be 
essential, since the other four enzymes are localized in the cytosol. Previous studies have 
hypothesized that intracellular pathogens such as Chlamydia, Mycoplasma and Rickettsia, which 
all appear to only possess a DPCK enzyme, also possess such a mechanism for dephospho-CoA 
uptake across the plasma membrane [27]. 
1.6.2 CoA utilization processes in metabolism 
CoA serves as the primary acyl group carrier in metabolism, especially in processes involved in 
energy metabolism, such as fatty acid biosynthesis and degradation, as well as the citric acid cycle 
[42]. CoA metabolism in the P. falciparum parasite is greatly altered from CoA metabolism in their 
hosts. Generally, CoA is found as acetyl-CoA in organisms where it functions as a link between  
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glycolysis (which occurs in the cytosol) and the citric acid cycle (which occurs in the mitochondrion) 
by serving as the metabolite that initiates the citric acid cycle to produce ATP. However, current 
biochemical studies suggest that in P. falciparum glycolysis is the key pathway for ATP generation 
in intraerythrocytic parasites, even though the genes encoding the citric acid cycle enzymes and 
mitochondrial electron transport chain (ETC) complexes are present [54].  
 
Furthermore, in most organisms succinyl-CoA (another vital CoA thioester) predominantly acts as 
a citric acid cycle intermediate; however, in P. falciparum it is also utilized for the de novo synthesis 
of heme (an important cofactor in parasite biology) and all the enzymes in the pathway have been 
characterized. In addition to P. falciparum having the ability to synthesize heme de novo, the 
intraerythrocytic parasites can also obtain heme from host hemoglobin if the heme biosynthetic 
pathway has been inactivated. However, for the survival of the mosquito as well as liver life stages 
of the parasite, de novo synthesis of heme (and thus the availability of succinyl-CoA) is an absolute 
necessity [55]. Additionally, P. falciparum parasites require a sufficient source of fatty acids for the 
synthesis of lipid species that are important for parasite membrane and lipid body biogenesis, as 
well as for glycosylphosphatidylinositol (GPI) moieties that serve to anchor parasite membrane 
proteins. Compared to uninfected erythrocytes, the fatty acid concentrations in infected 
erythrocytes are 6-fold higher [56]. Interestingly, Vaughan et al. [57] discovered that fatty acid 
biosynthesis is non-essential in blood stage parasites, since the deletion of FabI from P. falciparum 
has no apparent effect on blood stage replication when compared to wild type parasites. 
Consequently, Plasmodium fatty acid biosynthesis type II (FAS-II) takes place entirely during liver 
stage development, and fatty acid biosynthesis requires CoA to activate ACPs on which this 
process depends [56-57].  
1.6.3 CoA biosynthesis and utilization as an antimalarial drug target 
There are currently four potential drug targets in CoA metabolism in P. falciparum that are under 
investigation. The four potential targets in the CoA biosynthetic pathway that small molecule 
inhibitors can act upon are shown schematically in Figure 1.7. The first target entails the inhibition 
of pantothenic acid uptake (Figure 1.7, Target 1). P. falciparum acquires pantothenic acid using an 
H+:pantothenic acid symport mechanism with a 1:1 stoichiometry as discussed earlier. Therefore, 
the transport of one H+ is coupled to the transport of one pantothenic acid molecule down an 
electrochemical gradient. Since no candidate genes for the biosynthetic pathway of pantothenic 
acid have been identified in the parasite’s genome thus far, this uptake mechanism is the only 
source of pantothenic acid available to the parasite [27]. Saliba et al. [58] have demonstrated that 
the provitamin pantothenol interferes with the uptake of pantothenic acid when they studied this 
uptake mechanism in P. falciparum infected erythrocytes and in parasites isolated from their host  
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cells. Although it remains unclear whether pantothenol gains access into infected erythrocytes via 
the NPPs in a similar fashion to that of pantothenic acid, or whether it gains access through an 
alternative mechanism, it is evident that pantothenic acid analogues have some potential to 
interfere with the uptake of pantothenic acid and therefore propose pantothenic acid uptake as a 
viable drug target [46, 58]. 
 
 
Figure 1.7. The biosynthesis of CoA (left) proceeds via a universal five step pathway catalyzed by PanK, PPCS, 
PPCDC, PPAT and DPCK. There are four major biological targets for inhibitors in the CoA biosynthetic pathway 
of P. falciparum: 1) Pantothenic acid uptake 2) PanK, as the first CoA biosynthetic enzyme, 3) CoA-dependent 
enzymes, after its transformation into antimetabolites, and 4) fatty acid biosynthesis, when an anti-CoA serves 
as substrate for ACP synthase in its activation of apo-ACP. 
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The second target identified is CoA biosynthesis, with the first step in the pathway (i.e. 
phosphorylation of pantothenic acid by PanK) as the specific target (Figure 1.7, Target 2). Previous 
studies have illustrated that P. falciparum has the ability to biosynthesize its own CoA, and it is 
therefore not dependent on the host for its CoA needs; this makes selective inhibition of PfPanK a 
desirable target. Even though the PfPanK enzyme has not been successfully overexpressed and 
purified from the organism or from a heterologous expression system, studies have investigated 
the catalytic effect of PfPanK present in P. falciparum lysates [27]. These studies determined that 
PfPanK has an extremely high affinity for pantothenic acid (KM = 0.3 µM) [52], compared to three 
human isoforms hPanK1β, hPanK2 and hPanK3 with KM values of 5.7 µM, 25.4 µM and 9.5 µM, 
respectively [59]. Additionally, Spry et al. [60] demonstrated that a group of pantothenic acid 
analogues inhibited the phosphorylation of pantothenic acid by PfPanK in a competitive manner 
with Ki values (the dissociation constant for the inhibitor) in the nanomolar range. Recently, a study 
showed that CoA biosynthesis can be targeted by a chemically diverse set of inhibitors that do not 
resemble pantothenic acid; these compounds’ IC50s ranged between 120 nM and 6 µM against 
blood-stage parasites [61]. Collectively, these facts suggest that PfPanK might be an attractive 
antiplasmodial target.  
 
The third possible target is CoA utilization (Figure 1.7, Target 3). Compounds with this mode of 
action are usually pantothenic acid analogues that act as substrates for PanK and can possibly be 
processed downstream in the pathway to the corresponding CoA antimetabolites. Since the 
terminal sulfhydryl group has been replaced by inactive moieties in these antimetabolites, this will 
adversely affect all CoA-dependent processes. One of these is fatty acid biosynthesis (the fourth 
possible target), which is dependent on ACPs for acquiring their phosphopantetheine prosthetic 
groups from CoA. If CoA is replaced by antimetabolites, it will lead to the synthesis of inactive 
ACPs, thereby blocking fatty acid biosynthesis (Figure 1.7, Target 4) [44-45]. According to Prigge 
et al. [62], the P. falciparum genome appears to encode an ACP synthase enzyme that has a 29% 
sequence homology with the ACP synthase found in E. coli. Although it is known that E. coli ACP 
synthase has the ability to transfer inactive moieties to ACP, the products of which then function as 
inhibitors of FAS-II, it remains to be determined whether P. falciparum ACP synthase also shows 
the same relaxed substrate specificity function. Given that there is a vast difference between 
human ACPs and Plasmodium ACPs, there might be definite selectivity for Plasmodium ACPs by 
pantothenic acid analogues. However, this hypothesis remains to be corroborated by experimental 
evidence.  
 
Most malaria research thus far has focused on the blood-stage of the parasite, given that it is this 
stage that causes the characteristic symptoms of the disease [63]. As a result, most of the  
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antibiotic drugs that are currently being used to treat malaria target the blood-stage of the parasite 
[64]. However, a previous study has determined that fatty acid biosynthesis is non-essential in 
blood stage parasites and FAS-II takes place entirely during liver stage development [57]. 
Therefore, fatty acid biosynthesis is an attractive target for antimalarial drug design, given that this 
will target the liver stage of the parasite. Consequently, inhibition of progression through the liver 
stage of the parasite would prevent onset of the blood-stage of the disease, including the 
characteristic symptoms of the disease. 
1.7 Pantothenic acid analogues as potential small molecule inhibitors  
In recent years, many compounds based on the structure of pantothenic acid have been 
synthesized and tested for their antimicrobial activity against various organisms. A detailed review 
of the various compounds tested since 1940 was published by Spry et al. [27]. The antimicrobial 
activity of these pantothenic acid analogues varied considerably, with some analogues possessing 
growth-promoting activity for organisms that need an exogenous supply of pantothenic acid, some 
analogues not showing any antimicrobial activity, and finally, some that antagonized the growth 
promoting activity of pantothenic acid [27].  
 
Consequently, pantothenic acid analogues can be used to influence all four CoA-based drug 
targets: 1) by either competing with or inhibiting pantothenic acid transport, 2) by either competing 
with pantothenic acid for PanK activity or by inhibiting the enzyme itself, 3) by acting as a substrate 
for PanK leading to the formation of downstream CoA antimetabolites or 4) by inhibiting fatty acid 
biosynthesis since CoA is replaced by antimetabolites which will lead to the synthesis of inactive 
ACPs due to the lack of the terminal sulfhydryl group needed for fatty acid biosynthesis. However, 
pantothenic acid uptake is not regarded as a feasible target, since many organisms can synthesize 
pantothenic acid de novo, in addition to being able to transport pantothenic acid into the cell [44-
46].  
 
Although CoA analogues have been widely used as inhibitors of enzymatic activity or as 
mechanistic probes, they cannot be transported across the cell membrane. As a result, inhibition 
can only occur if a pantothenic acid analogue with good cell permeability and PanK activity is 
applied [65]. This redirects the attention back to PanK as a drug target. Consequently, the 
development of pantothenic acid analogues that inhibit PanK activity completely or analogues that 
compete with pantothenic acid for PanK activity to have an effect downstream is vital. Given that 
this study will focus on S. aureus and P. falciparum, only pantothenic acid analogues that are 
relevant as antimicrobial agents in respect to these two organisms will be discussed.   
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1.7.1 Pantothenic acid analogues tested on S. aureus  
1.7.1.1 Overview of pantothenic acid analogues tested on S. aureus 
Various compounds based on pantothenic acid have been designed, synthesized and tested as 
inhibitors of the CoA biosynthetic pathway in several bacteria (including S. aureus) since 1940; 
these were summarized by Spry et al. in a review in 2008 [27]. Similar to the de novo biosynthesis 
of pantothenic acid by bacteria via the condensation of pantoic acid and β-alanine (Scheme 1.3, 
pathway on the left) [27], pantothenic acid can be synthesized chemically through the 
condensation of β-alanine with (R)-(-)-pantolactone instead of pantoic acid (Scheme 1.3, pathway 
on the right).  
 
Since the structural determination of pantothenic acid in 1940 [27], various analogues of it have 
been synthesized. These include pantoyltaurine-related compounds, N-pantoyl-substituted amines, 
pantoylhydrazide- and pantothenone-related compounds, as well as analogues of pantothenic acid 
with a modified pantoyl moiety, all of which were prepared in an attempt to generate analogues 
with an activity similar to that of pantothenic acid [27, 66-67]. In general, the pantothenic acid 
analogues with the best antimicrobial activity were those in which the pantoyl moiety remained 
unmodified, while modifying the β-alanine moiety. Examples of these compounds include 
pantoyltauramide, pantoyltaurine (Scheme 1.6) and α-methyl pantothenic acid [66, 68]. However, 
most of these studies only reported antimicrobial action of these compounds on whole organisms, 
and therefore their mechanism of action still remains uncertain [27]. 
 
 
Scheme 1.3. Synthesis of pantothenic acid using the two moieties, pantoyl (red) and β-alanine (blue). (Left) 
Pantothenic acid is synthesized de novo in bacteria by condensing β-alanine (blue) and pantoic acid (red). 
(Right) Chemical synthesis of pantothenic acid by condensing β-alanine (blue) with (R)-(-)-pantolactone (red). 
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1.7.1.2 N-substituted pantothenamides tested on S. aureus.  
Another group of potential small molecule inhibitors that have been investigated since 1970, with a 
similar backbone to pantothenic acid, is the N-substituted pantothenamides (referred to as 
pantothenamides from here on). These analogues are structurally different from pantothenic acid 
by having a secondary or tertiary amide instead of the carboxylic acid moiety (Scheme 1.4A). They 
are synthesized by condensing either a primary or secondary amine to the carboxylic acid of 
pantothenic acid to form a new secondary or tertiary amide bond (Scheme 1.4B) [27, 32]. Seeing 
as the carboxylic acid moiety has been replaced with a secondary or tertiary amide, these 
pantothenamides do not have the ability to accept L-cysteine in the condensation reaction 
catalyzed by PPCS to form a pantetheine analogue with a sulfhydryl moiety (Scheme 1.1, Step 2). 
Pantothenamides have been shown to act as inhibitors of E. coli, S. aureus, Lactobacillus 
arabinosus and Lactobacillus casei to name but a few [27, 69]. Furthermore, pantothenamides act 
as inhibitors (or alternative substrates) of type I and type II PanKs; however, type III PanKs are 
refractory to inhibition by pantothenamides due to the fully enclosed pantothenic acid binding 
pocket of PanK-III. In addition, the pantothenic acid binding pocket is situated above the ATP-
binding cleft and is only accessible by passing through the ATP binding site [59].  
 
 
Scheme 1.4. (A) Structural differences between pantothenic acid and N-substituted pantothenamides. (B) 
General illustration of the preparation of pantothenamides by condensing a primary or secondary amine to the 
carboxylic acid of pantothenic acid to form a new secondary or tertiary amide bond.  
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Previous studies investigated numerous types of pantothenamides (Scheme 1.5) on S. aureus, 
which included linear and branched alkyl substitutions as well as various aromatic and polar 
substituents. Virga et al. [12], tested a series of pantothenamides against SaPanK-II and found that 
molecules with linear alkyl tails, as well as linear alkyl tails with polar substituents displayed the 
highest percentage inhibition of the enzyme’s pantothenic acid phosphorylation activity. However, 
when these pantothenamides where tested against S. aureus in whole cell inhibition studies, only 
the pantothenamides with linear alkyl substitutions showed inhibition. This was unexpected, since 
both groups displayed inhibition of the enzyme. Further experiments suggested that the 
introduction of a polar atom into the linear alkyl chain must prevent the uptake of such 
pantothenamides into the cell. The compounds that showed the most potent inhibition of S. aureus 
and SaPanK-II were N5-Pan and N7-Pan; indicated in the blue box in Scheme 1.5. These results 
indicated that linear alkyl substitutions have a higher inhibitory effect than aromatic or polar 
substituents [12, 29]. Additionally, N7-Pan and N-nonyl pantothenamide (N9-Pan) were tested for 
their cytotoxicity potential against human HepG2 liver cells and it was found that neither compound 
strongly inhibited the growth of human hepatocytes (the lowest concentrations causing ≥50% 
reduction in cell viability were 64 and 128 µg/mL, respectively), suggesting that pantothenamides 
are viable leads for developing selective antimicrobial agents [30].  
 
The inhibition of SaPanK-II by these pantothenamides can be explained using the four available 
enzyme crystal structures (PDB codes: 2EWS, 4M7Y, 4M7X and 4NB4). All of these structures 
either have ADP or a non-hydrolyzable ATP analogue bound to the active site of the enzyme. The 
pantothenic acid binding pocket is completely exposed to the solvent when no other substrate 
apart from ADP or the non-hydrolyzable ATP analogue is bound to the active site. This would thus 
create space for the extended pantothenic acid analogues to bind in the active site pocket [32]. 
The crystal structures show that when the pantothenamides (i.e. N5-Pan, N7-Pan and N-[2-(1,3-
benzodioxol-5-yl)-ethyl] pantothenamide (N354-Pan) [37]) bind to the active site, a conformational 
change occurs and the active site gets closed off from the surrounding solvent. This closed 
conformation is predicted to be the active form of the enzyme; however, since there is no crystal 
structure available with pantothenic acid bound in the active site, this still needs to be confirmed. 
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Scheme 1.5. Various amide functional groups that have been used as pantothenic acid analogues in previous 
studies against SaPanK-II and S. aureus [12]. N5-Pan and N7-Pan (indicated in the blue box) are the most potent 
inhibitors of S. aureus and SaPanK-II. 
 
Given that pantothenamides could potentially have a similar binding mode to pantothenic acid, they 
could either act as competitive inhibitors of the enzyme (i.e. acting on Target 2 in Figure 1.6), or as 
alternative substrates. In the latter case, they will be phosphorylated by SaPanK-II and 
subsequently be converted into CoA antimetabolites and inactive ACPs (i.e. act on Targets 3 and 4 
in Figure 1.6) [44-46]. This has resulted in uncertainty about the exact mode of action of these  
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compounds in S. aureus – an uncertainty which is reflected in the current literature. For example, 
Leonardi et al. [29], discovered that pantothenamides (specifically N7-Pan) are converted into CoA 
antimetabolites in S. aureus (i.e. N7-Pan acts as a substrate for SaPanK-II), followed by the 
biosynthesis of inactive downstream products (such as inactive ACPs) in intact cells through 
radioactive labelled compounds. On the other hand, findings by Choudhry et al. [30] suggested that 
these compounds are inhibitors of the SaPanK-II enzyme itself and that it does not act as a 
substrate for SaPanK-II. However, it is also possible that the direct spectrophotometric assay used 
by Choudhry et al. was not sensitive enough to detect phosphorylation of the pantothenamides; 
these authors also did not examine the metabolism of pantothenamides in intact cells [29].  
 
Taken together, these studies illustrate that pantothenamides are excellent potential small 
molecule inhibitors of S. aureus, with low cytotoxicity towards human HepG2 liver cells; however, 
our poor understanding of their exact mechanism of action has hampered their development as 
clinically relevant agents.  
1.7.2 Pantothenic acid analogues tested on Plasmodium  
1.7.2.1 Overview of pantothenic acid analogues tested on Plasmodium 
Since Trager illustrated in 1943 that pantothenic acid is a prerequisite for the survival of 
Plasmodium lophurae parasites in infected erythrocytes, the pursuit of pantothenic acid analogues 
as feasible leads for the development of antimalarials became possible [70]. Given that 
pantoyltaurine and pantoyltauramide (Scheme1.6) previously showed antibacterial activity towards 
bacteria that also require pantothenic acid for survival, these two pantothenic acid analogues were 
tested first for antimalarial activity. Pantoyltaurine and pantoyltauramide, together with several 
other N-substituted pantoyltauramides, were screened first against avian malaria infected ducks, 
canaries and chickens, because the procedures for in vitro cultivation of P. falciparum parasites 
were not yet established. These compounds were found to be inactive against P. lophurae-infected 
ducks, Plasmodium gallinaceum-infected chickens and Plasmodium relictum-infected canaries 
when included into their diets; however, pantoyltauramide showed some activity against P. 
gallinaceum-infected chickens when it was administered intravenously. This antimalarial activity 
was antagonized when pantothenic acid was co-administered with pantoyltauramide, which 
suggested that the antimalarial activity of pantoyltauramide is as a result of inhibition of pantothenic 
acid utilization [27].  
 
Another series of N-substituted pantoyltauramides (Scheme1.6) were synthesized by Winterbottom 
et al. [71], in 1947 in an attempt to increase their absorption and excretion characteristics relative 
to pantoyltaurine. These compounds were found to be more active when included into the diets of 
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P. gallinaceum-infected chickens. Indeed, some of the compounds tested showed similar or 
increased activity towards P. gallinaceum-infected chickens compared to the standard antimalarial, 
quinine. The most active compound was four times and sixteen times more potent than quinine 
when tested against a standardized, blood induced infection of P. gallinaceum, in which peak 
parasitaemia was reached four days postinfection and seven days postinfection, respectively. 
Furthermore, a variety of pantothenone analogues (Scheme 1.6) were also tested against various 
Plasmodium parasites; some of the compounds showed good antiplasmodial activity and the 
activity was antagonized upon the addition of pantothenic acid [27].  
 
 
Scheme 1.6. Various pantothenic acid analogues tested against a variety of Plasmodium species in vivo.  
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After the procedure to cultivate blood-stage Plasmodium parasites in vitro was established, 
numerous studies were carried out with the same compounds to test their in vitro antiplasmodial 
activity and the results obtained were similar to that of the previous in vivo results. The most potent 
inhibitor, p-chloro-benzyl pantoyltauramide, indicated in the N-substituted pantoyltauramide series 
(Scheme 1.6, blue box), was also tested against P. falciparum. This inhibitor showed increased 
antiplasmodial activity compared to what was seen in ducks. Various other analogues such as N-
aryl substituted and halogenated phenyl-substituted pantoyltauramides were also tested against a 
variety of Plasmodium parasites, with some promise of antimicrobial activity [27].  
  
More recently, Saliba et al. [58, 72] showed that P. falciparum is also inhibited by pantothenol 
(Scheme 1.6, indicated in the red box), which is the provitamin form of pantothenic acid, through a 
mechanism that involved competition with pantothenic acid. The H+-coupled transport of 
pantothenic acid across the parasite plasma membrane was not inhibited by pantothenol; instead 
pantothenol inhibited the phosphorylation of pantothenic acid by PfPanK. However, it is still unclear 
whether pantothenol actually undergoes phosphorylation and whether this is the only site of action 
within the parasite [58]. Another example of a pantothenic acid analogue that acts as an inhibitor of 
P. falciparum is CJ-15,801 (Scheme 1.6, indicated in the red box), which is a fungal natural product 
isolated from Seimatosporium sp. CL28611 [72]. CJ-15,801 exerts its antiplasmodial activity on the 
parasite via competitive inhibition of pantothenic acid metabolism (inhibiting the utilization of 
pantothenic acid), given that the antiplasmodial activity is completely antagonized by the addition 
of extracellular pantothenic acid [72]. Various other compounds based on the pantothenol structure 
(referred to as N-pantoyl substituted amines; Scheme 1.6) have shown antiplasmodial activity 
towards P. falciparum in a similar manner to pantothenol. The in vitro antiplasmodial activity of 
these compounds ranged between 10–200 µM, which suggests that these compounds could 
translate into potent inhibitors of P. falciparum [27, 58, 60, 72].  
1.7.2.2 N-substituted pantothenamides tested on P. falciparum 
The discovery of the in vitro antiplasmodial activity of pantothenol and CJ 15,801 in 2005 by Saliba 
et al. [58, 72], lead to an increased interest in targeting CoA metabolism in P. falciparum with 
pantothenic acid analogues [58, 72]. Although pantothenamides have been investigated as 
possible inhibitors of bacteria since 1970, the first pantothenamides tested for antiplasmodial 
activity against P. falciparum in vitro was only completed in 2013 [73-74]. The two pantothenamide 
libraries that were tested included a range of amines that represented four chemical motifs, i.e. 
primary alkyl amines, primary aliphatic amines containing heteroatom substituents, secondary 
cyclic amines, and primary amines containing aromatic substituents (some of the pantothenamides 
tested are shown in Scheme 1.7). Both of the pantothenamide libraries were tested for inhibition of  
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the proliferation of P. falciparum (3D7 strain). Surprisingly, none of the pantothenamides tested 
showed antiplasmodial activity at a clinically relevant concentration, with most of the compounds 
having an IC50 >200 µM; the best hit compound was N-phenethyl pantothenamide (N-PE-PanAm) 
(indicated in the blue box) with an IC50 of 53 ± 11 µM [46, 73-74].  
 
 
Scheme 1.7. Various pantothenamides tested against P. falciparum. N-phenethyl pantothenamide (indicated in 
the blue box) was the most potent inhibitor.  
1.8 N-substituted pantothenamides are susceptible to enzyme-
mediated hydrolysis  
Inhibitor tests done with both N5-Pan and N7-Pan to determine the inhibitor activity against 
SaPanK-II gave Ki-values in the nanomolar range in the in vitro studies, but the promising 
antimicrobial activity is lost when such tests are performed in vivo. A possible explanation for this 
loss of antimicrobial activity was uncovered in December 2011 when a patent application was 
published by Jansen et al. [75], regarding the antimicrobial activity of pantothenamides. They 
discovered that in 1% tryptone medium N5-Pan acted as an antimicrobial agent, but with the 
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addition of 10% serum or plasma, its antimicrobial activity was completely eradicated. 
Subsequently, they proposed that this effect might be due to enzymatic degradation of one specific 
amide bond (indicated in red in Scheme 1.8) in the pantothenamides by pantetheinase enzymes; 
this would lead to the formation of pantothenic acid and the corresponding amine (Scheme 1.8). 
Such a degradation pathway would account for the observed loss of antimicrobial activity [75].  
 
 
Scheme 1.8. Pantothenamide degradation by the enzyme pantetheinase. (Left) The native function of 
pantetheinase is to catalyze the hydrolysis of the CoA metabolite pantetheine (PantSH) to pantothenic acid and 
cysteamine. (Right) The scissile amide bond (indicated in red) of pantothenamides is susceptible to degradation 
by pantetheinase. 
 
Jansen et al. [76] also tested this hypothesis against P. falciparum. Although N5-Pan and N7-Pan 
act as potent inhibitors of bacteria in vitro, these pantothenamides are not known to have activity 
against P. falciparum parasites [27]. N5-Pan is a poor inhibitor of P. falciparum growth in vitro and 
only achieves >90% inhibition at a concentration of 1 mM, which is clinically irrelevant [76]. Since 
P. falciparum parasites are cultured with human serum, it was hypothesized that the 
pantothenamides are also degraded by pantetheinases present in the serum, thereby reducing its 
potency. Indeed, when N5-Pan was tested against P. falciparum parasites in the presence of an 
inhibitor of pantetheinase activity, the antimalarial activity of N5-Pan was maintained, with an 
increase in anti-parasite potency (IC90) by a factor of 200 compared to N5-Pan alone [76].  
 
Furthermore, Spry et al. [73] found that if pantothenamides are tested as inhibitors of the P. 
falciparum parasite in aged media, i.e. media in which the pantetheinases present in the commonly 
used serum substitute Albumax were deactivated through pre-incubation at 37°C, the potency of 
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the pantothenamides tested were enhanced. Even pantothenamides that previously showed no 
inhibition in freshly prepared medium (i.e. with the pantetheinase activity intact), displayed 
inhibition of parasite growth at sub-micromolar concentrations in aged (pre-incubated) media [73].  
 
Pantetheinases are encoded by the Vanin gene family (that forms part of the nitrilase superfamily), 
of which three human genes (VNN1, VNN2 and VNN3), two murine genes (Vanin-1 and Vanin-2) 
and one homologue in Drosophila are known [77-78]. Pantetheinase, also known as pantetheine 
hydrolyse, plays a major role in recycling CoA by catalyzing the hydrolysis of one specific amide 
linkage in PantSH (Scheme 1.9) via an invariant Glu-Lys-Cys catalytic triad to yield pantothenic 
acid (for reuse in CoA biosynthesis) and the small aminothiol cysteamine (β-mercaptoethylamine), 
a powerful antioxidant [79-81]. Numerous studies have provided evidence that suggests that the 
oxidative state of a cell is regulated by cysteamine [78-79, 82]. Cysteamine controls cellular levels 
of glutathione, interacts with cysteines, reduces peroxides and inhibits various enzymes, including 
transglutaminases. It has also been shown that both, cysteamine and cystamine (the disulphide of 
cysteamine) are cytoprotective and may also remove toxic, reactive aldehyde species [81]. 
Moreover, recent findings were put forward that Vanin does not only play a role in oxidative stress, 
but also in cell migration, inflammation and diseases such as cardiovascular disease, although 
their exact roles have not yet been identified [78-79, 83]. From a substrate recognition perspective, 
pantetheinase is extremely selective for compounds containing the pantothenate moiety, while the 
nature of the amide substituent is not as relevant and can be modified to a range of different 
functional groups [77, 79-80]. 
 
 
Scheme 1.9. Mechanism for the hydrolysis of pantetheine (PantSH) as catalyzed by pantetheinase to produce 




Stellenbosch University  https://scholar.sun.ac.za
Chapter 1 
Coenzyme A: Biosynthesis, Potential Drug Targets and Small Molecule Inhibitors 
 
~ 35 ~ 
 
In the patent application mentioned above, the authors also investigated whether inhibition of 
pantetheinase activity might possibly keep the antimicrobial activity of pantothenamides intact, 
since inhibition of pantetheinase eliminates the potential hydrolysis of these compounds. They 
found that by inhibiting pantetheinase activity (through combination with an inhibitory PantSH 
analogue), breakdown of pantothenamides were prevented and their antimicrobial activity were 
preserved. Therefore, Jansen et al. suggested the use of a combination of an antimicrobial 
pantothenamide with an inhibitor of host panthetheinase as a strategy for the development of new 
antimalarials [75].  
 
Since such a strategy would involve the separate optimization of the properties of two compound 
sets that may lead to other complications, de Villiers et al. [74] instead decided to modify the 
pantothenamides in such a way that they are resistant to pantetheinase-mediated degradation, 
while maintaining their antiplasmodial potency. This modification was achieved by displacing the 
amide bond that is normally cleaved by pantetheinase by exchanging the β-alanine moiety of the 
pantothenamides with either a glycine (to give α-pantothenamides) or a γ-aminobutyric acid (to 
give homopantothenamides) moiety (Figure 1.8). First, they tested to see if these modifications 
made the pantothenamides more resistant to hydrolysis by performing in vitro pantetheinase 
assays. They found that the modified analogues experienced only 5–15% hydrolysis in 24h, in 
comparison to pantothenamides that contained the normal β-alanine moiety which were 
hydrolyzed completely within this time-frame. Furthermore, they also determined that these 
modified pantothenamides have increased antiplasmodial potency when growth assays were 
conducted with ring-stage P. falciparum parasites. These results confirm that the degradation of 
pantothenamides by pantetheinase can be prevented by the modification of their structures [74].  
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Figure 1.8. Displacement of the scissile amide bond of pantothenamides leads to increased pantetheinase 
resistance. α-Pantothenamides have the β-alanine moiety of pantothenamides replaced with glycine and homo-
pantothenamides have it replaced with γ-aminobutyric acid. These moieties are indicated in red.  
1.9 Problem statement 
Our current knowledge was reviewed in the previous sections to serve as background to highlight 
the two main objectives of this study: 
i) To elucidate the role of PanK in the mode of action of inhibitory pantothenamides in S. 
aureus.  
ii) To develop inhibitors that are resistant to pantetheinase-mediated degradation while 
retaining good antimicrobial activity. 
i) Mode of action of the pantothenamides in S. aureus 
The first part of this project builds upon previous studies of the pantothenamides performed in our 
research group. In these studies, a method was developed to synthesize a library of pantothen-
amides, which were then screened against various organisms for growth inhibitory potential, 
including S. aureus [46, 84]. While selected compounds were also characterized through various in 
vitro assays [46], their exact mode of action still had not been determined. Since the previous 
studies showed that S. aureus is only inhibited by pantothenamides that retained the β-alanine 
moiety (i.e. was highly selective), this suggested a role for PanK (the first point where selectivity 
can be exerted) in the mode of action of these compounds. Therefore, the first goal of this study 
was to elucidate the role of PanK in the mode of action of inhibitory pantothenamides in S. aureus.  
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Two mechanisms of action have been proposed for pantothenamide-mediated inhibition, with 
PanK playing a central role in both: 1) Inhibition based on the pantothenamides inhibiting PanK 
activity directly (Target 2 in Figure 1.6), and 2) metabolic activation of the molecules by PanK (i.e. 
by them acting as alternative substrates of PanK), followed by their conversion to CoA 
antimetabolites for subsequent inhibition of the ACPs and/or other CoA-dependent processes 
(Targets 3 and 4 in Figure 1.6).  
 
Consequently, these two mechanisms can be distinguished based on the nature of the interaction 
of the pantothenamides with PanK, i.e. as inhibitors, or as alternative substrates. Such a distinction 
would shed light on the mode of action of the pantothenamides in a particular organism. This 
distinction can be achieved by means of detailed kinetic analyses of SaPanK-II’s activity towards 
the various compounds in comparison to its native substrate, and by testing the growth inhibition of 
a pantothenamide analogue in which the terminal hydroxyl has been removed (Figure 1.9). Such 
an analogue cannot act as a PanK substrate and be phosphorylated; consequently, it can only act 
as an inhibitor of PanK.  
 
 
Figure 1.9. Pantothenamides. (Left) Pantothenamide with the 4'-hydroxyl-group. (Right) Pantothenamide in 
which the 4'-hydroxyl is removed (4'-deoxy-pantothenamide). 
 
In Chapter 2 our findings towards answering this research question is presented in the form of a 
published article [47] of which I am co-first author, followed by additional supporting experiments 
which were not included in the publication.  
ii) Developing antimicrobial pantothenamides that are resistant to 
pantetheinase-mediated degradation  
The discovery by Jansen et al. [75] that pantothenamides lost their in vivo antimicrobial activity due 
to degradation by pantetheinase, an enzyme found in plasma and serum, indicated that the 
inhibitors could retain their potency if the pantetheinase activity was inhibited. This was confirmed 
by experiments in which pantetheinase inhibitors were used in combination with pantothenamides. 
Under these conditions the breakdown of the pantothenamides was prevented and their 
antimicrobial activity was preserved [75, 85]. However, the pantetheinase inhibitors used in these 
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proof of concept studies are not suited for medicinal use due to poor selectivity for microbial versus 
host targets.  
 
The second goal of this study was therefore to develop PanK inhibitors that are also resistant to 
pantetheinase-mediated degradation. In view of the fact that de Villiers et al. [74], already 
established that a modification to the β-alanine moiety of pantothenamides prevented it from being 
hydrolyzed by pantetheinase, we decided to further expand on this strategy. The proposal in this 
regard was to protect the pantothenamide scissile amide bond from hydrolysis by either increasing 
the steric bulk around this group though the addition of adjacent methyl groups, or by replacing it 
with bioisostere moieties that should withstand degradation. Additionally, since pantetheinase is 
highly substrate specific for the pantoyl moiety of the pantothenamides, removal or replacement of 
the 4’-hydroxyl should result in it not being recognized as a substrate. In the second part of the 
study these various strategies were evaluated using the N7-Pan and N-PE-PanAm scaffolds, since 
these pantothenamides were previously shown to have excellent potential as inhibitors of S. 
aureus and P. falciparum proliferation, respectively. This allowed us to determine which 
modifications can be made to counter breakdown by pantetheinase, while retaining inhibitory 
potency.  
 
The findings addressing this research question are discussed in detail in Chapters 3 and 4, with 
one aspect of the work resulting in another publication [86] (see manuscript as attached addendum 
in this thesis), while a second aspect of the work is currently being incorporated into an additional 
manuscript. Finally, a general conclusion, future strategies and perspectives on this work are 
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N-substituted pantothenamides are analogues of pantothenic acid, the vita-
min precursor of CoA, and constitute a class of well-studied bacterial
growth inhibitors that show potential as new antibacterial agents. Previous
studies have highlighted the importance of pantothenate kinase (PanK;
EC 2.7.1.33) (the first enzyme of CoA biosynthesis) in mediating pantothen-
amide-induced growth inhibition by one of two proposed mechanisms:
first, by acting on the pantothenamides as alternate substrates (allowing
their conversion into CoA antimetabolites, with subsequent effects on
CoA- and acyl carrier protein-dependent processes) or, second, by being
directly inhibited by them (causing a reduction in CoA biosynthesis). In
the present study we used structurally modified pantothenamides to probe
whether PanKs interact with these compounds in the same manner. We
show that the three distinct types of eubacterial PanKs that are known to
exist (PanKI, PanKII and PanKIII) respond very differently and, conse-
quently, are responsible for determining the pantothenamide mode of
action in each case: although the promiscuous PanKI enzymes accept them
as substrates, the highly selective PanKIIIs are resistant to their inhibitory
effects. Most unexpectedly, Staphylococcus aureus PanK (the only known
example of a bacterial PanKII) experiences uncompetitive inhibition in a
manner that is described for the first time. In addition, we show that pan-
tetheine, a CoA degradation product that closely resembles the pantothen-
amides, causes the same effect. This suggests that, in S. aureus,
pantothenamides may act by usurping a previously unknown role of pante-
theine in the regulation of CoA biosynthesis, and validates its PanK as a
target for the development of new antistaphylococcal agents.
Introduction
The N-substituted pantothenamides are a class of pan-
tothenic acid (Pan, vitamin B5) analogues that were
first described in 1970 as growth inhibitors of selected
lactic acid bacteria and Escherichia coli [1]. Because
Pan is the biosynthetic precursor of the universal acyl
group carrier CoA (Fig. 1A), which serves to activate
Abbreviations
ACP, acyl carrier protein; AcpH, [ACP]hydrolase; dN5, DL-40-deoxy-N-pentylpantothenamide; DPCK, dephospho-CoA kinase; EcPanKI,
Escherichia coli type I pantothenate kinase; HoPanAm, homopantothenamide; HoPan, homopantothenic acid; HRMS, high resolution mass
spectrometry; LDH, lactate dehydrogenase; MIC, minimal inhibitory concentration; N354-Pan, N-[2-(1,3-benzodioxol-5-yl)ethyl]
pantothenamide; N5-Pan, N-pentyl pantothenamide; N7-Pan, N-heptyl pantothenamide; n-PanAm, n-pantothenamide; PanK, pantothenate
kinase; Pan, pantothenic acid; PantSH, pantetheine; PK, pyruvate kinase; P-Pan, 40-phosphopantothenic acid; P-PantSH, 40-
phosphopantetheine; PPAT, phosphopantetheine adenylyltransferase; SaPanKII, Staphylococcus aureus type II pantothenate kinase;
a-PanAm, a-pantothenamide.
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Fig. 1. Biosynthesis of CoA and the potential targets of the pantothenamide mode of action. (A) Biosynthesis of CoA from Pan in the five-
step pathway catalyzed by panothenate kinase (PanK), phosphopantothenoylcysteine synthetase (PPCS), phosphopantothenoylcysteine
decarboxylase (PPCDC), phosphopantetheine adenylyltransferase (PPAT) and dephospho-CoA kinase (DPCK), or from PantSH in the
three-step salvage pathway consisting of PanK, PPAT and DPCK. (B) The three major biological targets of N5-Pan: (i) PanK, the first CoA
biosynthetic enzyme; (ii) CoA-dependent enzymes, after its transformation into the antimetabolite ethyldethiacarba-CoA; and (iii) fatty acid
biosynthesis, when ethyldethiacarba-CoA serves as substrate for AcpS to form a crypto-ACP instead of the catalytically active holo-ACP.
Holo- and crypto-ACP are recycled back to apo-ACP by AcpH.
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these groups for both acyl transfer reactions and
biological Claisen condensation reactions [2], pantothen-
amides have raised much interest as antimetabolite-
based lead compounds for the development of new
selective antimicrobial agents [3]. Although recent
studies have again highlighted the potential of these
compounds [4–6], attempts at improving their potency
are hampered by the fact that their mode of action still
has not been unambiguously defined and appears to
show variation between different organisms.
The first mode of action study, which was conducted
in E. coli using N-pentyl pantothenamide (N5-Pan),
the prototypical example of the class, showed that it is
transformed into the CoA antimetabolite ethyldethia-
carba-CoA by three of the five CoA biosynthetic
enzymes (Fig. 1B) [7]. These enzymes are pantothenate
kinase (PanK; EC 2.7.1.33), the first enzyme of the
pathway that usually catalyzes the ATP-dependent
phosphorylation of Pan to give 40-phosphopantothe-
nic acid (P-Pan), and the fourth and fifth enzymes
phosphopantetheine adenylyltransferase (PPAT) and
dephospho-CoA kinase (DPCK), which transform
40-phosphopantetheine (P-PantSH) into CoA through
the addition of adenylyl and phosphate groups, respec-
tively (Fig. 1A). Moreover, the formation of ethylde-
thiacarba-CoA took place faster than the five-step
conversion of Pan into CoA when conducted under
competitive conditions in vitro. This suggested that
N5-Pan exerted its inhibitory effect by reducing the
rate of CoA synthesis, and/or through its biosynthetic
product inhibiting enzymes and processes dependent
on CoA.
A second study focused on fatty acid biosynthesis as
the target for pantothenamide-induced bacterial
growth inhibition, based on the essential requirement
of the holo-acyl carrier protein (holo-ACP) in type II
fatty acid synthase systems (as found in E. coli) [8].
Although holo-ACP is formed when [ACP]synthase
transfers the P-PantSH group from CoA to apo-ACP
[9], it is also possible for CoA analogues such as
ethyldethiacarba-CoA to serve as the substrate instead;
this leads to the formation of crypto-ACPs that do not
have the requisite thiol group and are therefore unable
to act as acyl carriers (Fig. 1B). N5-Pan treatment
led to the formation of the N5-Pan-containing crypto-
ACP (ethyldethiacarba-ACP) as predicted, and to a
reduction in normal holo-ACP levels. CoA levels
apparently remained unaffected. Ethyldethiacarba-
ACP was also shown to accumulate and persist in N5-
Pan-treated cells even after N5-Pan was removed from
the culture, suggesting that ethyldethiacarba-ACP is a
poor substrate for the [ACP]hydrolase (AcpH) that is
responsible for ACP prosthetic group turnover [10,11].
In combination, these factors were considered to result
in the complete inhibition of fatty acid biosynthesis;
this has subsequently been hailed as the major tar-
get for pantothenamide-induced growth inhibition in
bacteria.
Several subsequent studies have drawn this asser-
tion into question. First, studies of the purified AcpH
and E. coli strains in which the acpH gene was
either knocked out or overexpressed indicated that
the accumulation of ethyldethiacarba-ACP following
N5-Pan treatment is not a result of reduced ACP
turnover because this crypto-ACP was found to be
readily hydrolyzed by AcpH [12]. Instead, N5-Pan
treatment caused a significant reduction in the CoA
pool (in contrast to the previous findings), indicating
N5-Pan-mediated inhibition of CoA biosynthesis.
Attempts at identifying the specific target by individ-
ual overexpression of the CoA biosynthetic genes
failed because these strains instead showed an
increase in N5-Pan sensitivity. This again pointed to
the increased flux of the antimetabolite through the
pathway as an important additional determinant of
pantothenamide-meditated growth inhibition. Second,
an investigation of pantothenamide-mediated inhibi-
tion of Staphylococcus aureus identified PanK as its
point of action [13] because only pantothenamides
that caused inhibition of the S. aureus PanK enzyme
in vitro (using a standard kinase assay that couples
ADP formation to NADH reduction) showed cell
growth inhibition. However, a subsequent study
revisited these results and used [c-32P]ATP to demon-
strate that S. aureus PanK phosphorylates both N5-
Pan and its heptyl analogue N7-Pan, and that this
(as in the case of E. coli) also leads to the formation
of modified crypto-ACPs and the inhibition of fatty
acid synthesis [14]. However, because no studies have
investigated the relative importance of the two inhibi-
tion modes, the role of PanK in the pantothenamide-
mediated growth inhibition of S. aureus remains
unresolved.
Although the exact mode of action of the pantothen-
amides still remains a matter of debate, these studies
have all clearly highlighted the importance of PanK in
mediating their growth inhibitory effects by one of
two mechanisms: (a) by acting as the cellular target of
inhibition, leading to the suppression of CoA bio-
synthesis or (b) by accepting pantothenamides as sub-
strates, thereby allowing them to be converted into
CoA analogues that exert their effects on CoA- and
ACP-dependent processes. Unfortunately, structure–
activity relationship studies that set out to establish a
correlation between the growth inhibitory potency of a
a pantothenamide and its potential to act as either an
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inhibitor or substrate of the target organism’s PanK
have not been able to provide more insight into the
enzyme’s apparent dual role in pantothenamide-based
inhibition [15,16].
Importantly, the distinction between a pantothen-
amide acting as either a PanK substrate or inhibitor
may be linked to other aspects of CoA metabolism.
For example, only organisms with PanKs that show
poor substrate selectivity are able to form CoA from
pantetheine (PantSH) (a CoA-derived degradation
product structurally related to the pantothenamides)
by means of a salvage pathway made up of PanK,
PPAT and DPCK (Fig. 1A) [2]. PanKs occur as one
of three distinct forms, known as type I, type II and
type III PanK enzymes, respectively [17–20], with only
PanKI and PanKII (the subscript denotes the type)
showing activity towards both Pan and PantSH [21].
Organisms such as Pseudomonas aeruginosa that have
PanKIII enzymes cannot salvage CoA from pan-
tetheine [22] and are also resistant to pantothenamide-
induced growth inhibition [17,20]. This suggests that
the inhibition mode of the pantothenamides (as struc-
tural mimics of PantSH) may be linked to the targeted
organism’s PanK type and its ability to salvage CoA.
In the present study, we explored the existence of
such links through a combination of bacterial cell
growth inhibition and kinetic characterization studies.
We find that PanK type is the major determinant of
the pantothenamide mode of action, and particularly
so in S. aureus, which has a unique CoA metabolism
supported by a PanKII with several exceptional fea-
tures [14,20]. These results not only provide significant
new insights for antimetabolite-based antimicrobial
drug design, but also add to our understanding of the
implications of PanK diversity for CoA metabolism
and regulation.
Results
Pantothenamide library and study design
The link between PanK type and pantothenamide-
induced bacterial cell growth inhibition was investi-
gated using a library of N-substituted pantothenamides
that was previously prepared in our laboratory and
recently used to identify antiplasmodial pantothen-
amides that are resistant to pantetheinase-mediated
degradation [5,23]. The library was constructed from
Pan and two Pan analogues: a-pantothenic acid, which
has the b-alanine of Pan replaced with glycine, and ho-
mopantothenic acid (HoPan) in which it is exchanged
for c-aminobutyric acid. The acids were subsequently
coupled to 47 different amines representing a variety
of chemical motifs, yielding three sets of pantothen-
amides, referred to as a-pantothenamides (a-PanAm),
n-pantothenamides (n-PanAm, where n signifies
‘normal’) and homopantothenamides (HoPanAm),
respectively (Table 1).
Although a-pantothenic acid has not previously been
studied in the context of PanK and/or CoA inhibitors,
HoPan was shown to act as a competitive inhibitor of a
murine PanKII (MmPanK1a) and to negatively affect
CoA levels in mice in vivo [24]. The same result was
found in insect cells [25]. By contrast, E. coli type I
PanK (EcPanKI), which is known to accept a range of
pantothenic acid analogues [21], does not accept HoPan
as a substrate, nor is it significantly inhibited by it
[15,24,26]. This diverse response indicated that such
modifications in the Pan structure could successfully be
used to probe PanK activity and inhibition.
Organisms with different PanK types exhibit
different pantothenamide-induced growth
inhibition profiles
Three bacterial species, representing all three PanK
types, were selected to evaluate the potency of the
pantothenamide library members: E. coli, a Gram-
negative bacterium with a typical PanKI, the
Gram-positive S. aureus, the only bacterium known to
have an active (albeit atypical) PanKII (normally only
eukaryotes have PanKII enzymes) and P. aeruginosa, a
Gram-negative PanKIII-containing bacterium [2].
Although P. aeruginosa has been shown to be resistant
to N5-Pan inhibition as a result of the selectivity of its
PanKIII enzyme [20], it was included in the present
study because we considered that the smaller a-PanAm
series could potentially be accommodated in its active
site. As in several previous studies [16,27], growth inhi-
bition assays were conducted in 1% tryptone (pancre-
atic digest of casein), a medium that contains low
amounts (< 1 lM) of Pan [28]. Such Pan concentrations
are not strictly physiologically relevant to humans with
bacterial infections because the concentration of total
Pan (i.e. free Pan and Pan bound up in CoA and other
Pan-derived metabolites) in human whole blood ranges
between 1 and 3 lM [29,30]. However, it allows suscep-
tibility data to be obtained under conditions where Pan
is not sufficiently abundant to counteract any potential
inhibition, and therefore serves the point of investigat-
ing the mode of action of these compounds.
Susceptibility tests were performed by obtaining
minimal inhibitory concentration (MIC) values for
those compounds that showed inhibition in initial
screens performed at 200 and 50 lM, respectively. The
structures and MIC values for the pantothenamides
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Table 1. MIC values for the inhibition of E. coli or S. aureus grown for 20 h in 1% tryptone medium in the presence of the indicated
pantothenamides at different concentrations. The reported values represent the mean of two or more independent experiments; the errors




















PanAm entry RAm group
E. coli MIC (µM) S. aureus MIC (µM)
a-PanAm n-PanAm HoPanAm a-PanAm n-PanAm HoPanAm
1 N
H
50–200 > 200 > 200 > 200 30.8  4.3 > 200
2 N
H
50–200 > 200 > 200 > 200 50–200 > 200
3 N
H
50–200 64.4  8.2 > 200 > 200 18.0  0.6 > 200
4 N
H
50–200 50–200 > 200 > 200 3.14  1.20 > 200
5 N
H
> 200 > 200 > 200 > 200 0.77  0.04 > 200
6 N
H








> 200 > 200 > 200 > 200 50–200 > 200
9 N
H




















136  26 > 200 > 200 > 200 24.7  0.3 > 200
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Table 1. (Continued).
PanAm entry RAm group
E. coli MIC (µM) S. aureus MIC (µM)
a-PanAm n-PanAm HoPanAm a-PanAm n-PanAm HoPanAm
15 N
H






















































NHAc > 200 > 200 > 200 > 200 > 200 > 200
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Table 1. (Continued).
PanAm entry RAm group
E. coli MIC (µM) S. aureus MIC (µM)











> 200 > 200 > 200 > 200 47.7  7.9 > 200
30 N
H













































> 200 > 200 > 200 > 200 > 200 > 200
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tested are given in Table 1. Importantly, the data
obtained for the n-PanAm set correlate well with the
results of previous pantothenamide structure–activity
relationship studies, with the MIC values differing by
no more than 10-fold (some differences are expected
due to variation in the amount of Pan present in tryp-
tone) [8,14,15].
Comparative analysis of the results indicated that
E. coli was only inhibited by a small number of
a-PanAm and n-PanAm series members, most of which
had MIC values in the 50–100 lM range. Previous stud-
ies have demonstrated that, at least in some cases
(such as with n-PanAm-5, otherwise known as N-heptyl
pantothenamide or N7-Pan), this relatively poor inhibi-
tion profile can be ascribed to TolC-dependent efflux
because TolC-defective strains do show sensitivity
[8,15]. By contrast, S. aureus was only inhibited by
n-PanAm compounds. These showed MIC values that
varied by almost two orders of magnitude, with the best
inhibitors (n-PanAm-5/N7-Pan and n-PanAm-6) having
MIC values of ~ 0.7 lM. As expected, P. aeruginosa
showed no inhibition by any of the pantothenamides
tested, including the smaller sized a-PanAm series.
Pantothenamide-mediated growth inhibition
correlates with PanK activity in E. coli but not
S. aureus
Next, we investigated whether the differences in the
E. coli and S. aureus growth inhibition profiles could
Table 1. (Continued).
PanAm entry RAm group
E. coli MIC (µM) S. aureus MIC (µM)
a-PanAm n-PanAm HoPanAm a-PanAm n-PanAm HoPanAm
40 N
S



































> 200 > 200 > 200 > 200 > 200 > 200
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be correlated with the activity and/or selectivity of
their respective PanKs. The pantothenamides that
showed the most potent growth inhibition were
tested as substrates of the purified overexpressed
enzymes at a fixed concentration (100 lM) using an
established pyruvate kinase/lactate dehydrogenase
(PK/LDH)-based coupled enzyme assay that links
ADP production to the consumption of NADH [7].
Although this assay measures the enzymes’ activity
indirectly, it has been shown previously that the
expected monophosphorylated ester is produced and
that the PK/LDH-assay is a viable alternative for
measuring PanK activity [7,13,21,31]. The correspond-
ing compounds that have the same amide substituent
but different substitutions of the b-alanine moiety
were included for comparison. The data indicate that,
for EcPanKI, compounds that show growth inhibition
belong to the a- and n-PanAm series and have spe-
cific activities very similar to that measured for Pan,
whereas the HoPanAms, which do not inhibit E. coli
growth, show poor PanK activity (Fig. 2A). However,
PanK activity is not necessarily a predictor of growth
inhibition because even a- and n-PanAm compounds
that do not show growth inhibition still show similar
specific activity levels. Unexpectedly, the situation is
reversed in S. aureus, with only the non-inhibitory
HoPanAm members showing S. aureus type II PanK
(SaPanKII) activity approaching that seen for Pan
(Fig. 2B).
To further investigate these differences and their rel-
evance to the pantothenamide mode of action, kinetic
profiles were obtained for both enzymes with Pan and
the three pantothenamides with N-pentyl substituents
[i.e. a-PanAm-3, n-PanAm-3 (referred to as N5-Pan
from here on) and HoPanAm-3] (Fig. 2C). These con-
firm that the pantothenamides that acted as E. coli
inhibitors (N5-Pan and a-PanAm-3) have EcPanKI
activity profiles that closely resemble that of Pan.
HoPanAm-3, which did not act as an E. coli growth
inhibitor, is clearly a poor EcPanKI substrate. By con-
trast, the S. aureus growth inhibitor N5-Pan has a very
different activity profile that shows both a lower
apparent Km (K
app
m ) and significantly reduced turnover
compared to Pan (Fig. 2D). The two pantothenamides
that did not show inhibition of S. aureus, a-PanAm-3
and HoPanAm-3, are apparently poor and excellent
substrates, respectively.
To confirm these trends, we extended the studies
to other selected growth inhibitory pantothenamides.
We found that EcPanKI also accepts a-PanAm-12
and a-PanAm-14 as substrates (Fig. 2E), whereas
SaPanKII shows the same unusual kinetic profile for
n-PanAm-5, n-PanAm-9, n-PanAm-12 and n-PanAm-
29 that combines a low Kappm with low turnover
(Fig. 2F). Among these compounds, n-PanAm-5 (N7-
Pan) showed the lowest turnover; importantly, it is
also the pantothenamide that exhibits the most
potent growth inhibition of S. aureus identified to
date [13,14]. These results strongly suggest that in
E. coli PanK activity is a necessary (but not suffi-
cient) requirement for pantothenamides to show
growth inhibition. By contrast, pantothenamides that
show growth inhibition of S. aureus bind its PanK
enzyme with high apparent affinity, yet show poor
turnover.
Quantifying the variations in PanK kinetics:
constructing a kinetic model
Several previous studies have used the Michaelis–
Menten equation to obtain kinetic parameters for
both EcPanKI and SaPanKII acting on a range of
substrates [7,13,14,16,32–34]. In the present study we
took special care to obtain all measurements dur-
ing the initial phase of the reaction (< 10% substrate
consumed), and found that EcPanKI has a hyper-
bolic activity profile only for Pan, whereas it
shows sigmoidal saturation curves for the pantothen-
amides (Fig. 3A). SaPanKII has sigmoidal satura-
tion curves for both Pan and HoPanAm-3 (the low
Kappm for N5-Pan limited our ability to determine if
this is also true in its case). These findings indicate
that some substrates have a positive cooperative
effect on PanK catalysis, a phenomenon that has
previously only been described for certain PanKIIIs
[35].
The sigmoidal saturation data were best described
by a simple Hill-type equation (Eqn 1) derived
according to a mechanism based on a dimeric
enzyme with one active site per subunit; the avail-
able structural data shows that both EcPanKI and
SaPanKII conform to this description [20,26,36]. This
mechanism, shown schematically for SaPanKII acting
on Pan in Fig. 3B, is based on the assumption that
only enzyme states with both of the active sites
occupied (e.g. EPan.Pan) have to be considered and
lead to product formation (as is usually the case for
cooperative enzymes). The differential binding of the
substrate to the two active sites is described by the
parameter a that modifies the dissociation constant
for the enzyme form with substrate bound in both
active sites. In Eqn (1), kf denotes the rate of trans-
formation (phosphorylation) of Pan, ET is the total
enzyme concentration and KPan is the dissociation
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constant of Pan; Vmax is then equal to 2kfET, and
KPan0:5 (the K0.5 value for Pan) is numerically equal to
the concentration of Pan where vPanK = 0.5Vmax.
Note that, from these conditions, it follows that
KPan ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
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Fig. 2. Activity of EcPanKI and SaPanKII towards selected pantothenamides. (A) The specific activities for EcPanKI towards Pan (dashed line)
and the pantothenamides (bars) at 100 lM. The data were obtained from a single experiment performed in triplicate; the error bars denote
the SD. (B) The data for SaPanKII against Pan (dashed line) and the same panel of pantothenamides (bars). (C) Activity profiles for EcPanKI
with Pan, a-PanAm-3, N5-Pan and HoPanAm-3 as substrates. For information on statistical analysis and equations used to fit the data, see
Table 2. (D) As for (C) but with SaPanKII. (E) EcPanKI activity profiles with the E. coli growth inhibitory pantothenamides N5-Pan, a-PanAm-
12 and a-PanAm-14 as substrates, with the Pan profile shown for comparison. Description and data analysis is as indicated for (C). (F)
SaPanKII activity profiles of the S. aureus growth inhibitory pantothenamides N5-Pan, n-PanAm-5 (N7-Pan), n-PanAm-9, n-PanAm-12 and
n-PanAm-29, with the Pan profile shown for comparison. Note the y-axis break. Description and data analysis is as indicated for (C).
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vPanK ¼2  kf  ½EPanPan ¼
2  kf  ET  a ½PanKPan
 2











Fitting Eqn (1) to the saturation data showed a good
fit in all cases, as exemplified by the curve of SaPanKII
with Pan (Fig. 3C), and allowed determination of the
relevant kinetic parameters. These values, summarized
in Table 2, indicate that although for E. coli there is
general agreement between a pantothenamide’s growth
inhibitory potency and the specific activity that EcPanKI
shows towards it, there is no direct correlation, as would
be expected if the enzyme merely served as a gateway for
the metabolic activation of these compounds, which
subsequently have their inhibitory effect elsewhere. For
S. aureus, potency correlates with compounds that have
the unusual combination of very low (< 5 lM) values of
K0.5 and low turnover rates, and, consequently, very
high apparent specificity constants (kcat/K0.5).
N5-Pan has an inhibitory binding interaction with
SaPanKII but not with EcPanKI
To further investigate the importance of the activity
profile differences, we obtained kinetic profiles for
both enzymes acting on mixtures of Pan and N5-Pan;
this pantothenamide was chosen for this particular
experiment because it inhibits both E. coli and
S. aureus growth and therefore allows for a compara-
tive analysis. For each experiment, the total substrate
concentration was increased at the same time as
maintaining a constant ratio of Pan:N5-Pan; in subse-
quent experiments, the amount of Pan in the ratio
was increased in a stepwise manner, from 0% (pure
N5-Pan) to 100% (pure Pan). The combined turnover
of Pan and N5-Pan was measured using the PK/
LDH-based assay that responds to the formation of
ADP.
The results demonstrate that, for EcPanKI, the
resulting activity profiles show very small differences,
and that there is a gradual progression from the profile
for Pan to that for N5-Pan (Fig. 4A). However, for
SaPanKII, even small amounts (i.e. 5%) of N5-Pan
exert both an inhibitory effect (at mixture concentra-
tions of 50 lM and higher) and an apparent stimula-
tory effect (at mixture concentrations of ~ 12.5 lM and
below) on activity (Fig. 4B). Overall, the impact of
N5-Pan on SaPanKII activity is unexpectedly complex.
In comparison, mixtures of Pan and HoPanAm-3,
which acts as a substrate of SaPanKII but does not show
S. aureus growth inhibition, yielded essentially the same
kinetic profile regardless of the composition of the sub-
strate mixture (Fig. 4C). These results confirm that





























































































Fig. 3. Constructing a kinetic model for
SaPanKII activity. (A) Activity profiles for
EcPanKI and SaPanKII shown in Fig. 2C,D
at low substrate concentration to highlight
the sigmoidal nature of the curves. (B)
Schematic representation of the SaPanKII
kinetic model, based on an enzyme with
two subunits, from which Eqn (1) is
derived. KPan is the dissociation constant
of Pan, and a denotes the change in
dissociation constant in the enzyme form
with Pan bound to both subunits. This is
the active form of the enzyme (shown in
green), which catalyzes the
phosphorylation reaction as denoted by
the arrow with the open square. (C) Fitting
Eqn (1) to the data points for the activity
of SaPanKII towards Pan, with the line
indicating the best fit and the shaded area
showing the 90% confidence interval.
Parameter values and SEs are given in
Table 2.
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S. aureus have multifaceted interactions with its PanK
enzyme, and that they do not simply act as alternative
substrates.
DL-40-Deoxy-N5-Pan acts as an inhibitor of
SaPanKII turnover and S. aureus growth
To simplify the analysis of the interaction of
N5-Pan with SaPanKII, we prepared its structural
analogue DL-40-deoxy-N-pentylpantothenamide (dN5)
by NaBH4-mediated reduction of a ketoamide precur-
sor, to give the product as the racemate (Fig. 5A).
This compound is expected to exclusively act as an
inhibitor because it has the 40-OH group of N5-Pan
removed, thereby preventing it from being a PanK sub-
strate (although all other binding interactions are
retained).
Experiments were performed on both EcPanKI
and SaPanKII using reaction mixtures that contained
25 lM Pan and increasing concentrations of either
N5-Pan or dN5. The addition of N5-Pan increased
the total observed activity for EcPanKI as expected
for an alternate substrate, whereas dN5 acted as a
very poor inhibitor of the enzyme (IC50 ~ 500 lM)
(Fig. 5B). Full kinetic analysis subsequently indicated
that this is the result of a minor reduction of the
Vappmax (data not shown), confirming that the 4
0-OH
group is an important determinant for ligand bind-
ing in EcPanKI [26].
By contrast, both N5-Pan and dN5 showed the
same apparent inhibitory effect on SaPanKII with IC50
values of 4.8  1.2 and 7.3  0.9 lM, respectively
(Fig. 5C). For this enzyme, full kinetic analysis again
showed a dual effect (Fig. 5D), with dN5 causing a
small but significant reduction in the Kapp0:5 for Pan and
a large reduction in the Vappmax. Additionally, growth
inhibition tests performed in minimal medium showed
that dN5 has a MIC of ~ 50 lM for S. aureus but does
not inhibit E. coli (Fig. 6). By comparison, N5-Pan
still has a much lower MIC (approximately 1.5 lM)
for S. aureus under these conditions. Nonetheless, this
result unambiguously shows that even pantothenamide
analogues unable to act as PanK substrates have a
negative impact on S. aureus growth.
Expanding the kinetic model to account for
complex interaction of N5-Pan with SaPanKII
We next used the dN5 data to expand the kinetic
model for SaPanKII to include a mechanism that
could account for the dual stimulatory/inhibitory effect
exerted by both dN5 and N5-Pan. Because the N5-Pan
saturation kinetics did not show substrate inhibition at
high concentrations, we started with an uncompetitive
inhibition mechanism for dN5 [i.e. one in which it only
binds to the SaPanKII–Pan ([EPan]) complex]. In addi-
tion, we also included a competitive inhibition mecha-
nism in which dN5 can bind to any unoccupied active
site. This led to the mechanistic scheme shown in
Fig. 7A, which can be translated into a rate equation
that assumes that only the [EPan.Pan], [EPan.dN5] and
[EdN5.Pan] complexes have catalytic activity, and in
which no enzyme form that has only one active site
occupied is considered (Eqn 2). The parameters in this
equation are defined as those used in Eqn (1), with the
addition of KdN5 (dissociation constant for the com-
petitive inhibition by dN5) and KdN50 (dissociation
constant for the uncompetitive inhibition by dN5):
Equation (2) was able to describe the data very well
(Fig. 5D, solid lines) and accounted for both the stim-
ulatory effect of the inhibitor at low substrate concen-
trations and the reduction in Vappmax at high substrate
concentrations. These effects are based on the dissocia-
tion constants for the binding of dN5 in a competitive
(KdN5 = 3.81  0.45 lM) and uncompetitive (KdN50 =
41.0  7.1 lM) binding mode, respectively, which
clearly show that, for dN5, the former is the stronger
interaction (Table 3). Additionally, the dissociation
constant for Pan (KPan = 9.31  0.70 lM) and the
value for a (0.111  0.017 lM) were also calculated in
this manner. The K0.5 value of 27.9 lM calculated from
these values is almost identical to the value of 27.8 lM
obtained by fitting Eqn 1 to the Pan activity profile
(Fig. 3C and Table 2).
The newly expanded mechanism can easily account
for the data obtained from SaPanKII acting on mix-
tures of Pan and N5-Pan (Fig. 4B) by modifying the
competitive inhibition component exerted by dN5 to
that of a competitive substrate with catalytic turnover.
This confers activity on the two boxed complexes in
vPanK ¼2  kf  ½EPanPan þ 2  kf  ½EPandN5 ¼
Vmax  ½PanKPan
 
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Fig. 7A as shown in Fig. 7B, and gives the corre-
sponding rate equation Eqn (3) that was fitted to the
Pan/N5-Pan experimental data, constraining the values
for VPanmax (the Vmax for Pan), KPan and a to those
obtained before. In this equation, kPanf and k
N5-Pan
f
denote the rates of phosphorylation of Pan and N5-
Pan respectively, giving VPanmax ¼ 2  kPanf  ET for Pan
and VN5-Panmax ¼ 2  kN5-Panf  ET for N5-Pan. Addition-
ally, KN5-Pan is the dissociation constant of N5-Pan
acting as a substrate, whereas KN5-Pan0 is the dissocia-
tion constant for the uncompetitive inhibition compo-
nent that it exerts:
The equation provided a very good description of the
experimental data set (Fig. 8A) and gave the parameter
values listed in Table 3. These indicate that, although
the dissociation constant of N5-Pan for binding at the
active site (i.e. as a substrate) is similar to that of dN5
(KN5-Pan = 2.22  0.48 lM), its dissociation constant
for binding as an uncompetitive inhibitor (KN5-
Pan0 = 4.89  0.66 lM) is much smaller. Because N5-
Pan also has a much reduced MIC compared to dN5,
this provides additional evidence for the uncompetitive
inhibition of SaPanKII as an important contributor to
the inhibition of S. aureus growth by N5-Pan.
Table 2. PanK kinetic parameters with Pan and various pantothenamides. Kinetic parameters were determined by keeping the ATP
concentration constant at 1.5 mM in all cases. All reported parameters are the mean of those obtained by fitting the given equation to the
data obtained for each individual experiments; the error values represent the range/2 (for parameters obtained from two independent
experiments) or SEM (for parameters obtained from three or more independent experiments). References to compounds tested in previous








fitted R2 valuec K0.5 (lM) kcat (s
1) kcat/K0.5 (mM
1s1) Nb Equation fitted R2 valuec
Pan 21.3  1.4 1.16  0.14 54.5  3.1 2 Michaelis–
Menten
0.9955 27.8  3.3 3.37  0.24 124  7 4 Eqn (1) 0.9928
a-PanAm-3 14.6  1.1 0.95  0.13 64.3  4.3 2 Modified
Eqn (1)d
0.9679 783  64 4.14  0.14 5.29  0.62 1e Michaelis–Menten 0.8719
n-PanAm-3
[N5-Pan]
15.6  1.2 1.06  0.03 68.6  3.4 2 Eqn (1) 0.9988 < 1.5f 0.44  0.03 > 290 4 Eqn (1) 0.8606
HoPanAm-3 720  95 0.62  0.04 0.87  0.17 1e Eqn (1) 0.8866 27.8  2.3 2.85  0.11 103  6 3 Eqn (1) 0.9740
a-PanAm-12 63  11 1.05  0.12 18.2  4.3 3 Eqn (1) 0.9881 ND
a-PanAm-14 151  56 1.37  0.15 13.8  6.6 3 Eqn (1) 0.9911 ND
n-PanAm-5
[N7-Pan]
ND 2.04  0.54 0.22  0.02 118  41 2 Eqn (1) 0.8677
n-PanAm-9 ND 4.94  0.94 0.33  0.12 65.4  11.8 2 Eqn (1) 0.9711
n-PanAm-12 ND 4.47  0.11 0.32  0.04 72.7  10.0 2 Eqn (1) 0.9326
n-PanAm-29 ND 3.49  0.50 0.75  0.06 232  59 3 Eqn (1) 0.9326
PantSH 23.6  2.1 1.00  0.09 42.4  0.3 3 Michaelis–
Menten
0.9949 < 1.5f 0.39  0.09 > 260 4 Eqn (1) 0.8714
a
In those cases where the Michaelis–Menten equation was used to fit the data, K0.5 is Km.
b
Number of independent experiments.
c
R2 value for the indicated equation fitted to the data averaged from all the experiments.
d
a-PanAm-3 showed inhibition of EcPanKI at high substrate concentrations; using a modified version of Eqn (1) that accounts for the uncompetitive substrate inhibition, a Ki of
720  120 lM was determined.
e
As a result of the high K0.5 value, kinetic parameters were determined by fitting the equation to the data from a single experiment performed in triplicate; errors indicate the SE of the fit.
f
The low K app0:5 values of these compounds cannot be reported with accuracy because they fall below the sensitivity limit of the assay.
vPanK ¼ 2  kPanf  ½EPanPan þ 2  kPanf  ½EPanN5-Pan þ 2  kN5-Panf  ½EN5-PanN5-Pan þ 2  kN5-Panf  ½EN5-PanPan
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In the absence of Pan, Eqn (3) reduces to a much
simpler form (Eqn 4), which describes the saturation
kinetics of inhibitory pantothenamides such as N5-
Pan.







This equation is equivalent to Eqn (1), which was
used to obtain the parameters shown in Table 2, if
K0.5 = KPan (i.e. if a = 1). This would indicate that
there is no differentiation in the binding of N5-Pan to
the enzyme’s two active sites.
SaPanKII atypical kinetic mechanism follows
from its role in CoA salvage biosynthesis
The question arises as to why there is such a selective
binding site in SaPanKII that it accepts N5-Pan at the
same time as excluding HoPanAm-3 (note that the lat-
ter did not show any uncompetitive inhibition mode;
Fig. 4C). Clearly, the selectivity is for compounds that
contain the natural b-alanine moiety, suggesting that
the site is predisposed to bind compounds containing
the native pantothenoyl group. Based on its close
structural similarity to n-PanAm series compounds
(such as N5-Pan), we considered PantSH (the substrate
of the CoA salvage pathway; Fig. 1A) as the most
likely natural ligand for this binding site.
To test such a hypothesis, we measured the activity
of EcPanKI and SaPanKII against mixtures that con-
tained 25 lM Pan and increasing concentrations of
PantSH. The results are strikingly similar to those
obtained for N5-Pan, with PantSH increasing the total
observed activity for EcPanKI but inhibiting SaPanKII
activity (Fig. 8B). Similarly, when constant ratio mix-
tures of Pan and PantSH were analyzed as conducted
for N5-Pan, the profiles clearly demonstrate that
PantSH has the same complex interaction with SaPan-
KII (Fig. 8C), showing both a stimulatory (at low con-
centrations) and an inhibitory (at high concentrations)
effect on turnover that is even more pronounced than
that caused by N5-Pan. Based on the similarity between
N5-Pan and PantSH, Eqn (3) was used to describe the
Pan/PantSH experimental data by substituting PantSH
for N5-Pan, and again constraining the Vappmax, KPan and
a values to those obtained previously. The equation
was able to describe the experimental data set well
(Fig. 8C), and gave values for KPantSH (binding at
the active site, i.e. as substrate) and KPantSH0 (binding in
an uncompetitive mode) of 0.46  0.08 lM and
6.03  1.27 lM, respectively (Table 3). In comparison
with the values obtained for N5-Pan, PantSH appears
to be the better substrate at the same time as showing
similar uncompetitive inhibition to N5-Pan. Conse-
quently, PantSH is more effective at activating SaPanKII
at low substrate concentrations (Fig. 8A,C, insets).
Interestingly, when the activity of SaPanKII activity
against constant ratio mixtures of Pan and n-PanAm-5
(N7-Pan, the most potent S. aureus growth inhibitor) was
measured and analyzed in a similar manner, the obtained
kinetic parameters were almost identical to those found
for PantSH (data not shown). Taken together, these































































































Fig. 4. Analyzing the interaction of Pan and N5-Pan with EcPanKI and SaPanKII under competitive conditions. (A) Kinetic profiles of mixtures
of Pan and N5-Pan determined with EcPanKI. The x-axis indicates the total substrate concentration (Pan and N5-Pan combined); for each
data set, the ratio of Pan:N5-Pan was kept at a constant value. The data points represent the mean of two independent experiments, each
performed in triplicate; the error bars denote the range/2. Because the curves progress from a hyperbolic to a sigmoidal shape, the solid
lines represent the best fit of the data to the Hill equation with the value for h (Hill coefficient) constrained to between 1 and 2. (B) Kinetic
profiles of mixtures of Pan and N5-Pan determined with SaPanKII as described for (A). The solid line represents the best fit of Eqn (1) to the
100% Pan data. (C) Kinetic profiles of mixtures of Pan and HoPanAm-3 determined for SaPanKII as described for (A).
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inhibition of S. aureus growth mimic the interactions of
PantSH with SaPanKII.
Discussion
Although several previous studies have investigated
the growth inhibitory potency of pantothenamides
against various bacteria, and/or have shown that
these compounds act as substrates of the target
organisms’ PanK enzymes, none have been able to
establish a clear link between these two features
[1,6–8,12,14–16,26,32,37]. In the present study, we
performed the first detailed comparative kinetic
analysis of pantothenamides that cause bacterial
growth inhibition, showing that PanK type deter-
mines their mode of action. For organisms with
PanKI enzymes, our data indicate that pantothen-
amides only show growth inhibition if they are
accepted as alternate PanK substrates. This corre-
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Fig. 5. dN5 as a PanK inhibitor. (A) Synthetic scheme for the preparation of dN5. (a) 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide
hydrochloride (EDC), hydroxybenzotriazole (HOBt), N,N-diisopropylethylamine (DIPEA), CH2Cl2; (b) NaBH4, methanol. (B) Activity/inhibition
profiles for EcPanKI when treated with N5-Pan and dN5 at a fixed concentration of 25 lM Pan. The data points represent the mean of two
independent experiments, each performed in triplicate; the error bars denote the range/2. The solid lines represent the best fits to the
Michaelis–Menten equation (for N5-Pan) or to Eqn (5) (for dN5). (C) Inhibition profiles for SaPanKII as described for EcPanKI in (A). (D)
Kinetic profiles for SaPanKII with Pan in the presence of increasing concentrations of dN5 (indicated on the right of each curve). The data
points represent the mean of two independent experiments, each performed in triplicate; the error bars denote the range/2. The solid lines
represent the best fit curves obtained by fitting Eqn (2) to all the data; the shaded areas indicate the 90% confidence intervals. The insert
shows the stimulatory effect of the inhibitor at low substrate concentrations which results from the change Pan’s saturation kinetics profile
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Fig. 6. dN5 as a bacterial cell growth
inhibitor. (A) Growth inhibition profiles for
E. coli grown in minimal medium in the
presence of increasing concentrations of
N5-Pan and DL-40-deoxy-N5-Pan (dN5). The
data points represent the mean of two
independent experiments, each performed
in triplicate; the error bars denote the
range/2. The solid lines represent the best
fits to Eqn (5). (B) Growth inhibition
profiles for S. aureus grown in minimal
medium as described for E. coli in (A).
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Fig. 7. Kinetic model for the interaction of dN5 and N5-Pan with SaPanKII. (A) Schematic representation of the SaPanKII kinetic model
adapted to account for the dual stimulatory/inhibitory effect shown by d5N. KPan is the dissociation constant of Pan and a denotes the
change in dissociation constant in the enzyme form with Pan bound to both subunits. KdN5 denotes the dissociation constant for
competitive inhibition, whereas KdN50 is the dissociation constant for uncompetitive inhibition. Note that, for the latter, it is assumed that
inhibition takes place through binding at an allosteric site as shown, although no evidence for such a site has yet been found. For enzyme
complexes shown in square brackets, the symmetrical alternative complex is not shown but implied. All active enzyme subunits are shown
in green, whereas the competitively and uncompetitively inhibited complexes are shown in shades of grey as indicated. (B) The model
shown in (A) can be modified to account for the interaction of the N5-Pan with SaPanKII by converting the two competitively inhibited
complexes [boxed and identified with an asterisk (*) and double dagger (‡), respectively] to catalytically active complexes that
phosphorylates N5-Pan (and Pan) as indicated. KN5-Pan’ is the dissociation constant for the uncompetitive inhibition shown by N5-Pan.
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that is dependent on their metabolic activation to
form inhibitory CoA antimetabolites and/or inactive
crypto-ACPs, and that these act as inhibitors of tar-
get(s) downstream of CoA biosynthesis. Such an
analysis is in agreement with the conclusions of pre-
vious studies [8,12] and is supported by recent crys-
tallographic data showing that growth inhibitory
pantothenamides bind to PanKI enzymes in a man-
ner similar to Pan [38,39].
For S. aureus, which is the only bacterium known
to have an active type II PanK, the situation is very
different. Specifically, we demonstrate that growth
inhibitory pantothenamides have a complex interac-
tion with this organism’s PanK enzyme, acting as
substrates that stimulate its activity when present at
low concentrations but turning into uncompetitive
inhibitors as their concentrations gradually increase.
Additionally, we show that a pantothenamide ana-
logue that cannot act as PanK substrates can still inhi-
bit S. aureus growth. Taken together, these results
clearly show that, in this organism, growth inhibition
is likely the result of several factors working in combi-
nation: first, by being converted into CoA antimetabo-
lites and crypto-ACPs (and having concomitant
negative effects on fatty acid biosynthesis as was
found in a previous study) [14] and, second, by reduc-
ing CoA levels by inhibiting the first step of its bio-
synthesis. This multifaceted mode of action is most
likely one of the reasons why the pantothenamides
(such as N7-Pan) show much higher potency against
Table 3. Kinetic parameters for SaPanKII determined from fitting various data sets to the indicated equations.
Data set Equation Parameter Valuea Unit
dN5 inhibition data (Fig. 5D) Eqn (2) Vmax 6.47  0.15 lmolmin1mg
KPan 9.31  0.70 lM
a 0.111  0.017
KdN5 (competitive inhibition) 3.81  0.45 lM
KdN50 (uncompetitive inhibition) 41.0  7.1 lM
Pan:N5-Pan mix data (Fig. 4B; Fig. 8A) Eqn (3) VN5-Panmax 0.755  0.100 lmolmin1mg
KN5-Pan (substrate) 2.22  0.48 lM
KN5-Pan’ (uncompetitive inhibition) 4.89  0.66 lM
Pan:PantSH mix data (Fig. 8C) Eqn (3)b V PantSHmax 0.656  0.061 lmolmin1mg
KPantSH (substrate) 0.46  0.08 lM
KPantSH’ (uncompetitive inhibition) 6.03  1.27 lM
aErrors indicate the SE.




























































































Fig. 8. The interaction of SaPanKII with PantSH mimics that of N5-Pan. (A) Fitting Eqn (3) to the data obtained from SaPanKII acting on
mixtures of Pan and N5-Pan (Fig. 3B); the solid lines represent the best fit curves, whereas the shaded areas indicate the 90% confidence
intervals. The insert shows the stimulatory effect caused by the presence of 5% N5-Pan (purple) compared to the 100% Pan curve (black).
(B) Inhibition profiles for EcPanKI and SaPanKII treated with PantSH at a fixed concentration of 25 lM Pan. The data points represent the
mean of two independent experiments, each performed in triplicate; the error bars denote the range/2. The solid lines represent the best
fits to the Michaelis–Menten equation (for EcPanKI) or Eqn (S5) (for SaPanKII). (C) Kinetic profiles of mixtures of Pan and PantSH
determined with SaPanKII performed and analyzed as for (A).
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S. aureus than any other bacterium that has been
tested to date.
The kinetic model that was constructed for
SaPanKII provides an accurate description of the vari-
ous data sets obtained for the enzyme acting on its
native substrate (Pan), on various pantothenamides
and on combinations of the two. Specifically, our
model indicates that SaPanKII is inhibited by the panto-
thenamides (and by PantSH) via an uncompetitive
mechanism, which would imply the existence of an
allosteric site in which n-PanAm series compounds
bind. However, only two SaPanKII structures have
been deposited in the Protein Data Bank to date, nei-
ther of which has the natural substrate Pan bound.
These structures provide no indication of the likely
location of such an allosteric site. Moreover, the more
recently published structure [i.e. that of a ternary com-
plex of the enzyme bound to a phosphorylated pant-
othenamide (N354-Pan) and ADP (Protein Data Bank
code: 4NB4)] [39] indicates that the enzyme has dis-
tinct open and closed conformations, with the latter
preventing the product from being released; this dis-
covery complicates the structural investigation of a
potential uncompetitive inhibition mode through allo-
steric inhibition even further. Consequently, we cannot
exclude the possibility that alternative kinetic models
(including those that do not need to invoke the exis-
tence of an allosteric site) could also provide accurate
descriptions of our data. Nonetheless, our proposed
mechanism is the simplest one giving an accurate
description of the total data set at the same time as
taking all the information that is currently available
on the enzyme into account.
Regardless of the mechanism or structural basis of
the interaction between the growth inhibitory pantothen-
amides and SaPanKII, our finding that PantSH (the
only pantothenamide known to occur naturally) [40,41]
mirrors this complex and specific interaction suggests
that it is a native ligand of the enzyme. Such a character-
istic could be a compensatory regulatory mechanism for
SaPanKII because, unlike other type I and type II
PanKs, this enzyme does not experience any feedback
inhibition by CoA or its thioesters [14]. This is most
likely as result of S. aureus maintaining higher levels of
intracellular CoA as part of its unique redox biology
because it does not contain any glutathione but instead
uses CoA (and most likely the recently discovered
low molecular weight thiol bacillithiol), as well as a
highly specific CoA disulfide reductase, to maintain its
intracellular redox potential [42,43]. Our findings sug-
gest that CoA biosynthesis in S. aureus may be regu-
lated by a unique mechanism in which PantSH
stimulates SaPanKII activity when it is present at low
concentrations but inhibits it at high concentrations.
Such an analysis is supported by previous findings
showing that P-PantSH does not accumulate in either
intra- or extracellular compartments, confirming that
the regulation of CoA biosynthesis in S. aureus appar-
ently occurs at the level of SaPanKII [14].
Clearly, such a conclusion has important implica-
tions for S. aureus physiology that will have to be
explored further, especially in light of the fact that the
CoA and ACP degradation pathways responsible for
PantSH formation remain very poorly characterized in
all organisms [2]. Nonetheless, the evidence reported in
the present study suggests that the specific interaction
of SaPanKII with PantSH presents a unique opportu-
nity for the development of new antistaphylococcal
agents, one which the pantothenamides have already
started to exploit.
Materials and methods
General materials and methods
All the pantothenamides and precursors were prepared and
their purity confirmed by 1H NMR analysis, as described
previously [23]. The pantothenamides were dissolved in
50% acetonitrile–water solution to yield stock solutions at
a concentration of 50 mM and assays were performed with
the final acetonitrile concentration never exceeding 3% (v/
v). Pantetheine was obtained by the reduction of the disul-
fide pantethine (Sigma-Aldrich, St Louis, MO, USA) in the
presence of 1.5 equivalents of dithiothreitol or tris(2-carb-
oxyethyl)phosphine. General chemicals, reagents and media
were purchased from Sigma-Aldrich, Merck Chemicals
(Darmstadt, Germany) or Acros Organics (Thermofisher,
Fair Lawn, NJ, USA) and were of the highest purity. Sol-
vents used for reactions were Chromasolv HPLC grade sol-
vents (Sigma-Aldrich) and the hexanes, dichloromethane
and ethyl acetate used for purification were purchased from
Merck Chemicals. Dry N,N-dimethylformamide was pre-
pared by shaking up over potassium hydroxide, distilled
under reduced pressure and a nitrogen atmosphere, and
finally stored over 4-A molecular sieves in the dark. Dry
dichloromethane was distilled from CaH2 under a nitrogen
atmosphere.
The E. coli K12 strain was available in our laboratory,
whereas S. aureus RN4220 and P. aeruginosa ATCC 27853
where kind gifts from L. M. T. Dicks at the Department of
Microbiology (Stellenbosch University). EcPanKI and
SaPanKII were overexpressed and purified as described pre-
viously [7,14,34]. PK and LDH used in the kinetic assays
were obtained from Roche (Basel, Switzerland).
All 1H and 13C NMR spectra were obtained using a 300-
MHz Varian VNMRS (75 MHz for 13C) or 400-MHz
Varian Unity Inova (100 MHz for 13C) instruments (Varian
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Inc., Palo Alto, CA, USA) at the Central Analytical Facil-
ity (CAF) of the University of Stellenbosch. All chemical
shifts (d) were recorded using the residual solvent peak
and reported in p.p.m. All high resolution mass spectrome-
try (HRMS) was performed on a Waters API Q-TOF
Ultima spectrometer (Waters, Milford, MA, USA) at the
MS unit of CAF. All OD600 measurements and kinetic
studies were performed using a Thermo Varioskan spectro-
photometer (Thermo Scientific, Bremen, Germany). Inhibi-
tion studies were performed in Greiner Bio-One Cellstar
flat-bottomed 96-well suspension plates (Greiner Bio-One
GmbH, Frickenhausen, Germany). Kinetic studies were
performed in Greiner Bio-One polystyrene flat-bottomed
96-well plates. The MICs were determined by plotting the
percentage (relative to a control containing no inhibitor)
bacterial cell growth against the logarithm of increasing
compound concentration, followed by fitting Eqn (5) to
the data (with the values of y0 and a generally fixed at 0
and 100, respectively).
y ¼ y0 þ a
1þ xIC50
 b ð5Þ
Kinetic data were fitted according to the derived equa-
tions. Analysis of all concentration–response curves
and kinetic data was carried out using SIGMAPLOT, ver-
sion 12 (Systat Software Inc., Chicago, IL, USA) or




Pentylamine (803 lL, 6.96 mmol) and diethyl phosphoryl
cyanide (1.05 mL, 7.25 mmol) were added to a solution of
CBz-b-alanine (1.41 g, 6.32 mmol) in dry N,Ndimethylform-
amide (8 mL) at room temperature. The reaction mixture
was cooled to 0 °C before triethylamine (1.85 mL,
13.3 mmol) was added. The reaction mixture was stirred
for 2 h at 0 °C and left to stir overnight at room tempera-
ture. Ethyl acetate (50 mL) was added and the organic
layer was washed sequentially with 5% citric acid
(3 9 10 mL), 1 M aqueous NaHCO3 (2 9 10 mL) and sat-
urated sodium chloride (1 9 10 mL). The organic layer
was dried (Na2SO4), filtered and concentrated in vacuo
before purification by flash column chromatography (3:2 to
4:1 ethyl acetate:hexanes) afforded the carbamate (1.50 g,
81%) as a white solid. Rf = 0.18. dH (300 MHz; CDCl3)
0.87 (3H, t, J = 6.9 Hz, –CH3), 1.26–1.33 (4H, m, –CH2–),
1.54 (2H, m, –CH2–), 2.38 (2H, t, J = 6.0 Hz, –CH2–), 3.19
(2H, q, J = 7.2, 12.9 Hz, –CH2–), 3.45 (2H, q, J = 6.2,
11.8 Hz, –CH2–), 5.09 (2H, s, –CH2–), 5.34 (2H, br s, –
NH–) and 7.32–7.36 (5H, m, –CH–). dC (400 MHz; CDCl3;
25 °C) 14.0, 22.3, 29.0, 29.2, 36.1, 37.1, 39.5, 66.6, 128.0,





5.13 mmol) was dissolved in methanol (80 mL) at room
temperature followed by the addition of palladium on acti-
vated carbon (Pd/C) (80.0 mg, 0.752 mmol). The reaction
mixture was stirred overnight at room temperature under a
H2 gas balloon. Additional Pd/C (100 mg, 0.940 mmol)
was added and the reaction mixture was stirred for a fur-
ther 5 h under H2. The reaction mixture was filtered and
concentrated in vacuo to give the desired amide (800 mg,
99%) as a white solid. Rf = 0.05 (10% methanol/dichlo-
romethane). dH (300 MHz; CDCl3) 0.87 (3H, t, J = 7.1 Hz,
–CH3), 1.29–1.33 (4H, m, –CH2–), 1.50 (2H, m, –CH2–),
2.28 (2H, t, J = 5.6 Hz, –CH2–), 2.98 (2H, t, J = 6.1 Hz, –
CH2–), 3.20 (2H, q, J = 7.3, 12.9 Hz, –CH2–) and 6.85
(1H, br s, –NH–). dC (300 MHz; CDCl3; 25 °C) 14.4, 22.7,




A solution of pinacolone (10 mL, 83.4 mmol) in water
(160 mL) was added to a solution of NaOH (8.00 g, 200
mmol) and potassium permanganate (12.2 g, 77.2 mmol) in
water (196 mL) at 0 °C. The reaction mixture was stirred for
1 h at 0 °C, allowed to warm up to room temperature and
stirred for an additional 2 h. The reaction mixture was
filtered through celite, acidified to pH 2 with concentrated
sulphuric acid, and the aqueous layer was extracted with
diethyl ether (3 9 40 mL). The combined organic extracts
were dried (Na2SO4), filtered and concentrated in vacuo.
Bulb-to-bulb distillation (110 °C, 27.5 mmHg) gave the acid
(3.99 g, 77%) as a clear oil. dH (300 MHz; CDCl3) 1.23–1.33
(9H, m, –CH3).




N,N-Diisopropylethylamine (1.23 mL, 7.06 mmol) was
added dropwise over 5 min to a solution of 3-amino-N-
pentylpropanamide (800 mg, 5.06 mmol) in dichlorome-
thane (40 mL) at 0 °C. Hydroxybenzotriazole (172.2 mg,
1.27 mmol), 3,3-dimethyl-2-oxo-butyric acid (820 mg,
6.30 mmol) and 1-ethyl-3-(3-dimethylaminopropyl) carbo-
diimide hydrochloride (1.34 g, 6.99 mmol) were then added
consecutively and the reaction mixture was stirred over-
night at room temperature. The reaction was quenched by
the addition of 3 M HCl (50 mL) and the organic layer was
washed with 3 M HCl (1 9 50 mL) and saturated NaHCO3
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(1 9 50 mL). The organic layer was dried (Na2SO4), fil-
tered and concentrated in vacuo before purification by flash
column chromatography (0.75 : 1 ethyl acetate : hexanes)
afforded the desired amide (700 mg, 57%) as a white solid.
Rf = 0.27. dH (300 MHz; CDCl3) 0.75 (3H, t, J = 7.0 Hz, –
CH3), 1.14–1.19 (13H, m, –CH3–, –CH2–), 1.33–1.40 (2H,
m, –CH2–), 2.34 (2H, t, J = 6.1 Hz, –CH2–), 3.07 (2H, q,
J = 7.0, 13.1 Hz, –CH2–), 3.42 (2H, q, J = 6.1, 12.6 Hz, –
CH2–), 5.57 (1H, br s, –NH–) and 7.47 (1H, br s, –NH–).
dC (400 MHz; CDCl3; 25 °C) 13.9, 22.3, 26.2, 29.0, 29.2,
35.2, 35.4, 39.6, 42.9, 160.4 and 170.6, 203.0. HRMS: m/z




tanamide (700 mg, 2.89 mmol) was dissolved in methanol
(28 mL) at 0 °C under an inert atmosphere followed by the
addition of sodium borohydride (NaBH4, 163.44 mg,
4.32 mmol) in portions. The reaction mixture was stirred for
1 h at 0 °C and left to stir overnight at room temperature.
Additional NaBH4 (163.44 mg, 4.32 mmol) was added and
the reaction mixture was stirred for another 3 h at room tem-
perature. The reaction was quenched by the addition of satu-
rated ammonium chloride (28 mL) and methanol was
removed in vacuo. The aqueous solution was extracted with
ethyl acetate (3 9 30 mL) and the combined organic extracts
were dried (Na2SO4), filtered and concentrated in vacuo to
yield dN5 (760 mg, 96%) as a colourless oil. Rf = 0.39 (10%
methanol/dichloromethane). dH (300 MHz; CDCl3): 0.83
(3H, t, J = 7.1 Hz, –CH3), 0.93–0.95 (9H, m, –CH3–), 1.24–
1.27 (4H, m, –CH2–), 1.43–1.48 (2H, m, –CH2–), 2.37 (2H, t,
J = 6.2 Hz, –CH2–), 3.13 (2H, q, J = 7.0, 13.6 Hz, –CH2–),
3.47 (2H, q, J = 6.6, 12.7 Hz, –CH2–), 3.66 (1H, s, –CH–),
6.38 (1H, br s, –NH–) and 7.17 (1H, br s, –NH–); dC
(400 MHz; CDCl3; 25 °C): 13.9, 22.3, 25.9, 29.0, 29.2, 35.0,
35.2, 35.6, 39.6, 79.4, 171.1 and 172.7. HRMS: m/z [M+H]+
273.2172 (calculated [C14H29N2O3]
+ = 273.2173).
Bacterial growth inhibition tests of
pantothenamide library
The MICs of the library of N-substituted pantothenamides
(Table 1, entries 1–47) against E. coli K12, S. aureus
RN4220 or P. aeruginosa ATCC 27853 were determined by
microbroth dilution in 96-well microtiter flat-bottomed
plates and turbidometric analysis at OD600. Starter cultures
of either E. coli K12, S. aureus RN4220 or P. aeruginosa
ATCC 27853 in 1% tryptone were prepared by inoculation
with four separate colonies grown on LB agar plates. The
starter culture was grown to exponential phase and then
diluted 10 000-fold in the same medium. A 10-lL aliquot
of the diluted cell suspension was used to inoculate each
well of a 96-well plate containing 100 lL of 1% tryptone
broth supplemented with the specific compound of interest
(diluted from 50 mM stock solutions prepared in 50% aque-
ous acetonitrile to aid solubility). The compounds that
exhibited positive results in initial screens at 200 lM were
subsequently tested at 50 lM; those that still showed inhibi-
tion at this concentration were submitted to concentration–
response analysis. Final concentrations of compounds were
in the range 0.039–200 lM depending on the potency of the
pantothenamide. The plates were incubated at 37 °C for
20 h before the cell densities were measured (OD600). The
extent of growth in each well was determined by normaliz-
ing the OD600 values relative to those of the negative control
(containing 3% acetonitrile instead of pantothenamide),
which was taken as 100% bacterial cell growth. Each com-
pound was tested in triplicate and all experiments were
repeated at least once after the initial experiment.
Bacterial growth inhibition studies of N5-Pan and
dN5 in minimal media
The inhibition of E. coli K12 and S. aureus RN4220 by N5-
Pan and dN5 was tested in minimal media appropriate for
each bacterium. For E. coli, this medium consisted of
0.8 mM MgSO4, 10 mM citric acid, 60 mM K2HPO4, 20 mM
NaNH4HPO4 and 0.5% glucose; for S. aureus, it contained
40 mM KCl, 160 mM NaCl, 5.3 mM MgSO4, 30 mM
(NH4)2SO4, 0.11 mM CaCl2, 1.0 mM KH2PO4, 0.02 mM
FeSO4, 0.04 mM MnSO4, 0.03 mM citric acid, 100 mM Tris,
28 mM glucose, 0.8 mM L-arginine, 1.0 mM L-proline,
1.9 mM L-glutamic acid, 1.5 mM L-valine, 1.5 mM L-threo-
nine, 1.0 mM L-phenylalanine, 1.3 mM L-leucine, 0.78 mM
L-cysteine, 0.4 lM biotin, 6.6 lM thiamine and 16 lM
nicotinic acid [45]. The inhibition was determined by con-
centration–response analysis as described above with minor
modifications. Briefly, starter cultures of E. coli K12 and
S. aureus RN4220 in 1% tryptone were inoculated with four
separate colonies grown on LB agar plates. The starter cul-
ture was grown to exponential phase and then diluted 10-
fold into the applicable minimal media. A 10-lL aliquot of
the diluted cell suspension was used to inoculate each well of
a 96-well flat-bottomed plate containing 100 lL of minimal
medium. Subsequently, the media was supplemented with
either N5-Pan or dN5. For E. coli and S. aureus, the final
concentrations of N5-Pan varied in the range 0.781–100 lM
and 0.391–50 lM, respectively; for both organisms, dN5 was
varied in the range 1.56–200 lM. The plates were incubated
at 37 °C for 24 h before the cell densities were measured
(OD600) and analyzed further as described above. Each com-
pound was tested in either two (E. coli) or three (S. aureus)
independent experiments, each performed triplicate.
PanK assays
PanK activity was determined using a continuous spectro-
photometric assay that coupled the production of ADP to
the consumption of NADH and was monitored by the
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decrease in A340, as described previously [7]. An extinction
coefficient of 6220 M1cm1 was used for NADH. Each
300-lL reaction mixture contained 50 mM Tris-HCl
(pH 7.6), 10 mM MgCl2, 20 mM KCl, 1.5 mM ATP, 0.5 mM
NADH, 0.5 mM phosphoenolpyruvate, 3 units of PK,
3 units of LDH and either 3.0 lg of EcPanKI or 1.5 lg of
SaPanKII. When PantSH was tested as substrate, 0.5 mM of
tris(2-carboxyethyl)phosphine was also added to the reaction
mixture. The concentration ranges (and ratios of substrate
used in the mixture experiments) are indicated as appropri-
ate. The reaction was initiated by the addition of substrate
(or mixtures of substrates, or mixtures of substrates and
inhibitors) and was monitored for 5 min at 25 °C.
Statistical analysis
Using the raw kinetic data, initial velocities were calculated
for each substrate concentration (or substrate mixture, or
substrate/inhibitor mixture) by linear regression of the read-
ings made in the 50s period after the initial 10 s (i.e. the
period from 10 to 60 s after the reaction was started). For
each experiment, the three readings made for each data
point were averaged and plotted with the SD to give the
respective kinetic profile. Kinetic parameters reported in
Table 2 were determined for each experiment by fitting the
appropriate equation to the data; the reported values are
the mean values of the parameters determined from all the
individual independent experiments, and are given with
errors that indicate the range/2 or SEM as appropriate. The
parameters (Table 3) were determined in a global fit by
minimizing the squared difference between experimental
data points and model simulation of the appropriate equa-
tion, and are given with errors that indicate the SE.
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Chapter 2 (continued) 
Variation In Pantothenate Kinase Type Determines 
The Mode of Action In Bacteria 
 
Additional Information 
Apart from the work presented in the accompanying manuscript, a number of additional 
experiments were performed to corroborate some of the findings. The results of these studies were 
not published, but are reported below. In addition, the synthetic strategies that were used to obtain 
valuable substrates/inhibitors needed for this study are also discussed.  
2.1 Additional kinetic parameters 
2.1.1 N7-Pan: pantothenic acid mixed kinetics with SaPanK-II 
During the initial review of the manuscript reprinted in the preceding section, one of the reviewers 
questioned our decision to use N5-Pan instead of N7-Pan for all kinetic analyses, given that N7-
Pan is the most potent pantothenamide inhibitor against S. aureus (see Table 1 in the manuscript). 
Our reasoning was that N5-Pan inhibits bacterial growth for both E. coli and S. aureus allowing for 
a comparative kinetic analysis, while N7-Pan inhibits only S. aureus.  
 
Nonetheless, and in view of the reviewer’s comment, we set out to perform an additional 
experiment where constant ratio mixtures of pantothenic acid and N7-Pan (instead of N5-Pan) 
were used. This was done to confirm that the trend observed for N5-Pan also holds for N7-Pan. 
The experiment was performed as described in the manuscript. Figure 2.1A shows the interaction 
of pantothenic acid and N7-Pan with SaPanK-II under competitive conditions. This indicates that 
N7-Pan has a significant inhibitory effect on the activity of the enzyme at higher concentrations, 
even in mixtures containing only 5% N7-Pan. In addition, it also shows increased activity at lower 
substrate concentrations. These results are consistent with the results shown in Figures 8A and 8C 
in the manuscript obtained for mixtures of N5-Pan/pantothenic acid and PantSH/pantothenic acid, 
respectively. Figure 2.1B shows the fit of the kinetic model described in the article to the 
pantothenic acid/N7-Pan mix data. The kinetic parameters obtained in this manner were nearly 
identical to those obtained for constant ratio mixtures of pantothenic acid and PantSH (Table 3 in 
the manuscript). This indicates that the pantothenamides that do show inhibition of S. aureus 
growth mimic the interactions of PantSH with SaPanK-II. 
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Figure 2.1. (A) The kinetic profiles of mixtures of pantothenic acid (Pan) and N7-Pan with SaPanK-II under 
competitive conditions. The concentration indicated on the X-axis (note the axis-break) is the total substrate 
concentration (Pan and N7-Pan combined); for each data set, the ratio of Pan: N7-Pan was kept constant as 
indicated. The data points represent the mean of two independent experiments, each performed in triplicate; the 
error bars denote the range/2. The solid line represents the best fit of Equation 1 (see manuscript) to the 100% 
Pan data. (B) Fitting Equation 3 (see manuscript) to the experimental data obtained in (A). The solid lines 
represent the best fit curves, while the shaded area indicates the 90% confidence intervals for these fits.  
2.2 Synthetic strategies for the production of 4’-deoxy-N-pentyl 
pantothenamide (2.9) 
In the published manuscript we described the synthesis of 4’-deoxy-N-pentylpantothenamide (2.9, 
4’-deoxy-N5-Pan), a N5-Pan analogue in which the 4’-hydroxyl (OH) group has been removed. 
This modification gives an analogue that can only act as an inhibitor of SaPanK-II, providing a very 
useful tool to help determine the exact mode of action of the pantothenamides in S. aureus. In the 
manuscript, the synthesis of racemic 4’-deoxy-N5-Pan 2.9 [(R/S)-4’-deoxy-N5-Pan 2.9] is 
described (Figure 5A). The synthetic preparation of (R/S)-4’-deoxy-N5-Pan 2.9 is straightforward 
given that a ketone at the 2’-position can be selectively reduced in the final step to afford both 
enantiomers of the alcohol at this position. However, the resulting racemic mixture cannot be 
separated into the respective enantiomers, making it impossible to confirm that the data of the 
kinetic characterization studies in fact only reflect that of the R-isomer as expected. To do this 
would require a stereoselective synthetic preparation of (R)-4’-deoxy-N5-Pan 2.9; this is 
significantly more challenging given that we either have to make use of a chiral reducing agent , or 
a starting material that contains the correct stereocenter. Below the various attempts at the 
synthesis of racemic (R/S)-4’-deoxy-N5-Pan 2.9 as well as the enantiomerically pure (R)-4’-deoxy-
N5-Pan 2.9 are outlined and discussed.  
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2.2.1 Synthesis of (R/S)-4’-deoxy-N-pentyl pantothenamide [(R/S)-2.9] 
Synthetically it is challenging to selectively remove the 4’-OH-group of N5-Pan, due to the 
presence of a second hydroxy and two amide functionalities in the molecule. The envisioned 
strategies for the synthesis of (R/S)-4’-deoxy-N5-Pan 2.9 [(R/S)-2.9] were therefore based on using 
a starting material that already has the hydroxyl functional group at the 4’-carbon removed to 
construct the target molecule. Two methods were envisaged whereby this could be accomplished 
based on the retrosynthesis shown in Scheme 2.1.  
 
 
Scheme 2.1. Proposed retrosynthesis of (R/S)-4’-deoxy-N-pentyl pantothenamide 2.9. (Method 1) Reaction of 
pivaldehyde 2.5 with an isocyanide 2.4, followed by removal of the carboxylate protecting group and coupling of 
pentylamine 2.8 in the final step of the synthesis. (Method 2) Coupling a moiety with no hydroxyl functional 
group at the 4’-carbon (2.11) to a primary amine which already contains the pentyl functional group (2.17).  
 
The retrosynthesis of both methods were based on the coupling of three fragments via two amide 
bond formations. In method 1 there is a disconnection between the 1’- and 2’-carbons in the 
pantoyl moiety, and a second disconnection between the carbonyl carbon of the β-alanine moiety 
and the N-substituent. The first amide bond is formed during the 1’ and 2’ carbon bond formation 
by coupling aldehyde 2.5 to isocyanide 2.4 through Lewis acid activation. The second amide bond 
is formed during the coupling of acid 2.7 and heptylamine 2.8 to afford racemic 2.9. In method 2 
there is a disconnection between the carbonyl carbon of the β-alanine moiety and the N-
substituent, and a second disconnection between the 1’-carbon of the pantoyl moiety and the 
amine at the β-carbon position of the β-alanine moiety. In this method the amide bond between 
acid 2.18 and heptylamine 2.8 is formed first, while the second amide bond is formed during the 
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coupling of ketoacid 2.11 and amine 2.17. While method 1 was attempted without success 
(discussed in detail below), racemic 2.9 was successfully synthesized using method 2 (this is the 
method reported in the accompanying manuscript).   
 
Method 1, shown in Scheme 2.2, was based on the synthesis of (R/S)-4’-deoxy pantothenic acid 
prepared in a previous study in our group [1], and involved five linear steps that included two 
coupling reactions. During the first step, β-alanine benzyl ester (2.1; prepared from β-alanine 
benzyl ester tosylate salt) was formylated to amide 2.3 by the addition of acetic formic anhydride 
(2.2; prepared by stirring acetic anhydride with formic acid). The acetic acid (CH3COOH) that 
formed during the course of the reaction was removed through an aqueous work-up step that 
proved to be adequate to obtain pure amide 2.3 in 72% yield, which correlates well with the 
previously reported yield of 64% [1].  
 
 
Scheme 2.2. Synthesis route of (R/S)-4'-deoxy-N-pentyl pantothenamide 2.9 using Method 1. Formation of a C–C 
bond through the reaction of isocyanide 2.4 with pivaldehyde 2.5. Deprotection of ester 2.6 successfully gave 
acid 2.7; however, the final step did not give adequate amounts of material to allow for successful purification of 
the final product (2.9). 
 
In addition to Koekemoer’s method, an alternative method, described by Suchý et al. [2], was 
attempted to formylate the β-alanine benzyl ester tosylate salt directly. This method involves  
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treatment of amino acid esters with imidazole in warm (60°C) dimethylformamide (DMF), and does 
not require dry, inert conditions. Mechanistically, DMF acts as the formyl donor, whereas imidazole 
acts as an acyl transfer agent. β-alanine benzyl ester tosylate salt was accordingly treated with 
imidazole and heated in DMF for 48h. However, we obtained a very low yield (29%) compared to 
published results (79% yield) [2]. Additionally, this method also proved to be time-consuming, since 
the reaction has to stir for 48h compared to Koekemoer’s method that only has to stir for 4.5h. As a 
result, we continued to use the three-step formylating procedure developed by Koekemoer [1], 
since no purification, other than an aqueous work-up, was required and a satisfactory 72% yield 
was obtained.  
 
The second step entailed the dehydration of amide 2.3 to isocyanide 2.4 by phosphoryl chloride 
(POCl3) and triethylamine (Et3N). Initial dehydration of amide 2.3 with POCl3 did not proceed to 
completion as 1H NMR spectroscopic analysis indicated that only 50% of amide 2.3 was 
dehydrated. This might be attributed to experimental conditions not being thoroughly anhydrous or 
to the use of poor quality POCl3 reagent. POCl3 reacts with water (H2O) to give hydrochloric acid 
(HCl) and phosphoric acid (H3PO4), which can lead to an inadequate amount of POCl3 to fully 
dehydrate amide 2.3. The dehydration step was therefore repeated on the same reaction using the 
same number of POCl3 equivalents (equiv.) to ensure full conversion of amide 2.3 to isocyanide 
2.4. Isocyanide 2.4 was next used in the first C–C bond formation reaction by adding it to aldehyde 
2.5. This reaction was facilitated through Lewis acid activation with silicon tetrachloride (SiCl4). The 
reaction was quenched, with subsequent hydration leading to the formation of amide 2.6. 
Unfortunately, only a 20% yield was obtained after purification by flash column chromatography 
(FCC), but this gave sufficient material to allow the next step to be attempted.  
 
Step 4 entailed the deprotection of ester 2.6 with palladium black (Pd black) in a 4.4% formic 
acid/methanol (MeOH) solution. The benzyl protecting group was removed within 4h to afford 
carboxylic acid 2.7 in an excellent 94% yield after filtration and the purity was confirmed with 1H 
NMR spectroscopic analysis. To form the final amide bond a diphenylphosphoryl azide (DPPA)-
mediated coupling (adapted from Shioiri et al. [3]) was attempted by treating a solution of 
carboxylic acid 2.7 and pentylamine 2.8 in DMF with DPPA and Et3N. Regrettably, the reaction 
gave a mixture of products that did not lend itself to further purification. As a result of the very poor 
overall yield (only 11% up to carboxylic acid 2.7), along with the formation of a mixture of products 
in the final step, this synthetic route was not pursued any further. Consequently, method 2 was 
investigated as an alternative, and it finally allowed for the successful synthesis of (R/S)-2.9. A 
detailed description of this method is reported in the accompanying manuscript.   
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2.2.2 Synthesis of (R)-4’-deoxy-N-pentyl pantothenamide [(R)-2.9] 
Due to the lack of stereo control in the synthetic procedures used for the preparation of (R/S)-2.9 
as outlined above, a racemic mixture is obtained. Virga et al. [4] reported that the R-configuration 
at the 2’–OH position of substrates/inhibitors is necessary for optimal binding of the 4'–OH group to 
the PanK binding pocket. Therefore, only one of the enantiomers in the racemic mixture is 
postulated to act as an inhibitor. Consequently, we wanted to develop a stereoselective synthetic 
procedure allowing for the preparation of (R)-2.9; this could then be used for physiologically more 
relevant inhibition studies on S. aureus. A stereoselective synthesis of (R)-2.9 could be achieved 
by using a chiral reducing agent or by using a starting material with the correct stereochemistry. 
Scheme 2.3 proposes an asymmetric synthesis for (R)-2.9 in five linear steps. Overall, the 
synthetic strategy is a modification of method 2 outlined for the preparation of the (R/S)-2.9, with 




Scheme 2.3. Proposed synthetic route for the preparation of (R)-4'-deoxy-N-pentyl pantothenamide 2.9 in six 
steps starting from pinacolone (2.10). Solid arrows indicate synthetic steps that were successfully performed, 
whereas arrows in dotted lines indicate theoretical synthetic procedures that were not performed. 
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In step one, ketoacid 2.11 is synthesised according to Tuck et al. [5], through the oxidation of 
pinacolone 2.10 by potassium permanganate (KMnO4) in a single step which produced ketoacid 
2.11 in a 77% yield. This is followed by an amide coupling, which entails the coupling of ketoacid 
2.11 with (R)-proline methyl ester HCl salt 2.12 in the presence of N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide (EDC) hydrochloride, N,N-diisopropylethylamine (DIPEA) and hydroxy-benzo-
triazole (HOBt) to give ketoamide 2.13. EDC acts as an activating agent for the carboxyl group, 
allowing for nucleophilic acyl substitution with an amine. The experimental procedure for this 
coupling reaction was done as described by Nelson et al. [6]. Although these authors reported an 
84% yield for this coupling, only a 60% yield of ketoamide 2.13 was obtained after purification by 
FCC. Theoretically, the subsequent reduction of ketoamide 2.13 in step 3 and lactonization of 
hydroxy amide 2.14 in step 4 should generate lactone 2.15 in an R:S ratio of 93:7. The more rapid 
lactonization of the R,S-isomer is due to the lower energy transition state or intermediate along the 
lactonization pathway [6]. Separation of the diastereomers via FCC should be possible after the 
lactonization of hydroxy amide 2.14 to (R,S)- and (S,S)-2.15 [6]. 
 
Nelson et al. [6] used 5% ruthenium on activated carbon (Ru/C) under 60 psi hydrogen (H2) gas in 
a Parr reactor to reduce ketoamide 2.13. However, since a similar ketoamide was successfully 
reduced using a metal hydride in the synthesis of (R/S)-2.9, we decided to use this method in our 
first attempt to reduce ketoamide 2.13. Consequently, sodium borohydride (NaBH4) was first used 
as a reducing agent in step 3, since it is a mild reducing agent and is selective toward ketones as 
opposed to amides. Various reaction conditions were tested (shown in Table 2.1) which included 
changes in temperature, time and the number of equiv. of reducing agent; however, the reduction 
of the ketone was unsuccessful and the starting material was recovered, even at 6 equiv. of 
NaBH4. Following this, we attempted to reduce ketoamide 2.13 with either lithium borohydride 
(LiBH4) or lithium aluminium hydride (LiAlH4) using varying reaction conditions as summarized in 
Table 2.1. Unfortunately, none of these reagents were able to reduce ketoamide 2.13 successfully, 
since the starting material was recovered after each reaction. 
 
Given that we were unsuccessful in reducing ketoamide 2.13 using a metal hydride, we finally 
attempted the reduction by using a Parr reactor and 5% Ru/C as described in literature [6]. To this 
end, 5% Ru/C and ketoamide 2.13 was heated to 50°C and stirred for 72h under 60 psi H2 gas 
pressure, followed by lactonization of hydroxy amide 2.14 [in the presence of p-toluenesulfonic 
acid (PTSA)] to (R,S)- and (S,S)-lactone 2.15 under vacuum to remove the MeOH side product. 
From the 1H NMR spectrum of the crude product it was unclear whether the reduction was 
successful; however, High Resolution Mass Spectroscopy (HRMS) did not show any product 
formation and the starting material was recovered. The procedure was repeated, but this time the  
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reaction mixture was degassed by three alternating nitrogen/vacuum cycles to remove dissolved 
oxygen from within the solvent, before it was inserted into the Parr reactor. Additionally, the 
lactonization step was performed without vacuum and the time was increased from 5h to 48h. The 
reduction of ketoamide 2.13 was successful and (R,S)- and (S,S)-2.15 were separated by FCC and 
obtained in a combined yield of 48% over the two steps. Although literature [6] reported a 10:1 ratio 
for (R,S):(S,S) we obtained only a 5:1 ratio. 1H NMR data were consistent with those reported 
previously for (R,S)-2.15 [6] and confirmed that R,S is indeed the major diastereomer.  
 
Table 2.1. Various reaction conditions attempted for the reduction of ketoamide 2.13. 
Reducing agent Attempt 1 Attempt 2 
NaBH4 
1) 0°C, 1h, 3 equiv. then  
2) overnight at rt 
1) 0°C, 1h, 6 equiv. then  
2) 36h at rt 
LiBH4 
1) 0°C, 1h, 2 equiv. then  
2) overnight at rt 
1) 0°C, 1h, 4 equiv. then  
2) 24h at rt then  
3) additional 2 equiv., 24h at rt 
LiAlH4 
1) -78°C, 2h, 1 equiv. then  
2) 0°C, 2h then  
3) overnight at rt 
1) -78°C, 2h, 2 equiv. then  
2) 0°C, 2h then  
3) overnight at rt. 
b
 rt, room temperature  
 
Since the reduction of ketoamide 2.13 was challenging and Parr reactors are not readily available 
in many research facilities, we decided to pursue an alternative strategy in which the racemic 
hydroxy acid 2.16 is prepared first, followed by its coupling to (R)-proline methyl ester HCl salt 2.12 
to form the hydroxy amide 2.14. This would be followed by lactonization (mediated by PTSA 
catalysis) to give (R,S)- and (S,S)-lactone 2.15 as shown in Scheme 2.4. Given that this method 
does not involve any stereochemical control, the product is expected to be obtained a 1:1 ratio of 
R:S enantiomers; however, it should be possible to separate these stereoisomers after the 
formation of the diastereomers (R,S)- and (S,S)-lactone 2.15.  
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Scheme 2.4. Proposed alternative synthetic route for the synthesis of (R)-4'-deoxy-N-pentyl pantothenamide 2.9 
starting either from 3,3-dimethyl-2-oxo-butyric acid (2.11) or from pinacolone (2.10). This synthesis was 
successfully executed except for the final amide coupling in step 5.  
 
Our first attempt at the synthesis of racemic hydroxy acid 2.16 was through the reduction of 
ketoacid 2.11 based on a method reported in the literature [7]. In this method 1 equiv. of NaBH4 
was used and the reaction was stirred for 2h at 0°C. However, in our hands this was not sufficient 
to give complete reduction of the ketone. Therefore, 2 equiv. of NaBH4 was used and the reaction 
was stirred for 4h at 0°C, followed by stirring overnight at room temperature (rt). Thin layer 
chromatography (TLC) showed that all of the starting material was consumed. The protocol 
stipulates that the reaction mixture must be acidified to pH 2 before extraction with diethyl ether. 
Subsequently, the organic layer is washed with H2O until a pH of 4 is reached. Using this method 
we only obtained a 5% yield of racemic hydroxy acid 2.16, instead of the 67% yield that was 
reported [7]. We expect that this low yield is due to the loss of the product during the extensive 
aqueous work-up. Consequently an alternative method for the preparation of racemic hydroxy acid 
2.16 was explored.  
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Hydroxy acid 2.16 can also be prepared from pinacolone 2.10 in a two-step synthesis (Scheme 
2.4). A method by Fuson et al. [8], was used to oxidize pinacolone 2.10 with selenium dioxide 
(SeO2) to form keto aldehyde 2.20 which was purified using a Claisen Vigreux distillation at 
atmospheric pressure and used without any further purification in the next step. In the following 
step, as described by Köntös et al. [9], aldehyde 2.20 was heated in an aqueous sodium hydroxide 
(NaOH) solution and underwent an internal Cannizzaro reaction in the strong basic medium 
resulting in the formation of the sodium salt of racemic hydroxy acid 2.16, which, after acidification 
and recrystallization with 1,2-dichloroethane (DCE), was obtained in an overall yield (over the two 
steps) of 34% [9]. This method was preferentially used for the synthesis of racemic hydroxy acid 
2.16 due to the higher overall yield. Additionally, in an effort to separate the two hydroxy acid 2.16 
isomers a resolution was attempted by conversion to the (1S, 2R)-(+)-ephedrine salt followed by 
fractional crystallization; however, this method did not give satisfactory results. 
 
Consequently, racemic hydroxy acid 2.16 was coupled to (R)-proline methyl ester HCl salt 2.12 
using an amide coupling reaction in the presence of EDC, DIPEA and HOBt to give the 
diastereomers of hydroxy amide 2.14. After an aqueous work-up this was immediately lactonized 
to (R,S)- and (S,S)-lactone 2.15 in the presence of PTSA, followed by purification  by FCC. The 
isomers were obtained in a 1:1 ratio in a combined yield of 64% (over the two steps). Even though 
the Ru/C reduction method gave a 5:1 ratio of (R,S):(S,S)-2.15 compared to the 1:1 ratio obtained 
for the coupling of racemic hydroxy acid 2.16, the Ru/C method has an overall lower yield and will 
only give a marginally higher yield for (R,S)-2.15. Therefore, either method can be used for the 
synthesis of (R,S)-2.15. 
 
Following the successful separation of (R,S)- and (S,S)-2.15 in step 3, the (R,S)-isomer 
(stereochemistry was confirmed with 1H NMR spectroscopic analysis [6]) was subjected to acid 
hydrolysis in step 4 to afford the R-hydroxy acid HCl salt (2.16) in a 73% yield. The final step of the 
synthesis entailed an amide bond formation between 2.16 and amine 2.17. The amine was 
prepared by coupling commercially available carboxylic acid 2.18 to pentylamine 2.8 using diethyl 
phosphoryl cyanide (DEPC) in the presence of Et3N by adapting a method from Yamada et al. [10] 
to form 2.19, followed by successful removal of the benzyl carbamate protecting group through 
hydrogenation with H2 gas in the presence of palladium on activated carbon (10% Pd/C) to yield 
amine 2.17 as a pure white solid upon filtration in an excellent yield (89%) over two steps. The 
purity of amine 2.17 was confirmed with 1H NMR spectroscopic analysis. Subsequently, amine 
2.17 and R-hydroxy acid HCl salt 2.16 were coupled using an EDC coupling reaction with DIPEA 
and HOBt. The reaction gave a mixture of products which were subsequently separated by FCC. 
Unfortunately, according to NMR spectroscopic analysis, none of these were target compound (R)- 
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2.9. The coupling was also attempted by using DPPA as activation reagent, but regrettably NMR 
spectroscopic analysis indicated that this coupling was also unsuccessful. Consequently, after 
several months of attempting to synthesize (R)-2.9 with no success, we decided to use (R/S)-2.9 in 
the biological experiments set out in the accompanying manuscript. 
2.3 Conclusion 
The biological results obtained for N7-Pan in combination with pantothenic acid were consistent 
with the results obtained for N5-Pan in combination with pantothenic acid in the manuscript 
(Figures 8A and 8C). Additionally, the model described in the manuscript also fitted our 
experimental data well, with the kinetic parameters being nearly identical to those obtained for 
constant ratio mixtures of pantothenic acid and PantSH. 
 
Virga et al. [4] reported that PanK enzymes require the R-configuration at the 2’-OH position of 
their substrates or inhibitors for optimal binding of the 4'-OH group in the active site. Therefore, we 
attempted the asymmetric synthesis of (R)-2.9; however, after numerous attempts this synthesis 
was not pursued any further due to low yielding reactions and a failure to perform the final amide 
bond formation. Consequently, we decided to use (R/S)-2.9 in our biological experiments, and 
demonstrated that it showed excellent inhibition of the enzyme. It would be beneficial to attempt to 
synthesize (R)-2.9 once more in future experiments. However, (S)-2.9 should also be synthesized 
and tested to prove that it is indeed less effective than (R)-2.9. This will also confirm the reports by 
Virga et al. [4] that only the R-isomer is biologically active.  
2.4 Experimental section 
2.4.1 Materials and methods  
General chemicals and reagents were purchased from Sigma-Aldrich, Merck Chemicals 
(Darmstadt, Germany) or Acros Organics (ThermoFisher, Fair Lawn, NJ, USA) and were of the 
highest purity. Solvents used for reactions were CHROMASOLV HPLC grade solvents from 
Sigma-Aldrich, while the hexanes, dichloromethane (DCM) and ethyl acetate (EtOAc) used for 
purification were purchased from Merck Chemicals. Dry DMF was prepared by shaking up over 
potassium hydroxide (KOH), distilled under reduced pressure and a nitrogen atmosphere, and 
finally stored over 4 Å molecular sieves in the dark. Dry DCM was distilled from calcium hydride 
(CaH2) under a nitrogen atmosphere while dry tetrahydrofuran (THF) was distilled from sodium 
(Na) under a nitrogen atmosphere. 
 
Stellenbosch University  https://scholar.sun.ac.za
Chapter 2 
Variation in pantothenate kinase type determines the mode of action in bacteria 
 
~ 81 ~ 
 
All 1H and 13C NMR spectra were obtained using a 300 MHz Varian VNMRS (75 MHz for 13C), 400 
MHz Varian Unity Inova (100 MHz for 13C) or 600 MHz Varian Unity Inova (150 MHz for 13C) 
instruments at the Central Analytical Facility (CAF) of the University of Stellenbosch. All chemical 
shifts (δ) were recorded using the residual solvent peak and reported in p.p.m. All HRMS were 
performed on a Waters API Q-TOF Ultima spectrometer (Waters, Milford, MA, USA) at the Mass 
Spectrometry unit of CAF. 
2.4.2 Synthetic preparation of 4’-deoxy N5-Pan (2.9) 
 
N-Formyl β-alanine benzyl ester (2.3)  
 
To a solution of β-alanine benzyl ester tosylate salt (3.00 g, 8.46 mmol) in 
H2O (20 mL) was added 1 M NaOH until the pH was adjusted to 10.5. The 
aqueous solution was extracted with DCM (4 × 25 mL) and dried (Na2SO4). 
The solvent was removed in vacuo to yield β-alanine benzyl ester (2.1) (1.29 g, 7.19 mmol) as a 
colourless oil. Acetic formic anhydride (2.2), prepared by stirring acetic anhydride (7.50 mL) with 
formic acid (3.30 mL) for 2.5h at 55°C, was added. The reaction mixture was refluxed at 70°C for 
2h and cooled to rt. DCM (25 mL) was added and the organic layer was washed with saturated 
sodium bicarbonate (NaHCO3) (2 × 25 mL) and H2O (2 × 25 mL). The organic layer was dried 
(Na2SO4), filtered and concentrated in vacuo to yield ester 2.3 (1.26 g, 72%) as a yellow oil. Rf = 
0.38 (3:1 EtOAc: Hexanes). δH (300 MHz; CDCl3; 25°C) 2.60 (2H, t, J =  6.0 Hz, -CH2-), 3.56 (2H, 
q, J = 7.0 Hz, -CH2-), 5.15 (2H, s, -CH2-), 6.11 (1H, br s, -NH-), 7.32-7.39 (5H, m, arom) and 8.14 
(1H, s, -CH). 1H NMR data are consistent with those previously reported [1]. 
 
Isocyanide β-alanine benzyl ester (2.4)  
 
To a solution of ester 2.3 (1.26 g, 6.11 mmol) in THF (15 mL) at -78°C, under 
an inert atmosphere was added Et3N (4.26 mL, 30.6 mmol). A solution of 
POCl3 (570 µL, 6.11 mmol) in THF (15 mL) was added slowly at -78°C while 
stirring continuously. After the addition was complete, the reaction mixture was stirred for an 
additional 3h at 0°C. The reaction was quenched by the addition of cold H2O (50 mL) and the 
aqueous layer was extracted with diethyl ether (3 × 30 mL). The combined organic extracts were 
washed with H2O (3 × 30 mL), dried (MgSO4), filtered and concentrated in vacuo to yield 
isocyanide 2.4 (947 mg, 82%) as a black smelly oil. Rf = 0.35 (3:1 EtOAc: Hexanes). δH (300 MHz; 
CDCl3; 25°C) 2.75-2.81 (2H, m, -CH2-), 3.68-3.73 (2H, m, -CH2-), 5.18 (2H, s, -CH2-) and 7.34-7.39 
(5H, m, arom). 1H NMR data are consistent with those previously reported [1]. 
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(R/S)-Benzyl 4’-deoxy-pantothenate (2.6)  
 
SiCl4 (689 µL, 6.01 mmol) was added to a solution of isocyanide 2.4 
(947 mg, 5.01 mmol) in dry DCM (25 mL) at 0°C under an inert 
atmosphere. The reaction mixture was stirred vigorously for 5 min 
before aldehyde 2.5 (653 µL, 6.01 mmol) was added at 0°C. The reaction mixture was warmed to 
25°C and stirred for an additional 2h. The reaction was quenched by the addition of saturated 
potassium carbonate (K2CO3) (5 mL), filtered through Celite and the aqueous layer was extracted 
with DCM (3 × 30 mL). The combined organic extracts were washed with H2O (3 × 30 mL), dried 
(MgSO4), filtered and concentrated in vacuo. Purification by FCC (1:1 EtOAc: Hexanes) yielded 
deoxy ester 2.6 (294 mg, 20%) as a light yellow oil. Rf = 0.23 (FCC conditions). δH (400 MHz; 
CDCl3; 25°C) 0.95 (9H, s, -CH3), 2.60 (2H, t, J = 5.8 Hz, -CH2-), 3.56 (2H, q, J = 6.2 Hz, -CH2-), 
3.64 (1H, d, J = 5.0 Hz, -CH-), 5.13 (2H, s, -CH2-), 6.61 (1H, br s, -NH-) and 7.33-7.36 (5H, m, 
arom). OH proton not observed. 1H NMR data are consistent with those previously reported [1]. 
 
(R/S)-4’-Deoxy-pantothenic acid (2.7)  
 
To a solution of deoxy ester 2.6 (294 mg, 1.00 mmol) in 4.4% formic 
acid/MeOH (20 mL) was added Pd (black) (147 mg, 1.38 mmol) at rt. The 
reaction mixture was stirred for 4h at rt before Pd (black) was removed by 
filtration and the filtrate was concentrated in vacuo to afford acid 2.7 (191 mg, 94%) as a colourless 
oil. Rf = 0.21 (5% MeOH in DCM). δH (300 MHz; CDCl3; 25°C) 0.98 (9H, s, -CH3), 2.59 (2H, t, J = 
5.9 Hz, -CH2-), 3.55 (2H, q, J = 5.9 Hz, -CH2-), 3.72 (1H, s, -CH-) and 6.82 (1H, br s, -NH-). OH 
protons not observed. 1H NMR data are consistent with those previously reported [1]. 
 
3,3-Dimethyl-2-oxo-butyric acid (2.11) 
 
To a solution of NaOH (8.00 g, 200 mmol) and KMnO4 (12.2 g, 77.2 mmol) in H2O 
(196 mL) at 0°C, was added a solution of pinacolone (2.10) (10 mL, 83.4 mmol) in 
H2O (160 mL). The reaction mixture was stirred for 1h at 0°C and an additional 2h 
at rt. The reaction mixture was filtered through Celite, acidified to pH 2 with concentrated sulphuric 
acid (H2SO4), and the aqueous layer was extracted with diethyl ether (3 × 40 mL). The combined 
organic extracts were dried (Na2SO4), filtered and concentrated in vacuo. Bulb-to-bulb distillation 
(110°C, 27.5 mmHg) gave carboxylic acid 2.11 (3.99 g, 77%) as a clear oil. δH (300 MHz; CDCl3; 
25°C) 1.32 (9H, s, -CH3). OH proton not observed. 
1H NMR data are consistent with those 
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DIPEA (3.00 mL, 17.2 mmol) was added drop-wise over 5 min to a solution of (R)-
proline methyl ester HCl salt (2.12) (2.76 g, 16.6 mmol) in DCM (54 mL) at 0°C. HOBt 
(396 mg, 2.93 mmol), racemic hydroxy acid 2.16 (2.00 g, 15.1 mmol) and EDC 
hydrochloride (3.19 g, 16.6 mmol) were then added consecutively at 0°C and the 
reaction mixture was stirred overnight at rt. The reaction was quenched by the addition of 3 M HCl 
(54 mL) and the organic layer was washed with 3 M HCl (1 × 54 mL) and saturated NaHCO3 (1 × 
54 mL). The organic layer was dried (Na2SO4), filtered and concentrated in vacuo to afford crude 
racemic hydroxy amide 2.14. To a solution of racemic hydroxy amide 2.14 in toluene (50 mL) was 
added PTSA (432 mg, 2.27 mmol) and the reaction mixture was stirred for 48h at rt. The toluene 
was removed in vacuo before purification with FCC (9:1 DCM: EtOAc) afforded (R,S)- and (S,S)-
lactone 2.15 as white solids in a combined yield of 64%. The ratio of (R,S)-lactone 2.15 to (S,S)-
lactone 2.15  was 1:1. 
 
(R,S)-lactone 2.15 Rf = 0.19 (FCC conditions). δH (400 MHz; CDCl3; 25°C) 1.11 (9H, s, -CH3), 1.86-
2.08 (3H, m, -CH2-), 2.45-2.52 (1H, m, -CH2-), 3.52-3.57 (1H, m, -CH2-), 3.71-3.78 (1H, m, -CH2-), 
4.19 (1H, dd, J = 6.6, 10.2 Hz, -CH-) and 4.50 (1H, s, -CH-). 1H NMR data are consistent with 
those previously reported [6]. 
 
(S,S)-lactone 2.15 Rf = 0.37 (FCC conditions). δH (400 MHz; CDCl3; 25°C) 1.19 (9H, s, -CH3), 1.88-
2.05 (2H, m, -CH2-), 2.26-2.41 (2H, m, -CH2-), 3.48-3.64 (2H, m, -CH2-), 4.22 (1H, t, J = 7.8 Hz, -




To a solution of ketoamide 2.13 (1.00 g, 4.14 mmol) in MeOH (50 mL) was added 5% 
Ru/C (500 mg, 4.95 mmol) and the reaction mixture was degassed by three alternating 
nitrogen/vacuum cycles. The reaction mixture was heated to 50°C and pressurized to 
60 psi of H2 pressure and stirred for 72h. The reaction mixture was cooled to rt, 
depressurized, filtered through a pad of Celite and concentrated in vacuo to afford crude racemic 
hydroxy amide 2.14. To a solution of racemic hydroxy amide 2.14 in toluene (30 mL) was added 
PTSA (120 mg, 0.63 mmol) and the reaction mixture was stirred for 48h at rt. The toluene was 
removed in vacuo before purification with FCC (9:1 DCM: EtOAc) afforded (R,S)- and (S,S)-lactone 
2.15 as white solids in a combined yield of 48%. The ratio of (R,S)-lactone 2.15 to (S,S)-lactone 
2.15  was 5:1. Analytical data are identical to those reported above.  
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2-Hydroxy-3,3-dimethylbutanoic acid (2.16) 
 
To a solution of ketoacid 2.11 (3.00 g, 23.1 mmol) in MeOH (100 mL) at 0°C under an 
inert atmosphere was added NaBH4 (1.75 g, 46.1 mmol) in small portions. The 
reaction mixture was stirred for 4h at 0°C, and left to stir overnight at rt. The solvent 
was removed in vacuo and the resulting crude residue was dissolved in H2O (20 mL) and acidified 
to pH 2 (with cooling) with 3 M HCl. The aqueous layer was extracted with diethyl ether (4 × 25 
mL) and the combined organic extracts were washed with H2O until the pH of a washing became 
pH 4. The combined organic extracts were dried (Na2SO4), filtered, concentrated in vacuo and 
lyophilized to yield racemic hydroxy acid 2.16 (152 mg, 5%) as a white solid. Rf = product on 
baseline (10% MeOH in DCM). δH (400 MHz; CDCl3; 25°C) 1.02 (9H, s, -CH3) and 3.87 (1H, s, -
CH3). OH protons not observed. 
1H NMR data are consistent with those previously reported [7]. 
 
2-Hydroxy-3,3-dimethylbutanoic acid (2.16) 
 
 NaOH (20% aqueous, 220 mL, 550 mmol) was added slowly to a solution of keto 
aldehyde 2.20 (56.1 g, 491 mmol) heated to 80°C. The reaction mixture was stirred 
overnight at 80°C. The reaction mixture was cooled to 0°C and acidified to pH 2 with 
concentrated HCl. The aqueous layer was extracted with diethyl ether (4 × 200 mL). The combined 
organic extracts were dried (MgSO4), filtered, concentrated in vacuo and lyophilized. The crude 
product was recrystallized from DCE to afford racemic hydroxy acid 2.16 (43.5 g, 67%) as white 
crystals. Analytical data are identical to those reported above.  
 
(R)-2-Hydroxy-3,3-dimethylbutanoic acid ((R)-2.16) 
 
(R,S)-lactone 2.15 (500 mg, 2.37 mmol) was dissolved in 3 M HCl (30 mL) and 
refluxed overnight. The reaction mixture was lyophilized before purification with FCC 
(5:1:1:1 EtOAc: H2O: MeOH: Acetonitrile (CH3CN)). Purified R-hydroxy acid 2.16 was 
lyophilized to afford a white solid (230 mg, 73%). Rf = 0.44 (FCC conditions). δH (400 MHz; CDCl3; 




To a solution of carbamate 2.19 (1.50 g, 5.13 mmol) in MeOH (80 mL) at rt 
was added Pd/C (80.0 mg, 0.752 mmol). The reaction atmosphere was 
filled with H2 gas and the reaction mixture was stirred overnight at rt under 
H2. Additional Pd/C (100 mg, 0.940 mmol) was added and the reaction mixture was stirred for a 
further 5h under H2. The reaction mixture was filtered and concentrated in vacuo to give amide 
2.17 (800 mg, 99%) as a white solid. Rf = product on baseline (10% MeOH in DCM). δH (300 MHz; 
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CDCl3; 25°C) 0.87 (3H, t, J = 7.1 Hz, -CH3), 1.29-1.33 (4H, m, -(CH2)2-), 1.50-1.59 (4H, m, -CH2- 
and -NH2), 2.28 (2H, t, J  = 5.6 Hz, -CH2-), 2.98 (2H, t, J = 6.1 Hz, -CH2-), 3.20 (2H, q, J = 7.3 Hz, -
CH2-) and 6.85 (1H, br s, -NH-). δC (300 MHz; CDCl3; 25°C) 14.4, 22.7, 29.5, 29.6, 38.0 38.3, 39.7 
and 172.4. (MS) [M+H]+ 159.1499 (Calculated [C8H19N2O]
+ = 159.15). 
 
Benzyl 3-oxo-3-(pentylamino) propylcarbamate (2.19) 
 
Pentylamine (2.8) (803 µL, 6.96 mmol) and DEPC (1.05 mL, 6.96 
mmol) were added to a solution of Cbz-β-alanine (2.18) (1.41 g, 
6.32 mmol) in dry DMF (8 mL) at rt. The reaction mixture was 
cooled to 0°C before Et3N (1.85 mL, 13.3 mmol) was added. The reaction mixture was stirred for 
2h at 0°C and left to stir overnight at rt. EtOAc (50 mL) was added and the organic layer was 
washed with 5% citric acid (3 × 10 mL), 1 M aqueous NaHCO3 (2 × 10 mL) and saturated sodium 
chloride (NaCl) (1 × 10 mL). The organic layer was dried (Na2SO4), filtered and concentrated in 
vacuo before purification by FCC (3:2 to 4:1 EtOAc: Hexanes) afforded carbamate 2.19 (1.50 g, 
81%) as a white solid. Rf = 0.18 (FCC conditions). δH (300 MHz; CDCl3; 25°C) 0.87 (3H, t, J = 6.9 
Hz, -CH3), 1.26-1.33 (4H, m, -(CH2)2-), 1.54-1.61 (2H, m, -CH2-), 2.38 (2H, t, J = 6.0 Hz, -CH2-), 
3.19 (2H, q, J = 7.3 Hz, -CH2-), 3.45 (2H, q, J = 6.3 Hz, -CH2-), 5.09 (2H, s, -CH2-), 5.44 (1H, br s, -
NH-), 5.56 (1H, br s, -NH-) and 7.32-7.36 (5H, m, arom). δC (400 MHz; CDCl3; 25°C) 14.0, 22.3, 
29.0, 29.2, 36.1, 37.1, 39.5, 66.6, 128.0, 128.1, 128.5, 136.5, 156.8 and 171.3. (MS) [M+H]+ 
293.1866 (Calculated [C16H25N2O3]




 SeO2 (111.2 g, 1.00 mol) was added to a solution of MeOH (100 mL) and H2O (5 mL) 
and the reaction mixture was refluxed until all the SeO2 dissolved. Pinacolone (2.10) 
(122 mL, 976 mmol) was added rapidly and the clear solution became red and then black after a 
few minutes. The reaction mixture was refluxed overnight. The reaction mixture was cooled to rt 
and filtered to remove the precipitated selenium. The yellow to orange filtrate was distilled at 
atmospheric pressure using a Claisen vigreux distillation setup and the distillate was collected from 
110 – 120°C to afford keto aldehyde 2.20 (56.1 g, 50%) as a yellow oil. The product was used 
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Chapter 3 
Developing PanK Inhibitors That Are Resistant To 
Pantetheinase-Mediated Degradation 
3.1 Introduction 
Drug-resistant pathogens are a major cause for the increase in morbidity and mortality worldwide. 
These pathogens include, but are not limited to, MRSA, ESBL-producing Escherichia coli, 
vancomycin-resistant enterococci, MDR and XDR M. tuberculosis and penicillin- and macrolide-
resistant pneumococci [1-2]. The current arsenal of available antibiotics which has been 
successfully used for decades as treatments against bacteria—including S. aureus—is being 
rendered ineffective due to bacteria becoming increasingly insensitive to these compounds [3-4]. 
Since S. aureus makes use of all known mechanisms to develop antibiotic resistance (as 
discussed in detail in Chapter 1), new antimicrobials with novel modes of action are needed to 
decrease the prospect of cross-resistance [5].  
 
The CoA biosynthetic pathway, as well as the enzymes that subsequently utilize CoA, is seen as a 
potential novel target for antimicrobial chemotherapy development. The value of this pathway lies 
in CoA being an essential cofactor that needs to be synthesized de novo in all living organisms [6]. 
In S. aureus, CoA biosynthesis is an even more attractive target due to the accumulation of 
milimolar quantities of CoA in the organism. Moreover, CoA is involved in maintaining the redox 
balance in S. aureus through a unique CoA disulphide reductase system [1, 6].  
 
Previous studies have established that pantothenamides—amide analogues of pantothenic acid—
are potential small molecule inhibitors of CoA biosynthesis and utilization in S. aureus [1, 7-12]. 
Although the antibacterial activity of pantothenamides has been investigated since 1970 [6], our 
poor understanding of their mechanism of action hampered their development as clinically relevant 
agents. Furthermore, N5-Pan and N7-Pan, classical examples of the pantothenamide class, show 
inhibitor activity against SaPanK-II as well as S. aureus in the micro- and nanomolar range in the in 
vitro studies; however, pantothenamides do not translate into potent inhibitors in vivo [1, 6, 12-13]. 
In 2011 Jansen et al. [13] discovered that this loss of antimicrobial activity in vivo is due to 
enzymatic degradation of the pantothenamides by pantetheinase enzymes. These enzymes are 
encoded by the Vanin gene family (that forms part of the nitrilase superfamily), of which three 
human genes (VNN1, VNN2 and VNN3), two murine genes (Vanin-1 and Vanin-2) and one 
homologue in Drosophila are known [14-15]. Pantetheinase, also known as PantSH hydrolyse, 
catalyzes the hydrolysis of one specific amide linkage in PantSH (Scheme 1.8 and 1.9, Chapter 1) 
via an invariant Glu-Lys-Cys catalytic triad to yield pantothenic acid (for reuse in CoA biosynthesis) 
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and cysteamine (a powerful antioxidant) [16-18]. Pantetheinase is highly substrate specific for the 
pantothenate moiety, while the cysteamine structure moiety is less specific and alternative 
functional groups can replace the sulfhydryl functional group in the substrate [17, 19]. As a result, 
the pantothenamides are also hydrolyzed by pantetheinase leading to the formation of pantothenic 
acid and the corresponding amine (Scheme 1.8, Chapter 1), resulting in the loss of antimicrobial 
activity [13, 20]. 
 
The results of our study of the mode of action of the pantothenamides in S. aureus (as related in 
Chapter 2) that showed that these compounds exert their growth inhibitory effects at least partially 
by inhibiting PanK has contributed significantly to our knowledge in this regard. Additionally, recent 
findings on the breakdown of pantothenamides by pantetheinase through the hydrolysis of a 
specific amide linkage rendering them ineffective; we now have greater insight into how these 
compounds exert their antimicrobial activity. In combination, these findings show that new potent 
antistaphylococcal inhibitors based on the pantothenamide scaffold should show two main 
characteristics: 1) they should be resistant to the degradation caused by the pantetheinase 
enzymes and 2) they should still bear enough structural similarity to PantSH to exhibit the same 
complex interaction with SaPanK-II that causes the inhibitory profiles described in the previous 
Chapter.   
3.2 Study design and strategy 
With these requirements in mind, we set out to design and characterize new SaPanK-II inhibitors 
by making modifications to the pantothenamide core structure that would protect it against 
pantetheinase-mediated hydrolysis, while retaining the important interactions required for 
recognition by SaPanK-II. This can be achieved through one of three strategies: 1) by either 
making the scissile amide bond less accessible to the pantetheinase catalytic residues by 
increasing the steric bulk surrounding it, e.g. by addition of a methyl group, 2) by replacing the 
scissile amide bond with a bioisostere that would withstand pantetheinase degradation, or 3) by 
preventing the compound from being recognized as a substrate by pantetheinase by replacing or 
removing the 4’-hydroxyl group, since pantetheinase is highly substrate specific for the 
pantothenate motif (Figure 3.1) [17, 19].  
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Figure 3.1. Three strategies to protect the pantothenamide from pantetheinase mediated hydrolysis: 1) Addition 
of steric bulk in the regions of the molecule highlighted in blue, 2) Substitution of the scissile amide bond with a 
bioisostere in the regions highlighted in green, or 3) Removal or replacement of the 4’-hydroxyl highlighted in 
the orange block.  
 
N-Heptyl pantothenamide (3.10, N7-Pan), a member of the pantothenamide library designed and 
synthesized by de Villiers et al. [12], has previously been demonstrated to show the most potent 
inhibition against S. aureus with a MIC value in the nanomolar range. This also correlates with 
other studies of the pantothenamides in which N7-Pan 3.10 was also the best pantothenamide 
inhibitor of S. aureus [1]. We consequently decided to use N7-Pan 3.10 as scaffold to synthesize 
ten analogues that would show increased resistance to pantetheinase-mediated degradation, while 
retaining the structural feature required for SaPanK-II binding (Figure 3.2).  
 
The first strategy was based on increasing the steric bulk surrounding the scissile amide bond and 
the compounds based on this strategy are indicated with a blue box in Figure 3.2. In two N7-Pan 
analogues the scissile amide bond was retained, but a methyl group was added to either the α- or 
β-position relative to the amide bond. This was expected to introduce steric hindrance and prevent 
or slow the hydrolysis of the amide bond. Furthermore, backbone N-methylation is one of many 
ways nature has developed to stabilize highly rich peptidic scaffolds and to resist protease-
mediated degradation. Chemists use N-methylation to enhance the pharmacological properties of 
peptides because it tends to increase the molecular cell permeability, as well as their stability 
towards enzymatic degradation [21]. Therefore, the third option for increasing steric bulk on N7-
Pan 3.10 was by N-alkylation of the amide nitrogen. The final N7-Pan analogue that was based on 
strategy 1 involved the introduction of a double bond. Although the introduction of a double bond in 
the -alanine moiety of the molecule is not technically seen as adding steric bulk in the vicinity of 
the scissile amide bond, the decreased rotational freedom that results from this modification may 
also reduce access to the amide carbonyl by preventing pantetheinase from binding the analogue 
in the orientation necessary for catalysis. 
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Figure 3.2. Structures of N7-Pan analogues designed to withstand pantetheinase-mediated hydrolysis using the 
strategies outlined in Figure 3.1 and the text. In each case the boxed region highlights the structural 
modification, while the colour (legend as in Figure 3.1) indicates which specific strategy was used to introduce 
degradation resistance.   
 
The second strategy was based on replacing the scissile amide bond with a bioisostere 
(compounds indicated with a green box in Figure 3.2). Exchange of the scissile amide for a 
hydrazide is one of three bioisosteric replacements that were employed in an attempt to render the 
N7-Pan analogues less susceptible to pantetheinase degradation. Various hydrazide derivatives 
have been claimed to possess antimicrobial, antimalarial, anti-Human Immunodeficiency Virus 
(HIV), antitumor, antimycobacterial, trypanocidal and anti-inflammatory activities [22]. Therefore, 
we set out so synthesize a N7-Pan analogue that incorporated the hydrazide bioisostere.  
 
The second bioisostere that we decided upon was a thioamide. Thioamides, formed by replacing 
the carbonyl oxygen in an amide bond with sulfur, has received considerable attention in synthetic 
medicinal chemistry, although less than a hand full of naturally occurring thioamides are known out 
of over 170 000 natural products [23-24]. Various thioamides have been developed as therapeutics 
against M. tuberculosis, as broad band anthelmintics and antifungals, and thioamides have also 
been discussed in support of inhibition of the anthrax lethal factor. Moreover, another thioamide,  
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closthioamide, represents an extremely active antibacterial agent against MRSA, with only 
moderate cytotoxicity [23]. The third and final bioisostere that we decided on was a bioisostere 
called sulfonamide (R1-S(=O)2-NH-R2). These bioisosteres are widely used in the agricultural and 
pharmaceutical industry. Due to the fact that the main pharmaceutical applications of the 
sulfonamides as clinical medicines include antibacterial agents, diuretics and HIV protease 
inhibitors [25-27], we suspected that the sulfonamide moiety should be pantetheinase-resistant.  
 
The third strategy was based on modifying the structure of N7-Pan 3.10 in such a way that 
pantetheinase would not recognize it as an alternative substrate (compounds indicated with an 
orange box in Figure 3.2). Previously, pantetheinase has been shown to require the pantothenate 
moiety for binding [17, 19]. We therefore wanted to test whether pantetheinase would still 
recognize pantothenamides as substrates if we either remove the 4’-hydroxyl group or replace the 
4’-hydroxyl group with another functional group such as a primary amine or a phosphate.  
3.3 Physicochemical properties of the proposed N7-Pan analogues 
With the dramatic increase in MDR pathogens and the need for novel antibiotics, it is imperative to 
understand as much as possible from preceding efforts in drug discovery and drug development 
settings and to apply the lessons learned to the discovery of prospective antibiotics [28]. Lipinski’s 
landmark study [29] epitomized the first systematic attempt to correlate the physicochemical 
properties of certain drugs within the World Drug Index (WDI) database which included the 
predicted successful initial hits as well as the subsequent late stage leads. By making use of 
experimental and computational approaches Lipinski et al. [29] connected the physicochemical 
properties of drugs with both, their oral bioavailability and the subsequent difficulties encountered 
during preclinical and clinical progression for the first time. The most important discovery in this 
study was the identification of an ideal property space for orally available drug candidates, now 
called “Lipinski’s rules”, “the rule of 5” or “Lipinski’s rules of 5” since all four properties relate to the 
number 5. Today it is common to analyse these properties prior to synthesizing novel candidates 
[28-30]. Approximately 90% of all oral compounds pass three of the four following rules:  
 
1. The molecular weight (M/W) ≤ 500 g.mol-1 
2. The lipophilicity, expressed as the partition coefficient (LogP or cLogP) ≤ 5 and ≥ 0  
3. The number of hydrogen bond (H-bond) donors ≤ 5  
4. The number of hydrogen bond (H-bond) acceptors ≤ 10  
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Consequently, we analyzed the predicted physicochemical properties of the N7-Pan analogues 
described above. The Lipinski rule of 5 physicochemical properties for these compounds is shown 
in Table 3.1. The molecular weight of a compound is probably the most useful measure of 
molecular size as it is very easy to calculate. In literature, increasing molecular weight is related to 
poorer blood brain barrier permeability as well as poorer intestinal permeability [29]. According to 
Lipinski’s rule of 5 most oral drugs have a molecular weight ≤ 500 g.mol-1; all of the proposed N7-
Pan analogues are compliant to this rule.  
 
Lipophilicity is the most important physical property of a drug in relation to its absorption, 
distribution, potency, and elimination. If a drug is too lipophilic it may be insoluble in aqueous 
media such as blood or gastrointestinal fluid, or bind too strongly to plasma proteins and therefore 
the free blood concentration will be too low to produce the desired effect. Alternatively, the drug will 
distribute into lipid bi-layers and be unable to reach the inside of the cell. Conversely, if the drug is 
not lipophilic enough, it will not be absorbed through the gut wall due to a lack of membrane 
solubility. Lipophilicity is expressed as the partition coefficient (LogP or cLogP), where P (partition) 
is a measure of the relative affinity of a molecule for the lipid and aqueous phases in the absence 
of ionization. P is calculated by:  
   
          
          
 
Where            is equal to the concentration of the drug in the octanol phase and            is 
equal to the concentration of the drug in the aqueous phase.  
 
Octanol is the most frequently used lipid phase in pharmaceutical research since it is has a polar 
and non-polar region like a membrane phospholipid.                   is relatively easy to measure 
and frequently correlates well with various biological properties, in addition to being predicted fairly 
accurately with computational models. Using these computational models, cLogP for a molecule 
can be calculated from a sum of fragmental or atom-based terms plus various corrections [31-33]:  
                                 . 
In this study, values of cLogP were calculated with calculator plugins in the program MarvinSketch 
6.0.6. The calculation method that was used is a weighted method which uses equal weights of 
three individual methods. In the first method (VG) LogP data is applied from a publication by 
Viswanadhan et al. [34], in the second method (PHYS) LogP data is applied from the Physical 
Properties (PHYSPROP) database [35] distributed by the Syracuse Research Corporation and in 
the third method (KLOP) LogP data is applied from a publication by Klopman et al. [36]. We found  
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that all of the proposed N7-Pan analogues obey Lipinski’s rule of 5 except N-hexyl-
pantothenhydrazide (3.33, N6-pantothenhydrazide) which had a value of -0.02, indicating that it is  
not lipophilic enough to be considered a suitable drug candidate.  
 
The last two rules of Lipinski are based on H-bond interactions. Intermolecular H-bonds are 
practically non-existent between small molecules in water, while intramolecular H-bonds are more 
easily formed in water since they are entropically more favoured. Consequently, de-solvation and 
formation of a neutral molecule is unfavourable if the compound forms many hydrogen or ionic 
bonds with water. Given that most oral drugs are absorbed through the gut wall by transcellular 
absorption, the number of H-bond donors or acceptors must be limited, otherwise the drug will not 
get absorbed from the gut into the blood [37]. When evaluating our proposed N7-Pan analogues 
against these criteria, we found that all are compliant to the desired amount of H-bond donors (≤ 5) 
and acceptors (≤ 10). The number of H-bond donors and H-bond acceptors were also calculated 
using the calculator plugins in the program MarvinSketch 6.0.6.  
 
In recent years the Lipinski rule of 5 model has been expanded to include more in silico 
characterized properties such as the Polar Surface Area (PSA ≤ 140 Å2), the number of rotatable 
bonds (NRotBs ≤ 10-20), the distribution coefficient (LogD7.4 ≤ 5 and ≥ 0) and the fraction of sp
3-
hybridized carbon atoms (Fsp3) [28, 30]. These additional physicochemical properties for the N7-
Pan analogues are also shown in Table 3.1. The PSA is a measure of what proportion of the 
surface of the molecule is comprised of polar groups, compared to the proportion of hydrophobic 
groups. Our N7-Pan analogues are in good agreement with the optimal PSA of ≤ 140 Å2, except 
for 4’-phospho-N-heptyl pantothenamide (3.74, 4’-phospho-N7-Pan). Furthermore, the NRotBs 
also play an important role in the absorption potential and permeability of a drug. A rotatable bond 
is defined as any single non-ring bond, attached to a non-terminal, non-hydrogen atom. However, 
amide C–N bonds are not counted because of their high barrier to rotation. All of the N7-Pan 
analogues have between 11 and 14 NRotBs which is in good agreement with the suggested 10-20 
NRotBs [30].  
 
The distribution coefficient is similar to the partition coefficient; however, if a drug can ionize then 
the observed partitioning (P) between water and octanol will be pH-dependent. Thus, the 
distribution coefficient is the effective lipophilicity of a drug at a given pH, and is a function of both 
the lipophilicity of the un-ionized drug and the degree of ionization. The distribution coefficient can 
be calculated using the equation:  
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Where            is equal to the concentration of the drug in the octanol phase,           
        is equal 
to the concentration of the ionized drug in the aqueous phase and           
           is equal to the 
concentration of the un-ionized drug in the aqueous phase. 
 
For most of the N7-Pan analogues the partition coefficient is equal to the distribution coefficient 
since these analogues cannot ionize. It is only 4’-phospho-N7-Pan 3.74 and (R/S)-4’-amino-N-
heptyl pantothenamide (3.56, (R/S)-4’-amino-N7-Pan) that are able to ionize due to the 
modifications made at the 4’-position of N7-Pan. Unfortunately, the LogD7.4 values for these 
compounds fall outside the limits of the proposed LogD7.4 values. The NRotBs and the distribution 
coefficients of each N7-Pan analogue were also calculated using the calculator plugins in the 
program MarvinSketch 6.0.6.  
 
The final physicochemical property that we investigated was the molecular topology, Fsp3. Fsp3 is 
the number of sp3-hybridized carbon atoms divided by the total number of carbon atoms. Aqueous 
solubility, plasma protein binding, potassium channel inhibition, as well as Caco-2 permeability are 
all influenced by Fsp3, some favourably and others unfavourably by increased Fsp3. Specifically, 
the aqueous solubility is increased by an increase in Fsp3 [38]. We found that the Fsp3 % 
calculated for the N7-Pan analogues are between 86.7% and 93.3%, except for (E)-N-heptyl CJ-
pantothenamide (3.27, (E)-N7-CJ-Pan) with a Fsp3 % of 75%. Therefore, these N7-Pan analogues 
should have a high aqueous solubility.   
 
All of the proposed N7-Pan analogues pass at least three of the four rules set by Lipinski’s rules of 
5, in addition to the expanded in silico characterized properties. We therefore expect that these 
compounds will be orally bioavailable if they translate into potent inhibitors. 
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PSA (Å2) NRotBs LogD7.4 Fsp
3 
 
316.44 0.72 4 4 98.66 12 0.72 0.875 
 
330.46 1.26 4 4 98.66 12 1.26 0.882 
 
330.46 1.14 4 4 98.66 12 1.14 0.882 
 
330.46 0.94 4 3 89.87 12 0.94 0.882 
 
314.42 0.93 4 4 98.66 11 0.93 0.750 
 
317.42 -0.02 5 5 110.7 12 -0.02 0.867 
 
332.50 1.61 3 4 81.59 12 1.61 0.875 
 
352.49 0.26 5 4 115.7 12 0.26 0.933 
 
315.45 0.61 4 4 104.5 12 -1.29 0.875 
 
300.43 2.00 3 3 78.43 11 2.00 0.875 
 
396.42 0.60 6 5 145.2 14 -2.46 0.875 
a  
Values of cLogP and LogD7.4 were calculated with calculator plugins in the program MarvinSketch 6.0.6, 2013 from ChemAxon (Budapest, Hungary). cLogP and LogD7.4 values were 






) set to 0.1 mol.dm
-3
 [34-36]. We did not consider 
tautomerization in our calculations. PSA was calculated with the same program, but excluded sulfur and phosphorus atoms from the calculations. NRotB, H-bond donors and H-bond 
acceptors were calculated using the same program. The values that fall outside the limits of the physicochemical properties are indicated in red. 
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3.4 Synthesis of pantetheinase-resistant N7-Pan analogues 
Since none of the proposed molecules are commercially available, a large portion of this study was 
dedicated to the synthesis of these potential pantetheinase-resistant S. aureus growth inhibitors 
based on the scaffold of N7-Pan. We first focused on the analogues that have steric bulk in close 
proximity to the scissile amide bond increased, followed by the preparation of the N7-Pan 
bioisosteres. Lastly, we prepared the required analogues where the 4’-hydroxyl group is removed 
or replaced to prevent substrate recognition.  
3.4.1 Increasing steric bulk surrounding the N7-Pan scissile amide bond 
3.4.1.1 N-Heptyl α-methyl pantothenamide (3.7) and N-heptyl β-methyl pantothenamide 
(3.8)   
In the first two N7-Pan analogues the scissile amide bond was retained, but a methyl group was 
added to either the α- or β-position relative to the amide bond. This should introduce steric 
hindrance and should prevent or slow the hydrolysis of the amide bond. The synthesis of N-heptyl 
α-methyl pantothenamide (3.7, N7-α-methyl-Pan) and N-heptyl β-methyl pantothenamide (3.8, N7-
β-methyl-Pan) was based on a modified method of Jana [39] (Scheme 3.1), involving a 
condensation- and a coupling reaction. Since α- and β-methyl pantothenic acids (3.4 and 3.5) are 
not commercially available, these were synthesized first. (R/S)-3-Amino isobutyric acid 3.1 and 
(R/S)-3-aminobutyric acid 3.2 were condensed with (R)-(-)-pantolactone 3.3. The compounds were 
partially purified by anion exchange chromatography (to remove the amines and protonate the 
carboxylate) before further purification by FCC gave amides 3.4 and 3.5 as white-yellow powders 
(which became oils upon standing) in 86% and 82% yield, respectively. Activation of the 
carboxylate by DPPA was used for the final amide bond formation. Specifically, a solution of 
carboxylic acid 3.4 or 3.5 and heptylamine (3.6) in DMF was treated with DPPA and Et3N. 
Subsequent purification by FCC gave amide 3.7 (from 3.4) as a yellow oil in 43% yield. 
Unfortunately, only a 17% yield was obtained for amide 3.8 (yellow oil) (from 3.5) after purification. 
DPPA coupling reactions require strictly anhydrous conditions to achieve successful amide bond 
formations [40]. Given that carboxylic acid 3.5 was found to be very hygroscopic, the low yield 
obtained for amide 3.8 could be attributed to this fact. Additionally, the low yield could also be due 
to a possible competing coupling reaction at the unprotected 4’-hydroxyl position. 
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Scheme 3.1. Synthetic route for the preparation of N-heptyl α-methyl pantothenamide (3.7) and N-heptyl β-
methyl pantothenamide (3.8). N-heptyl α-methyl pantothenamide 3.7 was prepared from (R/S)-3-amino-isobutyric 
acid 3.1 in two steps, while N-heptyl β-methyl pantothenamide 3.8 was prepared from (R/S)-3-aminobutyric acid 
3.2 in two steps. 
3.4.1.2 N-Methyl N-heptyl pantothenamide (3.11)   
N-alkylation of amides is a useful way to prepare more substituted analogues. Generally, N-
substituted amides are synthesized through nucleophilic substitution with alkyl halides under basic 
conditions; however, this method requires the use of strong bases and alkyl halides. Recently, Xia 
et al. [41] developed a method for N-alkylation of amides under neutral conditions that suppresses 
the overalkylation of primary amides. Therefore, we first attempted to synthesize N-methyl-N-heptyl 
pantothenamide (3.11, N-methyl-N7-Pan) using the method of Xia et al. This entails the Cu-
catalyzed N-methylation of amides in which an organic peroxide, specifically dicumyl peroxide 
(DCP), serves as the methylating agent. It has been suggested that this mechanism proceeds via a 
radical process [41].  
 
The first method that we attempted consisted of a two-step linear synthesis (Scheme 3.2, Method 
1). In the first step, calcium pantothenate was exchanged to its free acid 3.9 using Amberlite IR120 
H+-cation exchange resin, followed by coupling to heptylamine (3.6) using DPPA in the presence of 
Et3N. Subsequent purification by FCC gave amide 3.10 as a pure white solid in moderate yield 
(47%). In the final step, we attempted N-alkylation of amide 3.10 using DCP as the methylating 
agent in the presence of copper chloride (CuCl); however, this was unsuccessful and alkyl 3.11 
was not obtained in this manner.  
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Scheme 3.2. Proposed methods for the synthesis of N-methyl-N-heptyl pantothenamide (3.11) by Cu-catalyzed 
N-alkylation of the scissile amide’s nitrogen atom using DCP as the methylating agent. In method 1 and 2 we 
attempted to prepare N-methyl-N-heptyl pantothenamide 3.11 from pantothenic acid 3.9, while in method 3 we 
attempted to prepare N-methyl-N-heptyl pantothenamide 3.11 from Cbz-β-alanine (3.14). 
 
Given that the N-alkylation failed on amide 3.10 (which has an unprotected 1,3-diol on the pantoyl 
moiety), we proposed that protection of the 1,3-diol might increase the likelihood of N-alkylation on 
the amide (Scheme 3.2, Method 2). Consequently, a standard method described by Van der 
Westhuyzen [42] was used to protect the 1,3-diol with a p-methoxybenzylidene (PMB) protecting 
group. 1,3-Diol 3.10 was protected using p-methoxy-benzaldehyde dimethyl acetal and a catalytic 
amount of (±)-10-camphorsulfonic acid (CSA) in THF. p-Methoxybenzylidene 3.12 was obtained in 
a good yield (76%) as a white solid upon purification by FCC. Subsequently, 3.12 was subjected to 
N-alkylation using DCP and CuCl. Unfortunately, even with protection of the 1,3-diol, the N-
alkylation did not take place. Therefore, in a final attempt to alkylate the scissile amide we decided 
to use commercially available carboxybenzyl (Cbz) protected β-alanine (3.14) which does not 
contain the 1,3-diol (Scheme 3.2, Method 3). Seeing as DPPA and DEPC-activated coupling 
reactions are mechanistically and experimentally similar, a DEPC coupling reaction was explored 
as the first step of method 3. A solution of Cbz-β-alanine (3.14) and heptylamine (3.6) in DMF was  
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treated with DEPC and Et3N. Purification by FCC gave carbamate 3.15 as a pure white powder in 
an excellent 93% yield. The next step of the synthesis entailed N-alkylation of the amide; amide 
3.15 was subsequently treated with DCP and CuCl, but without success. After three attempts this 
method was not pursued any further.   
 
In view of the fact that we were unsuccessful with the N-alkylation of the scissile amide’s nitrogen, 
we decided to first mono-alkylate heptylamine (3.6) and to subsequently couple the resulting 
secondary amine (3.17) to pantothenic acid (3.9) to obtain the desired product 3.11 (Scheme 3.3). 
First, we set out to mono-alkylate heptylamine (3.6) through nucleophilic substitution with an alkyl 
halide under basic conditions (Scheme 3.3, Method 1). A method, described by Jablonski et al. 
[43], was used to attempt mono-alkylation with methyliodide (CH3I) in the presence of a base (N-
methylmorpholine), but this was unsuccessful. Alternatively, we decided to use methylamine∙HCl 
as alkylating reagent and react it with heptylbromide (3.18) (Scheme 3.3, Method 2). While 
investigating this method as alternative it was found that Salvatore et al. [44-45] have developed 
an efficient method for the direct N-alkylation of amines that gives mono-alkylated amines 
predominantly or exclusively. This is achieved by performing this reaction in the presence of either 
cesium hydroxide (CsOH) or cesium carbonate (Cs2CO3) in DMF. Consequently, heptylbromide 
(3.18) was treated with either CsOH (CsOH∙H2O was scrupulously dried) or Cs2CO3 in the 
presence of methylamine∙HCl in DMF, but once again, target compound 3.17 did not form during 
this reaction.  
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While investigating possible alternative routes for the preparation of target compound 3.11, the 
alkylated amine 3.17 became commercially available from Sigma-Aldrich, which greatly simplified 
the synthesis of the desired product. The synthesis of 3.11 was based on a method that exploits 
the known reactivity of activated thioesters towards amines in a two-step linear synthesis method 
(Scheme 3.4) previously published from our research group [46]. In the first step, calcium 
pantothenate was converted into its free acid 3.9 and was subsequently coupled to thiophenol 
(3.19) using a DEPC-assisted coupling in the presence of Et3N. Following an aqueous work-up and 
purification by FCC, thioester 3.20 was obtained as a yellow oil (which solidified upon standing) in 
53% yield. In the final step, 3.20 was coupled to N-methyl heptylamine (3.17) by aminolysis of the 
thioester; subsequent purification by FCC afforded target amide 3.11 as a yellow oil, in an excellent 
yield of 86%.   
 
 
Scheme 3.4. Synthetic route for the preparation of N-methyl-N-heptyl pantothenamide (3.11) from pantothenic 
acid 3.9 using a two-step linear method that was developed by Van Wyk and Strauss [46].  
3.4.1.3 (E)-N-Heptyl CJ pantothenamide ((E)-3.27)   
In 2001, Sugie et al. [47] reported that the pantothenic acid analogue CJ-15,801 (a fermentation 
product of Seimatosporium sp., Scheme 1.6, Chapter 1), inhibits the growth of three MDR strains 
of S. aureus with MIC values ranging from 28.8-230 µM [47]. Unpublished results from related 
studies in our laboratory indicated that amide analogues of CJ-15,801 are resistant to 
pantetheinase degradation. Consequently, we decided to incorporate the double bond from CJ-
15,801 into our N7-Pan analogues. Although the introduction of a double bond in the -alanine 
moiety of the molecule is not technically seen as adding steric bulk in the vicinity of the scissile 
amide bond, the decreased rotational freedom that results from this modification may also reduce 
access to the amide carbonyl by preventing pantetheinase from binding the analogue in the 
orientation necessary for catalysis. The synthesis of (E)-N7-CJ-Pan 3.27 was based on a method 
developed by Van der Westhuyzen [42] that consists of six steps; two fragments are prepared 
separately which are then coupled using a Pd-catalyzed coupling to introduce the enamide moiety,  
which is subsequently deprotected to afford target compound (E)-3.27 (Scheme 3.5).  
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The first step in the synthesis of fragment 1 (amide 3.22) consisted of the ring opening and 
subsequent aminolysis of (R)-(-)-pantolactone 3.3, which was achieved with 30% ammonia (NH3) 
in MeOH. The product was partially purified by the removal of NH3 and MeOH in vacuo. The crude 
amide 3.21 was lyophilized to afford a white powder in excellent yield (94%) which was 
subsequently used in the next step without further purification. In the second step, amide 3.21 was 
treated with isopropenyl methyl ether (IPM) and a catalytic amount of PTSA in a 1:1 ratio of DCM 
and acetone to protect the 2,4-diol. After purification by FCC, acetonide 3.22 (fragment 1), was 
obtained in 79% yield, a slightly higher yield than the 62% obtained by Van der Westhuyzen [42].  
 
 
Scheme 3.5. Synthetic route for the preparation of (E)-N-Heptyl CJ pantothenamide (3.27) from (R)-(-)-
pantolactone 3.3 and propiolic acid 3.23 using a six-step method that was developed by Van der Westhuyzen 
[42]. 
 
Next, we had to prepare fragment 2 (bromo acrylamide 3.25). In the first step of the synthesis, 
propiolic acid (3.23) was mono-brominated by refluxing in 48% aqueous hydrobromic acid (HBr), 
followed by cooling on an ice bath. Pure bromo acid 3.24 was isolated as a grey solid upon 
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filtration of the resulting precipitate. Unfortunately, only a 20% yield was obtained, but this gave 
sufficient material to allow the next step to be attempted. In the second step the bromo acid 3.24 
was successfully coupled to heptylamine (3.6) using a standard N,N-diisopropylcarbodiimide (DIC) 
and 4-N,N-dimethylaminopyridine (DMAP)-mediated coupling procedure in DCM, after which 
purification by FCC afforded the second fragment, acrylamide 3.25, as yellow solid in a moderate 
yield (46%). 
 
After the successfully completed syntheses of fragment 1 and 2, a Pd-catalyzed coupling 
procedure was used to introduce the enamide moiety (step 3). This coupling reaction is known to 
stereoselectively prepare E-enamides in excellent yield from amides and bromo acrylamides using 
commercially available reagents [48]. In addition to the Pd-catalyst, a base (in this case we used 
potassium carbonate, K2CO3) is needed to neutralize the HBr that forms during the course of the 
reaction, while a phase transfer-catalyst (cetyltrimethylammonium bromide, CTAB) assists in this 
neutralization process. An appropriate ligand for the Pd is also required. The ligand employed by 
Van der Westhuyzen [42] was the bisphosphine ligand, Xantphos (4,5-Bis(diphenylphosphino)-9,9-
dimethyl-xanthene), a ligand often employed in Pd-catalyzed C–N bond formation systems [42]. 
Bromo acrylamide 3.25 (fragment 2) and amide 3.22 (fragment 1) were therefore coupled and 
subsequently purified by FCC (to separate the E- and Z-isomers) to afford enamide (E)-3.26 and 
(Z)-3.26 in 50% and 10% yield, respectively, with an E:Z ratio of 5:1. Given that the deprotected 
pantoyl moiety is extremely acid sensitive and will lactonize at a low pH, the deprotection of the 
acetonide was carried out using mild conditions at a neutral pH. In the final step the acetonide 
protecting group was successfully removed from both (E)-3.26 and (Z)-3.26 using bismuth (III) 
chloride (BiCl3) in aqueous CH3CN. Subsequent purification by FCC gave (E)-3.27 as a white solid 
in 30% yield and (Z)-3.26 as a yellow oil in 62% yield, respectively. The absolute stereochemistry 
of the E- and Z-isomers was confirmed with 1H NMR spectroscopic analysis – the vinylic proton 
shifts as well as the J-couplings were consistent with those previously reported by Van der 
Westhuyzen [42]. 
3.4.2 Preparation of bioisosteres of N7-Pan  
3.4.2.1 N-Hexyl pantothenhydrazide (3.33)  
The first bioisosteric replacement that we decided upon was a hydrazide. Methodologies reported 
for the direct preparation of carboxylic acid hydrazides from carboxylic acids are generally 
inefficient. Instead, the standard method for preparing carboxylic acid hydrazides is by 
hydrazinolysis of the corresponding esters in MeOH or EtOH [22, 49-50]. However, in the case of 
α,β-unsaturated esters, the main product is usually the pyrazolidinone due to an undesired 
Michael-type cyclization. Consequently, Zhang et al. [49] developed an alternative method for the 
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synthesis of hydrazides—including those of α,β-unsaturated acids—involving preforming activated 
esters or amides by means of HOBt and EDC hydrochloride treatment, followed by their reaction 
with hydrazine [49]. We based our method for the synthesis of N6-Pantothenhydrazide 3.33 (a N7-
Pan analogue) on the known reactivity of activated thioesters towards amines and decided to 
activate the carboxylic acid for hydrazinolysis with a thioester, rather than an ester.  
 
This synthetic route that was developed consisted of a four-step linear synthesis that included a 
thioesterification, as well as reductive amination (Scheme 3.6). In step 1, calcium pantothenate 
was converted into free acid 3.9 using Amberlite IR120 resin and was subsequently coupled to 
ethanethiol (3.28) using a DEPC-assisted coupling reaction in the presence of Et3N to facilitate the 
thioesterification. Following an aqueous work-up and purification by FCC, thioester 3.29 was 
obtained as a yellow oil in 60% yield. Next, 3.29 was treated with hydrazine hydrate in EtOH and 
refluxed overnight. Following this, hydrazide 3.30 was obtained as a yellow oil upon removal of the 
solvent in vacuo and was subsequently used in the next step without any further purification.  
 
 
Scheme 3.6. Synthetic route for the preparation of N-hexyl pantothenhydrazide (3.33) from pantothenic acid 3.9 
in four steps. 
 
The final two steps entailed a reductive amination for which a general method described by 
Andreini et al. [50] was used. Hydrazide 3.30 was reacted with hexanal (3.31) in EtOH by stirring at 
reflux for 48h. After purification by FCC, imine 3.32 was obtained in a satisfactory yield of 77%. In 
the final step, 3.32 was reduced to afford the target compound N6-pantothenhydrazide 3.33. 
Initially we attempted the reduction of imine 3.32 with NaBH4 in MeOH; however, the reduction was  
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unsuccessful and the starting material was recovered. Next, imine 3.32 was treated with sodium 
cyanoborohydride (NaBH3CN)—a reagent that is only reactive towards protonated imines [51]—in 
a 3:2 mixture of MeOH and DCM and the pH was adjusted first to pH 3, and then to pH 1 after the 
first half hour. Purification by FCC afforded 3.33 as a yellow oil, but unfortunately only in a 27% 
yield. 
3.4.2.2 N-Heptyl pantothenthioamide (3.36)   
The second bioisosteric replacement that we decided upon was a thioamide. The synthetic 
preparation of thioamides has been accomplished using various reagents, such as phosphorus 
pentasulfide, bis(tricyclohexyltin) sulfide with boron trifluoride, hydrogen sulfide in the presence of 
an acid, bis(trimethylsilyl) sulfide with cobalt (II) chloride hexahydrate, 2,4-bis(p-methoxyphenyl)-
1,3-dithiaphosphetane 2,4-disulfide (Lawesson’s reagent), as well as thionation of gem-dichlorides 
with thioacetic acid, potassium xanthate or sodium hydrogen sulfide [24, 52]. We decided to base 
the synthesis of N-heptyl pantothenthioamide (3.36, N7-pantothenthioamide) on the conversion of 
the carbonyl oxygen of the scissile amide bond to sulfur using Lawesson’s reagent.  
 
The synthetic route that we developed consisted of a four-step linear synthesis that included a 
thionation and a condensation reaction (Scheme 3.7). In step 1, a solution of Cbz-β-alanine (3.14) 
and heptylamine (3.6) in DMF was treated with DEPC and Et3N to facilitate the amide bond 
formation. The side products and unreacted amine were removed through an aqueous work-up, 
which proved to be adequate to obtain amide 3.15 as a pure white powder in an excellent 93% 
yield. The second step of the synthesis entailed the thionation of the scissile amide bond based on 
a method from Kuehne et al. [53] and Otani et al. [54]. Amide 3.15 was treated with Lawesson’s 
reagent in toluene and the reaction mixture was refluxed overnight. Subsequent purification by 
FCC afforded thioamide 3.34 as a light yellow powder in good yield (67%).  
 
The third step of the synthesis entailed the deprotection of carbamate 3.34. The benzyl carbamate 
protecting group was successfully removed by refluxing overnight in a 1:1 solution of MeOH and 
concentrated HCl. The crude product was lyophilized to afford the HCl salt of amine 3.35 (white 
powder) which was subsequently used in the next step without any further purification. In the final 
step amine 3.35 was condensed with (R)-(-)-pantolactone 3.3 in the presence of Et3N to facilitate 
the amide bond formation. Subsequent purification by FCC afforded target compound 3.36 as a 
yellow oil. Unfortunately, a very low yield (7%) was obtained in the final step. This low yield could 
be attributable to the fact that the HCl salt of amine 3.35 was used which decreased the total Et3N 
concentration in the reaction mixture. Furthermore, a large quantity of (R)-(-)-pantolactone 3.3 was 
recovered during FCC. The formation of amide bonds from esters are extremely difficult and 
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usually require high temperatures. In the final step we condensed amine 3.35 with (R)-(-)-
pantolactone 3.3, which is a very stable ester in the form of a five membered ring lactone.  
 
 
Scheme 3.7. Synthetic route for the preparation of N-heptyl pantothenthioamide (3.36) from Cbz-β-alanine (3.14) 
in a four-step synthesis. 
3.4.2.3 N-Heptyl pantoyltauramide (3.44)   
The third and final bioisosteric replacement performed in this study involved the synthesis of N-
heptyl pantoyltauramide (3.44, N7-pantoyltauramide). In this molecule the scissile amide bond was 
replaced with a sulfonamide (R1-S(=O)2-NH-R2) moiety. The synthesis of N7-pantoyltauramide 
3.44 was based on a method developed by Jana [39] and comprised of five linear steps that 
included a protection and activation reaction (Scheme 3.8).  
 
Taurine (2-aminoethanesulfonic acid, 3.37) was protected with benzyl chloroformate (CbzCl, 3.38) 
and the excess CbzCl was azeotroped off by co-evaporation with toluene, EtOH and DCM. The 
crude carbamate 3.39 was lyophilized and subsequently used in the next step without any further 
purification. In the second step, the sulfonic acid on carbamate 3.39 was activated by fluorination 
using (diethylamino)sulphur trifluoride (DAST, 3.40) to make it more reactive towards primary 
amines. After purification by FCC, tauryl fluoride 3.41 was obtained in 80% yield, a much higher 
yield than Jana’s reported 44%. Step 3 entailed the aminolysis of tauryl fluoride 3.41 with  
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heptylamine (3.6) in DCM at 50°C. In this reaction, heptylamine (3.6) was successfully coupled 
after 20h to afford tauramide 3.42 as a yellow-orange powder in an excellent yield of 83% upon 
purification with FCC.  
 
 
Scheme 3.8. Synthetic route for the preparation of N-heptyl pantoyltauramide (3.44) from taurine 3.37 using the 
five-step linear method that was developed by Jana [39]. 
 
The fourth step of the synthesis involved the deprotection of carbamate 3.42 using concentrated 
HCl in the presence of MeOH. The benzyl formate protecting group was successfully removed by 
refluxing overnight in a 1:1 solution of MeOH and concentrated HCl. The crude amine 3.43 was 
lyophilized to afford the product as the HCl salt (white powder) in an excellent yield (82%). It was 
subsequently used in the next step without any further purification. The final step of the synthesis 
entailed the formation of an amide bond by aminolysis of (R)-(-)-pantolactone 3.3 with amine 3.43 
in the presence of Et3N. The reaction was complete after refluxing for 7h and amide 3.44 was 
purified by FCC. Spectroscopic analysis confirmed the formation of the target compound; however, 
impurities were still present. As a result, amide 3.44 was subjected to further purification by solid  
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phase extraction (SPE). Amide 3.44, dissolved in DCM, was loaded onto a DCS-NH2 SPE column 
and eluted with CH3CN. The second purification was successful and amide 3.44, free of any 
impurities, was obtained, but unfortunately with only an 18% yield in the final step. 
3.4.3 Removal of 4’-OH group from N7-Pan  
3.4.3.1 (R/S)-4’-Deoxy-N-heptyl pantothenamide (3.49)  
The first N7-Pan analogue in which the 4’-hydroxyl group was altered is structurally identical to 
(R/S)-4’-deoxy-N5-Pan 2.9, the synthesis of which is described in the manuscript reproduced in 
Chapter 2. However, to maintain the same core structure of the series, (R/S)-4’-deoxy-N-heptyl 
pantothenamide (3.49, (R/S)-4’-deoxy-N7-Pan) was synthesized using the method developed 
previously for (R/S)-4’-deoxy-N5-Pan 2.9 (Scheme 3.9). The procedure consisted of a four-step 
linear synthesis that included two coupling reactions and a deprotection reaction.  
 
A solution of Cbz-β-alanine (3.14) and heptylamine (3.6) in DMF was treated with DEPC and Et3N 
in the first step to facilitate the amide bond formation. The side products and unreacted amine were 
removed through an aqueous work-up, which proved to be adequate to obtain amide 3.15 as a 
pure white powder in an excellent 93% yield. The second step of the synthesis entailed the 
deprotection of carbamate 3.15, with the benzyl carbamate protecting group being successfully 
removed with H2 in the presence of 10% palladium on activated carbon (Pd/C), to yield amine 3.45 
as a pure white powder in a yield of 96% upon filtration. The purity of amine 3.45 was confirmed 
with NMR spectroscopic analysis. 
 
Step 3 entailed an amide coupling in the presence of EDC hydrochloride using amine 3.45 and 
acid 3.46 (synthesised according to Tuck et al. [55] through the oxidation of pinacolone (3.47) by 
KMnO4). The coupling was assisted with HOBt and DIPEA, which resulted in the formation of the 
second amide bond. The experimental procedure (as described in Chapter 2) was followed; 
however, a yield of only 22% was obtained for 3.48 after purification by FCC compared to the 57% 
yield obtained in the equivalent coupling used to prepare (R/S)-4’-deoxy-N5-Pan 2.9. This low yield 
could be attributed to the low purity of carboxylic acid 3.46 as it was found to degrade over time 
and it was not used immediately. The final step of the synthesis (step 4) entailed the reduction of 
ketone 3.48. Since three carbonyl groups were present in the molecule (1 × ketone and 2 × 
amides), NaBH4 was used for the reduction due to its selectivity toward ketones as opposed to 
amides. Ketone 3.48 was therefore treated with NaBH4 to afford target compound 3.49 as a white 
powder in a good 78% yield after an aqueous work-up. 
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Scheme 3.9. Synthetic route for the preparation of (R/S)-4’-deoxy-N-heptyl pantothenamide (3.49) from Cbz-β-
alanine (3.14) through a four-step linear synthesis based on the equivalent protocol developed for preparation of 
the pentyl (N5-Pan) homologue as described the manuscript reproduced in Chapter 2 [12]. 
3.4.3.2  (R/S)-4’-Amino-N-heptyl pantothenamide (3.56)  
The second N7-Pan analogue in which the 4’-hydroxyl was modified had this group replaced with a 
4’-amino group in order to prevent its recognition by pantetheinase as a substrate. The original 
synthetic procedure for the synthesis of (R)-4’-amino-N7-Pan 3.56 was based on a method 
developed by Yan et al. [56] for the preparation of (R)-4’-amino PantSH from pantethine (the 
disulfide of PantSH, Scheme 1.1B, Chapter 1). Yan et al. [56] first attempted to install the 4’-amine 
via activation of the 4’-hydroxyl, followed by nucleophilic substitution with sodium azide (NaN3) and 
subsequent reduction of the azide to afford the 4’-amine. In this work, activation of the 4’-hydroxyl 
was first attempted with 4-toluenesulfonyl chloride (TsCl) and 2,4,6-triisopropyl-benzenesulfonyl 
chloride (TIPBSCl); however, these sulfonyl chlorides failed to activate the 4’-hydroxyl group. The 
more reactive methylsulfonyl chloride (MsCl) proved to be reactive enough to mesylate the 4’-
hydroxyl group. However, when nucleophilic substitution of the mesylated 4’-OH was attempted 
with NaN3, the reaction still failed to take place. This could be attributable to steric hindrance 
caused by the dimethyl groups on the adjacent quaternary carbon. Consequently, the authors used 
reductive amination to install the 4’-amine after preparation of the 4’-aldehyde; this method proved 
to be successful and allowed for the preparation of (R)-4’-amino PantSH [56]. We therefore also  
used this method in our first attempt of the synthesis of target compound 3.56 (Scheme 3.10). 
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Scheme 3.10. Proposed synthetic route for the preparation of (R)-4’-amino-N-heptyl pantothenamide (3.56) from 
pantothenic acid 3.9, adapted from the method developed by Yan et al. [56]. 
 
The proposed synthetic route consisted of an eight-step linear synthesis which included protection, 
oxidation, reductive amination, and deprotection reactions. In the first step, calcium pantothenate 
was exchanged to the free acid 3.9 using Amberlite IR120 resin. This compound was subsequently 
coupled to heptylamine (3.6) using DPPA in the presence of Et3N to facilitate the amide bond 
formation. Subsequent purification by FCC gave amide 3.10 as a pure white solid in a moderate  
yield (47%). In the second step, tert-butyldimethylsilyl chloride (TBSCl) with imidazole was used to 
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protect both the primary and secondary hydroxyl groups of 3.10, and the product was purified with 
FCC to afford the TBS ether 3.50 in 83% yield, slightly lower than the reported 98%. Step 3 
entailed the selective removal of the TBS-protecting group from the primary alcohol of TBS ether 
3.50. This TBS protecting group was successfully cleaved with pyridinium p-toluenesulfonate 
(PPTS) in MeOH, before purification by FCC afforded hydroxyl 3.51 as a yellow oil in 86% yield 
that correlates well with the reported yield (92%) of Yan et al. [56]. Additionally, the 1H NMR data 
are consistent with those previously reported in literature [56]. Subsequently, in step 4, hydroxyl 
3.51 was oxidized to the aldehyde using Dess-Martin periodinane, before purification by FCC gave 
aldehyde 3.52 as a yellow oil in an excellent yield of 96%.  
 
Yan et al. [56] reported the execution of steps 4 to 7 with only partial purification in step 6 before 
carrying out step 7. Consequently, we also decided to carry out steps 5 to 7 (Scheme 3.10) in the 
same manner. Step 5 entailed the metal hydride-mediated reductive amination of aldehyde 3.52 
using dimethoxybenzyl amine (DMBNH2) in DCE, followed by NaBH4-mediated reduction of the 
imine to afford amine 3.53. The use of protecting groups on the amine is crucial during the metal 
hydride reductive amination to prevent over-alkylation. Without a protecting group, multiple 
alkylation reactions typically occur, resulting in the formation of undesired secondary or tertiary 
amine products. Removal of a DMB protecting group from a secondary amine is not widely 
reported and harsh reaction conditions are generally required; however, the removal of a DMB 
protecting group from an amide is much easier. Therefore, to facilitate the DMB deprotection, 
amine 3.53 was transformed into the corresponding 9-fluorenylmethyl carbamate (Fmoc) in step 6. 
Amine 3.53 was treated with Fmoc chloride and DIPEA in a 4:1 ratio of dioxane and H2O and 
carbamate 3.54 was partially purified by FCC to remove excess unreacted Fmoc chloride. The 
partially purified carbamate 3.54 was subsequently used in the next step without any further 
purification. In step 7, both the DMB and TBS protecting groups are removed using trifluoroacetic 
acid (TFA) under standard reaction conditions. Purification by FCC was performed to isolate the 
reaction product; however, NMR spectroscopic analysis indicated that none of the isolated 
compounds were the desired product (carbamate 3.55).  
 
Since we were unable to successfully synthesize carbamate 3.55 by carrying out steps 5 to 7 
without purification, we decided to repeat these steps with purification after each reaction. Thus, 
aldehyde 3.52 was once more treated with DMBNH2, followed by NaBH4-mediated reduction of the 
imine. However, subsequent purification by FCC did not afford amine 3.53. The reaction conditions 
were thus modified in an attempt to successfully synthesize amine 3.53. Specifically, the reaction 
temperature was increased to reflux, the solvent was changed to toluene to increase the reflux 
temperature and the duration of the reaction was varied. Unfortunately, none of these conditions 
resulted in the successful formation of the desired product.  
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Given that we were unsuccessful in using the N7-Pan analogue for the synthesis of (R)-3.56, we 
decided to revert to the benzyl ester derivative of pantothenic acid 3.9 and to perform the reaction 
with this compound (Scheme 3.11). Briefly, in step 1 benzyl bromide (3.57) in DMF was used to 
alkylate the sodium salt of acid 3.9, giving ester 3.58 as a yellow oil in good yield (74%) after 
purification by FCC and the 1H NMR data are consistent with those previously reported in literature 
[57]. The second step entailed the protection of the primary and secondary alcohols in the pantoyl 
moiety of 3.58 as TBS ethers. The side products were removed through an aqueous work-up, 
followed by FCC to remove unreacted TBS chloride. This method allowed for 3.59 to be obtained, 
which was then used in the next step without any further purification. In step 3, the primary 
hydroxyl of 3.59 was deprotected to afford 3.60 after purification by FCC; this was oxidized to the 
aldehyde 3.61 in step 4 with a 77% yield over the two steps. Next, we attempted the reductive 
amination of aldehyde 3.61 with DMBNH2 and NaBH4; however, once again we were unable to 
successfully synthesize protected amine 3.62. Consequently, this method by Yan et al. [56] was 
not pursued any further.   
 
 
Scheme 3.11. Alternative proposed synthetic route for the preparation of (R)-4’-amino-N-heptyl pantothenamide 
(3.56) from pantothenic acid 3.9, adapted from the method developed by Yan et al. [56]. 
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Seeing as we have already prepared aldehyde 3.61 and found it to be easier to visualize on TLC 
compared to aldehyde 3.52 due to the presence of a benzyl group, we decided to use this 
compound to attempt alternative metal hydride reductive amination methods. The formation of 
unwanted secondary and tertiary alkylated amines is a general problem during metal hydride 
reductive amination reactions; thus the ammonia source has to be protected. However, this in itself 
produces problems, since protecting groups add functional groups and structural complexity to a 
molecule, which can have unfavourable effects on reactivity, in addition to increasing the number 
steps in a synthetic route [58]. Mirriyala et al. [59] developed an alternative and more selective 
reductive amination method for the preparation of primary amines from ketones, using NH3 and 
titanium (IV) isopropoxide-NaBH4. Unfortunately, when this method was applied to aldehydes it 
predominately resulted in the formation of secondary amines [59].  
 
Recently, Dangerfield et al. [58] developed a protecting group-free synthesis of primary amines by 
optimizing reaction conditions for the metal hydride/NH3-mediated reductive amination of 
aldehydes. This new method primarily afforded primary amines and it was also found to be 
applicable to a wide range of functionalized substrates [58]. Consequently, we decided to use this 
method to synthesize amine 3.63 (Scheme 3.12, Method 1). Aldehyde 3.61 was dissolved in a 
saturated solution of ammonium acetate (NH4OAc) in EtOH, followed by treatment with NaBH3CN 
and 30% aqueous ammonium hydroxide, and was then refluxed overnight. Subsequently, the 
mixture was concentrated in vacuo and the residue was loaded onto pre-washed Dowex W50-X8 
H+-ion exchange resin and washed several times with H2O to remove the excess salt. The product 
was then eluted with 15% to 30% aqueous ammonium hydroxide, the eluent was lyophilized and 
finally analyzed using NMR spectroscopy; however, no product was obtained.  
 
In a final attempt to utilize aldehyde 3.61, we tried a transamination procedure as described by de 
Kimpe et al. [60] (Scheme 3.12, Method 2). This method entails the formation of N-benzyl imine 
3.65 by treating aldehyde 3.61 with benzylamine (3.64) in the presence of MgSO4 (step 1), 
followed by isomerization with potassium tert-butoxide (tBuOK) to afford the conjugated N-
(benzylidine) amine 3.66 (step 2). The final step (step 3) entails acid hydrolysis of 3.66 to remove 
the benzyl protecting group and subsequent addition of base to afford amine 3.63. Therefore, in 
step 1 aldehyde 3.61 was treated with benzylamine 3.64; however, the reaction did not proceed at 
room temperature, at reflux or when an additional equiv. of 3.64 was added. Consequently, after 
many failed attempts to introduce the 4’-amino group via reductive amination and transamination, 
this strategy was not pursued any further. 
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Scheme 3.12. Alternative proposed synthetic routes for the preparation of (R)-4’-amino-N-heptyl pantothenamide 
(3.56). (Method 1) An alternative method for the metal hydride-mediated reductive amination of aldehyde 3.61 
based on a method developed by Dangerfield et al. [58]. (Method 2) An alternative method for the transamination 
of aldehyde 3.61 based on a method that was developed by de Kimpe et al. [60]. 
 
A thorough literature search revealed a method, developed by Kopelevich et al. [61] in 1979, that 
utilizes a Gabriel-type synthesis with potassium phthalimide (3.67) (Scheme 3.13) to introduce the 
4’-amine functionality onto pantothenic acid 3.9. This was achieved by preparing (R/S)-4’-amino-2-
hydroxy-3,3-dimethylbutanoic acid (3.69), which was subsequently coupled to β-alanine (Scheme 
1.3, Chapter 1) to afford (R/S)-4’-amino pantothenic acid. Given that a similar strategy in the 
synthesis of (R/S)-4’-deoxy-N7-Pan 3.49 to prepare acid 3.46 was used, before coupling it to 
amine 3.45 (Scheme 3.9), we decided to apply this method to the synthesis of (R/S)-3.56. While an 
important disadvantage of this method is the formation of a mixture of enantiomers at the 2’-
hydroxyl group, as was the case with (R/S)-3.49, we decided to proceed with the synthesis with the 
intention of revisiting the enantioselective syntheses in the case that the racemate was found to 
have desirable biological activity. 
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Scheme 3.13. Synthetic route for the preparation of (R/S)-4’-amino-N-heptyl pantothenamide (3.56) using 
phthalimide to introduce the 4’-amine, based on methods adapted from Kopelevich et al. [62] and de Villiers et 
al. [12].  
 
We used an adapted experimental procedure from Kopelevich et al. [62], leading to a five-step 
linear synthesis that included a condensation and coupling reaction. In the first step, (R)-(-)-
pantolactone 3.3 was condensed with potassium phthalimide (3.67) (synthesised according to 
Wang et al. [63] by stirring phthalimide with KOH in a mixture of MeOH and EtOH) at 250°C, before 
purification by FCC afforded phthalimide 3.68 as a pale yellow solid in excellent yield (86%) and 
the 1H NMR data are consistent with those previously reported in literature [62]. Although we start 
off with an R-configuration at the hydroxyl in (R)-(-)-pantolactone 3.3, phthalimide 3.68 is a mixture 
of enantiomers. We hypothesize that this is due to potassium phthalimide (3.67) acting as a base 
that deprotonates at the α-carbon, i.e. at the (R)-hydroxyl position, leading enolization and 
racemization. In the second step, the phthaloyl protecting group was successfully removed using 
hydrazine hydrate in EtOH and amine 3.69 was obtained as a pure white powder upon 
recrystallization with chloroform in moderate yield (57%). Subsequently, in step 3, primary amine 
3.69 was protected with CbzCl 3.38 in aqueous NaOH. The reaction mixture was washed with  
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diethyl ether to remove excess unreacted CbzCl 3.38 and the aqueous layer was lyophilized to 
afford carbamate 3.70 as a white powder in a much higher yield (93%) than the 67% yield reported 
by Kopelevich et al. [62].  
 
Step 4 entailed an EDC-assisted coupling between acid 3.70 and amine 3.45 (as previously 
described in the synthesis of (R/S)-3.49 in Chapter 2 [12]) in the presence of HOBt and DIPEA, 
which resulted in the formation of the second amide bond. After purification by FCC, amide 3.71 
was obtained as a yellow oil in 50% yield; this result correlates well with the yield obtained in the 
similar coupling used to prepare (R/S)-4’-deoxy-N5-Pan 2.9 as described in Chapter 2. The final 
step of the synthesis involved the deprotection of carbamate 3.71 by treatment with H2 in the 
presence of 10% Pd/C, to yield target compound (R/S)-3.56 as a pure white solid upon filtration in 
an excellent 89% yield. The purity was confirmed by 1H NMR spectroscopic analysis. 
3.4.3.3 4’-Phospho-N-heptyl pantothenamide (3.74)  
The synthetic route for preparation of 4’-phospho-N7-Pan 3.74 was based on a method developed 
by Strauss et al. [57] and comprised of three linear steps that included a phosphorylation and 
deprotection step (Scheme 3.14). In the first step, calcium pantothenate was converted into the 
free acid 3.9 using Amberlite IR120 resin and was subsequently coupled to heptylamine (3.6) using 
DEPC in the presence of Et3N to facilitate the amide bond formation. The side products and 
unreacted amine were removed through aqueous work-up; this proved to be adequate and amide 
3.10 was subsequently used in the next step without any further purification. In the second step, 
hydroxyl 3.10 was phosphorylated with dibenzylchlorophosphate 3.72 (prepared in situ by reacting 
dibenzylphosphite and N-chlorosuccinimide in toluene for 2h, followed by filtration of the 
succinimide) in pyridine at -40°C, before purification by FCC afforded 3.73 as a yellow solid in a 
34% yield. The final step of the synthesis entailed its deprotection; the benzyl protecting groups 
were successfully removed with H2 in the presence of 10% Pd/C to yield target compound 3.74 as 
a clear oil in an excellent yield (98%) upon filtration and the purity was confirmed by 1H NMR 
spectroscopic analysis.  
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Scheme 3.14. Synthetic route for the preparation of 4’-phospho-N-heptyl pantothenamide (3.74) from 
pantothenic acid using a method developed by Strauss et al. [57].  
3.5 Biological evaluation of N7-Pan analogues 
The next objective was to evaluate whether the ten N7-Pan derivatives prepared above retained 
their potency towards S. aureus. We evaluated the compounds in two different ways: first, we 
subjected all of the N7-Pan derivatives to kinetic analysis using heterologously purified SaPanK-II 
enzyme to determine whether they have the same kinetic parameters associated with the mode of 
action of the parent compound N7-Pan 3.10. Second, we investigated the whole cell inhibition of S. 
aureus RN4220 by these compounds. 
3.5.1 Kinetic characterization of S. aureus pantothenate kinase (SaPanK-II) 
using the N7-Pan analogues as alternate substrates 
SaPanK-II was overexpressed in E. coli and purified using Ni2+-based immobilized metal ion affinity 
chromatography (IMAC) in similar fashion as was described in the accompanying manuscript in 
Chapter 2. The purified SaPanK-II was subsequently assayed for its ability to catalyze the ATP-
dependent phosphorylation of the N7-Pan analogues using an established enzyme-coupled assay 
[64]. In this continuous assay (Figure 3.3), one molecule of substrate (pantothenic acid 3.9 in the 
figure; N7-Pan analogues in this study) reacts with one molecule of ATP to form the 
phosphorylated product (4’-phospho-pantothenic acid in Figure 3.3) and one molecule of ADP. 
Pyruvate kinase (PK) regenerates ATP from the ADP molecule by transferring the phosphate from 
phosphoenol pyruvate (PEP), leading to the formation of one molecule of pyruvate. This pyruvate 
molecule is consumed by lactose dehydrogenase (LDH) to generate one molecule of lactate with 
the concomitant oxidation of one molecule of NADH to NAD+. The decrease of NADH is followed 
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spectrophotometrically at A340 over time. From the slope of the curves obtained in this manner 
initial rates are calculated that are used to obtain the kinetic parameters.  
 
 
Figure 3.3. Coupled enzymatic assay to quantify the [ADP] produced by the PanK reaction. 
 
Each N7-Pan analogue was tested as substrate of SaPanK-II and the Michaelis-Menten kinetic  
parameters (summarized Table 3.2) were determined by utilizing measurements from the initial 
phase of each reaction (<10% substrate consumed). The kinetic profiles obtained are shown in 
Figure 3.4. We predicted that the N7-Pan analogues that would exhibit the same mode of action as 
N7-Pan 3.10, would also show its unusual combination of kinetic parameters which includes a high 
apparent affinity (KM
app) and low turnover (kcat) resulting in a high apparent catalytic efficiency 
(kcat/KM
app). However, not one of the analogues exhibited such a profile.  
 




app (µM) kcat (s
-1) kcat/KM (mM
-1.s-1) Nb Equation fitted 
3.9 27.8 ± 3.3 3.37 ± 0.24 124 ± 7 4 Hill equation 
3.10 2.04 ± 0.54 0.22 ± 0.02 118 ± 41 2 Michaelis-Menten 
3.7 35.3 ± 1.3 1.77 ± 0.02 50.3 ± 2.5 2 Michaelis-Menten 
3.8 67.5 ± 16 1.64 ± 0.18 25.3 ± 5.3 4 Michaelis-Menten 
3.11 487 ± 127 5.79 ± 1.4 12.0 ± 0.31 2 Michaelis-Menten 
3.27 39.3 ± 2.9 2.46 ± 0.19 62.5 ± 0.41 2 Michaelis-Mentenc 
3.44 51.7 ± 27 5.29 ± 1.9 107 ± 15 3 Michaelis-Mentenc 
3.36 111 ± 96 3.46 ± 2.0 38.7 ± 13 4 Michaelis-Mentenc 
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3.33 37.0 ± 17 1.74 ± 0.31 52.1 ± 16 4 Michaelis-Menten 
3.56 - - - 2 - 
3.49 ND ND ND ND ND 
3.74 ND ND ND ND ND 
a  
Kinetic parameters were determined by keeping the ATP concentration constant at 1.5 mM in all cases. All reported 
parameters are the mean of those obtained by fitting the given equation to each experiment’s individual data set; errors 
indicate the range/2 (for parameters obtained from two independent experiments) and the SEM (for parameters 
obtained from three or more independent experiments). 
b 
 Number of independent experiments. 
c 
Certain N7-Pan analogues showed inhibition of SaPanK-II at high substrate concentrations; using a Michaelis-Menten 
equation that accounts for the uncompetitive substrate inhibition, a Ki for each compound was determined – (E)-N7-CJ-
Pan 3.27 = 205 ± 8.8 µM, N7-pantoyltauramide 3.44 = 279 ± 93 µM and N7-pantothenthioamide 3.36 = 225 ± 137 µM.
 
 
Compared to N7-Pan 3.10 which has a KM
app of 2.04 ± 0.54 µM, all of the N7-Pan analogues with 
steric bulk introduced (Figure 3.4A) had much lower affinities for SaPanK-II, suggesting that they 
are poor substrates. N7-α-methyl-Pan 3.7 has the highest affinity with a KM
app of 35.3 ± 1.3 µM, 
which is comparable to that of the native substrate, pantothenic acid 3.9 (KM
app = 27.8 ± 3.3 µM), 
while N-Methyl-N7-Pan 3.11 is the poorest substrate with a KM
app of 487 ± 127 µM. This value is 
more than 15-fold higher than the KM
app of pantothenic acid 3.9. 
 
 
Figure 3.4. (A) Kinetic profiles for SaPanK-II with pantothenic acid 3.9 (dark green), N7-Pan 3.10 (grey) and the 
N7-Pan analogues with steric bulk introduced (N7-α-methyl-Pan 3.7 (black), N7-β-methyl-Pan 3.8 (red), N-methyl-
N7-Pan 3.11 (light green) and (E)-N7-CJ-Pan 3.27 (dark blue)). (B) Kinetic profiles for SaPanK-II with pantothenic 
acid 3.9 (dark green), N7-Pan 3.10 (grey) and the bioisostere N7-Pan analogues (N6-pantothenhydrazide 3.33 
(cyan), N7-pantothenthioamide 3.36 (yellow) and N7-pantoyltauramide 3.44 (pink)). (C) Kinetic profiles for 
SaPanK-II with pantothenic acid 3.9 (dark green), N7-Pan 3.10 (grey) and (R/S)-4’-amino-N7-Pan 3.56 (light blue). 
 
Furthermore, compared to the low turnover (kcat = 0.22 ± 0.02 s
-1) of N7-Pan 3.10, all of the N7-Pan 
analogues with steric bulk introduced had a much higher turnover. N7-β-methyl-Pan 3.8 has the 
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lowest turnover with a kcat of 1.64 ± 0.18 s
-1, but this is still roughly 7-fold higher than for the N7-
Pan 3.10 value. N-Methyl-N7-Pan 3.11 has the highest turnover with a kcat of 5.79 ± 1.4 s
-1, which 
is higher than what we observe for pantothenic acid 3.9 (kcat = 3.37 ± 0.24 s
-1), while (E)-N7-CJ-
Pan 3.27 and N7-α-methyl-Pan 3.7 have kcat-values of 2.46 ± 0.19 s
-1 and 1.77 ± 0.02 s-1, 
respectively. Since none of the N7-Pan analogues with steric bulk added show the same unusual 
combination of kinetic parameters observed for N5-Pan and N7-Pan 3.10 (as described in Chapter 
2) and consequently do not have the same complex interaction with SaPanK-II, it is doubtful that 
they would act as uncompetitive inhibitors of the enzyme as is the case with N7-Pan.  
 
Of the three N7-Pan bioisosteres (Figure 3.4B), the kinetic parameters of N6-pantothenhydrazide 
3.33 was the closest to that of N7-Pan 3.10. It had a relatively low affinity for SaPanK-II (KM
app = 
37.0 ± 17 vs. 2.04 ± 0.54 µM for N7-Pan 3.10) and a higher turnover (kcat = 1.74 ± 0.31 vs. 0.22 ± 
0.02 s-1). N7-pantothenthioamide 3.36 was also a poor substrate for SaPanK-II with a KM
app of 111 
± 96 µM. This large SEM is attributed to the variation in the parameters obtained from the standard 
kinetic equation fits due to 3.36 being a poor substrate. Furthermore, it has a turnover which is 
comparable to that of pantothenic acid 3.9, with kcat-values of 3.46 ± 2.0 s
-1 and 3.37 ± 0.24 s-1, 
respectively. Consequently, it is unlikely that these two bioisosteres would act as uncompetitive 
inhibitors of the enzyme, given that they do not show the same complex interaction observed with 
N7-Pan 3.10. In contrast, N7-pantoyltauramide 3.44 showed a lower affinity for SaPanK-II 
compared to N7-Pan 3.10 (KM
app = 51.7 ± 27 vs. 2.04 ± 0.54 µM) with a much higher turnover (kcat 
= 5.29 ± 1.9 s-1 vs. 0.22 ± 0.02 s-1), suggesting that it is an excellent substrate for SaPanK-II and 
not an inhibitor of the enzyme. This is supported by its turnover which is 1.5-fold higher than what 
we observe for pantothenic acid 3.9 (kcat = 3.37 ± 0.24 s
-1). 
 
(R/S)-4’-Amino-N7-Pan 3.56, the N7-Pan analogue in which the 4’-hydroxyl was replaced with a 4’-
amine, was also tested as a substrate (Figure 3.4C). It showed a kinetic profile comparable to that 
of N7-Pan 3.10 with a very low turnover and high affinity for SaPanK-II. We were unable to 
determine the kinetic parameters because the values obtained from fits of the standard kinetic 
equations fell below the sensitivity limit of the assay and were therefore not deemed trustworthy. 
Nonetheless, its kinetic profile suggests that like N7-Pan 3.10, (R/S)-4’-amino-N7-Pan 3.56 also 
has an unusual combination of kinetic parameters and therefore might act as an uncompetitive 
inhibitor of the enzyme. We subsequently tested this compound as an inhibitor of SaPanK-II (see 
below). Finally, neither (R/S)-4’-deoxy-N7-Pan 3.49 nor 4’-phospho-N7-Pan 3.74 were tested as 
substrates, since the terminal hydroxyl were removed in the case of the former, making it 
impossible to be phosphorylated; in the case of the second, the compound is a product analogue, 
since it is already phosphorylated. 
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Subsequently, these compounds were tested as inhibitors of SaPanK-II using reaction mixtures 
that contained 25 µM pantothenic acid 3.9 and increasing concentrations of either (R/S)-4’-amino-
N7-Pan 3.56, (R/S)-4’-deoxy-N7-Pan 3.49 or 4’-phospho-N7-Pan 3.74. Surprisingly, even though 
(R/S)-4’-amino-N7-Pan 3.56 showed a similar kinetic profile to that of N7-Pan 3.10 (i.e. high affinity 
with low turnover), it was a very poor inhibitor of SaPanK-II with an IC50 > 250 µM (Figure 3.5A). 
Therefore, (R/S)-4’-amino-N7-Pan 3.56 neither acts a substrate nor as an inhibitor of SaPanK-II. 
(R/S)-4’-Deoxy-N7-Pan 3.49 showed the same apparent inhibitory effect on SaPanK-II as N7-Pan 
3.10, with an IC50 value of ~ 5.5 µM (Figure 3.5B). Full kinetic analysis with (R/S)-4’-deoxy-N7-Pan 
3.49 showed a dual effect, with (R/S)-4’-deoxy-N7-Pan 3.49 causing a small but significant 
reduction in KM
app for pantothenic acid 3.9 and a large reduction in the Vmax
app (Figure 3.5C). These 
results are in agreement with the results obtained with (R/S)-4’-deoxy-N5-Pan 2.9 as described in 
Chapter 2.  
 
Unexpectedly, the product analogue 4’-phospho-N7-Pan 3.74 also showed an inhibitory effect on 
SaPanK-II with an IC50 value of ~ 40.5 µM (Figure 3.5B). This was very surprising, given that we do 
not expect the product analogue to bind to the enzyme and consequently inhibit the enzyme 
activity. Full kinetic analysis showed the same overall effect observed for (R/S)-4’-deoxy-N7-Pan 
3.49, with 4’-phospho-N7-Pan 3.74 causing a small but significant reduction in KM
app for 
pantothenic acid 3.9 and a large reduction in the Vmax
app (Figure 3.5D). However, SaPanK-II activity 
is positively influenced at very low concentrations of 4’-phospho-N7-Pan 3.74 and inhibited at 
higher concentrations. Even though the product analogue, 4’-phospho-N7-Pan 3.74 acts as an 
inhibitor of SaPanK-II, it is ~7-fold less potent than (R/S)-4’-deoxy-N7-Pan 3.49 which does not 
contain the 4’-hydroxyl. 
 
To summarise, the kinetic characterization results show that none of the N7-Pan analogues with 
steric bulk introduced or with bioisostere replacements showed a complex interaction (low 
turnover, high catalytic efficiency) with SaPanK-II similar to what was observed for N5-Pan and N7-
Pan 3.10. (R/S)-4’-Amino-N7-Pan 3.56 is the only N7-Pan analogue that showed a similar 
interaction to what was observed for N7-Pan 3.10, but enzyme inhibition assays showed that it acts 
as a very poor inhibitor of SaPanK-II, in addition to being a very poor substrate. Both (R/S)-4’-
deoxy-N7-Pan 3.49 and 4’-phospho-N7-Pan 3.74 were found to be good inhibitors of SaPanK-II. 
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Figure 3.5. N7-Pan analogues as inhibitors of SaPanK-II. (A) Inhibition profile of SaPanK-II when treated with 
(R/S)-4’-amino-N7-Pan 3.56 at a fixed concentration of 25 µM pantothenic acid 3.9. (B) Inhibition profile of 
SaPanK-II when treated with (R/S)-4’-deoxy-N7-Pan 3.49 (dark red) and 4’-phospho-N7-Pan 3.74 (purple) at a 
fixed concentration of 25 µM pantothenic acid 3.9. (C) Kinetic profiles for SaPanK-II with pantothenic acid 3.9 in 
the presence of increasing concentrations of (R/S)-4’-deoxy-N7-Pan 3.49 (indicated on the right of each curve). 
(D) Kinetic profiles for SaPanK-II with pantothenic acid 3.9 in the presence of increasing concentrations of 4’-
phospho-N7-Pan 3.74 (indicated on the right of each curve). 
3.5.2 Cell growth inhibition of S. aureus RN4220 by the N7-Pan analogues 
To determine if the obtained kinetic parameters correlated with the growth inhibition potential of 
these analogues in any way, whole cell inhibition assays were performed using S. aureus RN4220. 
Inhibition assays were performed using minimal medium (i.e. with no pantothenic acid 3.9 present) 
that is appropriate for S. aureus (see experimental section for details) [65]. While using minimal 
medium does not give practically relevant results, it does allow for even low levels of inhibition to 
be observed, and for small differences to be characterized. The bacteria were incubated for 24h at 
37°C with varying concentrations of each N7-Pan analogue and the MIC80 (minimum concentration 
needed to kill 80% of the organism) values were calculated as shown in Table 3.3. Of all of the N7- 
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Pan analogues tested, only N7-β-methyl-Pan 3.8, (E)-N7-CJ-Pan 3.27, (R/S)-4’-deoxy-N7-Pan 
3.49 and 4’-phospho-N7-Pan 3.74 had MIC80 values lower than 200 µM, with (R/S)-4’-deoxy-N7-
Pan 3.49 (MIC80 ~25 µM) and 4’-phospho-N7-Pan 3.74 (MIC80 ~1.8 µM) being the most potent. 
Surprisingly, 4’-phospho-N7-Pan 3.74 was the most potent inhibitor. This was also highly 
unexpected; given that it is generally believed that phosphorylated molecules are too polar to enter 
cells unassisted [66]. 
 
Consequently, the N7-Pan analogues that had MIC80 values lower than 200 µM were tested on 
bacteria grown in 1% tryptone medium (which contains ~1–5 μM pantothenic acid 3.9). The 
bacteria were incubated for 20h at 37°C with varying concentrations of each N7-Pan analogue. 
The results in Table 3.3 shows that of the four N7-Pan analogues tested, only 4’-phospho-N7-Pan 
3.74 had a MIC80 lower than 200 µM. The observed decrease in potency is due to the pantothenic 
acid 3.9 present in the growth medium antagonizing the inhibition exerted by the N7-Pan 
analogues. The MIC80 for 4’-phospho-N7-Pan 3.74 in 1% tryptone broth is ~24 µM, a value that 
compares poorly to that of N7-Pan 3.10, which has a MIC80 <0.77 µM against S. aureus grown in 
the same medium. 
 
Table 3.3. MIC80 values determined for S. aureus RN4220 with the N7-Pan analogues.a ND, 
not determined. 
S. aureus RN4220 
Compound MIC80 (minimal medium) (µM) MIC80 (1% tryptone) (µM) 
3.10 <0.078 <0.77 
3.7 >200 ND 
3.8 ~50 >200 
3.11 >200 >200 
3.27 ~25 >200 
3.44 >200 ND 
3.36 >200 ND 
3.33 >200 ND 
3.56 > 200 ND 
3.49 ~25 >200 
3.74 ~1.8 ~24 
a 
S. aureus RN4220 was grown in either minimal medium for 24 h or in 1% tryptone medium for 20 h in the presence of 
the indicated N7-Pan analogue at 37°C. The reported values represent the mean of two or more independent 
experiments. 
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3.5.3 Pantetheinase resistance of the N7-Pan analogues 
Given that the N7-Pan analogues did not show a complex interaction similar to that observed for 
N7-Pan 3.10, and also did not show the same potency compared to N7-Pan 3.10, the 
pantetheinase resistance of these analogues were not determined. However, unpublished results 
from related studies in our laboratory indicated that amide analogues of CJ-15,801 are resistant to 
pantetheinase degradation and we therefore expect that (E)-N7-CJ-Pan 3.27 will also be 
pantetheinase-resistant. Furthermore, Dr. Cristiano Macuamule determined during his PhD study 
that the α- and β-methyl pantothenamides, as well as the pantoyltauramides are pantetheinase-
resistant [67]. Given that pantetheinase is highly substrate specific for the pantothenate moiety and 
consequently does not accept substrates with a modification at the 4’-position [17, 19], we expect 
that 4’-phospho-N7-Pan 3.74, (R/S)-4’-deoxy-N7-Pan 3.49 and (R/S)-4’-amino-N7-Pan 3.56 will be 
pantetheinase-resistant seeing as the pantothenate moiety has been modified. 
3.6 Rationalizing the poor inhibition observed for the N7-Pan analogues 
After the completion of the aforementioned work, a crystal structure of SaPanK-II with 4’-phospho-
N7-Pan 3.73 bound in the active site was deposited into the Protein Data Bank (PDB) [68]. This 
crystal structure (PDB 4M7X) allowed us to rationalize why some of the N7-Pan analogues acted 
as poor substrates of SaPanK-II and as poor inhibitors of S. aureus RN4220.  
 
Figure 3.6 shows a representation of the active site of SaPanK-II, which is a dimer with two 
identical subunits (indicated in red and green), bound to 4’-phospho-N7-Pan 3.74. As seen in the 
picture, two amino acid residues have H-bonding interactions with 4’-phospho-N7-Pan 3.74: 
Arg113 forms H-bonds with the carbonyl oxygens of its two amide groups, while Thr172 has an H-
bonding interaction with the NH of one of the amide bonds. In the case of N-methyl-N7-Pan 3.11 
the H-bonding interaction with Thr172 is lost when the scissile amide bond is methylated. 
Furthermore, when the carbonyl oxygen is replaced with a sulfur to form the thioamide in N7-
pantothenthioamide 3.36, the H-bonding interaction is weakened with Arg113, since a sulfur atom 
is an extremely poor H-bonding acceptor. Additionally, since the sulfur atom is larger than the 
oxygen atom, this could also have a steric effect. The loss or weakening of these binding 
interactions are reflected in the increase in the KM
app-values for N-methyl-N7-Pan 3.11 (KM
app of 
487 ± 127 µM) and N7-pantothenthioamide 3.36 (KM
app of 111 ± 96 µM) compared to that of 
pantothenic acid 3.9 (KM
app of 27.8 ± 3.3 µM). This could explain the poor inhibition of S. aureus 
observed for these compounds; they do not interact with or inhibit the enzyme as N7-Pan 3.10 
does, nor are they good substrates of SaPanK-II that would metabolically activate them to exert an 
inhibitory effect by being converted into antimetabolites of CoA.  
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Figure 3.6. Crystal structure of SaPanK-II (PDB 4M7X), which is a dimer with two identical subunits (indicated in 
red and green), with 4’-phospho-N7-Pan 3.74 bound in the active site. 4’-Phospho-N7-Pan 3.74 forms H-bonding 
interactions with two amino acid residues; Arg113 forms H-bonding interactions with the two carbonyl oxygens 
of the amide bonds and Thr172 forms a H-bonding interaction with the NH of the scissile amide bond. 
 
Looking at the active site where 4’-phospho-N7-Pan 3.74 is bound (Figure 3.7) we can see that 
there is some space to accommodate structural modifications on the α- and β-carbons adjacent to 
the scissile amide bond (big yellow oval), as well as on the NH of the amide bond (small yellow 
oval). This suggests that the modifications resulting in the formation of N7-α-Methyl-Pan 3.7 and 
N7-β-methyl Pan 3.8, both of which showed some inhibition of S. aureus whole cell growth, can be 
accommodated in the active site. Additionally, there is also space to accommodate the methyl 
group on the nitrogen of the scissile amide bond as in the case of N-methyl-N7-Pan 3.11, although 
this leads to the loss of an H-bonding interaction as explained above. (E)-N7-CJ-Pan 3.27 contains 
a trans-enamide moiety which makes the molecule rigid and prevents the C–C bonds in the β-
alanine moiety from rotating. Consequently, the two amide bonds of (E)-N7-CJ-Pan 3.27 are in the 
same plane as the double bond. However, this is not the case with 4’-phospho-N7-Pan 3.74 – the 
amide bonds are not in the same plane and the molecule is free to rotate. These differences in 
molecular geometry could result in SaPanK-II not being able to bind (E)-N7-CJ-Pan 3.27 in the 
orientation necessary, and could explain why we observed poor inhibition against S. aureus, 
compared to the inhibition observed with 4’-phospho-N7-Pan 3.74. 
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Figure 3.7. Crystal structure of SaPanK-II (PDB 4M7X) as shown in Figure 3.6, but with the surface of the active 
site shown. This highlights the space that is available in the active site to accommodate modifications of the 
parent compound. Specifically, the big yellow oval indicates the space around the α-and β-carbons adjacent to 
the scissile amide bond, while the small yellow oval indicates the space around the NH of the amide bond, both 
of which is large enough to accommodate the methyl groups found in the methylated analogues of N7-Pan. 
3.7 Conclusion 
I have successfully synthesized ten N7-Pan analogues using various synthetic organic methods, 
and fully characterized all of the compounds analytically, kinetically and as bacterial growth 
inhibitors. The results presented here showed that none of the N7-Pan analogues showed the 
same complex interaction with SaPanK-II that is observed for N7-Pan 3.10, with the kinetic profiles 
of N7-α-methyl-Pan 3.7, N7-β-methyl Pan 3.8, (E)-N7-CJ-Pan 3.27 and N6-pantothenhydrazide 
3.33 showing the closest resemblance to N7-Pan 3.10. Both, (R/S)-4’-deoxy-N7-Pan 3.49 and 4’-
phospho-N7-Pan 3.74 acted as inhibitors of SaPanK-II. Inhibition from the latter was surprising, 
given that we did not expect the product analogue to bind to SaPanK-II and consequently inhibit 
the enzyme activity. Furthermore, only four of the ten N7-Pan analogues showed growth inhibition 
of S. aureus RN4220 below 200 µM in minimal medium, while 4’-phospho-N7-Pan 3.74 is the only 
N7-Pan analogue that showed inhibition below 200 µM in 1% tryptone medium, with an MIC80 of 
~25 µM. This was highly unexpected, seeing as it is generally believed that phosphorylated 
molecules are too polar to enter cells unassisted [66]. It is therefore possible that S. aureus has a 
specific uptake mechanism for phosphorylated pantothenic acid analogues (most likely phospho-
PantSH) but no reports on this have been made to date.  
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Additionally, we were able to use the SaPanK-II crystal structure—that only became available after 
we had already completed most of the experiments—to rationalize why some of the N7-Pan 
analogues did not show inhibition of either SaPanK-II or S. aureus RN4220. Two amino acid 
residues (Arg113 and Thr172) form critical H-bonding interactions with the pantothenamides in the 
active site; unfortunately, many of these were lost or weakened with the structural modifications 
that were implemented.  
 
Overall, our findings indicate that it will be challenging to develop potent pantetheinase-resistant 
inhibitors for S. aureus. From the results above it is evident that the H-bonding interactions 
between Arg113 and the carbonyl oxygens of the two amide bonds, as well as the H-bond between 
Thr172 and the NH of the scissile amide are extremely important for binding in the active site. 
Additionally, the space within the active site for the addition of steric bulk is also limited, seeing as 
the addition of a methyl group to the α- or β-position is already too big a perturbation on the 
pantothenamide structure. Consequently, to design potent pantetheinase-resistant inhibitors, 
smaller steric bulk must be considered and the H-bonding interactions will have to be kept intact by 
using bioisosteres that can still form H-bonding interactions. 
3.8 Experimental section 
3.8.1 Material and methods 
The N7-Pan analogues were dissolved in either a 50% CH3CN-H2O solution or dimethyl sulfoxide 
(DMSO) to yield stock solutions at a concentration of 50-200 mM. Kinetic assays and growth 
inhibition assays were done with the final CH3CN or DMSO concentration never exceeding 3% 
(v/v). General chemicals, reagents and media were purchased from Sigma-Aldrich, Merck 
Chemicals (Darmstadt, Germany) or Acros Organics (ThermoFisher, Fair Lawn, NJ, USA) and 
were of the highest purity. Solvents used for reactions were CHROMASOLV HPLC grade solvents 
from Sigma-Aldrich, while the hexanes, DCM and EtOAc used for purification were purchased from 
Merck Chemicals. Dry DMF was prepared by shaking up over KOH, distilled under reduced 
pressure and a nitrogen atmosphere, and finally stored over 4 Å molecular sieves in the dark. Dry 
DCM was distilled from CaH2 under a nitrogen atmosphere while dry THF was distilled from 
sodium under a nitrogen atmosphere. 
 
All 1H and 13C NMR spectra were obtained using a 300 MHz Varian VNMRS (75 MHz for 13C), 400 
MHz Varian Unity Inova (100 MHz for 13C) or 600 MHz Varian Unity Inova (150 MHz for 13C) 
instruments at the CAF of the University of Stellenbosch. All chemical shifts (δ) were recorded 
using the residual solvent peak and reported in p.p.m. All HRMS were performed on a Waters API 
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Q-TOF Ultima spectrometer (Waters, Milford, MA, USA) at the Mass Spectrometry unit of CAF. All 
OD600 and kinetic studies were done using a Thermo Varioskan spectrophotometer (Thermo 
Scientific, Bremen, Germany). Inhibition studies were performed in Greiner Bio-one Cellstar flat-
bottomed 96-well suspension plates (Greiner Bio-One GmbH, Frickenhausen, Germany). Kinetic 
studies were performed in Greiner Bio-one polystyrene flat-bottomed 96-well plates. The MIC80s 
were determined by plotting the percentage (relative to a control containing no inhibitor) bacterial 
cell growth against the logarithm of increasing compound concentration. Kinetic data were fitted 
using Michaelis-Menten equations. Analysis of all concentration-response curves and kinetic data 
were done using Sigmaplot, version 12 (Systat Software Inc., Chicago, IL, USA).  
3.8.2 Synthetic preparation of the N7-Pan analogues 
 
α-Methyl pantothenic acid (3.4) (mixture of diastereomers)  
 
  (R/S)-3-Amino isobutyric acid (3.1) (500 mg, 4.80 mmol) was dissolved 
in 1 M aqueous NaOH (4.80 mL, 4.80 mmol) and the solution was 
lyophilized. To the resulting white salt was added (R)-(-)-pantolactone 3.3 
(700 mg, 5.28 mmol) and the mixture was stirred under an inert atmosphere overnight at 130°C. 
The resulting sticky oil was dissolved in H2O and loaded onto a column (1 cm diameter) containing 
prewashed Amberlite IR120 (H+-form) ion exchange resin (500 mg). The free acid was eluted with 
H2O (1 × 10 mL) and lyophilized before purification by FCC (5:2:1:1 EtOAc: MeOH: H2O: CH3CN) 
afforded carboxylic acid 3.4 (0.97 mg, 86%) as a white-yellow powder. Rf = 0.47 (FCC conditions). 
δH (300 MHz; D2O; 25°C) 0.82 (3H, s, -CH3), 0.85 (3H, s, -CH3), 1.04 (3H, d, J = 7.1 Hz, -CH3), 
2.51-2.58 (1H, m, -CH-), 3.26-3.30 (2H, m, -CH2-), 3.31 (1H, d, J = 11.1 Hz, -CH-), 3.42 (1H, d, J = 
11.1 Hz, -CH-), 3.79 (1H, s, -CH-, diastereomer A) and 3.91 (1H, s, -CH-, diastereomer B). OH 
protons not observed. 1H NMR data are consistent with those previously reported [69].  
 
β-Methyl pantothenic acid (3.5) (mixture of diastereomers) 
 
 (R/S)-3-Aminobutyric acid (3.2) (500 mg, 4.80 mmol) was dissolved in 1 
M aqueous NaOH (4.80 mL, 4.80 mmol) and the solution was lyophilized. 
To the resulting white-yellow salt was added (R)-(-)-pantolactone 3.3 (700 
mg, 5.28 mmol) and the mixture was stirred under an inert atmosphere overnight at 130°C. The 
resulting sticky oil was dissolved in H2O and loaded onto a column (1 cm diameter) containing 
prewashed Amberlite IR120 (H+-form) ion exchange resin (500 mg). The free acid was eluted with 
H2O (1 × 10 mL) and lyophilized before purification by FCC (5:2:1:1 EtOAc: MeOH: H2O: CH3CN) 
afforded carboxylic acid 3.5 (1.30 g, 82%) as a white-yellow powder. Rf = 0.43 (FCC conditions).  
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δH (300 MHz; D2O; 25°C) 0.91 (3H, s, -CH3), 0.93 (3H, s, CH3), 1.21 (3H, d, J = 5.9 Hz, -CH3), 
2.35-2.50 (2H, m, -CH2-), 3.38 (1H, d, J = 11.2 Hz, -CH-), 3.51 (1H, d, J = 11.2 Hz, -CH-), 3.78 
(1H, d, J = 3.5 Hz, -CH-, diastereomer A), 3.96 (1H, d, J = 3.5 Hz, -CH-, diastereomer B), and 
4.26-4.34 (1H, m, -CH-). OH protons not observed. 1H NMR data are consistent with those 
previously reported (unpublished) [70]. 
 
N-Heptyl α-methyl-pantothenamide (3.7)  
 
 Heptylamine (3.6) (191 µL, 1.29 mmol) and DPPA (278 µL, 
1.29 mmol) were added to a solution of carboxylic acid 3.4 
(250 mg, 1.07 mmol) in anhydrous DMF (3 mL) at rt under an 
inert atmosphere. After cooling the mixture to 0°C, Et3N (180 µL, 1.29 mmol) was added. The 
reaction mixture was stirred for an additional 2h at 0°C and left to stir overnight at rt. DMF was 
removed in vacuo and Amberlite IR400 (OH--form) resin was added (2.50 g). The reaction mixture 
was filtered and lyophilized before purification by FCC (10% MeOH in DCM) afforded amide 3.7 
(151 mg, 43%) as a yellow oil. Rf = 0.41 (FCC conditions). δH (400 MHz; CDCl3; 25°C) 0.85 (3H, t, 
J = 6.7 Hz, -CH3), 0.92 (3H, s, -CH3), 1.01 (3H, s, -CH3), 1.15 (3H, d, J = 7.0 Hz, -CH3), 1.25-1.34 
(8H, m, -(CH2)4-), 1.46-1.50 (2H, m, -CH2-), 2.50-2.61 (1H, m, -CH-), 3.14-3.27 (2H, m, -CH2-), 
3.31-3.45 (2H, m, -CH2-), 3.49 (2H, s, -CH2-), 3.94 (1H, s, -CH-, diastereomer A), 3.99 (1H, s,  
-CH-, diastereomer B), 5.89 (1H, br s, -NH-) and 7.29 (1H, br s, -NH-). OH protons not observed. 
δC (100 MHz; CDCl3; 25°C) 14.3, 16.0, 21.9, 22.8, 22.8, 29.1, 29.7, 31.9, 39.5, 39.9, 40.9, 41.1, 




N-Heptyl β-methyl-pantothenamide (3.8)  
 
Heptylamine (3.6) (344 µL, 2.32 mmol) and DPPA (500 µL, 
2.32 mmol) were added to a solution of carboxylic acid 3.5 
(450 mg, 1.93 mmol) in anhydrous DMF (3 mL) at rt under an 
inert atmosphere. After cooling the mixture to 0°C, Et3N (323 µL, 2.32 mmol) was added. The 
reaction mixture was stirred for an additional 2h at 0°C and left to stir overnight at rt. DMF was 
removed in vacuo and Amberlite IR400 (OH--form) resin was added (2.50 g). The reaction mixture 
was filtered and lyophilized before purification by FCC (10% MeOH in DCM) afforded amide 3.8 
(106 mg, 17%) as a white solid. Rf = 0.19 (FCC conditions). δH (300 MHz; CDCl3; 25°C) 0.86 (3H, 
apparent t, J = 6.7 Hz, -CH3), 0.90 (3H, s, -CH3), 1.00 (3H, s, -CH3), 1.03 (3H, d, J = 3.2 Hz, -CH3), 
1.24-1.29 (8H, m, -(CH2)4-), 1.47-1.53 (2H, m, -CH2-), 2.27-2.35 (1H, m, -CH2-), 2.44-2.53 (1H, m,  
-CH2-), 3.17-3.28 (2H, m, -CH2-), 3.45-3.56 (2H, m, -CH2-), 3.94 (1H, s, -CH-, diastereomer A), 
3.99 (1H, s, -CH-, diastereomer B), 4.29-3.37 (1H, m, -CH-), 5.83 (1H, br s, -NH-) and 7.47 (1H, br 
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s, -NH-). OH protons not observed. δC (75 MHz; CDCl3; 25°C) 14.1, 20.0, 20.2, 21.7, 22.6, 26.9, 
28.9, 29.5, 31.7, 39.5, 39.7, 42.1, 42.6, 70.8, 77.2, 170.8 and 172.4. (HRMS) [M+H]+ 331.2589 
(Calculated [C17H35N2O4]
+ = 331.2597). 
 
N-Heptyl pantothenamide (3.10)  
 
Calcium pantothenate (1.00 g, 4.15 mmol) was exchanged to 
the free acid by dissolving the salt in H2O (15 m) and passing 
the solution through a column (1.50 cm diameter) of pre-
washed Amberlite IR-120 (H+-form) ion exchange resin (1.10 g). The free carboxylic acid was 
eluted with H2O (1 × 15 mL), followed by lyophilization of the collected column eluate to afford the 
free carboxylic acid 3.9 as a clear oil (860 mg, 3.92 mmol). Heptylamine (3.6) (698 µL, 4.71 mmol) 
and DPPA (1.02 mL, 4.71 mmol) were added to a solution of carboxylic acid 3.9 (860 mg, 3.92 
mmol) in anhydrous DMF (5 mL) at rt under an inert atmosphere. After cooling the mixture to 0°C, 
Et3N (656 µL, 4.71 mmol) was added. The reaction mixture was stirred for an additional 2h at 0°C 
and left to stir overnight at rt. DMF was removed in vacuo and Amberlite IR400 (OH- form) resin 
was added (5.00 g). The reaction mixture was filtered and lyophilized before purification by FCC 
(10% MeOH in DCM) afforded amide 3.10 (580 mg, 47%) as a white solid. Rf = 0.27 (FCC 
conditions). δH (300 MHz; CDCl3; 25°C) 0.85 (3H, t, J = 7.0 Hz, -CH3), 0.92 (3H, s, -CH3), 1.02 (3H, 
s, -CH3), 1.25-1.34 (8H, m, -(CH2)4-), 1.46 (2H, t, J = 6.5 Hz, -CH2-), 2.40 (2H, t, J = 6.0 Hz, -CH2-), 
3.19 (2H, q, J = 7.0 Hz, -CH2-), 3.49 (2H, s, -CH2-), 3.53-3.59 (2H, m, -CH2-), 3.98 (1H, s, -CH-), 
5.79 (1H, br s, -NH-) and 7.33 (1H, br t, J = 6.2 Hz, -NH-). OH protons not observed. 1H NMR data 
are consistent with those previously reported [1]. 
 
N-Methyl-N-heptyl pantothenamide (3.11) 
 
To a solution of thioester 3.20 (200 mg, 0.642 mmol) in 
CH3CN (7 mL) at rt was added N-methyl heptylamine (3.17) 
(130 µL, 0.771 mmol). The reaction mixture was stirred 
overnight at 35°C. The reaction mixture was concentrated in vacuo before purification by FCC 
(15% MeOH in DCM) afforded amide 3.11 (182 mg, 86%) as a yellow oil. Rf = 0.28 (FCC 
conditions). δH (400 MHz; CDCl3; 25°C) 0.85-0.89 (3H, m, -CH3), 0.90 (3H, s, -CH3), 1.00 (3H, s, 
-CH3), 1.23-1.33 (8H, m, -(CH2)4-), 1.44-1.56 (2H, m, -CH2-), 2.51 (2H, qin, J = 5.5, 9.4 Hz, -CH2-), 
2.90 (3H, d, J = 18.7 Hz, -CH3), 3.20 (1H, t, J = 7.4, -CH2-), 3.28-3.37 (1H, m, -CH2-), 3.47 (2H, s,  
-CH2-), 3.54 (2H, quin, J = 5.5 Hz, -CH2-), 3.98 (1H, s, -CH-) and 7.47 (1H, br s, -NH-). OH protons 
not observed. δC (100 MHz; CDCl3; 25°C) 14.2, 21.8, 21.8, 22.8, 27.0, 29.2, 29.3, 31.9, 32.7, 33.3, 
39.6, 48.2, 50.2, 71.2, 77.2, 171.5 and 173.4. (HRMS) [M+H]+ 331.2601 (Calculated [C17H35N2O4]
+ 
= 331.2597). 
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To an oven dried two-neck round bottomed flask containing 1,3-
diol 3.10 (200 mg, 0.632 mmol) at rt under an inert atmosphere 
was added anhydrous THF (10 mL) and crushed molecular 
sieves (1.00 g). To the reaction mixture were added CSA (14.7 
mg, 63.2 µmol) and p-methoxybenzaldehyde dimethyl acetal 
(215 µL, 1.26 mmol) and the reaction mixture was stirred 
overnight at rt. The reaction mixture was filtered and concentrated in vacuo before purification by 
FCC (5% MeOH in DCM) gave p-methoxybenzylidene 3.12 (230 mg, 76%) as a white solid. Rf = 
0.23 (FCC conditions). δH (400 MHz; CDCl3; 25°C) 0.85 (3H, t, J = 6.6 Hz, -CH3), 1.09 (6H, s, 
-(CH3)2), 1.24-1.33 (8H, m, -(CH2)4-), 1.41-1.52 (2H, m, -CH2-), 2.38 (2H, t, J = 6.3 Hz, -CH2-), 
3.16-3.29 (2H, m, -CH2-), 3.46-3.59 (2H, m, -CH2-), 3.67 (2H, d, J = 7.3 Hz, -CH2-), 3.82 (3H, s, 
-CH3), 4.07 (1H, s, -CH-), 5.45 (1H, s, -CH-), 5.82 (1H, br s, -NH-), 6.89-6.94 (2H, m, arom), 7.01 
(1H, br s, -NH-) and 7.28-7.44 (2H, m, arom). δC (100 MHz; CDCl3; 25°C) 14.3, 19.3, 22.0, 22.8, 
27.1, 29.1, 29.7, 32.0, 33.3, 35.3, 36.3, 39.8, 55.5, 78.6, 84.0, 101.5, 113.9, 128.1, 130.3, 159.9, 
169.8 and 171.0. (HRMS) [M+H]+ 435.2845 (Calculated [C24H39N2O5]
+ = 435.2859). 
 
Benzyl 3-(heptylamino)-3-oxopropylcarbamate (3.15) 
 
Heptylamine (3.6) (700 µL, 4.72 mmol) and DEPC (716 µL, 
4.72 mmol) were added to a solution of Cbz-β-alanine (3.14) 
(1.00 g, 4.29 mmol) in anhydrous DMF (6 mL) at rt under an 
inert atmosphere. The reaction mixture was cooled to 0°C before Et3N (1.25 mL, 9.00 mmol) was 
added. The reaction mixture was stirred for 2h at 0°C and left to stir overnight at rt. EtOAc (50 mL) 
was added and the organic layer was washed with 5% aqueous citric acid (3 × 10 mL), 1 M 
aqueous NaHCO3 (2 × 10 mL) and sat. aqueous NaCl (1 × 10 mL). The organic layer was dried 
(Na2SO4), filtered and concentrated in vacuo to afford carbamate 3.15 (1.28 g, 93%) as a white 
solid. Rf = 0.21 (3:1 EtOAc: Hexanes). δH (400 MHz; CDCl3; 25°C) 0.85 (3H, t, J = 6.7 Hz, -CH3), 
1.22-1.33 (8H, m, -(CH2)4-), 1.42-1.51 (2H, m, -CH2-), 2.38 (2H, t, J = 5.9 Hz, -CH2-), 3.19 (2H, q, J 
= 7.0, Hz, -CH2-), 3.45 (2H, q, J = 6.2, Hz, -CH2-), 5.09 (2H, s, -CH2-), 5.43 (1H, br s, -NH-), 5.52 
(1H, br s, -NH-) and 7.30-7.38 (5H, m, arom.). δC (100 MHz; CDCl3; 25°C) 14.3, 22.8, 27.1, 29.2, 
29.8, 31.9, 36.3, 37.4, 39.8, 66.8, 128.2, 128.3, 128.7, 136.8, 156.8 and 171.3. (HRMS) [M+H]+ 
321.2177 (Calculated [C18H29N2O3]
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S-Phenyl thiopantothenate (3.20) 
 
Calcium pantothenate (1.00 g, 4.15 mmol) was exchanged to the free 
acid by dissolving the salt in H2O (15 mL) and passing the solution 
through a column (1.50 cm diameter) of pre-washed Amberlite IR-
120 (H+-form) ion exchange resin (1.10 g). The free carboxylic acid was eluted with H2O (1 × 15 
mL), followed by lyophilization of the collected column eluate to afford the free carboxylic acid 3.9 
as a clear oil (860 mg, 3.92 mmol). Thiophenol (3.19) (443 µL, 4.31 mmol) and DEPC (654 µL, 
4.31 mmol) were added to a solution of carboxylic acid 3.9 (860 mg, 3.92 mmol) in anhydrous DMF 
(5 mL) at rt under an inert atmosphere. The reaction mixture was cooled to 0°C before Et3N (1.15 
mL, 8.23 mmol) was added. The reaction mixture was stirred for 2h at 0°C and left to stir overnight 
at rt. EtOAc (50 mL) was added and the organic layer was washed with 5% aqueous citric acid (3 × 
10 mL), 1 M aqueous NaHCO3 (2 × 10 mL) and sat. aqueous NaCl (1 × 10 mL). The organic layer 
was dried (Na2SO4), filtered and concentrated in vacuo before purification by FCC (2:1 to 4:1 
EtOAc: Hexanes) afforded thioester 3.20 (0.650 g, 53%) as a yellow oil (which solidified upon 
standing). Rf = 0.23 (3:1 EtOAc: Hexanes). δH (300 MHz; CDCl3; 25°C) 3.92 (3H, s, -CH3), 1.02 
(3H, s, -CH3), 2.91 (2H, t, J = 5.1 Hz, -CH2-), 3.50 (2H, d, J = 5.0 Hz, -CH2-), 3.59-3.66 (2H, m, 
-CH2-), 4.01 (1H, s, -CH-), 7.12 (1H, br s, -NH-) and 7.39-9.45 (5H, m, arom). OH protons not 




To an oven dried round bottomed flask containing (R)-(-)-pantolactone 3.3 (1.20 
g, 9.22 mmol) was added anhydrous 30% NH3 in MeOH (14 mL) at rt under an 
inert atmosphere. The reaction mixture was stirred overnight at rt. The reaction 
mixture was concentrated in vacuo to afford amide 3.21 (1.28 g, 94%) as a white solid which was 
subsequently used in the next step without any further purification. δH (300 MHz; DMSO-d6; 25°C) 
0.81 (3H, s, -CH3), 0.83 (3H, s, -CH3), 3.16 (1H, dd, J = 5.9, 10.6 Hz, -CH2-), 3.28 (1H, dd, J = 5.6, 
10.3 Hz, -CH2-), 3.66 (1H ,d, J = 5.9 Hz, -CH-), 4.46 (1H, t, J = 5.6 Hz, -OH), 5.21 (1H, d, J = 5.3 
Hz, -OH) and 7.12 (2H, s, -NH2). 




To an oven dried two-neck round bottomed flask containing 2,4-diol 3.21 (1.00 g, 
6.79 mmol) was added anhydrous acetone (20 mL) and anhydrous DCM (20 mL) at 
rt under an inert atmosphere. The reaction mixture was cooled to 10°C before 
isopropenyl methyl ether (1.30 mL, 13.6 mmol) was added, followed by a solution of PTSA (129 
mg, 0.679 mmol) in anhydrous acetone (5 mL) dropwise. The reaction mixture was stirred  
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overnight at rt and was subsequently neutralized by adding Et3N (500 µL). The resulting solution 
was dried (Na2SO4), filtered and concentrated in vacuo before purification by FCC (2:1 EtOAc: 
Hexanes) afforded acetonide 3.22 (1.00 g, 79%) as a white solid. Rf = 0.36 (FCC conditions). δH 
(300 MHz; DMSO-d6; 25°C) 0.91 (3H, s, -CH3), 0.93 (3H, s, -CH3), 1.36 (3H, s, -CH3), 1.37 (3H, s, 
-CH3), 3.16 (1H, d, J = 11.7 Hz, -CH2-), 3.61 (1H, d, J = 11.7 Hz, -CH2-), 3.97 (1H, s, -CH-), 6.82 
(1H, br s, -NH2) and 7.18 (1H, br s, -NH2). 
1H NMR data are consistent with those previously 
reported [73]. 
 
 (E)-β-Bromoacrylic acid (3.24) 
 
To a solution of 48% aqueous HBr (5.50 mL) was added propiolic acid (3.23) (880 
µL, 14.3 mmol) dropwise at rt. The reaction mixture was stirred at reflux for 1.5h, 
where after it was cooled on an ice bath. The resulting precipitate was filtered and pure bromo acid 
3.24 (425 mg, 20%) was obtained as a grey solid which was subsequently used in the next step 
without any further purification. δH (300 MHz; DMSO-d6; 25°C) 6.54 (1H, d, J = 13.8 Hz, -CH-) and 
7.71 (1H, d, J = 13.8 Hz, -CH-). OH proton not observed. 1H NMR data are consistent with those 




Heptylamine (3.6) (589 µL, 3.97 mmol) and DMAP (64.8 mg, 0.530 
mmol) were added to a solution of bromo acid 3.24 (400 mg, 2.65 
mmol) in anhydrous DCM (5 mL) at rt under an inert atmosphere. The reaction mixture was cooled 
to 0°C before DIC (451 µL, 2.91 mmol) was added dropwise. The reaction mixture was warmed to 
rt and left to stir overnight at rt. The reaction mixture was filtered through a pad of Celite and the 
solvent was removed in vacuo. The resulting crude residue was re-dissolved in EtOAc (30 mL) and 
the organic layer was washed with sat. aqueous NaHCO3 (2 × 10 mL) and sat. aqueous NaCl (1 × 
10 mL). The organic layer was dried (Na2SO4), filtered and concentrated in vacuo before 
purification by FCC (1:2 EtOAc: Hexanes) afforded amide 3.25 (300 mg, 46%) as a yellow solid. Rf 
= 0.46 (FCC conditions). δH (400 MHz; CDCl3; 25°C) 0.86 (3H, t, J = 6.7 Hz, -CH3), 1.26-1.33 (8H, 
m, -(CH2)4-), 1.48-1.55 (2H, m, -CH2-), 3.27 (2H, q, J = 5.9 Hz, -CH2-), 5.44 (1H, br s, -NH-), 6.43 
(1H, d, J = 13.5 Hz, -CH-) and 7.44 (1H, d, J = 13.5 Hz, -CH-). δC (100 MHz; CDCl3; 25°C) 14.3, 
22.8, 27.1, 29.1, 29.7, 31.9, 40.0, 122.5, 131.2 and 163.7. (HRMS) [M+H]+ 248.0646 (Calculated 
[C10H19Br
79NO]+ = 248.0650) and [M+H]+ 250.0626 (Calculated [C10H19Br
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To an oven dried Schlenk tube were added palladium acetate 
(Pd(OAc)2) (33.0 mg, 0.147 mmol), Xantphos (128 mg, 0.221 
mmol), K2CO3 (406 mg, 2.94 mmol), CTAB (107 mg, 0.294 
mmol), amide 3.22 (275 mg, 1.47 mmol), bromide 3.25 (400 mg, 1.61 mmol) and anhydrous 
toluene (3.70 mL) at rt under an inert atmosphere. The reaction mixture was degassed by three 
alternating nitrogen/vacuum cycles until no further gas evolution was observed. The reaction 
mixture was stirred for 1h at 50°C after which H2O (79.4 µL, 4.41 mmol) was added and the 
reaction mixture was stirred for an additional 4h at 55°C. The resulting reaction mixture was cooled 
to rt, diluted with EtOAc (50 mL) and the organic layer was washed with H2O (2 × 15 mL). The 
organic layer was dried (Na2SO4), filtered and concentrated in vacuo before purification by FCC 
(1:1 to 3:1 EtOAc: Hexanes) afforded (E)- and (Z)-amide 3.26 in a combined yield of 60% as a 
white-yellow solid and yellow oil respectively (E:Z ratio of 5:1).  
 
(E)-amide 3.26: Rf = 0.28 (1:1 EtOAc: Hexanes). δH (300 MHz; CDCl3; 25°C) 0.85 (3H, t, J = 6.7 
Hz, -CH3), 0.99 (3H, s, -CH3), 1.05 (3H, s, -CH3), 1.25-1.33 (8H, m, -(CH2)4-), 1.44 (2H, s, -CH2-), 
1.46 (3H, s, -CH3), 1.50 (3H, s, -CH3), 3.28 (2H, d, J = 12.9 Hz, -CH2-), 3.30 (1H, d, J = 12.9 Hz, 
-CH2-), 3.68 (1H, d, J = 11.7 Hz, -CH2-), 4.17 (1H, s, -CH-), 5.37 (1H, br s, -NH-), 5.79 (1H, d, J = 
13.8 Hz, -CH-), 7.71 (1H, dd, J = 10.7, 13.9 Hz, -CH-) and 8.23 (1H, br d, J = 10.0, -NH-). δC (75 
MHz; CDCl3; 25°C) 14.1, 18.7, 18.8, 22.6, 26.9, 26.9, 29.0, 29.7, 31.7, 32.9, 33.4, 39.6, 71.5, 99.1, 




(Z)-amide 3.26: Rf = 0.63 (1:1 EtOAc: Hexanes). δH (300 MHz; CDCl3; 25°C) 0.86 (3H, t, J = 6.7 
Hz, -CH3), 1.05 (6H, s, -(CH3)2), 1.25-1.34 (8H, m, -(CH2)4-), 1.46 (3H, s, -CH3), 1.49-1.54 (2H, m, 
-CH2-), 1.61 (3H, s, -CH3), 3.26-3.33 (2H, m, -CH2-), 3.29 (1H, d, J = 11.7 Hz, -CH2-), 3.69 (1H, d, J 
= 11.7 Hz, -CH2-), 4.19 (1H, s, -CH-), 4.95 (1H, d, J = 8.8 Hz, -CH-), 5.32 (1H, br s, -NH-),  7.24 
(1H, dd, J = 8.8, 11.2 Hz, -CH-) and 11.6 (1H, br d, J = 11.2, -NH-). δC (75 MHz; CDCl3; 25°C) 
14.3, 18.9, 19.3, 22.2, 22.8, 23.2, 27.1, 29.8, 29.9, 31.9, 33.5, 39.4, 71.6, 99.5, 100.8, 118.4, 
133.4, 167.9 and 169.0. (HRMS) [M+H]+ 355.2589 (Calculated [C19H35N2O4]
+ = 355.2597). 
 
(E)-N-Heptyl CJ-pantothenamide ((E)-3.27) 
 
To a solution of acetonide (E)-3.26 (200 mg, 0.564 mmol) in 
CH3CN (4.70 mL) at rt were added H2O (203 µL, 11.3 mmol) 
and BiCl3 (35.6 mg, 0.113 mmol). The reaction mixture was  
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stirred overnight at rt. The reaction mixture was filtered through a pad of Celite and the solvent was 
removed in vacuo. The resulting crude residue was re-dissolved in EtOAc (20 mL) and the organic 
layer was washed with sat. aqueous NaHCO3 (2 × 10 mL). The aqueous layer was extracted with 
EtOAc (1 × 10 mL) and the combined organic layers were dried (Na2SO4), filtered and 
concentrated in vacuo before purification by FCC (100% EtOAc) afforded hydroxyl (E)-3.27 (53.1 
mg, 30%) as a white solid. Rf = 0.12 (FCC conditions). δH (400 MHz; DMSO-d6; 25°C) 0.79 (3H, s, 
-CH3), 0.82 (3H, s, -CH3), 0.83 (3H, t, J = 7.0 Hz, -CH3), 1.20-1.29 (8H, m, -(CH2)4-), 1.35-1.42 (2H, 
m, -CH2-), 3.04 (2H, q, J = 6.2 Hz, -CH2-), 3.13 (1H, dd, J = 5.1, 10.5 Hz, -CH2-), 3.32 (1H, d, J = 
5.5 Hz, -CH2-), 3.84 (1H, d, J = 5.5 Hz, -CH-), 5.83 (1H, d, J = 14.1 Hz, -CH-), 7.55 (1H, dd, J = 
10.9, 14.1 Hz, -CH-), 7.75 (1H, br t, J = 5.5 Hz, -NH-) and 10.1 (1H, br d, J = 10.9 Hz, -NH-). OH 
protons not observed. δC (100 MHz; DMSO-d6; 25°C) 15.2, 21.1, 21.1, 23.3, 27.7, 29.6, 30.5, 32.5, 
40.2, 46.8, 71.5, 76.1, 106.6, 134.0, 165.8 and 173.7. (HRMS) [M+H]+ 315.2289 (Calculated 
[C16H31N2O4]
+ = 315.2284). 
 
(Z)-N-Heptyl CJ-pantothenamide ((Z)-3.27) 
 
To a solution of acetonide (Z)-3.26 (40.0 mg, 0.113 mmol) in 
CH3CN (1.00 mL) at rt were added H2O (40.7 µL, 2.26 mmol) 
and BiCl3 (7.13 mg, 22.6 µmol). The reaction mixture was 
stirred overnight at rt. The reaction mixture was filtered through a pad of Celite and the solvent was 
removed in vacuo. The resulting crude residue was re-dissolved in EtOAc (10 mL) and the organic 
layer was washed with sat. aqueous NaHCO3 (2 × 5 mL). The aqueous layer was extracted with 
EtOAc (1 × 10 mL) and the combined organic layers were dried (Na2SO4), filtered and 
concentrated in vacuo before purification by FCC (3:1 EtOAc: Hexanes) afforded hydroxyl (Z)-3.27 
(21.9 mg, 62%) as a yellow oil. Rf = 0.35 (FCC conditions). δH (300 MHz; DMSO-d6; 25°C) 0.79 
(3H, s, -CH3), 0.83 (3H, s, -CH3), 0.84 (3H, apparent t, J = 7.3 Hz, -CH3), 1.20-1.31 (8H, m,  
-(CH2)4-), 1.36-1.45 (2H, m, -CH2-), 3.04-3.11 (2H, m, -CH2-), 3.16 (1H, dd, J = 5.3, 10.6 Hz,  
-CH2-), 3.34 (1H, d, J = 7.0 Hz, -CH2-), 3.85 (1H, d, J = 4.7 Hz, -CH-), 5.13 (1H, d, J = 8.8 Hz,  
-CH-) 7.11 (1H, dd, J = 8.8, 11.2 Hz, -CH-), 7.97 (1H, t, J = 5.6 Hz, -NH-) and 11.8 (1H, br d, J = 
11.2 Hz, -NH-). OH protons not observed. δC (75 MHz; DMSO-d6; 25°C) 14.4, 20.4, 21.5, 22.5, 
26.9, 29.5, 31.7, 38.6, 39.1, 40.7, 67.9, 75.0, 100.9, 132.6, 167.9 and 172.5. (HRMS) [M+H]+ 
315.2278 (Calculated [C16H31N2O4]
+ = 315.2284). 
 
S-Ethyl thiopantothenate (3.29) 
 
Calcium pantothenate (1.00 g, 4.15 mmol) was exchanged to the free 
acid by dissolving the salt in H2O (15 mL) and passing the solution 
through a column (1.50 cm diameter) of pre-washed Amberlite IR-120 
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(H+-form) ion exchange resin (1.10 g). The free carboxylic acid was eluted with H2O (1 × 15 mL), 
followed by lyophilization of the collected column eluate to afford the free carboxylic acid 3.9 as a 
clear oil (870 mg, 3.97 mmol). Ethanethiol (3.28) (324 µL, 4.37 mmol) and DEPC (633 µL, 4.37 
mmol) were added to a solution of carboxylic acid 3.9 (870 mg, 3.97 mmol) in anhydrous DMF (8 
mL) at rt under an inert atmosphere. The reaction mixture was cooled to 0°C before Et3N (1.16 mL, 
8.33 mmol) was added. The reaction mixture was stirred for 2h at 0°C and left to stir overnight at rt. 
EtOAc (50 mL) was added and the organic layer was washed with 5% aqueous citric acid (3 × 10 
mL), 1 M aqueous NaHCO3 (2 × 10 mL) and sat. aqueous NaCl (1 × 10 mL). The organic layer 
was dried (Na2SO4), filtered and concentrated in vacuo before purification by FCC (3:1 to 4:1 
EtOAc: Hexanes) afforded thioester 3.29 (0.620 g, 59%) as a yellow oil. Rf = 0.19 (3:1 EtOAc: 
Hexanes). δH (300 MHz; CDCl3; 25°C) 0.91 (3H, s, -CH3), 1.01 (3H, s, -CH3), 1.22 (3H, t, J = 7.3 
Hz, -CH3), 2.79 (2H, t, J = 6.0 Hz, -CH2-), 2.85 (2H, q, J = 7.2 Hz, -CH2-), 3.49 (2H, d, J = 3.5 Hz, 
-CH2-), 3.54-3.63 (2H, m, -CH2-), 4.01 (1H, s, -CH-) and 7.12 (1H, br s, -NH-). OH protons not 




To a solution of thioester 3.29 (0.620 g, 2.35 mmol) in EtOH (24 mL) at 
rt was added 50-60% hydrazine hydrate (500 µL, 5.18 mmol). The 
reaction mixture was stirred at reflux overnight. The reaction mixture 
was cooled to rt and concentrated in vacuo to afford hydrazide 3.30 (510 mg, 93%) as a yellow oil 
which was subsequently used in the next step without any further purification. HRMS [M+H]+ 
234.1446 (Calculated [C9H20N3O4]




To a solution of hydrazide 3.30 (350 mg, 1.50 mmol) in 
anhydrous EtOH (15 mL) at rt under an inert atmosphere was 
added hexanal (3.31) (185 µL, 1.50 mmol). The reaction 
mixture was stirred at reflux for 48h. The reaction mixture was cooled to rt and concentrated in 
vacuo before purification by FCC (5% to 10% MeOH in DCM) afforded imine 3.32 (367 mg, 77%) 
as a yellow oil. Rf = 0.24 (10% MeOH in DCM). δH (300 MHz; CDCl3; 25°C) 0.91 (6H, s, -(CH3)2), 
0.99 (3H, s, -CH3), 1.25-1.39 (6H, m, -(CH2)3-), 1.44-1.57 (2H, m, -CH2-), 2.83 (2H, t, J = 6.5 Hz, 
-CH2-), 3.47 (2H, s, -CH2-), 3.58-3.64 (2H, m, -CH2-), 3.99 (1H, s, -CH-), 7.16 (1H, t, J = 5.3 Hz, 
-CH-), 7.34 (1H, br t, J = 6.0 Hz, -NH-) and 7.42 (1H, br t, J = 5.7 Hz, -NH-). OH protons not 
observed. δC (75 MHz; CDCl3; 25°C) 13.9, 20.4, 21.5, 22.4, 25.9, 26.2, 31.4, 34.4, 39.3, 53.4, 70.9, 
77.4, 148.8, 173.2 and 173.9. HRMS [M+H]+ 316.2239 (Calculated [C15H30N3O4]
+ = 316.2236). 
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N-Hexyl pantothenhydrazide (3.33) 
 
To a solution of imine 3.32 (145 mg, 0.460 mmol) in MeOH 
(3 mL) and DCM (2 mL) at rt was added NaBH3CN (34.7 mg, 
0.552 mmol). The reaction mixture was acidified to pH 3 by 
the addition of 3 M aqueous HCl and the resulting solution was stirred at rt for 0.5h. Subsequently, 
the reaction mixture was acidified to pH 1 and the reaction mixture was stirred for an additional 5h 
at rt. The reaction was quenched by the addition of sat. aqueous NaHCO3 (5 mL) and the resulting 
solution was filtered and concentrated in vacuo. The resulting crude residue was re-dissolved in 
EtOAc (40 mL) and the organic layer was washed with H2O (2 × 15 mL) and sat. aqueous NaCl (2 
× 15 mL). The organic layer was dried (Na2SO4), filtered and concentrated in vacuo before 
purification by FCC (10:1:1:2 EtOAc: MeOH: H2O: CH3CN) afforded hydrazide 3.33 (39.4 mg, 27%) 
as a yellow oil. Rf = 0.28 (FCC conditions). δH (300 MHz; CDCl3; 25°C) 0.85 (3H, apparent t, J = 
6.7 Hz, -CH3), 0.91 (3H, s, -CH3), 0.98 (3H, s, -CH3), 1.27-1.35 (6H, m, -(CH2)3-), 1.41-1.52 (2H, m, 
-CH2-), 2.39 (2H, t, J = 5.6 Hz, -CH2-), 2.76 (2H, t, J = 7.3 Hz, -CH2-), 3.47 (2H, s, -CH2-), 3.51-3.63 
(2H, m, -CH2-), 3.98 (1H, s, -CH-), 7.42 (1H, br t, J = 6.0 Hz, -NH-) and 8.21 (1H, br s, -NH-). OH 
protons not observed. δC (75 MHz; CDCl3; 25°C) 14.0, 20.6, 21.3, 22.6, 26.7, 27.8, 29.7, 31.7, 




Benzyl 3-(heptylamino)-3-thioxopropylcarbamate (3.34) 
 
To a solution of amide 3.15 (400 mg, 1.25 mmol) in 
anhydrous toluene (20 mL) at rt under an inert atmosphere 
was added Lawesson’s reagent (554 mg, 1.37 mmol). The 
reaction mixture was stirred at reflux overnight. The reaction mixture was cooled to rt, diluted with 
EtOAc (50 mL) and washed with 10% aqueous NaOH (3 × 15 mL) and sat. aqueous NaCl (1 × 20 
mL). The organic layer was dried (MgSO4), filtered and concentrated in vacuo before purification 
by FCC (1% to 2% MeOH in DCM) afforded thioamide 3.34 (282 mg, 67%) as a yellow solid. Rf = 
0.18 (2% MeOH in DCM). δH (300 MHz; CDCl3; 25°C) 0.86 (3H, t, J = 6.6 Hz, -CH3), 1.24-1.36 (8H, 
m, -(CH2)4-), 1.57 (2H, s, -CH2-), 1.55-1.66 (2H, m, -CH2-), 3.80 (2H, t, J = 6.0 Hz, -CH2-), 3.57-
3.65 (2H, m, -CH2-), 5.09 (2H, s, -CH2-), 5.34 (1H, br s, -NH-), 7.31-7.39 (5H, m, arom) and 7.43 
(1H, br s, -NH-). δC (75 MHz; CDCl3; 25°C) 14.0, 22.6, 26.9, 27.9, 28.9, 31.7, 41.0, 45.9, 46.2, 
66.8, 128.0, 128.2, 128.5, 136.4, 156.6 and 201.6. HRMS [M+H]+ 337.1945 (Calculated 
[C18H29N2O2S]
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3-Amino-N-heptylpropanethioamide hydrochloride salt (3.35) 
 
To a solution of carbamate 3.34 (280 mg, 0.832 mmol) in MeOH (6 
mL) was added concentrated HCl (6 mL) and the resulting solution 
was stirred at reflux overnight. The reaction mixture was cooled to rt and quenched by the addition 
of H2O (20 mL). The aqueous solution was extracted with DCM (2 × 15 mL) after which the 
aqueous phase was lyophilized to yield the HCl salt of amine 3.35 (210 mg, >100%) as a white 
powder which was subsequently used in the next step without any further purification.  
 
N-Heptyl pantothenthioamide (3.36) 
 
Et3N (361 µL, 2.59 mmol) and (R)-(-)-pantolactone 3.3 (338 
mg, 2.59 mmol) were added to a solution of amine 3.35 (210 
mg, 1.04 mmol) in EtOH (10 mL) and the resulting solution 
was stirred at reflux for 48h. The reaction mixture was cooled to rt and the solvent was removed in 
vacuo. The crude residue was purified by FCC (10% MeOH in DCM) to afford amide 3.36 (23.6 
mg, 7%) as a yellow oil. Rf = 0.32 (FCC conditions). δH (300 MHz; CDCl3; 25°C) 0.86 (3H, apparent 
t, J = 7.0 Hz, -CH3), 1.02 (3H, s, -CH3), 1.04 (3H, s, -CH3), 1.24-1.34 (8H, m, -(CH2)4-), 1.50 (2H, t, 
J = 7.0 Hz, -CH2-), 2.54 (2H, t, J = 6.2 Hz, -CH2-), 3.21-3.35 (2H, m, -CH2-), 3.47-3.61 (4H, m, 
-(CH2)2-), 4.02 (1H, d, J = 4.1 Hz, -CH-), 6.70 (1H, br s, -NH-) and 7.17 (1H, br s, -NH-). OH 
protons not observed. δC (75 MHz; CDCl3; 25°C) 14.3, 21.5, 21.8, 22.8, 27.1, 29.1, 29.8, 31.9, 




N-Carbobenzoxy taurine sodium salt (3.39) 
 
To a solution of taurine (3.37) (4.00 g, 32.0 mmol) in 1 M aqueous NaOH 
(32 mL) at rt was added a solution of Cbz chloride (3.38) (7.00 mL, 48.0 
mmol) in dioxane (42 mL). To this was added another portion of 1 M 
aqueous NaOH (48 mL) and the reaction mixture was stirred for 1h at rt. The aqueous solution was 
extracted with EtOAc (2 × 125 mL) and the aqueous layer was concentrated in vacuo, followed by 
sequential co-evaporation with toluene (1 × 100 mL), EtOH (1 × 100 mL), and DCM (3 × 100 mL). 
The resulting crude product was lyophilized to yield taurine sodium salt 3.39 as a white powder. 
The crude product was subsequently used in the next step without any further purification. 
 
N-Carbobenzoxy tauryl fluoride (3.41)  
 
To a slurry of sulfonic acid 3.39 (500 mg, 1.78 mmol) in anhydrous DCM 
(20 mL) at 0°C under an inert atmosphere was added a solution of 
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(diethylamino)sulphur trifluoride (DAST, 3.40) (585 µL, 4.45 mmol) in DCM (5 mL). The reaction 
mixture was stirred for 2h at 0°C and concentrated in vacuo before purification by FCC (1:1 to 3:1 
DCM: Hexanes) afforded tauryl fluoride 3.41 (370 mg, 80%) as a yellow powder. Rf = 0.78 (10% 
MeOH in DCM). δH (300 MHz; CDCl3; 25°C) 3.62 (2H, q, J = 5.6 Hz, -CH2-), 3.74 (2H, q, J = 5.9 
Hz, -CH2-), 5.13 (2H, s, -CH2-), 5.31 (1H, br s, -NH-) and 7.33-7.38 (5H, m, arom.). δC (75 MHz; 
CDCl3; 25°C) 35.7, 50.8, 67.4, 128.2, 128.4, 128.6, 135.8 and 156.1. δF (282 MHz; CDCl3; 25°C) 
56.8. HRMS [M+H]+ 262.0538 (Calculated [C10H13FNO4S]
+ = 262.0549). 
 
N-Carbobenzoxy N’-heptyltauramide (3.42)  
 
Heptylamine (3.6) (1.05 mL, 7.10 mmol) was added to a 
solution of tauryl fluoride 3.41 (370 mg, 1.42 mmol) in 
anhydrous DCM (5 mL) under an inert atmosphere, followed 
by stirring for 20h at 50°C. The reaction mixture was cooled to rt and quenched by the addition of 
10% aqueous HCl (20 mL). The aqueous solution was extracted with DCM (2 × 15 mL) and the 
combined organic extracts were dried (MgSO4), filtered and concentrated in vacuo. Purification by 
FCC (10% MeOH in DCM) yielded tauramide 3.42 (420 mg, 83%) as a yellow-orange powder. Rf = 
0.66 (FCC conditions). δH (300 MHz; CDCl3; 25°C) 0.86 (3H, t, J = 6.7 Hz, -CH3), 1.26-1.30 (8H, m, 
-(CH2)4-), 1.52-1.57 (2H, m, -CH2-), 3.05 (2H, q, J = 6.7 Hz, -CH2-), 3.18 (2H, t, J = 5.6 Hz, -CH2-), 
3.64-3.70 (2H, m, -CH2-), 4.39 (1H, br s, -NH-), 5.11 (2H, s, -CH2-), 5.41 (1H, br s, -NH-) and 7.31-
7.37 (5H, m, arom.). δC (75 MHz; CDCl3; 25°C) 14.1, 22.6, 26.5, 28.8, 30.3, 31.7, 36.1, 43.4, 52.1, 




N-Heptyltauramide hydrochloride salt (3.43)  
 
To a solution of carbamate 3.42 (420 mg, 1.81 mmol) in MeOH (8 mL) 
was added concentrated HCl (8 mL) and the resulting solution was 
stirred at reflux overnight. The reaction mixture was cooled to rt and quenched by the addition of 
H2O (20 mL). The aqueous solution was extracted with DCM (2 × 15 mL) after which the aqueous 
phase was lyophilized to yield the HCl salt of amine 3.43 (250 mg, 82%) as a white powder, which 
was subsequently used in the next step without any further purification. HRMS [M+H]+ 223.1474 
(Calculated [C9H23N2O2S]
+ = 223.1480). 
 
N-Heptyl pantoyltauramide (3.44) 
 
Et3N (337 µL, 2.42 mmol) and (R)-(-)-pantolactone 3.3 (315 
mg, 2.42 mmol) were added to a solution of amine 3.43 (250 
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mg, 0.966 mmol) in EtOH (8 mL) and the resulting solution was stirred for 7h at reflux. The reaction 
mixture was cooled to rt and the solvent was removed in vacuo. The crude residue was purified by 
FCC (5% to 10% MeOH in DCM) before purification by SPE (Supelco 500 mg (3 mL) DSC-NH2 
column, conditioned the column with DCM, washed the sorbent with diethyl ether and eluted the 
product with CH3CN) afforded amide 3.44 (59.8 mg, 18%) as a white oil. Rf = 0.11 (10% MeOH in 
DCM). δH (400 MHz; CDCl3; 25°C) 0.86 (3H, t, J = 7.0 Hz, -CH3), 0.96 (3H, s, -CH3), 1.03 (3H, s, 
-CH3), 1.25-1.36 (8H, m, -(CH2)4-), 1.52-1.60 (2H, m, -CH2-), 3.07 (2H, q, J = 6.7 Hz, -CH2-), 3.19-
3.24 (2H, m, -CH2-), 3.52 (2H, s, -CH2-), 3.72-3.80 (2H, m, -CH2-), 4.03 (1H, s, -CH-), 4.93 (1H, br 
t, J = 5.9 Hz, -NH-) and 7.4 (1H, br s, -NH-). OH protons not observed. δC (100 MHz; CDCl3; 25°C) 
14.3, 20.9, 21.6, 22.8, 26.7, 29.0, 30.5, 31.9, 34.2, 39.5, 43.6, 51.7, 71.4, 78.4 and 173.8. HRMS 
[M+H]+ 353.2102 (Calculated [C15H33N2O5S]
+ = 353.2110). 
 
3-Amino-N-heptylpropanamide (3.45)  
 
To a solution of carbamate 3.15 (1.46 g, 4.56 mmol) in MeOH (50 mL) 
at rt was added 10% Pd/C (194 mg, 1.82 mmol). The reaction 
atmosphere was filled with H2 gas and the reaction mixture was stirred overnight at rt. The reaction 
mixture was filtered and concentrated in vacuo to give amine 3.45 (820 mg, 96%) as a white solid. 
Rf = product on baseline (10% MeOH in DCM). δH (400 MHz; CDCl3; 25°C) 0.85 (3H, t, J = 7.0 Hz, 
-CH3), 1.25-1.32 (8H, m, -(CH2)4-), 1.44-1.53 (2H,  m, -CH2-), 1.96 (2H, br s, -NH2), 2.30 (2H, t, J  = 
5.9 Hz, -CH2-), 2.99 (2H, t, J = 5.9 Hz, -CH2-), 3.19 (2H, q, J = 7.0 Hz, -CH2-) and 6.95 (1H, br s, 
-NH-). δC (100 MHz; CDCl3; 25°C) 14.2, 22.8, 27.1, 29.1, 29.7, 31.9, 38.0, 38.2, 39.6 and 172.3. 
HRMS [M+H]+ 187.1807 (Calculated [C10H23N2O]
+ = 187.1810). 
 
3,3-Dimethyl-2-oxo-butyric acid (3.46)  
 
 To a solution of NaOH (8.00 g, 200 mmol) and KMnO4 (12.2 g, 77.2 mmol) in H2O 
(196 mL) at 0°C was added a solution of pinacolone (3.47) (10 mL, 83.4 mmol) in H2O 
(160 mL). The reaction mixture was stirred for 1h at 0°C and an additional 2h at rt. The 
reaction mixture was filtered through a pad of Celite, acidified to pH 2 with concentrated H2SO4, 
and the aqueous layer was extracted with diethyl ether (3 × 40 mL). The combined organic extracts 
were dried (Na2SO4), filtered and concentrated in vacuo. Bulb-to-bulb distillation (110°C, 27.5 
mmHg) gave carboxylic acid 3.46 (3.99 g, 77%) as a clear oil. δH (300 MHz; CDCl3; 25°C) 1.32 
(9H, s, -CH3). OH proton not observed. 
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3,3-Dimethyl-2-oxo-N-(3-oxo-3-(heptylamino)propyl)butanamide (3.48)  
 
DIPEA (674 µL, 3.87 mmol) was added drop-wise over 5 min to 
a solution of heptylamine (3.6) (700 mg, 3.76 mmol) in DCM (30 
mL) at 0°C under an inert atmosphere. HOBt (127 mg, 0.939 mmol), carboxylic acid 3.46 (537 mg, 
4.13 mmol) and EDC hydrochloride (583 mg, 3.76 mmol) were then added consecutively and the 
reaction mixture was stirred overnight at rt. The reaction was quenched by the addition of 3 M 
aqueous HCl (25 mL) and the organic layer was washed with 3 M aqueous HCl (1 × 25 mL) and 
sat. aqueous NaHCO3 (1 × 25 mL). The organic layer was dried (Na2SO4), filtered and 
concentrated in vacuo before purification by FCC (2:1 EtOAc: Hexanes) afforded amide 3.48 (251 
mg, 22%) as a white powder. Rf = 0.31 (FCC conditions). δH (600 MHz; CDCl3; 25°C) 0.85 (3H, t, J 
= 6.7 Hz, -CH3), 1.23-1.30 (8H, m, -(CH2)4-), 1.31 (9H, s, -(CH3)3), 1.43-1.52 (2H, m, -CH2-), 2.40 
(2H, t, J = 6.2 Hz, -CH2-), 3.20 (2H, q, J = 7.0 Hz, -CH2-), 3.53 (2H, q, J = 6.2 Hz, -CH2-), 5.58 (1H, 
br s, -NH-) and 7.48 (1H, br s, -NH-). δC (150 MHz; CDCl3; 25°C) 16.7, 25.2, 25.2, 28.9, 28.9, 29.5, 
29.5, 31.5, 32.2, 34.3, 37.8, 38.0, 42.3, 163.0, 173.2 and 205.7. HRMS [M+H]+ 299.2332 
(Calculated [C16H31N2O3]
+ = 299.2335). 
 
(R/S)-4’-Deoxy N-heptyl-pantothenamide (3.49)  
 
To a solution of ketoamide 3.48 (200 mg, 0.670 mmol) in 
anhydrous MeOH (30 mL) at 0°C under an inert atmosphere 
was added NaBH4 (38.0 mg, 1.01 mmol) in small portions. The 
reaction mixture was stirred for 1h at 0°C, and left to stir overnight at rt. The reaction was 
quenched by the addition of sat. aqueous ammonium chloride (NH4Cl) (10 mL) and the MeOH was 
removed in vacuo. The aqueous solution was extracted with EtOAc (3 × 20 mL) and the combined 
organic extracts were dried (Na2SO4), filtered and concentrated in vacuo to yield hydroxyl 3.49 
(158 mg, 78%) as a white powder. Rf = 0.51 (10% MeOH in DCM). δH (400 MHz; CDCl3; 25°C) 
0.85 (3H, t, J = 6.7 Hz, -CH3), 0.97 (9H, s, -(CH3)3), 1.23-1.35 (8H, m, -(CH2)4-), 1.45-1.53 (2H, m, 
-CH2-), 2.39 (2H, t, J = 6.0 Hz, -CH2-), 3.19 (2H, q, J = 7.0 Hz, -CH2-), 3.55 (2H, q, J = 6.5 Hz, 
-CH2-), 3.65 (1H, s, -CH-), 5.70 (1H, br s, -NH-) and 6.87 (1H, br s, -NH-). OH proton not observed. 
δC (100 MHz; CDCl3; 25°C) 14.3, 22.8, 26.1, 26.1, 26.1, 27.1, 29.1, 29.8, 31.9, 35.2, 35.5, 35.9, 
39.9, 79.6, 171.4 and 173.0. HRMS [M+H]+ 301.2497 (Calculated [C16H33N2O3]





To a solution of 1,3-diol 3.10 (810 mg, 2.56 mmol) in 
anhydrous DMF (10 mL) at rt was added imidazole (1.04 
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g, 15.3 mmol) and TBS chloride (2.31 g, 15.3 mmol). The reaction mixture was stirred overnight at 
rt. The reaction was quenched by the addition of H2O (50 mL) and the aqueous layer was 
extracted with EtOAc (3 × 50 mL). The combined organic extracts were washed with sat. aqueous 
NaCl (2 × 15 mL) and the organic layer was dried (Na2SO4), filtered and concentrated in vacuo 
before purification by FCC (1:2 EtOAc: Hexanes) afforded 3.50 (1.16 g, 83%) as a yellow oil. Rf = 
0.38 (FCC conditions). δH (400 MHz; CDCl3; 25°C) 0.01 (3H, s, -CH3), 0.02 (3H, s, -CH3), 0.04 (3H, 
s, -CH3), 0.07 (3H, s, -CH3), 0.84 (3H, s, -CH3), 0.85-0.88 (3H, m, -CH3), 0.89 (9H, s, -(CH3)3), 0.93 
(9H, s, -(CH3)3), 1.23-1.33 (8H, m, -(CH2)4-), 1.43-1.52 (2H, m, -CH2-), 2.38 (2H, t, J = 5.6 Hz, 
-CH2-), 3.17-3.25 (2H, m, -CH2-), 3.32 (1H, d, J = 9.4 Hz, -CH2-), 3.39 (1H, d, J = 9.7 Hz, -CH2-),  
3.51 (2H, q, J = 6.2 Hz, -CH2-), 4.00 (1H, s, -CH-), 5.79 (1H, br t, J = 5.0 Hz, -NH-) and 6.81 (1H, 
br t, J = 6.5 Hz, -NH-). δC (100 MHz; CDCl3; 25°C) -9.98, -9.92, -9.80, -9.67, 13.8, 16.4, 16.5, 18.0, 
21.2, 21.3, 21.4, 21.4, 21.5, 22.3, 24.4, 25.0, 27.2, 30.3, 30.4, 31.5, 35.1, 35.1, 35.6, 36.0, 64.3, 
73.7, 166.1 and 168.4. HRMS [M+H]+ 545.4164 (Calculated [C28H61N2O4Si2]





To a solution of 3.50 (1.05 g, 1.94 mmol) in anhydrous MeOH 
(20 mL) at 0°C under an inert atmosphere was added PPTS 
(510 mg, 2.03 mmol) in small portions. The reaction mixture 
was allowed to slowly warm up to rt and left to stir overnight at rt. The reaction mixture was 
concentrated in vacuo before purification by FCC (2:1 EtOAc: Hexanes) gave 3.51 (722 mg, 86%) 
as a yellow oil. Rf = 0.35 (FCC conditions). δH (300 MHz; CDCl3; 25°C) 0.01 (3H, s, -CH3), 0.09 
(3H, s, -CH3), 0.78 (3H, s, -CH3), 0.85 (3H, t, J = 7.0 Hz, -CH3), 0.94 (9H, s, -(CH3)3), 1.00 (3H, s, 
-CH3), 1.24-1.33 (8H, m, -(CH2)4-), 1.42-1.52 (2H, m, -CH2-), 2.37-2.42 (2H, m, -CH2-), 3.18-3.25 
(2H, m, -CH2-), 3.35-3.47 (2H, m, -CH2-), 3.54-3.61 (2H, m, -CH2-), 3.98 (1H, s, -CH-), 5.68 (1H, br 
s, -NH-) and 7.05 (1H, br t, J = 5.9 Hz, -NH-). OH proton not observed. δC (75 MHz; CDCl3; 25°C)  
-5.25, -5.10, 14.1, 18.0, 18.8, 22.6, 23.7, 25.8, 25.8, 25.8, 26.9, 28.9, 29.6, 31.7, 34.9, 35.6, 39.7, 







A solution of 3.51 (700 mg, 1.63 mmol) in anhydrous DCM (20 
mL) was added dropwise to a solution of Dess-Martin 
periodinane (759 mg, 1.79 mmol) in anhydrous DCM (30 mL) 
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at rt under an inert atmosphere. The reaction mixture was stirred for 0.5h at rt before a 1:1 mixture 
of sat. aqueous sodium thiosulfate (Na2S2O3) (30 mL) and sat. aqueous NaHCO3 (30 mL) was 
added to the reaction mixture. The resulting mixture was extracted with DCM (5 × 20 mL). The 
combined organic extracts were washed with sat. NaHCO3 (2 × 20 mL) and the organic layer was 
dried (Na2SO4), filtered and concentrated in vacuo before purification by FCC (1:1 to 2:1 EtOAc: 
Hexanes) afforded aldehyde 3.52 (670 mg, 96%) as a yellow oil. Rf = 0.26 (FCC conditions). δH 
(400 MHz; CDCl3; 25°C) 0.09 (3H, d, J = 5.0 Hz, -CH3), 0.16 (3H, d, J = 1.5 Hz, -CH3), 0.85 (3H, d, 
J = 6.6 Hz, -CH3), 0.91 (9H, d, J = 1.2 Hz, -(CH3)3), 0.95 (3H, s, -CH3), 1.08 (3H, s, -CH3), 1.23-
1.34 (8H, m, -(CH2)4-), 1.42-1.53 (2H, m, -CH2-), 2.35-2.49 (1H, m, -CH2-), 2.65-2.75 (1H, m,  
-CH2-), 3.17-3.25 (2H, m, -CH2-), 3.51-3.63 (2H, m, -CH2-), 4.22 (1H, s, -CH-), 5.93 (1H, br s,  
-NH-), 7.03 (1H, br t, J = 5.9 Hz, -NH-) and 9.57 (1H, s, -CH-). δC (100 MHz; CDCl3; 25°C) -4.10, 
-4.00, 14.3, 15.1, 18.5, 20.5, 22.8, 25.9, 26.0, 27.1, 29.1, 29.5, 29.5, 31.9, 40.0, 40.0, 43.3, 78.4, 
87.7, 172.5, 173.5 and 175.1. HRMS [M+H]+ 429.3168 (Calculated [C22H45N2O4Si]
+ = 429.3149). 
 
(R/S)-4’-Amino-N-heptyl pantothenamide (3.56) 
 
To a solution of carbamate 3.71 (150 mg, 0.334 mmol) 
(synthesis described on page 145) in MeOH (10 mL) at rt 
was added 10% Pd/C (14.3 mg, 0.134 mmol). The reaction 
atmosphere was filled with H2 gas and the reaction mixture was stirred overnight at rt. The reaction 
mixture was filtered and concentrated in vacuo to give amine 3.56 (93.5 mg, 89%) as a white solid. 
Rf = product on baseline (6:1 EtOAc: Hexanes). δH (600 MHz; CDCl3; 25°C) 0.86 (3H, t, J = 7.0 Hz, 
-CH3), 0.94 (3H, s, -CH3), 1.03 (3H, s, -CH3), 1.23-1.32 (10H, m, -(CH2)4- and -NH2), 1.45-1.51 (2H, 
m, -CH2-), 2.40 (2H, m, -CH2-), 2.76-2.81 (2H, m, -CH2-), 3.16-3.25 (2H, m, -CH2-), 3.49-3.60 (2H, 
m, -CH2-), 4.03 (1H, m, -CH-), 6.10 (1H, br s, -NH-) and 7.54 (1H, br s, -NH-). OH proton not 
observed. δC (150 MHz; CDCl3; 25°C) 16.7, 22.2, 22.2, 25.2, 26.4, 29.5, 31.6, 32.1, 34.3, 37.7, 




Benzyl pantothenate (3.58) 
 
To a solution of sodium pantothenate (2.00 g, 8.30 mmol) in 
anhydrous DMF (30 mL) at rt under an inert atmosphere was 
added benzyl bromide (3.57) (988 µL, 8.30 mmol). The reaction 
mixture was stirred at 70°C overnight. The reaction mixture was cooled to rt and concentrated in 
vacuo. The resulting crude residue was re-dissolved in EtOAc (150 mL) and the organic layer was 
washed with sat. aqueous NaCl (3 × 40 mL). The organic layer was dried (Na2SO4), filtered and 
concentrated in vacuo before purification by FCC (2:1 to 4:1 EtOAc: Hexanes) afforded ester 3.58 
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(1.89 g, 74%) as a yellow oil. Rf = 0.26 (3:1 EtOAc: Hexanes). δH (300 MHz; CDCl3; 25°C) 0.88 
(3H, s, -CH3), 1.00 (3H, s, -CH3), 2.60 (2H, t, J = 6.0 Hz, -CH2-), 3.45 (2H, t, J = 5.4 Hz, -CH2-), 
3.54-3.62 (2H, m, -CH2-), 3.97 (1H, d, J = 5.0 Hz, -CH-), 5.14 (2H, s, -CH2-), 7.12 (1H, br s, -NH-) 
and 7.33-7.40 (5H, m, arom). OH protons not observed. 1H NMR data are consistent with those 
previously reported [57]. 
 
(R)-Benzyl 3-(2,4-bis(tert-butyldimethylsilyloxy)-3,3-dimethylbutanamido)propanoate (3.59) 
 
To a solution of 1,3-diol 3.58 (1.89 g, 6.11 mmol) in anhydrous 
DMF (30 mL) at rt was added imidazole (2.50 g, 36.7 mmol) and 
TBS chloride (5.53 g, 36.7 mmol). The reaction mixture was 
stirred overnight at rt. The reaction was quenched by the addition of H2O (60 mL) and the aqueous 
layer was extracted with EtOAc (3 × 70 mL). The combined organic extracts were washed with sat. 
aqueous NaCl (2 × 25 mL) and the organic layer was dried (Na2SO4), filtered and concentrated in 
vacuo before partial purification by FCC (1:3 EtOAc: Hexanes) afforded 3.59 (3.30 g, > 100%) as a 
yellow oil, which was subsequently used in the next step without any further purification. Rf = 0.32 
(FCC conditions).  
 
(R)-Benzyl 3-(2-(tert-butyldimethylsilyloxy)-4-hydroxy-3,3-dimethylbutanamido)propanoate (3.60) 
 
 To a solution of 3.59 (2.60 g, 4.85 mmol) in anhydrous MeOH (50 
mL) at 0°C under an inert atmosphere was added PPTS (1.28 g, 
5.09 mmol) in small portions. The reaction mixture was allowed to 
slowly warm up to rt and left to stir overnight at rt. The reaction mixture was concentrated in vacuo 
before purification by FCC (1:1 EtOAc: Hexanes) afforded hydroxyl 3.60 (1.61 g, 78%) as a yellow 
oil. Rf = 0.37 (FCC conditions). δH (300 MHz; CDCl3; 25°C) 0.01 (3H, s, -CH3), 0.09 (3H, s, -CH3), 
0.75 (3H, s, -CH3), 0.94 (9H, s, -CH3)3), 0.99 (3H, s, -CH3), 2.58 (2H, t, J = 4.4 Hz, -CH2-), 3.33-
3.42 (2H, m, -CH2-), 3.55 (2H, q, J = 6.2 Hz, -CH2-), 4.00 (1H, s, -CH-), 5.13 (2H, s, -CH2-), 6.96 
(1H, br s, -NH-) and 7.32-7.39 (5H, m, arom). OH proton not observed. δC (75 MHz; CDCl3; 25°C) 
-5.32, -5.20, 19.0, 19.0, 23.2, 25.7, 25.7, 25.7, 34.0, 34.3, 40.4, 66.6, 69.8, 76.8, 126.8, 128.3, 
128.4, 135.5, 171.9 and 173.5. HRMS [M+H]+ 424.2509 (Calculated [C22H38NO5Si]
+ = 424.2519). 
 
(R)-Benzyl 3-(2-(tert-butyldimethylsilyloxy)-3,3-dimethyl-4-oxobutanamido)propanoate (3.61) 
 
A solution of hydroxyl 3.60 (1.51 g, 3.57 mmol) in anhydrous DCM 
(40 mL) was added dropwise to a solution of Dess-Martin 
periodinane (1.66 g, 3.92 mmol) in anhydrous DCM (50 mL) at rt 
under an inert atmosphere. The reaction mixture was stirred for 0.5h at rt before a 1:1 mixture of 
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sat. aqueous Na2S2O3 (70 mL) and sat. aqueous NaHCO3 (70 mL) was added to the reaction 
mixture. The resulting mixture was extracted with DCM (5 × 30 mL). The combined organic 
extracts were washed with sat. aqueous NaHCO3 (2 × 30 mL) and sat. aqueous NaCl (1 × 30 mL). 
The organic layer was dried (Na2SO4), filtered and concentrated in vacuo before purification by 
FCC (1:1 EtOAc: Hexanes) afforded aldehyde 3.62 (1.46 g, 97%) as a yellow to orange oil. Rf = 
0.63 (FCC conditions). δH (300 MHz; CDCl3; 25°C) 0.01 (3H, s, -CH3), 0.11 (3H, s, -CH3), 0.94 (9H, 
s, -(CH3)3), 0.98 (3H, s, -CH3), 1.04 (3H, s, -CH3), 2.55 (2H, t, J = 5.9 Hz, -CH2-), 3.52 (2H, q, J = 
6.2 Hz, -CH2-), 4.23 (1H, s, -CH-), 5.12 (2H, s, -CH2-), 6.91 (1H, br s, -NH-), 7.32-7.39 (5H, m, 
arom) and 9.56 (1H, s, -CH-). δC (75 MHz; CDCl3; 25°C) -5.27, -4.51, 16.0, 18.2, 25.6, 25.7, 25.7, 
33.0, 36.3, 37.7, 42.6, 66.7, 89.3, 128.4, 128.5, 128.6, 135.5, 172.2, 173.3 and 174.4. HRMS 
[M+H]+ 422.2342 (Calculated [C22H36NO5Si]
+ = 422.2363). 
 
Potassium phthalimide (3.67) 
 
To a solution of phthalimide (4.41 g, 30.0 mmol) in anhydrous EtOH (20 mL) at rt 
under an inert atmosphere was added a solution of KOH (4.21 g, 75.0 mmol) in 
anhydrous MeOH (20 mL). The reaction mixture was stirred for 1h at rt. The reaction 
mixture was filtered and the filter cake was washed with EtOH (3 x 10 mL) to afford potassium 
phthalimide 3.67 (4.57 g, 82%) as a white solid, which was subsequently used in the next step 
without any further purification.  
 
4-(1,3-Dioxoisoindolin-2-yl)-2-hydroxy-3,3-dimethylbutanoic acid (3.68) 
 
Potassium phthalimide (3.67) (5.00 g, 27.0 mmol) was added in small 
portions to (R)-(-)-pantolactone 3.3 (10.5 g, 81.0 mmol) heated to 140°C. 
The reaction mixture was stirred for an additional 0.5h at 250°C. The 
resulting homogeneous reaction mixture was cooled to rt, before purification by FCC (5:1:1:1 
EtOAc: MeOH: H2O: CH3CN) afforded 3.68 (6.46 g, 86%) as a pale yellow solid. Rf = 0.30 (FCC 
conditions). δH (300 MHz; CDCl3; 25°C) 1.07 (3H, s, -CH3), 1.22 (3H, s, -CH3), 3.94 (1H, d, J = 9.9 
Hz, -CH2-), 4.02 (1H, d, J = 9.1 Hz, -CH2-), 4.23 (1H, s, -CH-), 7.73-7.79 (2H, m, arom) and 7.81-
7.91 (2H, m, arom). OH protons not observed. 1H NMR data are consistent with those previously 
reported [62].  
 
4-Amino-2-hydroxy-3,3-dimethylbutanoic acid (3.69) 
 
To a refluxing solution of 3.68 (6.00 g, 21.6 mmol) in EtOH (45 mL) was added 
50-60% hydrazine hydrate (2.51 mL, 51.7 mmol). The reaction mixture was 
stirred at reflux for an additional 3h. The reaction mixture was cooled to rt and  
 
Stellenbosch University  https://scholar.sun.ac.za
Chapter 3 
Developing PanK inhibitors that are resistant to pantetheinase-mediated degradation 
 
~ 145 ~ 
 
70% aqueous acetic acid (60 mL) was added. The resulting solution was filtered through a pad of 
Celite to remove the precipitate and the filtrate was almost concentrated to dryness in vacuo. The 
crude residue was diluted with chloroform and the resulting precipitate upon standing was filtered 
and washed with chloroform (2 × 20 mL) to afford amine 3.69 (1.82 g, 57%) as a white powder. δH 
(300 MHz; D2O; 25°C) 1.01 (3H, s, -CH3), 1.08 (3H, s, -CH3), 2.99 (2H, s, -CH2-) and 3.85 (1H, s, 
-CH-). OH and NH2 protons not observed. 
1H NMR data are consistent with those previously 
reported [62].  
 
4-(Benzyloxycarbonylamino)-2-hydroxy-3,3-dimethylbutanoic acid (3.70) 
 
To a solution of amine 3.69 (900 mg, 6.12 mmol) and NaOH (500 mg, 
12.5 mmol) in H2O (20 mL) at 0 to 5°C was added CbzCl (3.38) (961 
µL, 6.73 mmol) dropwise over 1h. The reaction mixture was stirred for 
an additional 3h at 0 to 5°C. The aqueous layer was washed with diethyl ether (3 × 20 mL) and 
subsequently lyophilized to afford carbamate 3.70 (1.60 g, 93%) as a white solid. δH (300 MHz; 
CDCl3; 25°C) 0.80 (6H, s, -(CH3)2), 2.66-3.32 (2H, m, -CH2-), 3.65 (1H, s, -CH-), 4.96 (2H, s, -CH2-) 
5.63 (1H, br s, -NH-) and 7.15-7.42 (5H, m, arom). OH protons not observed. 1H NMR data are 
consistent with those previously reported [62].  
 
Benzyl 4-(3-(heptylamino)-3-oxopropylamino)-3-hydroxy-2,2-dimethyl-4-oxobutylcarbamate (3.71) 
 
DIPEA (145 µL, 0.832 mmol) was added drop-
wise over 5 min to a solution of amine 3.45 (152 
mg, 0.808 mmol) in DCM (12 mL) at 0°C under an 
inert atmosphere. HOBt (30.9 mg, 0.202 mmol), carboxylic acid 3.70 (250 mg, 0.889 mmol) and 
EDC hydrochloride (155 mg, 0.808 mmol) were then added consecutively and the reaction mixture 
was stirred overnight at rt. The reaction mixture was concentrated in vacuo before purification by 
FCC (6:1 EtOAc: Hexanes) afforded amide 3.71 (181 mg, 50%) as a yellow oil. Rf = 0.21 (FCC 
conditions). δH (600 MHz; CDCl3; 25°C) 0.86-0.89 (6H, m, -(CH3)2), 1.01 (3H, s, -CH3), 1.21-1.31 
(8H, m, -(CH2)4-), 1.43-1.48 (2H, m, -CH2-), 2.38 (2H, t, J = 6.2 Hz, -CH2-), 2.75 (1H, dd, J = 5.8, 
8.8 Hz, -CH2-), 3.18 (2H, q, J = 6.4 Hz, -CH2-), 3.37-3.41 (1H, m, -CH2-), 3.52 (2H, q, J = 5.9 Hz, 
-CH2-), 3.78 (1H, s, -CH-), 5.06 (2H, m, -CH2-), 5.40 (1H, br t, J = 6.4 Hz, -NH-), 5.99 (1H, br s, 
-NH-), 7.30-7.37 (5H, m, arom) and 7.45 (1H, br t, J = 5.6 Hz, -NH-). OH proton not observed. δC 
(150 MHz; CDCl3; 25°C) 14.8, 16.7, 16.7, 23.1, 25.2, 29.5, 31.6, 32.1, 34.3, 37.9, 38.8, 42.0, 42.3, 
69.8, 77.4, 130.7, 130.9, 131.2, 138.7, 160.7, 173.6 and 175.4. HRMS [M+H]+ 450.2956 
(Calculated [C24H40N3O5]
+ = 450.2968). 
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N-Heptyl pantothenamide 4'-O,O-dibenzylphosphate (3.73) 
 
Dibenzyl chlorophosphate (3.72) was prepared in situ 
by reacting N-chloro-succinimide (304 mg, 2.28 mmol) 
and dibenzylphosphite (598 mg, 2.28 mmol) in anhydrous toluene (4 mL) under an inert 
atmosphere for 2h at rt. The reaction mixture was filtered to remove the succinimide. To a solution 
of hydroxyl 3.10 (240 mg, 0.758 mmol) in anhydrous pyridine (4.50 mL) at -40°C under an inert 
atmosphere was added dibenzyl chlorophosphate (3.72) drop-wise with stirring. The reaction 
mixture was stirred for an additional 2h at -40°C and the mixture was placed in the -20°C freezer 
overnight. The reaction mixture was allowed to warm to rt and was subsequently quenched with 
H2O (3 mL) and concentrated in vacuo. The resulting crude residue was re-dissolved in EtOAc (30 
mL) and the organic layer was washed with 1 M aqueous H2SO4 (2 × 10 mL), 1 M aqueous 
NaHCO3 (2 × 10 mL) and sat. aqueous Na2SO4 (1 × 10 mL). The organic layer was dried 
(Na2SO4), filtered and concentrated in vacuo before purification by FCC (10% MeOH in DCM) 
afforded 3.73 (150 mg, 34%) as a yellow solid. Rf = 0.13 (FCC conditions). δH (400 MHz; CDCl3; 
25°C) 0.81 (3H, s, -CH3), 0.85 (3H, t, J = 7.0 Hz, -CH3), 1.05 (3H, s, -CH3), 1.22-1.31 (8H, m, 
-(CH2)4-), 1.43-1.50 (2H, m, -CH2-), 2.38 (2H, t, J = 5.8 Hz, -CH2-), 3.17 (2H, q, J = 7.0 Hz, -CH2-), 
3.52-3.60 (3H, m, -(CH2)2-), 3.87 (1H, s, -CH-), 3.98-4.04 (1H, m, -CH2-), 5.03 (2H, d, J = 8.6 Hz, 
-CH2-), 5.04 (2H, d, J = 8.6 Hz, -CH2-), 6.14 (1H, br s, -NH-), 7.27 (1H, br t, J = 7.8 Hz, -NH-) and 
7.31-7.39 (10H, m, arom). OH proton not observed. δC (100 MHz; CDCl3; 25°C) 14.3, 18.9, 21.4, 
22.8, 27.1, 29.2, 29.7, 31.9, 35.6, 36.3, 39.7, 39.9, 69.9, 69.9, 70.0, 73.8, 128.2, 128.9, 135.7, 
135.8, 171.2 and 172.6. δP (161 MHz; CDCl3; 25°C) 0.87. HRMS [M+H]
+ 577.3055 (Calculated 
[C30H46N2O7P]
+ = 577.3043). 
 
4’-Phospho-N-heptyl pantothenamide (3.74) 
 
To a solution of 3.73 (130 mg, 0.225 mmol) in MeOH (9 
mL) and H2O (1 mL) at rt was added 10% Pd/C (34.3 
mg, 0.322 mmol). The reaction atmosphere was filled 
with H2 gas and the reaction mixture was stirred overnight at rt. The reaction mixture was filtered 
and concentrated in vacuo to give 3.74 (87.5 mg, 98%) as a clear oil. Rf = 0.07 (10% MeOH in 
DCM). δH (300 MHz; D2O; 25°C) 0.78 (3H, t, J = 6.2 Hz, -CH3), 0.85 (3H, s, -CH3), 0.93 (3H, s, 
-CH3), 1.14-1.30 (8H, m, -(CH2)4-), 1.37-1.48 (2H, m, -CH2-), 2.43 (2H, t, J = 5.9 Hz, -CH2-), 3.08 
(2H, t, J = 6.5 Hz, -CH2-), 3.38-3.54 (2H, m, -CH2-), 3.61 (1H, m, -CH2-), 3.82 (1H, m, -CH2-) and 
3.98 (1H, s, -CH-). OH protons not observed. δC (150 MHz; D2O; 25°C) 14.3, 19.4, 21.3, 22.9, 
27.2, 29.2, 29.3, 32.1, 36.0, 39.0, 39.1, 40.2, 72.5, 74.8, 173.8 and 175.3. δP (161 MHz; CDCl3; 
25°C) 0.63. HRMS [M+H]+ 397.2102 (Calculated [C16H34N2O7P]
+ = 397.2104). 
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3.8.3 Characterization of the N7-Pan analogues 
3.8.3.1 Bacterial growth inhibition studies of the N7-Pan analogues in minimal media 
The MIC80s of the N7-Pan analogues against S. aureus RN4220 were determined by microbroth 
dilution in 96-well microtiter flat-bottomed plates and turbidimetric analysis at OD600. The S. aureus 
RN4220 strain was a kind gift from Prof L.M.T. Dicks at the Department of Microbiology, 
Stellenbosch University. The inhibition of S. aureus RN4220 by the N7-Pan analogues were tested 
in minimal media appropriate for S. aureus which contained 40.24 mM KCl, 162.6 mM NaCl, 5.274 
mM MgSO4∙7H2O, 30.27 mM (NH4)2SO4, 0.1129 mM CaCl2, 1.029 mM KH2PO4, 0.02158 mM 
FeSO4∙7H2O, 0.04483 mM MnSO4∙4H2O, 0.03123 mM citric acid, 99.88 mM Tris-HCl, 27.75 mM 
glucose, 0.8003 mM L-arginine, 1.015 mM L-proline, 1.936 mM L-glutamic acid, 1.513 mM L-
valine,1.484 mM L-threonine, 1.019 mM L-phenylalanine, 1.326 mM L-leucine, 0.7757 mM L-
cysteine, 0.4093 μM biotin, 6.649 μM thiamin and 16.25 μM nicotinic acid [65]. The inhibition was 
determined by concentration-response analysis. Starter cultures of S. aureus RN4220 in 1% 
tryptone were inoculated with four separate colonies grown on Luria Bertani (LB) agar plates. The 
starter culture was grown to mid-log phase and then diluted 10-fold into the minimal media. A 10 µl 
aliquot of the diluted cell suspension was used to inoculate each well of the 96-well flat-bottomed 
plate containing 100 µl of minimal medium supplemented with the specific N7-Pan analogue of 
interest. The final concentrations of the N7-Pan analogues varied in the range 0.0977–200 µM 
depending on the potency of the N7-Pan analogue. The plates were incubated at 37°C for 24h 
before the cell densities were measured (OD600). The extent of growth in each well was determined 
by normalizing the OD600 values relative to those of the negative control (containing no N7-Pan 
analogue), which was taken as 100% bacterial cell growth. Each compound was tested in either 
two or three independent experiments, each performed triplicate.  
3.8.3.2 Bacterial growth inhibition studies of the N7-Pan analogues in tryptone broth 
The MIC80s of the N7-Pan analogues against S. aureus RN4220 were determined by microbroth 
dilution in 96-well microtiter flat-bottomed plates and turbidimetric analysis at OD600. Starter 
cultures of S. aureus RN4220 in 1% tryptone broth were inoculated with four separate colonies 
grown on LB agar plates. The starter culture was grown to mid-log phase and then diluted 10 000-
fold into the same medium. A 10 µl aliquot of the diluted cell suspension was used to inoculate 
each well of the 96-well flat-bottomed plate containing 100 µl of 1% tryptone broth supplemented 
with the specific N7-Pan analogue of interest. The final concentrations of the N7-Pan analogues 
varied in the range 1.56–200 µM depending on the potency of the N7-Pan analogue. The plates 
were incubated at 37°C for 20h before the cell densities were measured (OD600). The extent of 
growth in each well was determined by normalizing the OD600 values relative to those of the  
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negative control (containing no N7-Pan analogue), which was taken as 100% bacterial cell growth. 
Each compound was tested in either two or three independent experiments, each performed 
triplicate.  
3.8.3.3 Construction of SaPanK-II, protein expression and purification 
The pET28a-Sa coaA construct containing the gene sequence of SaPanK-II was available in our 
laboratory. Protein was produced in LB media (500 mL), supplemented with 30 mg/L kanamycin, 
and inoculated with plasmid containing E. coli BL21*(DE3) starter culture. The culture was grown 
until mid-log phase was reached and induced with a final concentration of 0.5 mM IPTG and grown 
further at 37°C overnight. The His6-tagged protein was loaded to a 1.0 mL Amersham Biosciences 
HiTrap™ Chelating HP column (GE Healthcare) preloaded with Ni2+ with binding buffer (20 mM 
Tris-HCl, pH 7.9, 500 mM NaCl, 50 mM imidazole, 0.05% NaN3). After a wash step (85% binding 
buffer, 15% elution buffer) to remove any non-specifically bound proteins from the column, the 
target protein was eluted by stepwise increasing the concentration of imidazole in the elution buffer 
(20 mM Tris-HCl, pH 7.9, 500 mM NaCl, 500 mM imidazole, 0.05% NaN3). The fractions containing 
the most protein was pooled and buffer exchanged using the HiTrap™ Desalting column (GE 
Healthcare) into buffer exchange buffer (25 mM Tris-HCl, pH 8.0, 5.0 mM magnesium chloride 
(MgCl2), 5.0% glycerol). The protein concentrations were determined using Bradford in comparison 
to bovine serum albumin (BSA) standards from Biorad.   
3.8.3.4 PanK steady state kinetic analysis 
Pantothenate kinase activity was determined using a continuous spectrophotometric assay that 
coupled the production of ADP to the consumption of NADH, monitored by the decrease in 
absorbance at 340 nm, as described previously [74]. An extinction coefficient of 6220 M-1.cm-1 was 
used for NADH.  
 
Each 300 µL reaction mixture contained 50 mM Tris-HCl (pH 7.6), 10 mM MgCl2, 20 mM 
potassium chloride (KCl), 1.5 mM ATP, 0.5 mM NADH, 0.5 mM PEP, 3 units PK, 3 units LDH and 
1.5 µg SaPanK-II. The concentration ranges are indicated in the legends and axis labels of the 
figures described the results of the respective experiments. The reaction was initiated by the 
addition of substrate (or mixtures of substrates and inhibitors) and was monitored for 5 min at 
25°C. PK and LDH used in kinetic assays were from Roche (Basel, Switzerland). 
3.8.3.5 Data and statistical analysis 
Using the raw kinetic data initial velocities were calculated for each substrate concentration (or 
substrate mixture, or substrate/inhibitor mixture) by linear regression of the readings made in the  
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50 second period after the initial 10 seconds (i.e. the period from 10 to 60 seconds after the 
reaction was started). For each experiment the three readings made for each data point was 
averaged and plotted with the standard deviation to give the respective kinetic profile. Kinetic 
parameters reported in Table 3.2 were determined for each experiment by fitting the appropriate 
equation to the data; the reported values are the average values of the parameters determined 
from all the individual independent experiments, and are given with errors that indicate the range/2 
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Chapter 4 
Developing P. falciparum Inhibitors That Are 
Resistant to Pantetheinase-Mediated Degradation 
4.1 Introduction 
Malaria continues to present a major health challenge, specifically in resource limited countries [1]. 
Nearly one half of the world’s population is at risk of contracting malaria, with children less than 5 
years and pregnant woman being most susceptible of contracting the disease [2]. Despite decades 
of intensive efforts to control malaria, this disease still causes millions of clinical cases each year, 
with the WHO estimating that in 2013 ~584 000 people died from malaria worldwide, the majority 
of which lived in Africa [2-3]. There are five species of Plasmodium that are infectious to humans, 
namely Plasmodium vivax, Plasmodium malariae, Plasmodium ovale, Plasmodium knowlesi and 
Plasmodium falciparum, with the latter being the most virulent and primarily responsible for 
malaria-related deaths, although P. vivax also contributes significantly to the overall morbidity [1, 4-
5].  
 
P. falciparum has shown repeatedly that it has a substantial capability to develop antibiotic 
resistance to antimalarial drugs by means of evolutionary adaptation [6]. Consequently, the 
efficacy of the current available antimalarials is imperiled by the emergence of drug resistant 
strains of this parasite. The development of extensive resistance has already resulted in a 
considerable decrease in the efficacy of standard antimalarial drugs, including chloroquine, 
mefloquine, atabrine and pyrimethamine-sulfadoxine [3, 7]. Additionally, the development of 
resistance against the present generation drug, artemisinin and its derivatives, have also been 
observed. This has resulted in a resurgence of malaria and it is now even more imperative to 
develop new antimalarial drugs with novel mechanisms of action and/or different chemical origin to 
successfully counteract the development of antibiotic resistance [3].   
4.1.1 Transmission and life cycle of the malaria parasite  
Malaria is transmitted to humans by female Anopheles mosquitoes during a blood meal by injecting 
the human with parasites called sporozoites and completes its life cycle in two hosts; mosquito and 
human [4-5]. These sporozoites move to the liver where it invades hepatocytes, in which it grows 
and multiplies until it ruptures the hepatocyte and releases merozoites (daughter parasites) into the 
blood stream (Figure 4.1). Subsequently, the merozoites invade erythrocytes (red blood cells) and 
undergo asexual multiplication to form trophozoites followed by maturation into schizonts, with 
each schizont forming roughly 30 new merozoites. After the completion of this 48h cycle, the 
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erythrocyte will rupture to release the newly formed merozoites into the blood stream and each 
merozoite has the potential to infect a new erythrocyte and reinitiate the life cycle.  
 
Additionally, during the asexual blood stage some of the intraerythrocytic parasites develop into 
male and female gametocytes; these are taken up by an uninfected Anopheles mosquito into the 
gut during a blood meal where they mature to form male and female gametes. The fertilized zygote 
develops into either an ookinete or an oocyst and finally into sporozoites that move to the salivary 
glands of the mosquito ready to be injected into a new human host [4]. 
 
 
Figure 4.1. The life cycle of P. falciparum in the human host and the mosquito. Reproduced from ref [4]. 
4.1.2 Pantothenamides as potential small molecule inhibitors of the malaria 
parasite 
In Chapter 1 the CoA biosynthetic pathway was discussed in detail as a potential target for 
antimalarial drug development. Originally it was thought that pantothenamides are poor inhibitors 
of the CoA biosynthetic pathway and CoA-utilizing enzymes in P. falciparum since most of the 
examples tested for inhibition of the proliferation of the 3D7 strain of the parasite by de Villiers et 
al. [8], as well as Spry et al. [9], had IC50s >200 µM. The best hit, N-phenethyl pantothenamide 
(4.1, N-PE-PanAm) (boxed in Figure 4.2), showing antiplasmodial activity with an IC50 of 53 ± 11 
µM [10].  
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However, in 2011 Jansen et al. [11] discovered that this loss of antiplasmodial activity is due to 
pantetheinase enzymes present in the serum used to grow the parasites. When they tested N5-
Pan against P. falciparum in the presence of an inhibitor of pantetheinase activity, its antimalarial 
potency (IC90) was increased by a factor of 200 compared to N5-Pan alone [11]. Consequently, de 
Villiers et al. [8] retested the pantothenamides as inhibitors of the P. falciparum parasite in aged 
media (i.e. media in which the pantetheinases present in the commonly used serum substitute 
Albumax were inactivated through pre-incubation at 37°C) [8]. Under these conditions, the potency 
of the pantothenamides tested was similarly enhanced. Even pantothenamides that previously 
showed no inhibition in freshly prepared media (i.e. with the pantetheinase activity intact), 
displayed inhibition of parasite growth at sub-micromolar concentrations in aged (pre-incubated) 
media [8]. These findings indicated that pantothenamides have significant potential as 
antiplasmodial agents if their degradation by pantetheinases can be prevented, circumvented or 
resisted in some manner.  
4.2 Study design and strategy 
Given this background, we decided to also include P. falciparum into our study of the biological 
activity of pantetheinase-resistant pantothenamides. Previously, de Villiers et al. [8] established 
that the degradation of pantothenamides by pantetheinase can be prevented by the modification of 
their structures (discussed in detail in Chapter 1). This study demonstrated that the displacement 
of the scissile amide bond in pantothenamides (by forming either α-pantothenamides or homo-
pantothenamides) lead to an increased potency against P. falciparum parasites in fresh medium 
compared to the normal pantothenamides. Additionally, the α- and homo-pantothenamides were 
also more resistant to pantetheinase degradation compared to the normal pantothenamides when 
treated with recombinant human pantetheinase [8]. Consequently, we decided to expand the 
strategy used for the discovery of pantetheinase-resistant pantothenamides active against S. 
aureus as described in Chapter 3 and to synthesize the same set of analogues with added steric 
bulk, bioisostere replacement and 4’-hydroxyl derivatization, but with an amide substituent that 
showed optimum activity against P. falciparum. 
 
From a previous study by Spry et al. [9] N-PE-PanAm 4.1 was identified as the most potent 
analogue of those tested against the P. falciparum parasite with an IC50 of 53 ± 11 µM in fresh 
medium and an IC50 of 20 ± 2 nM (a value similar to that observed for chloroquine) in aged 
medium. Consequently, we set out to synthesize the same analogues that were synthesized as 
described in Chapter 3, but with the heptyl group as the amide substituent replaced with a 
phenethyl group. We expected that these nine N-PE-PanAm analogues should show increased 
resistance to pantetheinase-mediated degradation (Figure 4.2).  
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Figure 4.2. N-Phenethyl pantothenamide analogues that should withstand pantetheinase-mediated hydrolysis. In 
these analogues the scissile amide bond of N-phenethyl pantothenamide 4.1 is protected by either increasing 
the steric bulk surrounding it though the addition of a methyl group, by replacement with bioisosteres or by 
removing or replacing its 4’-hydroxyl group. The modifications relative to the parent compound are highlighted 
in each case, with orange indicating the modifications to be made to the 4’-hydroxyl, green indicating the 
modifications to be made to the scissile amide bond, and blue indicating the modifications to be made through 
the addition of steric bulk.  
 
We did not include the sulfonamide bioisostere in this study, since N-phenethyl pantoyltauramide 
(4.24, N-PE-pantoyltauramide) was synthesized previously in our laboratory by Mr. Collins Jana 
during his MSc study [12] and was tested for its antiplasmodial activity in fresh and aged media by 
Dr. Cristiano Macuamule during his PhD study [13]. This particular analogue exhibited inhibition of 
the proliferation of P. falciparum 3D7 strain with an IC50 of 35 ± 2 µM and 42 ± 0.4 µM in fresh and 
aged media, respectively. This indicated that N-PE-pantoyltauramide 4.24 was indeed resistant to 
pantetheinase-mediated degradation, but that the structural modification came at a significant cost 
in potency. 
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4.3 Physicochemical properties of the proposed N-Phenethyl 
pantothenamide analogues 
Before we synthesized the analogues of N-PE-PanAm 4.1 we first determined their 
physicochemical properties (as was done for the N7-Pan analogues) by looking at their adherence 
to Lipinski’s rules of 5, as well as at their extended in silico characterized properties. All of the 
analogues were found to obey at least three of the four Lipinski rules (Table 4.1): in all cases their 
molecular weights fall within the limit of ≤ 500 g.mol-1, and all of the compounds fall within the limits 
for the number of H-bond acceptors (≤ 10) and donors (≤ 5). However, N-benzyl 
pantothenhydrazide (4.12, N-Bn-PanHy), (R/S)-4’-amino-N-phenethyl pantothenamide (4.21, 
(R/S)-4’-amino-N-PE-PanAm) and 4’-phospho-N-phenethyl pantothenamide (4.23, 4’-Phospho-N-
PE-PanAm) fall outside the limit of ≤ 5 and ≥ 0  for their lipophilicity (cLogP), indicating that these 
analogues are not lipophilic enough and considered too hydrophilic to be a suitable drug candidate.  
 
Looking at the additional in silico characterized properties, only 4’-phospho-N-PE-PanAm 4.23 
have a higher PSA than the preferred ≤ 140 Å, while none of the N-PE-PanAm analogues exceed 
the optimal NRotB (≤ 10-20). For most of the analogues the partition coefficient is equal to the 
distribution coefficient since they do not contain ionizable groups. It is only 4’-phospho-N-PE-
PanAm 4.23 and (R/S)-4’-amino-N-PE-PanAm 4.21 that are able to ionize due to the modifications 
at the 4’-position; unfortunately their LogD7.4 values, as in the case with their cLogP values, fall 
outside the limits of the suggested LogD7.4 values. Compared to the N7-Pan analogues, all of the 
N-PE-PanAm analogues have a lower percentage of Fsp3 carbons with most of them having 50-
65.5% of Fsp3 carbons, except for (E)-N-phenethyl CJ-pantothenamide (E)-4.9, (E)-N-PE-CJ-
PanAm) which has 41.2% Fsp3 carbons.  
 
In summary, the proposed N-PE-PanAm analogues adhere to most of Lipinski’s rules of 5 
properties, as well as to most of the other in silico characterized properties. We therefore expected 
that these compounds should be orally bioavailable if they translate into potent inhibitors of 
parasite proliferation. 
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PSA (Å2) NRotBs LogD7.4 Fsp
3 
 
322.40 0.07 4 4 98.66 9 0.07 0.529 
 
336.43 0.62 4 4 98.66 9 0.62 0.556 
 
336.43 0.49 4 4 98.66 9 0.49 0.556 
 
336.43 0.30 4 3 89.87 9 0.30 0.556 
 
320.38 0.29 4 4 98.66 8 0.29 0.412 
 
329.39 -0.51 5 5 110.7 9 -0.51 0.500 
 
338.46 0.96 3 4 81.6 9 0.96 0.529 
 
321.41 -0.03 4 4 104.5 9 -1.93 0.529 
 
320.43 1.80 3 3 78.4 9 1.80 0.529 
 
402.38 -0.05 6 5 145.2 11 -3.10 0.529 
a  
Values of cLogP and LogD7.4 were calculated with calculator plugins in the program MarvinSketch 6.0.6, 2013 from ChemAxon (Budapest, Hungary). cLogP and LogD7.4 values were 






) set to 0.1 mol.dm
-3
 [14-16]. We did not consider 
automerization in our calculations. PSA was calculated with the same program, but excluded sulfur and phosphorus atoms from the calculations. NRotB, H-bond donors and H-bond 
acceptors were calculated using the same program. The values that fall outside the limits of the physicochemical properties are indicated in red. 
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4.4 Synthesis of pantetheinase-resistant N-phenethyl pantothenamide 
analogues 
The synthetic preparation of the nine N-PE-PanAm analogues was based on the synthetic routes 
that were developed as described in Chapter 3. Consequently, the synthesis of each analogue will 
not be discussed in detail here. Instead, a brief overview of the results obtained for each synthetic 
route will be provided. We first focused on the analogues that have steric bulk introduced in close 
proximity to the amide bond which is vulnerable to pantetheinase degradation, followed by the 
preparation of the analogues with bioisostere replacements. Lastly, we prepared the analogues 
where the 4’-hydroxyl group was removed or replaced to prevent substrate recognition. 
4.4.1 Introducing steric bulk to N-phenethyl pantothenamide 
4.4.1.1 α-Methyl-N-phenethyl pantothenamide (4.3) and β-methyl-N-phenethyl pantothen-
amide (4.4)   
The synthetic route for the preparation of α-methyl-N-phenethyl pantothenamide (4.3, α-Me-N-PE-
PanAm) and β-methyl-N-phenethyl pantothenamide (4.4, β-Me-N-PE-PanAm) consisted of a two-
step linear synthesis and included a condensation and coupling reaction (Scheme 4.1). Carboxylic 
acid 3.4 and 3.5 were prepared as discussed previously in Chapter 3 by condensation of the 
respective acids with (R)-(-)-pantolactone 3.3. A DPPA-mediated coupling was used for the final 
amide bond formation in step 2. As such, a solution of carboxylic acid 3.4 or 3.5 and 
phenethylamine (4.2) in DMF was treated with DPPA and Et3N. Subsequent purification by FCC 
gave amide 4.3 (when carboxylic acid 3.4 was coupled) as a yellow oil in 52% yield. Unfortunately, 
only a 30% yield was obtained for amide 4.4 (white solid) (when carboxylic acid 3.5 was coupled) 
after purification. DPPA-mediated coupling reactions require strictly anhydrous conditions to 
achieve successful amide bond formation [17]. Given that carboxylic acid 3.5 is very hygroscopic, 
the low yield obtained for amide 4.4 could be attributed to some moisture entering the reaction 
mixtures by association with this reagent. Additionally, the low yield could also be due to a possible 
competing coupling reaction at the unprotected 4’-hydroxyl position. 
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Scheme 4.1. Synthetic route for the preparation of α-methyl-N-phenethyl pantothenamide (4.3) and β-methyl-N-
phenethyl pantothenamide (4.4). 4.3 was prepared from (R/S)-3-amino-isobutyric acid 3.1 in two steps, while 4.4 
was prepared from (R/S)-3-aminobutyric acid 3.2 in two steps. 
4.4.1.2 N-Methyl N-phenethyl pantothenamide (4.6)   
The synthesis of N-methyl-N-phenethyl pantothenamide (4.6, N-Me-N-PE-PanAm) was based on a 
linear two-step synthesis that included an activation of the carboxylic acid and an aminolysis step 
(Scheme 4.2). Acid 3.9 was converted into the active thioester 3.20 in the first step by treating acid 
3.9 with thiophenol (3.19), DEPC and Et3N in DMF. In the final step, thioester 3.20 was reacted 
with N-methyl phenethylamine (4.5) to give target amide 4.6 via aminolysis. Subsequent 
purification by FCC gave the product as a yellow oil in an excellent 82% yield.   
 
 
Scheme 4.2. Synthetic route for the preparation of N-methyl-N-phenethyl pantothenamide (4.6) from pantothenic 
acid 3.9 using a two-step linear method that was developed by van Wyk and Strauss [18]. 
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4.4.1.3 (E)-N-Phenethyl CJ-pantothenamide ((E)-4.9)   
The synthetic route for the synthesis of (E)-N-PE-CJ-PanAm (4.9) consisted of a six-step synthesis 
that entailed the preparation of two fragments which was subsequently coupled using a Pd-
catalyzed reaction to introduce the enamide moiety (Scheme 4.3). Fragment 1 (amide 3.22) was 
prepared as discussed previously in Chapter 3 by aminolysis of (R)-(-)-pantolactone 3.3, followed 
by protection of the 2,4-diol 3.21 as the acetonide.  
 
In step 1 of the synthesis of the second fragment, bromo acid 3.24 was prepared by refluxing 
propiolic acid (3.23) in 48% aqueous HBr and subsequent filtration of the precipitate upon cooling 
on an ice bath. In the second step, bromo acid 3.24 was successfully coupled to phenethylamine 
(4.2) using a standard DIC- and DMAP-mediated coupling procedure performed in DCM, before 
purification by FCC afforded acrylamide 4.7 as pale yellow solid in a moderate 45% yield. 
 
 
Scheme 4.3. Synthetic route for the preparation of (E)-N-phenethyl CJ-pantothenamide ((E)-4.9) from (R)-(-)-
pantolactone 3.3 and propiolic acid 3.23 using a six-step method that was developed by van der Westhuyzen 
[19]. 
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A Pd-catalyzed reaction was used to introduce the enamide moiety in step 3 [19]. Bromo 
acrylamide 3.25 (fragment 2) and amide 3.22 (fragment 1) were coupled in toluene using 
Pd(OAc)2, Xantphos and CTAB to facilitate the enamide bond formation, with K2CO3 being added 
to neutralize the HBr formed during the course of the reaction. Subsequent purification by FCC (to 
separate the E- and Z-isomers) afforded enamide (E)-4.8 and (Z)-4.8 in 34% and 6%, respectively, 
with an E:Z ratio of 6:1. TLC analysis showed multiple side products, which could explain the low 
yield for the Pd-catalyzed coupling. In the final step, the acetonide protecting group was 
successfully removed with BiCl3 in aqueous CH3CN, before purification by FCC afforded (E)-4.9 as 
a white solid in 13% yield and (Z)-4.9 as a yellow oil in 46% yield, respectively. The absolute 
stereochemistry of the E- and Z-isomers was confirmed with 1H NMR spectroscopic analysis – the 
vinylic proton shifts as well as the J-couplings were consistent with those previously reported by 
Van der Westhuyzen [19]. 
4.4.2 Bioisostere replacement of the scissile amide in N-phenethyl 
pantothenamide 
4.4.2.1 N-Benzyl pantothenhydrazide (4.12)  
The synthetic route for the synthesis of N-Bn-PanHy 4.12 consisted of a four-step linear synthesis 
that included a thioesterification, as well as a reductive amination step (Scheme 4.4). Hydrazide 
3.30 was prepared as discussed previously in Chapter 3 by thioesterification of acid 3.9 with 
ethanethiol (3.28), followed by hydrazinolysis of thioester 3.29. Steps 3 and 4 entailed a metal 
hydride-mediated reductive amination of hydrazide 3.30. As such, hydrazide 3.30 was reacted with 
benzaldehyde (4.10) in EtOH by stirring at reflux for 48h. After purification by FCC, imine 4.11 was 
obtained in a satisfactory 72% yield. In the final step, imine 4.11 was subjected to a NaBH3CN-
mediated reduction before purification by FCC afforded hydrazide 4.12 as a yellow oil, but 
unfortunately with only a 7% yield in the final step. TLC analysis showed that the reaction did not 
proceed to completion; consequently, a very low yield was obtained for the final step.  
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Scheme 4.4. Synthetic route for the preparation of N-benzyl pantothenhydrazide (4.12) from pantothenic acid 3.9 
in four steps. 
4.4.2.2 N-Phenethyl pantothenthioamide (4.16)   
The synthetic route for the synthesis of N-phenethyl pantothenthioamide (4.16, N-PE-
pantothenthioamide) consisted of a four-step linear synthesis that included a thionation and a 
condensation reaction (Scheme 4.5). In step 1, a solution of Cbz-β-alanine (3.14) and 
phenethylamine (4.2) in DMF was treated with DEPC and Et3N to facilitate the amide bond 
formation. The side-products and unreacted amine were removed through an aqueous work-up, 
which proved to be adequate to obtain amide 4.13 as a pure white powder in an excellent 99% 
yield. The second step of the synthesis entailed the thionation of the scissile amide bond. As such, 
amide 4.13 was treated with Lawesson’s reagent in toluene and the reaction mixture was stirred at 
reflux overnight. Subsequent purification by FCC afforded thioamide 4.14 as a light yellow powder 
in moderate yield (51%). The third step of the synthesis entailed the deprotection of carbamate 
4.14 by refluxing overnight in a 1:1 solution of MeOH and concentrated HCl. The crude amine 4.15 
was lyophilized to afford the HCl salt of amine 4.15 as a white powder, which was subsequently 
used in the next step without any further purification.  
 
The final step of the synthesis involved an amide bond formation between amine 4.15 HCl salt and 
(R)-(-)-pantolactone 3.3 in the presence of Et3N to facilitate the amide bond formation. During the 
synthesis of N7-pantothenthioamide 3.36 a very low yield was obtained (7%) in the final step. 
Consequently, in the final step of the preparation of N-PE-pantothenthioamide 4.16 the amount of 
Et3N in the reaction was increased from 2.5 equiv. to 5 equiv. to account for the HCl salt in the  
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reaction. Hence, amine 4.15 HCl salt was condensed with (R)-(-)-pantolactone 3.3 in the presence 
of Et3N by stirring for 48h at reflux in EtOH. Subsequent purification by FCC afforded amide 4.16 
as a yellow oil. Although the yield was still low (30%), the increase in the amount of Et3N did 
increase the yield by three-fold. 
  
 
Scheme 4.5. Synthetic route for the preparation of N-phenethyl pantothenthioamide (4.16) from Cbz-β-alanine 
(3.14) in a four-step synthesis. 
4.4.3 Removal of the 4’-OH group from N-phenethyl pantothenamide 
4.4.3.1 (R/S)-4’-Deoxy-N-phenethyl pantothenamide (4.19)  
(R/S)-4’-Deoxy-N-phenethyl pantothenamide (4.19, (R/S)-4’-deoxy-N-PE-PanAm) was synthesized 
through a four-step linear synthesis that included a coupling reaction and a NaBH4-mediated 
reduction (Scheme 4.6). Amide 4.13 was synthesized via a DEPC-mediated coupling in step 1 as 
previously described for the synthesis of N-PE-pantothenthioamide 4.16 (Scheme 4.5). The 
second step of the synthesis entailed the deprotection of carbamate 4.13 with H2 in the presence 
of 10% Pd/C to yield amine 4.17 as a pure pale yellow solid upon filtration in an excellent 98% 
yield; the purity was confirmed with 1H NMR spectroscopic analysis. In step 3, an EDC coupling 
was used to facilitate the final amide bond formation. As such, amine 4.17 and acid 3.46 
(synthesized via the oxidation of ketone 3.47 by KMnO4) were treated with EDC hydrochloride, 
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DIPEA and HOBt in DCM at 0°C and stirred overnight at rt. Subsequent purification by FCC 
afforded amide 4.18 as a white powder in 20% yield. This low yield is attributed to the low purity of 
carboxylic acid 3.46 since it degrades over time and it was not used immediately after its 
preparation. In the final step ketone 4.18 was reduced with NaBH4, with hydroxyl 4.19 being 
obtained as a white solid in an excellent yield (94%) after an aqueous work-up.  
 
 
Scheme 4.6. Synthetic route for the preparation of (R/S)-4’-deoxy-N-phenethyl pantothenamide (4.19) from Cbz-
β-alanine (3.14) through a four-step linear synthesis developed in the manuscript described in Chapter 2 [20].  
4.4.3.2 (R/S)-4’-Amino-N-phenethyl pantothenamide (4.21)  
The synthetic route for the synthesis of (R/S)-4-amino-N-PE-PanAm (4.21) consisted of a five-step 
linear synthesis which included a condensation and coupling reaction (Scheme 4.7). Carbamate 
3.70 was synthesized in steps 1 to 3 (as previously described in Chapter 3) via a Gabriel-type 
synthesis to afford amine 3.69, which was subsequently protected with Cbz chloride (3.38) in 
aqueous NaOH to give carbamate 3.70 as a white powder in an excellent 93% yield.  
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Scheme 4.7. Synthetic route for the preparation of (R)-4’-amino-N-phenethyl pantothenamide (4.21) using 
phthalimide to introduce the 4’-amine. A method adapted from Kopelevich et al. [21] and de Villiers et al. [20] 
were used. 
 
In step 4, an EDC coupling was used to facilitate the amide bond formation. As such, acid 3.70 and 
amine 4.17 (synthesized by coupling Cbz-β-alanine (3.14) and phenethylamine (4.2) in the 
presence of DEPC and Et3N, followed by subsequent deprotection of the carbamate 4.13 with 10% 
Pd/C and H2) were treated with EDC hydrochloride, DIPEA and HOBt in DCM at 0°C and stirred 
overnight at rt. Subsequent purification by FCC afforded amide 4.20 as a yellow oil in 37% yield. 
The final step of the synthesis involved the deprotection of carbamate 4.20 by treatment with H2 in 
the presence of 10% Pd/C to yield target compound (R/S)-4.21 as yellow oil in a good yield (78%) 
upon filtration. The purity of (R/S)-4.21 was confirmed by NMR spectroscopic analysis.  
4.4.3.3 4’-Phospho-N-phenethyl pantothenamide (4.23)  
The synthetic route for the preparation of 4’-phospho-N-PE-PanAm (4.23) comprised of a three-
step linear synthesis that included a phosphorylation and deprotection step (Scheme 4.8). In the 
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first step calcium pantothenate was exchanged to free acid 3.9 using Amberlite IR120 resin and 
was subsequently coupled to phenethylamine (4.2) using DEPC in the presence of Et3N to 
facilitate the amide bond formation. The side products and unreacted amine were removed through 
an aqueous work-up, giving amide 4.1 which was subsequently used in the next step without any 
further purification. In the second step, the 4’-hydroxyl of 4.1 was phosphorylated with dibenzyl-
chlorophosphate 3.72 (prepared in situ by reacting dibenzylphosphite and N-chlorosuccinimide in 
toluene for 2h, followed by filtration of the succinimide) in pyridine at -40°C, before purification by 
FCC afforded 4.22 as a yellow oil in a 28% yield. The final step of the synthesis entailed the 
deprotection of 4.22 and the benzyl protecting groups were successfully removed with H2 in the 
presence of 10% Pd/C to yield target compound 4.23 as a clear oil in an excellent 99% yield upon 
filtration; the purity of 4.23 was confirmed by NMR spectroscopic analysis.  
 
 
Scheme 4.8. Synthetic route for the preparation of 4’-phospho-N-phenethyl pantothenamide (4.23) from 
pantothenic acid 3.9 using a method developed by Strauss et al. [22]. 
4.5 Determination of the antiplasmodial activity of the N-phenethyl-
pantothenamide analogues against P. falciparum 
The next objective was to evaluate whether the nine N-PE-PanAm analogues prepared above 
retained their potency towards P. falciparum compared to the parent compound N-PE-PanAm 4.1. 
Ideally, it would also have been good to test whether these N-PE-PanAm analogues act as 
substrates or as inhibitors of PfPanK and to determine their mode of action using the same 
experimental design that were used for SaPanK-II in Chapter 3. However, thus far no one has 
successfully overexpressed and purified soluble PanK enzyme from the organism or a 
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heterologous expression system, even though PanK activity has been observed in lysates for 
years [5]. Consequently, these N-PE-PanAm analogues were only tested against the P. falciparum 
parasite.  
 
The potency of these compounds were evaluated by testing them against P. falciparum in fresh 
medium (i.e. with active pantetheinase activity) as well as aged medium (i.e. medium in which the 
pantetheinases present in the commonly used serum substitute Albumax were deactivated through 
pre-incubation at 37°C). We decided to first test whether these analogues show antiplasmodial 
activity. Consequently, if antiplasmodial activity is observed in fresh and aged medium, the stability 
of the N-PE-PanAm analogues towards pantetheinase-mediated degradation will be confirmed by 
incubation with recombinant pantetheinase (human VNN1). Three of the nine N-PE-PanAm 
analogues were tested by Dr. Cristiano Macuamule during his PhD study [13] in our laboratory and 
the remaining six N-PE-PanAm analogues were sent to Dr. Kevin Saliba’s laboratory at The 
Australian National University, Canberra, Australia. The results of these tests are still outstanding 
and will therefore not be discussed here.  
4.5.1 Biological testing of the methylated and deoxy N-PE-PanAm analogues 
Three of the nine N-PE-PanAm analogues, namely α-Me-N-PE-PanAm 4.3, β-Me-N-PE-PanAm 
4.4 and (R/S)-4’-deoxy-N-PE-PanAm 4.19 were tested by Dr. Macuamule against P. falciparum. α-
Me-N-PE-PanAm 4.3 showed excellent antiplasmodial activity against the chloroquine-sensitive 
strain P. falciparum 3D7 (chloroquine IC50 = 11 ± 1 nM) in aged medium, with an IC50 of 29 ± 2 nM, 
a value which is only slightly higher than that of N-PE-PanAm 4.1 (20 ± 2 nM) in the same medium. 
Furthermore, in fresh medium, α-Me-N-PE-PanAm 4.3 showed exceptional antiplasmodial activity 
with an IC50 of 52 ± 6 nM, compared to N-PE-PanAm 4.1 (IC50 ~ 6200 nM). α-Me-N-PE-PanAm 4.3 
is thus more than 100-fold more potent in fresh medium compared to N-PE-PanAm 4.1. This 
illustrates that α-Me-N-PE-PanAm 4.3 is resistant to degradation by pantetheinase; this stability 
was further confirmed by incubation with recombinant pantetheinase (human VNN1) for 24 h. α-
Me-N-PE-PanAm 4.3 showed only a 26% ± 2% hydrolysis compared to the 96% ± 9% observed for 
N-PE-PanAm 4.1. These results were published as part of an article in Antimicrobial Agents and 
Chemotherapy [2]; the manuscript is attached as an addendum.  
 
β-Me-N-PE-PanAm 4.4 was tested in a similar manner. It showed increased antiplasmodial activity 
compared to N-PE-PanAm 4.1 in fresh medium with an IC50 of 14 ± 1 µM. β-Me-N-PE-PanAm 4.4 
also showed increased stability when incubated with recombinant pantetheinase, which correlates 
well with the limited degradation observed for α-Me-N-PE-PanAm 4.3. However, compared to α-
Me-N-PE-PanAm 4.3, its antiplasmodial potency is roughly 1000-fold lower. This indicates that the  
placement of the methyl group is an important consideration for target selectivity. 
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The final compound that was tested, (R/S)-4’-deoxy-N-PE-PanAm 4.19 did not act as an inhibitor, 
given that even at 200 µM the P. falciparum growth was still more than 50%. This suggests that 
PfPanK is predisposed to binding pantothenamides that act as alternative substrates, and 
therefore serves to metabolically activate the pantothenamides to exert an inhibitory effect by being 
converted into antimetabolites of CoA, thus targeting processes downstream. This result is 
currently being incorporated into another manuscript that will be submitted for publication in a peer 
reviewed journal. 
4.6 Conclusion 
Nine N-PE-PanAm analogues were successfully synthesized using various organic synthesis 
methods and all of the compounds were fully characterized synthetically. The methylated N-PE-
PanAm analogues showed stability towards degradation by pantetheinase. The antiplasmodial 
activity of α-Me-N-PE-PanAm 4.3 was 1000-fold higher than what we observed for β-Me-N-PE-
PanAm 4.4, which indicates that the placement of the methyl group targets selectivity in P. 
falciparum. In Chapter 3 we saw that the structural modifications to N7-Pan resulted in a loss of 
target specificity towards SaPanK-II. Therefore, it will be important to determine whether the N-PE-
PanAm analogues are still on target. 
4.7 Experimental section 
4.7.1 Material and methods 
The N-PE-PanAm analogues were dissolved in DMSO to yield stock solutions at a concentration of 
50-200 mM. General chemicals and reagents were purchased from Sigma-Aldrich, Merck 
Chemicals (Darmstadt, Germany) or Acros Organics (ThermoFisher, Fair Lawn, NJ, USA) and 
were of the highest purity. Solvents used for reactions were CHROMASOLV HPLC grade solvents 
from Sigma-Aldrich, while the hexanes, DCM and EtOAc used for purification were purchased from 
Merck Chemicals. Dry DMF was prepared by shaking up over KOH, distilled under reduced 
pressure and a nitrogen atmosphere, and finally stored over 4 Å molecular sieves in the dark. Dry 
DCM was distilled from CaH2 under a nitrogen atmosphere while dry THF was distilled from 
sodium under a nitrogen atmosphere. 
 
All 1H and 13C NMR spectra were obtained using a 300 MHz Varian VNMRS (75 MHz for 13C), 400 
MHz Varian Unity Inova (100 MHz for 13C) or 600 MHz Varian Unity Inova (150 MHz for 13C) 
instruments at CAF of the University of Stellenbosch. All chemical shifts (δ) were recorded using 
the residual solvent peak and reported in p.p.m. All HRMS were performed on a Waters API Q-
TOF Ultima spectrometer (Waters, Milford, MA, USA) at the Mass Spectrometry unit of CAF.  
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4.7.2 Synthetic preparation of the N-phenethyl pantothenamide analogues 
 
α-Methyl-N-Phenethyl pantothenamide (4.3) (mixture of diastereomers) 
 
Phenethylamine (4.2) (163 µL, 1.29 mmol) and DPPA (278 µL, 
1.29 mmol) were added to a solution of carboxylic acid 3.4 (250 
mg, 1.07 mmol) in anhydrous DMF (4 mL) at rt under an inert 
atmosphere. After cooling the mixture to 0°C, Et3N (180 µL, 1.29 mmol) was added. The reaction 
mixture was stirred for an additional 2h at 0°C and left to stir overnight at rt. DMF was removed in 
vacuo and Amberlite IR400 (OH--form) resin was added (2.50 g). The reaction mixture was filtered 
and lyophilized before purification by FCC (10% MeOH in DCM) afforded amide 4.3 (188 mg, 52%) 
as a yellow oil. Rf = 0.24 (FCC conditions). δH (600 MHz; CDCl3; 25°C) 0.90 (3H, s, -CH3, 
diastereomer A), 0.91 (3H, s, -CH3, diastereomer B), 0.99 (3H, s, -CH3, diastereomer A), 1.00 (3H, 
s, -CH3, diastereomer B), 1.10 (3H, d, J = 7.1 Hz, -CH3), 2.47-2.59 (1H, m, -CH-), 2.80 (2H, t, J = 
7.1 Hz, -CH2-), 3.28-3.38 (2H, m, -CH2-), 3.42-3.49 (2H, m, -CH2-), 3.51-3.58 (2H, m, -CH2-), 3.98 
(1H, apparent t, J = 5.1 Hz, -CH-, both diastereomers), 5.98 (1H, br s, -NH-), 7.17 (2H, d, J = 7.4 
Hz, arom), 7.22 (1H, d, J = 7.3 Hz, arom), 7.25 (1H, br s, -NH-) and 7.30 (2H, dd, J = 7.3, 7.4 Hz, 
arom). OH protons not observed. δC (150 MHz; CDCl3; 25°C) 15.7, 20.4, 20.4, 35.5, 40.6, 40.7, 
42.1, 48.7, 70.8, 77.5, 126.6, 128.6, 128.7, 138.7, 173.7, and 175.0. (HRMS) [M+H]+ 337.2124 
(Calculated [C18H29N2O4]
+ = 337.2127). 
 
β-Methyl-N-Phenethyl pantothenamide (4.4) (mixture of diastereomers) 
 
Phenethylamine (4.2) (590 µL, 4.68 mmol) and DPPA (1.01 mL, 
4.68 mmol) were added to a solution of carboxylic acid 3.5 (910 
mg, 3.90 mmol) in anhydrous DMF (6 mL) at rt under an inert 
atmosphere. After cooling the mixture to 0°C, Et3N (653 µL, 4.68 mmol) was added. The reaction 
mixture was stirred for an additional 2h at 0°C and left to stir overnight at rt. DMF was removed in 
vacuo and Amberlite IR400 (OH--form) resin was added (2.50 g). The reaction mixture was filtered 
and lyophilized before purification by FCC (10% MeOH in DCM) afforded amide 4.4 (398 mg, 30%) 
as a white solid. Rf = 0.28 (FCC conditions). δH (300 MHz; CDCl3; 25°C) 0.78 (3H, s, -CH3, 
diastereomer A), 0.79 (3H, s, -CH3, diastereomer B), 0.80 (3H, s, -CH3, diastereomer A), 0.81 (3H, 
s, -CH3, diastereomer B), 0.99 (3H, d, J = 6.2 Hz, -CH3), 2.12-2.21 (1H, m, -CH2-), 2.25-2.32 (1H, 
m, -CH2-), 2.67 (2H, t, J = 7.6 Hz, -CH2-), 3.15-3.23 (2H, m, -CH2-), 3.25-3.33 (2H, m, -CH2-), 3.66-
3.69 (1H, m, -CH-), 4.06-4.17 (1H, m, -CH-, diastereomer A), 4.47-4.51 (1H, m, -CH-, diastereomer 
A), 7.19 (3H, m, arom), 7.26-7.31 (2H, m, arom), 7.61 (1H, d, J = 8.2 Hz, -NH-) and 7.96 (1H, q, J 
= 5.9, 12.3 Hz, -NH-). OH protons not observed. δC (75 MHz; CDCl3; 25°C) 20.5, 20.8, 21.4, 35.6, 
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39.5, 41.7, 42.1, 42.2, 68.5, 75.4, 126.5, 128.8, 129.0, 139.9, 170.6 and 172.4. (HRMS) [M+H]+ 
337.2133 (Calculated [C18H29N2O4]
+ = 337.2127). 
 
N-Methyl-N-phenethyl pantothenamide (4.6) 
 
To a solution of thioester 3.20 (200 mg, 0.642 mmol) in CH3CN 
(7 mL) at rt was added N-methyl phenethylamine (4.5) (112 µL, 
0.770 mmol). The reaction mixture was stirred overnight at 35°C. 
The reaction mixture was concentrated in vacuo before purification by FCC (5% MeOH in DCM) 
afforded amide 4.6 (178 mg, 82%) as a yellow oil. Rf = 0.16 (FCC conditions). δH (600 MHz; CDCl3; 
25°C) 0.89 (3H, d, J = 14.6 Hz, -CH3), 1.00 (3H, d, J = 9.4 Hz, -CH3), 2.23 (1H, t, J = 5.9 Hz,  
-CH2-), 2.51 (1H, t, J = 5.6 Hz, -CH2-), 2.80-2.85 (2H, m, -CH2-), 2.86 (3H, d, J = 24.9 Hz, -CH3), 
3.36-3.45 (1H, m, -CH2-), 3.45-3.46 (1H, s, -CH2-), 3.48-3.50 (2H, m, -CH2-), 3.53-3.63 (2H, m, 
-CH2-), 3.97 (1H, dd, J = 2.6, 8.2 Hz, -CH-), 7.13-7.32 (5H, m, arom) and 7.39 (1H, br t, -NH-). OH 
protons not observed. δC (150 MHz; CDCl3; 25°C) 24.2, 24.2, 34.9, 35.8, 36.3, 38.6, 52.6, 54.2, 
73.6, 80.1, 129.1, 131.2, 131.4, 141.4, 174.4 and 179.5. (HRMS) [M+H]+ 337.2124 (Calculated 
[C18H29N2O4]




Phenethylamine (4.2) (1.00 mL, 7.95 mmol) and DMAP (130 mg, 1.06 
mmol) were added to a solution of bromo acid 3.24 (800 mg, 5.30 mmol) in 
anhydrous DCM (15 mL) at rt under an inert atmosphere. The reaction mixture was cooled to 0°C 
before DIC (903 µL, 5.83 mmol) was added dropwise. The reaction mixture was warmed to rt and 
left to stir overnight. The reaction mixture was filtered through a pad of Celite and the solvent was 
removed in vacuo. The resulting crude residue was re-dissolved in EtOAc (50 mL) and the organic 
layer was washed with sat. aqueous NaHCO3 (2 × 20 mL) and sat. aqueous NaCl (2 × 10 mL). The 
organic layer was dried (Na2SO4), filtered and concentrated in vacuo before purification by FCC 
(1:2 EtOAc: Hexanes) which afforded amide 4.7 (606 mg, 45%) as a pale yellow solid. Rf = 0.32 
(FCC conditions). δH (600 MHz; CDCl3; 25°C) 2.83 (2H, t, J = 7.0 Hz, -CH2-), 3.55 (2H, q, J = 7.0 
Hz, -CH2-), 5.77 (1H, br s, -NH-), 6.42 (1H, d, J = 13.5 Hz, -CH-), 7.18 (2H, d, J = 7.0 Hz, arom), 
7.23 (1H, d, J = 7.0 Hz, arom), 7.30 (2H, t, J = 7.6 Hz, arom) and 7.14 (1H, d, J = 13.5 Hz, -CH-). 
δC (150 MHz; CDCl3; 25°C) 38.0, 43.3, 125.4, 129.3, 131.4, 133.4, 141.2 and 166.2. (HRMS) 
[M+H]+ 254.0174 (Calculated [C11H13Br
79NO]+ = 254.0181) and [M+H]+ 256.0164 (Calculated 
[C11H13Br
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To an oven dried Schlenk tube were added Pd(OAc)2 (53.0 mg, 
0.236 mmol), Xantphos (205 mg, 0.354 mmol), K2CO3 (652 mg, 
4.72 mmol), CTAB (172 mg, 0.472 mmol), amide 3.22 (450 mg, 
2.36 mmol), bromide 4.7 (660 mg, 2.60 mmol) and anhydrous toluene (5.90 mL) at rt under an inert 
atmosphere. The reaction mixture was degassed by three alternating nitrogen/vacuum cycles until 
no further gas evolution was observed. The reaction mixture was stirred for 1h at 55°C after which 
H2O (128 µL, 7.11 mmol) was added and the reaction mixture was stirred for an additional 4h at 
55°C. The resulting reaction mixture was cooled to rt, diluted with EtOAc (50 mL) and the organic 
layer was washed with H2O (2 × 15 mL). The organic layer was dried (Na2SO4), filtered and 
concentrated in vacuo before purification by FCC (1:1 EtOAc: Hexanes) afforded (E)- and (Z)-
amide 4.8 in a combined yield of 40% as a yellow solids (E:Z ratio of 6:1).  
 
(E)-amide 4.8. Rf = 0.16 (FCC conditions). δH (600 MHz; CDCl3; 25°C) 0.99 (3H, s, -CH3), 1.04 
(3H, s, -CH3), 1.44 (3H, s, -CH3), 1.49 (3H, s, -CH3), 2.82 (2H, t, J = 7.0 Hz, -CH2-), 3.29 (1H, d, J = 
11.7 Hz, -CH2-), 3.58 (2H, q, J = 6.5 Hz, -CH2-), 3.69 (1H, d, J = 11.7 Hz, -CH2-), 4.17 (1H, s,  
-CH-), 5.49 (1H, br t, J = 5.3 Hz, -NH-), 5.73 (1H, d, J = 14.1 Hz, -CH-), 7.18-7.27 (3H, m, arom), 
7.29 (2H, t, J = 7.6 Hz, arom), 7.76 (1H, dd, J = 10.8, 13.8 Hz, -CH-) and 8.26 (1H, br d, J = 11.1 
Hz, -NH-). δC (150 MHz; CDCl3; 25°C) 21.3, 21.4, 23.7, 24.5, 36.0, 38.3, 43.2, 73.9, 102.1, 108.7, 
129.1, 130.7, 131.3, 131.4, 135.5, 141.6, 168.7 and 170.7. (HRMS) [M+H]+ 361.2126 (Calculated 
[C20H29N2O4]
+ = 361.2127). 
 
(Z)-amide 4.8. Rf = 0.54 (FCC conditions). δH (400 MHz; CDCl3; 25°C) 1.05 (6H, s, -(CH3)2), 1.46 
(3H, s, -CH3), 1.62 (3H, s, -CH3), 2.81 (2H, t, J = 7.03 Hz, -CH2-), 3.30 (1H, d, J = 11.7 Hz, -CH2-), 
3.54-3.62 (2H, m, -CH2-), 3.70 (1H, d, J = 10.9 Hz, -CH2-), 4.19 (1H, s, -CH-), 4.93 (1H, d, J = 9.4 
Hz, -CH-), 5.54 (1H, br t, J = 5.5 Hz, -NH-), 7.18-7.34 (6H, m, arom and -CH-) and 11.7  (1H, br d, 
J = 10.9 Hz, -NH-). δC (100 MHz; CDCl3; 25°C) 18.9, 19.3, 22.2, 29.6, 29.6, 33.5, 35.9, 40.4, 71.6, 
99.5, 100.8, 126.8, 128.8, 128.9, 133.5, 139.0, 168.0 and 169.1. (HRMS) [M+H]+ 361.2122 
(Calculated [C20H29N2O4]
+ = 361.2127). 
 
(E)-N-Phenethyl CJ-pantothenamide ((E)-4.9) 
 
To a solution of acetonide (E)-4.8 (270 mg, 0.749 mmol) in 
CH3CN (6.2 mL) at rt were added H2O (270 µL, 15.0 mmol) and 
BiCl3 (47.3 mg, 0.150 mmol). The reaction mixture was stirred 
overnight at rt. The reaction mixture was filtered through a pad of Celite and the solvent was  
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removed in vacuo. The resulting crude residue was re-dissolved in EtOAc (20 mL) and the organic 
layer was washed with sat. aqueous NaHCO3 (2 × 10 mL). The aqueous layer was extracted with 
EtOAc (1 × 10 mL) and the combined organic layers were dried (Na2SO4), filtered and 
concentrated in vacuo before purification by FCC (100% EtOAc) afforded hydroxyl (E)-4.9 (31.2 
mg, 13%) as a white solid. Rf = 0.28 (FCC conditions). δH (300 MHz; DMSO-d6; 25°C) 0.80 (3H, s, 
-CH3), 0.83 (3H, s, -CH3), 2.70 (2H, t, J = 7.3 Hz, -CH2-), 3.14 (1H, dd, J = 5.3, 10.0 Hz, -CH2-), 
3.29 (2H, t, J = 5.6 Hz, -CH2-), 3.86 (1H, d, J = 5.3 Hz, -CH-), 4.51 (1H, t, J = 5.6 Hz, -CH-) 5.84 
(1H, d, J = 14.1 Hz, -CH-), 7.19-7.22 (3H, m, arom), 7.27-7.31 (2H, m, arom), 7.57 (1H, dd, J = 
10.9, 13.8 Hz, -CH-), 7.90 (1H, br t, J = 5.6 Hz, -NH-) and 10.2 (1H, br d, J = 10.6 Hz, -NH-). OH 
protons not observed. δC (75 MHz; DMSO-d6; 25°C) 20.4, 21.6, 35.7, 39.7, 40.8, 67.9, 75.4, 105.7, 
126.5, 128.7, 129.1, 133.4, 140.1, 166.5 and 173.0. (HRMS) [M+H]+ 321.1818 (Calculated 
[C17H25N2O4]
+ = 321.1814). 
 
(Z)-N-Phenethyl CJ-pantothenamide ((Z)-4.9) 
 
To a solution of acetonide (Z)-4.8 (60.0 mg, 0.166 mmol) in CH3CN 
(1.5 mL) at rt were added H2O (59.9 µL, 3.33 mmol) and BiCl3 (10.5 
mg, 33.3 µmol). The reaction mixture was stirred overnight at rt. 
The reaction mixture was filtered through a pad of Celite and the solvent was removed in vacuo. 
The resulting crude residue was re-dissolved in EtOAc (15 mL) and the organic layer was washed 
with sat. aqueous NaHCO3 (2 × 10 mL). The aqueous layer was extracted with EtOAc (1 × 10 mL) 
and the combined organic layers were dried (Na2SO4), filtered and concentrated in vacuo before 
purification by FCC (2:1 EtOAc: Hexanes) afforded hydroxyl (Z)-4.9 (24.6 mg, 46%) as a yellow oil. 
Rf = 0.30 (FCC conditions). δH (400 MHz; DMSO-d6; 25°C) 0.77 (3H, s, -CH3), 0.82 (3H, s, -CH3), 
2.70 (2H, t, J = 7.4 Hz, -CH2-), 3.15 (1H, dd, J = 5.1, 10.5 Hz, -CH2-), 3.29-3.37 (2H, m, -CH2-), 
3.85 (1H, d, J = 5.5 Hz, -CH-), 4.50 (1H, t, J = 5.3 Hz, -CH-) 5.88 (1H, d, J = 4.7 Hz, -CH-), 7.11 
(1H, dd, J = 9.0, 11.3 Hz, -CH-), 7.16-7.21 (3H, m, arom), 7.26-7.29 (2H, m, arom), 8.09 (1H, br t, J 
= 5.9 Hz, -NH-) and 11.8 (1H, br d, J = 11.7 Hz, -NH-). OH protons not observed. δC (100 MHz; 
CDCl3; 25°C) 20.6, 21.7, 35.9, 40.1, 40.8, 68.1, 75.2, 100.9, 126.8, 129.0, 129.3, 133.1, 140.1, 
168.3 and 172.7. (HRMS) [M+H]+ 321.1827 (Calculated [C17H25N2O4]




To a solution of hydrazide 3.30 (301 mg, 1.29 mmol) in 
anhydrous EtOH (15 mL) at rt under an inert atmosphere was 
added benzaldehyde (4.10) (197 µL, 1.94 mmol). The reaction 
mixture was stirred at reflux for 48h. The reaction mixture was cooled to rt and concentrated in  
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vacuo before purification by FCC (10% MeOH in DCM) afforded imine 4.11 (300 mg, 72%) as a 
yellow solid. Rf = 0.38 (FCC conditions). δH (400 MHz; CDCl3; 25°C) 0.91 (3H, s, -CH3), 0.99 (3H, 
s, -CH3), 2.99-3.04 (2H, m, -CH2-), 3.48 (2H, s, -CH2-), 3.62-3.72 (2H, m, -CH2-), 4.01 (1H, s, 
-CH-), 7.38-7.43 (3H, m, arom), 7.45 (1H, br d, J = 7.8 Hz, -NH-), 7.62-7.64 (2H, m, arom), 7.82 
(1H, s, -CH-) and 9.60 (1H, br s, -NH-). OH protons not observed. δC (100 MHz; CDCl3; 25°C) 20.6, 
21.7, 33.0, 34.6, 39.6, 71.2, 77.7, 127.5, 129.0, 130.6, 133.6, 144.9, 173.5 and 174.7. (HRMS) 
[M+H]+ 322.1762 (Calculated [C16H24N3O4]
+ = 322.1767). 
 
N-Benzyl pantothenhydrazide (4.12) 
 
To a solution of imine 4.11 (280 mg, 0.871 mmol) in MeOH (6mL) 
and DCM (4 mL) at rt was added NaBH3CN (66.0 mg, 1.05 
mmol). The reaction mixture was acidified to pH 3 by the addition 
of 3 M aqueous HCl and the resulting solution was stirred at rt for 0.5h. Subsequently, the reaction 
mixture was acidified to pH 1 and the reaction mixture was stirred for an additional 5h at rt. The 
reaction was quenched by the addition of sat. aqueous NaHCO3 (10 mL) and the resulting solution 
was filtered and concentrated in vacuo. The resulting crude residue was re-dissolved in EtOAc (40 
mL) and the organic layer was washed with H2O (2 × 20 mL) and sat. aqueous NaCl (2 × 20 mL). 
The organic layer was dried (Na2SO4), filtered and concentrated in vacuo before purification by 
FCC (10% MeOH in DCM) afforded hydrazide 4.12 (19.4 mg, 7%) as a yellow oil. Rf = 0.34 (FCC 
conditions). δH (300 MHz; CDCl3; 25°C) 0.88 (3H, s, -CH3), 0.93 (3H, s, -CH3), 2.31 (2H, t, J = 6.0 
Hz, -CH2-) 3.40 (2H, d, J = 4.4 Hz, -CH2-), 3.38-3.52 (2H, m, -CH2-), 3.91 (2H, s, -CH2-), 3.93 (1H, 
s, -CH-), 7.25 (1H, br s, -NH-), 7.27-7.32 (5H, m, arom), 7.43 (1H, br t, J = 5.9 Hz, -NH-) and 8.32 
(1H, br s, -NH-). OH protons not observed. δC (75 MHz; CDCl3; 25°C) 20.6, 21.2, 33.9, 35.3, 39.3, 
55.9, 70.4, 76.9, 127.7, 128.6, 128.9, 137.1, 170.8 and 174.2. (HRMS) [M+H]+ 324.1924 
(Calculated [C16H26N3O4]
+ = 324.1923). 
 
Benzyl 3-oxo-3-(phenethylamino)propylcarbamate (4.13) 
 
Phenethylamine (4.2) (621 µL, 4.93 mmol) and DEPC (748 µL, 
4.93 mmol) were added to a solution of Cbz-β-alanine (3.14) 
(1.00 g, 4.48 mmol) in anhydrous DMF (7 mL) at rt under an 
inert atmosphere. The reaction mixture was cooled to 0°C before Et3N (1.31 mL, 9.41 mmol) was 
added. The reaction mixture was stirred for 2h at 0°C and left to stir overnight at rt. EtOAc (50 mL) 
was added and the organic layer was washed with 5% aqueous citric acid (3 × 10 mL), 1 M 
aqueous NaHCO3 (2 × 10 mL) and sat. aqueous NaCl (1 × 10 mL). The organic layer was dried 
(Na2SO4), filtered and concentrated in vacuo to afford carbamate 4.13 (1.45 g, 99%) as a white  
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solid. Rf = 0.30 (3:1 EtOAc: Hexanes). δH (300 MHz; CDCl3; 25°C) 2.34 (2H, t, J = 5.9 Hz, -CH2-), 
2.78 (2H, t, J = 6.9 Hz, -CH2-), 3.43 (2H, q, J = 6.2 Hz, -CH2-), 3.48 (2H, q, J = 7.0 Hz, -CH2-), 5.09 
(2H, s, -CH2-), 5.38 (1H, br s, -NH-), 5.52 (1H, br s, -NH-) and 7.16-7.36 (10H, m, arom). δC (75 
MHz; CDCl3; 25°C) 35.6, 36.0, 37.2, 40.6, 66.6, 126.6, 128.0, 128.5, 128.6, 136.6, 138.8, 156.6 
and 171.3. (HRMS) [M+H]+ 327.1705 (Calculated [C19H23N2O3]
+ = 327.1709). 
 
Benzyl 3-(phenethylamino)-3-thioxopropylcarbamate (4.14) 
 
To a solution of amide 4.13 (1.00 g, 3.06 mmol) in anhydrous 
toluene (50 mL) at rt under an inert atmosphere was added 
Lawesson’s reagent (1.36 g, 3.37 mmol). The reaction mixture 
was stirred at reflux overnight. The reaction mixture was cooled to rt, diluted with EtOAc (100 mL) 
and washed with 10% aqueous NaOH (3 × 30 mL) and sat. aqueous NaCl (1 × 40 mL). The 
organic layer was dried (MgSO4), filtered and concentrated in vacuo before purification by FCC 
(2% MeOH in DCM) afforded thioamide 4.14 (531 mg, 51%) as a yellow solid. Rf = 0.19 (FCC 
conditions). δH (600 MHz; CDCl3; 25°C) 2.75 (2H, apparent t, J = 4.7 Hz, -CH2-), 2.93 (2H, t, J = 
7.0 Hz, -CH2-), 3.58 (2H, q, J = 6.4, 12.3 Hz, -CH2-), 3.89 (2H, q, J = 6.2 Hz, -CH2-), 5.07 (2H, s, 
-CH2-), 5.34 (1H, br s, -NH-), 7.17-7.25 (4H, m, arom), 7.29-7.37 (6H, m, arom) and 7.57 (1H, br s, 
-NH-). δC (150 MHz; CDCl3; 25°C) 35.5, 39.0, 44.6, 49.4, 69.4, 129.1, 130.7, 131.0, 131.6, 139.0, 
141.0, 153.7 and 204.8. (HRMS) [M+H]+ 343.1480 (Calculated [C19H23N2O2S]




To a solution of carbamate 4.14 (520 mg, 1.52 mmol) in MeOH (11 mL) 
was added concentrated HCl (11 mL) and the resulting solution was stirred 
at reflux overnight. The reaction mixture was cooled to rt and quenched by the addition of H2O (35 
mL). The aqueous solution was extracted with DCM (3 × 20 mL) after which the aqueous phase 
was lyophilized to yield the HCl salt of amine 4.15 (390 mg, >100%) as a white-yellow powder 
which was subsequently used in the next step without any further purification.  
 
N-Phenethyl pantothenthioamide (4.16) 
 
Et3N (886 µL, 6.36 mmol) and (R)-(-)-pantolactone 3.3 (414 mg, 
3.18 mmol) were added to a solution of amine 4.15 (310 mg, 1.27 
mmol) in EtOH (15 mL) and the resulting solution was stirred at 
reflux for 48h. The reaction mixture was cooled to rt and the solvent was removed in vacuo. The 
crude residue was purified by FCC (10% MeOH in DCM) to afford amide 4.16 (130 mg, 30%) as a 
yellow oil. Rf = 0.51 (FCC conditions). δH (600 MHz; CDCl3; 25°C) 0.85 (3H, s, -CH3), 0.98 (3H, s, 
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-CH3), 2.83 (2H, t, J = 7.3 Hz, -CH2-), 3.42 (2H, d, J = 2.3 Hz, -CH2-), 3.49-3.55 (4H, m, -(CH2)2-), 
3.59-3.64 (2H, m, -CH2-), 3.99 (1H, s, -CH-), 6.80 (1H, br s, -NH-), 7.02 (3H, t, J = 7.0 Hz, arom), 
7.24 (1H, br s, -NH-) and 7.29 (2H, t, J =7.6 Hz, arom). OH protons not observed. δC (150 MHz; 
CDCl3; 25°C) 22.6, 24.1, 38.3, 41.9, 42.7, 42.8, 47.5, 73.9, 80.3, 129.2, 131.2, 131.3, 141.2, 175.5 
and 204.8. (HRMS) [M+H]+ 339.1746 (Calculated [C17H27N2O3S]




To a solution of carbamate 4.13 (950 mg, 2.91 mmol) in MeOH (50 mL) at 
rt was added 10% Pd/C (124 mg, 1.16 mmol). The reaction atmosphere 
was filled with H2 gas and the reaction mixture was stirred overnight at rt. The reaction mixture was 
filtered and concentrated in vacuo to give amine 4.17 (550 mg, 98%) as a white-yellow solid. Rf = 
product on baseline (10% MeOH in DCM). δH (600 MHz; CDCl3; 25°C) 1.55 (2H, br s, -NH2), 2.27 
(2H, t, J = 6.0 Hz, -CH2-), 2.80 (2H, t, J = 7.0 Hz, -CH2-), 2.94 (2H, t, J = 6.0 Hz, -CH2-), 3.49 (2H, 
q, J = 7.0 Hz, -CH2-), 6.98 (1H, br s, -NH-), 7.19-7.24 (3H, m, arom) and 7.27-7.33 (2H, m, arom). 
δC (150 MHz; CDCl3; 25°C) 38.3, 40.7, 41.0, 43.0, 129.0, 131.1, 131.4, 141.0 and 175.0 (HRMS) 
[M+H]+ 193.1343 (Calculated [C11H17N2O]




DIPEA (449 µL, 2.58 mmol) was added drop-wise over 5 min to a 
solution of amine 4.17 (480 mg, 2.50 mmol) in DCM (20 mL) at 0°C 
under an inert atmosphere. HOBt (59.3 mg, 0.439 mmol), 
carboxylic acid 3.46 (358 mg, 2.75 mmol) and EDC hydrochloride (480 mg, 2.50 mmol) were then 
added consecutively and the reaction mixture was stirred overnight at rt. The reaction was 
quenched by the addition of 3 M aqueous HCl (25 mL) and the organic layer was washed with 3 M 
aqueous HCl (1 × 25 mL) and sat. aqueous NaHCO3 (1 × 25 mL). The organic layer was dried 
(Na2SO4), filtered and concentrated in vacuo before purification by FCC (2:1 EtOAc: Hexanes) 
afforded amide 4.18 (150 mg, 20%) as a white powder. Rf = 0.35 (FCC conditions). δH (300 MHz; 
CDCl3; 25°C) 1.32 (9H, s, -(CH3)3), 2.35 (2H, t, J = 6.0 Hz, -CH2-), 2.79 (2H, t, J = 7.0 Hz, -CH2-), 
3.49-3.57 (4H, m, -(CH2)2-), 5.63 (1H, br s, -NH-), 7.15-7.26 (3H, m, arom), 7.28-7.33 (2H, m, 
arom) and 7.49 (1H, br s, -NH-). δC (100 MHz; CDCl3; 25°C) 26.5, 35.3, 35.5, 35.8, 40.9, 43.1, 
126.8, 128.8, 128.9, 138.9, 160.6, 171.0 and 203.3. (HRMS) [M+H]+ 305.1874 (Calculated 
[C17H25N2O3]
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(R/S)-4’-Deoxy N-phenethyl pantothenamide (4.19) 
 
To a solution of ketoamide 4.18 (150 mg, 0.493 mmol) in anhydrous 
MeOH (10 mL) at 0°C under an inert atmosphere was added NaBH4 
(28.0 mg, 0.739 mmol) in small portions. The reaction mixture was 
stirred for 1h at 0°C, and left to stir overnight at rt. The reaction was quenched at 0°C by the 
addition of sat. aqueous NH4Cl (10 mL) and the MeOH was removed in vacuo. The aqueous 
solution was extracted with EtOAc (3 × 15 mL) and the combined organic extracts were dried 
(Na2SO4), filtered and concentrated in vacuo to yield hydroxyl 4.19 (143 mg, 94 %) as a white 
solid. Rf = 0.35 (10% MeOH in DCM). δH (600 MHz; CDCl3; 25°C) 0.98 (9H, s, -(CH3)3), 2.36 (2H, t, 
J = 6.0 Hz, -CH2-), 2.80 (2H, t, J = 6.9 Hz, -CH2-), 3.50-3.60 (4H, m, -(CH2)2-), 3.64 (1H, d, J = 5.3 
Hz, -CH-), 5.63 (1H, br s, -NH-), 6.80 (1H, br s, -NH-), 7.18-7.25 (3H, m, arom) and 7.30-7.36 (2H, 
m, arom). OH proton not observed. δC (150 MHz; CDCl3; 25°C) 28.6, 37.6, 37.8, 38.2, 38.2, 43.3, 
82.1, 129.2, 131.2, 131.3, 141.2, 173.9 and 175.5. (HRMS) [M+H]+ 307.2023 (Calculated 
[C17H27N2O3]
+ = 307.2022). 
 
Benzyl 3-hydroxy-2,2-dimethyl-4-oxo-4-(3-oxo-3-(phenethylamino)propylamino) butyl-carbamate 
(4.20) 
 
DIPEA (149 µL, 0.857 mmol) was added drop-wise 
over 5 min to a solution of amine 4.17 (160 mg, 0.832 
mmol) in DCM (15 mL) at 0°C under an inert 
atmosphere. HOBt (31.9 mg, 0.208 mmol), carboxylic acid 3.70 (257 mg, 0.915 mmol) and EDC 
hydrochloride (175 mg, 0.915 mmol) were then added consecutively and the reaction mixture was 
stirred overnight at rt. The reaction mixture was concentrated in vacuo before purification by FCC 
(6:1 EtOAc: Hexanes) afforded amide 4.20 (140 mg, 37%) as a yellow oil. Rf = 0.34 (FCC 
conditions). δH (300 MHz; CDCl3; 25°C) 0.86 (3H, s, -CH3), 1.03 (3H, s, -CH3), 2.36 (2H, t, J = 5.6 
Hz, -CH2-), 2.78 (2H, t, J = 7.0 Hz, -CH2-), 3.42-3.58 (4H, m, -(CH2)2-), 3.77 (1H, d, J = 5.0 Hz, 
-CH-), 5.09 (2H, d, J = 2.3 Hz, -CH2-), 5.21 (1H, br t, J = 6.5 Hz, -NH-), 5.80 (1H, br t, J = 6.5 Hz, 
-NH-), 7.18-7.25 (3H, m, arom), 7.26-7.40 (7H, m, arom) and 7.42 (1H, br t, J = 6.6 Hz, -NH-). OH 
proton not observed. δC (75 MHz; CDCl3; 25°C) 20.4, 21.9, 35.1, 35.6, 36.1, 39.4, 40.7, 49.6, 67.3, 
74.6, 126.5, 128.1, 128.3, 128.5, 128.6, 128.7, 136.0, 138.7, 158.1, 171.0 and 172.6. (HRMS) 
[M+H]+ 456.2511 (Calculated [C25H34N3O5]
+ = 456.2498). 
 
(R/S)-4’-Amino N-phenethyl pantothenamide (4.21) 
 
To a solution of carbamate 4.20 (120 mg, 0.263 mmol) in MeOH 
(10 mL) at rt was added 10% Pd/C (11.2 mg, 0.105 mmol). The 
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reaction atmosphere was filled with H2 gas and the reaction mixture was stirred overnight at rt. The 
reaction mixture was filtered and concentrated in vacuo to give amine 4.21 (65.5 mg, 78%) as a 
yellow oil. Rf = product on baseline (6:1 EtOAc: Hexanes). δH (600 MHz; CDCl3; 25°C) 0.94 (3H, s, 
-CH3), 1.03 (3H, s, -CH3), 2.38 (2H, t, J = 6.2 Hz, -CH2-), 2.78 (2H, s, -CH2-), 2.79 (2H, apparent t, 
J = 6.9 Hz, -CH2-), 3.18 (2H, br s, -NH2), 3.41-3.59 (4H, m, -(CH2)2-), 4.03 (1H, s, -CH-), 6.08 (1H, 
br t, J = 5.4 Hz, -NH-), 7.18-7.25 (3H, m, arom), 7.28-7.34 (2H, m, arom) and 7.52 (1H, br t, J = 6.0 
Hz, -NH-). OH proton not observed. δC (150 MHz; CDCl3; 25°C) 22.2, 26.5, 37.6, 38.3, 38.9, 39.1, 
43.3, 55.6, 83.3, 129.1, 131.2, 131.3, 141.4, 173.7 and 175.7. (HRMS) [M+H]+ 322.2139 
(Calculated [C17H28N3O3]
+ = 322.2131). 
 
N-Phenethyl pantothenamide 4'-O,O-dibenzylphosphate (4.22) 
 
Dibenzyl chlorophosphate 3.72 was prepared in situ by 
reacting N-chlorosuccinimide (373 mg, 2.79 mmol) and 
dibenzylphosphite (732 mg, 2.79 mmol) in anhydrous 
toluene (4 mL) under an inert atmosphere for 2h at rt. The reaction mixture was filtered to remove 
the succinimide. To a solution of hydroxyl 4.1 (300 mg, 0.931 mmol) in anhydrous pyridine (5 mL) 
at -40°C under an inert atmosphere was added dibenzyl chlorophosphate 3.72 drop-wise with 
stirring. The reaction mixture was stirred for an additional 2h at -40°C and the mixture was placed 
in the -20°C freezer overnight. The reaction mixture was allowed to warm to rt and was 
subsequently quenched with H2O (3 mL) and concentrated in vacuo. The resulting crude residue 
was re-dissolved in EtOAc (40 mL) and the organic layer was washed with 1 M aqueous H2SO4 (2 
× 10 mL), 1 M aqueous NaHCO3 (2 × 10 mL) and sat. aqueous Na2SO4 (1 × 10 mL). The organic 
layer was dried (Na2SO4), filtered and concentrated in vacuo before purification by FCC (5% MeOH 
in DCM) afforded 4.22 (150 mg, 28%) as a yellow oil. Rf = 0.11 (FCC conditions). δH (600 MHz; 
CDCl3; 25°C) 0.80 (3H, s, -CH3), 1.04 (3H, s, -CH3), 2.34 (2H, t, J = 4.3 Hz, -CH2-), 2.76 (2H, t, J = 
7.2 Hz, -CH2-), 3.44-3.52 (4H, m, -(CH2)2-), 3.55 (1H, dd, J = 7.6, 10.3 Hz, -CH2-), 3.88 (1H, s, -CH-
), 3.98 (1H, dd, J = 6.9, 9.5 Hz, -CH2-), 5.03 (2H, d, J = 8.8 Hz, -CH2-), 5.05 (2H, d, J = 8.2 Hz, 
-CH2-), 6.16 (1H, br t, J = 5.6 Hz, -NH-), 7.02 (1H, br s, -NH-), 7.16-7.23 (5H, m, arom) and 7.28-
7.38 (10H, m, arom). OH proton not observed. δC (150 MHz; CDCl3; 25°C) 19.4, 21.9, 36.0, 36.3, 
36.7, 40.1, 41.4, 70.4, 70.5, 74.2, 74.3, 120.9, 124.3, 127.2, 128.7, 129.3, 129.4, 136.0, 139.5, 
171.8 and 173.2. δP (161.9 MHz; CDCl3; 25°C) 0.79. (HRMS) [M+H]
+ 583.2575 (Calculated 
[C31H40N2O7P]
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4’-Phospho-N-phenethyl pantothenamide (4.23) 
 
To a solution of 4.22 (120 mg, 0.206 mmol) in MeOH (9 mL) 
and H2O (1 mL) at rt was added 10% Pd/C (31.3 mg, 0.294 
mmol). The reaction atmosphere was filled with H2 gas and 
the reaction mixture was stirred overnight at rt. The reaction mixture was filtered and concentrated 
in vacuo to give hydroxyl 4.23 (82.3 mg, 99%) as a clear oil. Rf = 0.06 (10% MeOH in DCM). δH 
(300 MHz; D2O; 25°C) 0.76 (3H, s, -CH3), 0.83 (3H, s, -CH3), 2.26 (2H, t, J = 6.7 Hz, -CH2-), 2.66 
(2H, t, J = 6.7 Hz, -CH2-), 3.25-3.37 (4H, m, -(CH2)2-), 3.48 (1H, dd, J = 5.0, 9.7 Hz, -CH2-), 3.68 
(1H, dd, J = 4.7, 10.0 Hz, -CH2-), 3.87 (1H, s, -CH-), 7.14-7.18 (2H, m, arom) and 7.22-7.30 (3H, 
m, arom). OH protons not observed. δC (75 MHz; D2O; 25°C) 19.2, 21.2, 35.1, 36.1, 38.9, 39.0, 
41.2, 72.1, 75.0, 127.2, 129.3, 129.5, 139.8, 174.3 and 175.4. δP (161.9 MHz; D2O; 25°C). (HRMS) 
[M+H]+ 403.1625 (Calculated [C17H28N2O7P]
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Chapter 5 
Conclusion and Future Research Possibilities 
In this study we addressed the following two main objectives: 
iii) To elucidate the role of PanK in the mode of action of inhibitory pantothenamides in S. 
aureus.  
iv) To develop inhibitors that are resistant to pantetheinase-mediated degradation while 
retaining good antimicrobial activity. 
5.1 Summary of results achieved 
5.2.1 Elucidating the role of PanK in the mode of action of inhibitory 
pantothenamides in S. aureus  
Two mechanisms of action have been proposed for pantothenamide-mediated inhibition, with 
PanK playing a central role in both: 1) Inhibition based on the pantothenamides inhibiting PanK 
activity directly [Target 2 in Figure 31.6, Chapter 1], and 2) metabolic activation of the molecules by 
PanK (i.e. by them acting as alternative substrates of PanK), followed by their conversion to CoA 
antimetabolites for subsequent inhibition of the ACPs and/or other CoA-dependent processes 
[Targets 3 and 4 in Figure 1.6, Chapter 1].  
 
The results presented in Chapter 2 confirmed that the mode of action of bacterial pantothenamide 
inhibition is determined by the PanK type of the targeted organism. The results with E. coli, which 
has a type-I PanK, demonstrates that  pantothenamides exert their inhibitory activity by acting as 
alternative substrates for PanK-I, therefore PanK-I only serves to metabolically activate them. After 
phosphorylation by PanK, these compounds are converted to CoA antimetabolites which can 
inhibit a variety of CoA-dependent processes (Target 3, Figure 1.6, Chapter 1), and which cause 
the synthesis of inactive ACPs (Target 4, Figure 1.6, Chapter 1). These findings are in agreement 
with the conclusions of previous studies [1-4]. 
 
In S. aureus, which has an atypical PanK type-II, the situation is completely different. The results 
demonstrated that pantothenamides have a complex interaction with this organism’s PanK 
enzyme, acting as substrates that stimulate its activity when present at low concentrations, but 
turning into uncompetitive inhibitors as their concentrations gradually increase. Furthermore, we 
demonstrated that a pantothenamide analogue that cannot act as a PanK substrate can still inhibit 
S. aureus growth. These results suggest that in S. aureus growth inhibition is as a result of at least 
two factors working in combination: 1) by the formation of inactive ACPs and CoA antimetabolites 
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(as was observed in a previous study [4]) [Target 3 and 4, Figure 1.6, Chapter 1] and 2) by the 
reduction of CoA levels through the inhibition of SaPanK-II [Target 2, Figure 1.6, Chapter 1]. 
 
Furthermore, the kinetic model developed as part of the study predicts that pantothenamides (and 
PantSH) inhibit SaPanK-II via an uncompetitive mechanism; this could imply that SaPanK-II 
contains an allosteric binding site selective for the pantothenamides. However, only two SaPanK-II 
structures have been deposited into Protein Data Bank to date, neither of which has pantothenic 
acid bound in the active site. These structures present no indication of the possible location of such 
an allosteric site. Furthermore, a more recently published structure (the ternary complex of the 
enzyme bound to a phosphorylated pantothenamide (N354-Pan) and ADP) shows that SaPanK-II 
has distinct open and closed conformations, with the later preventing product release [5]. This 
discovery complicates the structural investigation to identify an allosteric site even further. 
Consequently, we cannot exclude the possibilty that alternative kinetic models could also provide 
accurate descriptions of our data; however, our kinetic model is the simplest one that gives an 
accurate description of the total data set while taking into account the current knowledge we have 
on SaPanK-II.  
 
Our finding that PantSH mirrors the same complex interaction with SaPanK-II observed for the 
normal pantothenamides suggests that CoA biosynthesis in S. aureus is regulated through a 
unique mechanism. Previous studies showed that SaPanK-II does not experience feedback 
inhibition by CoA or its thioesters, nor does regulation occur downstream of PanK in other CoA 
biosynthetic enzymes [4, 6-7]. The reason for this lack of feedback inhibition was thought to be 
because S. aureus, unlike other bacteria, does not rely on glutathione as its main redox buffer, but 
uses CoA instead and therefore needs high concentrations of this metabolite [8]. With these new 
findings we hypothesize that contrary to what was previously reported, CoA biosynthesis in S. 
aureus is indeed regulated at the PanK level, and that this regulation occurs by a unique 
mechanism by which low PantSH concentrations stimulate SaPanK-II activity and high PantSH 
concentrations inhibit SaPanK-II activity.  
 
To conclude, in this part of the study two major discoveries were made: first, the mode of action of 
the pantothenamides in S. aureus was elucidated, and second, a unique mechanism by which CoA 
biosynthesis can be regulated in S. aureus was uncovered.  
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5.2.2 Developing antimicrobial pantothenamides that are resistant to 
pantetheinase-mediated degradation  
In this part of the study we successfully synthesized ten N7-Pan analogues (Chapter 3) and nine 
N-PE-PanAm analogues (Chapter 4) using various synthetic organic methods, and fully 
characterized all of the compounds analytically. These analogues included methylations either on 
the α- or β-position relative to the scissile amide bond or the amide bond itself, three amide 
bioisosteres including sulfonamides, thioamides and hydrazides, an addition of a double bond in 
the β-alanine moiety as well as removal of the 4’-hydroxyl and its replacement with an amine and 
phosphate functional groups.  
 
The ten N7-Pan analogues were fully characterized in vitro in regards to 1) their interaction with 
SaPanK-II (using kinetic analysis) and 2) their potency as growth inhibitors of S. aureus. None of 
the analogues showed the same complex interaction with SaPanK-II that was observed for N7-Pan 
3.10. Of the ten N7-Pan analogues tested, only (R/S)-4’-deoxy-N7-Pan 3.49 and 4’-phospho-N7-
Pan 3.74 acted as inhibitors of SaPanK-II. Inhibition by the latter was surprising, since this would 
imply inhibition of the enzyme by its product. Furthermore, 4’-phospho-N7-Pan 3.74 was the only 
N7-Pan analogue that showed inhibition in 1% tryptone medium, with an MIC80 of ~25 µM. This 
was also highly unexpected, given that it is generally believed that phosphorylated molecules are 
too polar to enter cells unassisted [9]. It is therefore possible that S. aureus has a specific uptake 
mechanism for phosphorylated pantothenic acid analogues (most likely phospho-PantSH) but no 
reports on this have been made to date. 
 
Unfortunately, the SaPanK-II crystal structure with a pantothenamide bound only became available 
after we had already completed most of the experiments on the degradation-resistant pantothen-
amides. Having this structure to help guide the design strategy to achieve degradation resistance 
without losing selectivity (i.e. binding to PanK) may have prompted us not to pursue some of the 
structures. Nonetheless, using the structure we were able to rationalize why some of the N7-Pan 
analogues did not show inhibition of either SaPanK-II or S. aureus RN4220. Figure 5.1 shows a 
graphical illustration of the H-bonding interactions of SaPanK-II with 4’-phospho-N7-Pan 3.74 in the 
active site. Two amino acid residues (Arg113 and Thr172) form critical H-bonding interactions with 
the pantothenamides in the active site; unfortunately, many of these were lost or weakened with 
the structural modifications that were implemented. N-methyl-N7-Pan 3.11 lost a crucial H-bonding 
interaction with Thr172 when the NH of the scissile amide was methylated, while the H-bonding 
interaction with Arg113 was weakened when the carbonyl oxygen was replaced with a sulfur in N7-
pantothenthioamide 3.36.  
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Figure 5.1. Graphical illustration of the H-bonding interactions of SaPanK-II with 4’-phospho-N7-Pan 3.74 in the 
active site. Arg113 forms H-bonding interactions with the two carbonyl oxygens of the amide bonds and Thr172 
forms an H-bonding interaction with the NH of the scissile amide bond. Both, N-methyl-N7-Pan 3.11 and N7-
pantothenthioamide 3.36 (in the black boxes) lost one of these interactions, respectively (indicated in the red 
circles). 
 
Of the nine N-PE-PanAm analogues that were successfully synthesized, only three analogues 
have been tested against P. falciparum thus far. α-Me-N-PE-PanAm 4.3 showed excellent 
antiplasmodial activity with an IC50 comparable to that of chloroquine. β-Me-N-PE-PanAm 4.4 has 
a potency that is ~1000-fold lower than what we observe for α-Me-N-PE-PanAm 4.3. This indicates 
that the placement of the methyl group is an important consideration for target selectivity. 
Additionally, (R/S)-4’-deoxy-N-PE-PanAm 4.19 did not act as an inhibitor of P. falciparum, 
suggesting that pantothenamides act as substrates for PfPanK and subsequently targets 
processes downstream through the formation of CoA antimetabolites (Targets 3 and 4 in Figure 
1.7, Chapter 1).  
 
To conclude, in this part of the study a number of N7-Pan- and N-PE-PanAm analogues were 
successfully synthesized and characterized as inhibitors of S. aureus and P. falciparum, 
respectively. Although none of the N7-Pan analogues acted as good inhibitors of S. aureus, 
valuable information was obtained regarding the modifications that can and cannot be made to the 
pantothenamides to retain their potency. Lastly, we have obtained a promising result with one N-
PE-PanAm analogue, α-Me-N-PE-PanAm 4.3, which showed antiplasmodial activity with an IC50 
comparable to that of chloroquine. In light of the fact that the N7-Pan analogues were not good 
inhibitors of S. aureus, the remaining untested N-PE-PanAm analogues might not show good 
antiplasmodial activity either. However, their antiplasmodial activity remains to be determined.  
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5.2 Future research possibilities 
5.3.1 Elucidating the role of PanK in the mode of action of inhibitory 
pantothenamides in S. aureus 
The inhibition of SaPanK-II and S. aureus by 4’-phospho-N7-Pan 3.74—the product of the PanK-II 
catalyzed reaction—was highly unexpected. Consequently, additional experiments will have to be 
performed to help explain the inhibition observed. Future work will include kinetic assays with 4’-
phospho-N7-Pan 3.74 to determine the type of inhibition of SaPanK-II. Furthermore, we will also 
have to revisit the kinetic model developed as part of this study and determine whether it describes 
the data with the phosphorylated pantothenamides as well. Growth inhibition of S. aureus by the 
phosphorylated pantothenamides could also indicate that CoA antimetabolites are formed that 
inhibit targets other than PanK, such as fatty acid biosynthesis. However, previous studies have 
shown that some bacteria (especially some Gram-positives) have the ability to suppress fatty acid 
biosynthesis when exogenous fatty acids are present. This strict biochemical regulation of fatty 
acid biosynthesis by exogenous fatty acids means that these organisms are refractory to fatty acid 
biosynthesis inhibitors [10]. These implications will have to be considered for the development of 
antimicrobials that solely target fatty acid biosynthesis. 
5.3.2 Developing antimicrobial pantothenamides that are resistant to 
pantetheinase-mediated degradation 
It will be difficult to synthesize potent pantetheinase-resistant inhibitors for S. aureus because of 
the various H-bonding interactions that need to be retained; however, this could be achieved by 
selecting bioisosteres such as an imidazole, 1,2,4-triazole or a trifluoro-ethylamine that will retain 
the interactions (Figure 5.2). Future work will include synthesizing the N7-Pan analogues 
containing these three bioisosteres which can subsequently be characterized against SaPanK-II 
kinetically and as S. aureus growth inhibitors.  
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Figure 5.2. Suggested pantothenamides that will retain the H-bonding interactions with Arg113 and Thr172. 
These bioisosters include a trifluoroethylamine, imidazole, and a 1,2,4-triazole. 
 
To date, only three of the nine N-PE-PanAm analogues synthesized in this study have been tested 
for inhibition of proliferation of P. falciparum. Consequently, six N-PE-PanAm analogues remain to 
be tested as part of future work, in addition to testing whether the analogues that do show 
antiplasmodial activity are pantetheinase resistant. Furthermore, based on its potent inhibition of P. 
falciparum blood-stage proliferation, α-Me-N-PE-PanAm 4.3 is an excellent lead compound for 
further development. However, in this study a mixture of diastereomers (i.e. correct 
stereochemistry of the pantoyl 2’-OH group, but both stereoisomers at the methyl-bearing centre) 
were used. Additionally, no data relating to the compound’s pharmacokinetic properties 
(absorption, metabolism and excretion) or its toxicity are available at this stage. Therefore, future 
work will include synthesizing the two diastereomers of α-Me-N-PE-PanAm 4.3 and testing them 
separately in blood-stage proliferation assays to identify any differences in potency. The most 
potent isomer identified in this manner will be used to determine its pharmacokinetic properties as 
well as its toxicity in vivo. Moreover, substitutions with different functional groups can also be made 
on the ortho, meta or para-positions of the phenyl-ring to determine whether we can further 
increase the potency of α-Me-N-PE-PanAm 4.3. 
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5.3 Final remarks 
Although the CoA biosynthetic pathway has been under intense investigation for many years, it is 
evident that this pathway has a lot to offer in possible new antimicrobial and antimalarial strategies. 
The results of our study of the mode of action of the pantothenamides in S. aureus showed that 
these compounds exert their growth inhibitory effects at least partially by inhibiting PanK has 
contributed significantly to our knowledge in this regard. Furthermore, we identified a potent 
pantetheinase-resistant pantothenamide in this study through structural modifications of the 
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A Pantetheinase-Resistant Pantothenamide with Potent, On-Target,
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Pantothenamides inhibit blood-stage Plasmodium falciparum with potencies (50% inhibitory concentration [IC50], 20 nM)
similar to that of chloroquine. They target processes dependent on pantothenate, a precursor of the essential metabolic cofactor
coenzyme A. However, their antiplasmodial activity is reduced due to degradation by serum pantetheinase. Minor modification
of the pantothenamide structure led to the identification of -methyl-N-phenethyl-pantothenamide, a pantothenamide resistant
to degradation, with excellent antiplasmodial activity (IC50, 52  6 nM), target specificity, and low toxicity.
One-half of the world’s population (3.4 billion people) is atrisk of contracting malaria, with pregnant women and chil-
dren 5 years of age being especially vulnerable. In 2013, the
WHO estimated that malaria caused 584,000 deaths globally,
with the majority occurring in Africa (1). Although efforts to con-
trol and to eliminate malaria in the past 15 years have saved an
estimated 3.3 million lives (1), drug-resistant parasites continue to
emerge (2). This places the progress in the fight against the disease
under pressure, especially since there is no effective vaccine
against malaria (3). Several new drug targets have been identified
in recent years (4); however, these targets now need to be exploited
through the development of directed treatments.
We are interested in targeting the biosynthesis of the essential
cofactor coenzyme A (CoA) from the water-soluble vitamin B5
(pantothenate, compound 1 in Fig. 1) for antimalarial drug devel-
opment (5, 6). It has been shown that extracellular pantothenate is
essential for intracellular malaria parasites (7), which indicates
that Plasmodium falciparum does not utilize exogenous CoA but
must synthesize CoA de novo (8).
Pantothenate analogues interfere with the ability of P. falcipa-
rum to utilize the vitamin, with many analogues being character-
ized as growth inhibitors of the blood-stage parasites (9–11). Fur-
thermore, a recent study showed that CoA biosynthesis can be
targeted by a chemically diverse set of inhibitors that do not re-
semble pantothenate, the most potent of which had a 50% inhib-
itory concentration (IC50; the concentration that inhibits parasite
proliferation by 50%) of 120 nM against blood-stage parasites
(12). These studies support pantothenate utilization (and there-
fore CoA biosynthesis and CoA-dependent processes) as an anti-
plasmodial target.
Recently we showed that N-substituted pantothenamides
(PanAms), a specific class of pantothenate analogues, have excel-
lent antiplasmodial activity. Among these, N-phenethyl-panto-
thenamide (N-PE-PanAm) (compound 2 in Fig. 1) exhibited an
IC50 of 20 nM (13); this potency is comparable to that of chloro-
quine (14, 15). In practice, however, the antiplasmodial activity of
the PanAms is decreased since they are degraded by pantetheinase
(13), a ubiquitous enzyme of the Vanin protein family that is
present in serum (16, 17). Pantetheinase normally catalyzes the
hydrolysis of pantetheine (a CoA-derived metabolite) to form
pantothenate and cysteamine (18, 19), but it also acts on com-
pounds with a wide range of variations in the cysteamine moiety,
including the PanAms (Fig. 1) (13). In a previous study, we found
that replacement of the -alanine moiety of the PanAms with
either glycine or -aminobutyric acid gave rise to pantetheinase-
resistant variants, due to displacement of the scissile amide bond
(20). Unfortunately, these structural modifications also reduced
the potency of the resulting PanAms (IC50 values of 1 M),
indicating that their target (or targets) requires the pantothenate
core structure to be retained for optimal inhibition.
In light of this finding, we set out to develop a pantetheinase-
resistant PanAm in which the -alanine core was retained. This
was achieved by adding a methyl group to the carbon adjacent to
the amide carbonyl group, thereby increasing the steric bulk at this
center. We predicted that this modification would reduce the rate
of pantetheinase-mediated hydrolysis by limiting the access of the
enzyme’s cysteine nucleophile to the scissile amide bond. The
methylated version of N-PE-PanAm, i.e., -methyl-N-PE-
PanAm (-Me-N-PE-PanAm) (compound 3 in Fig. 1), was pre-
pared by condensing D,L-3-amino-isobutyrate to pantolactone,
followed by partial purification by cation-exchange chromatogra-
phy. The product, -methyl-D-pantothenate, was purified by flash
column chromatography (FCC) before being coupled to N-phen-
ethylamine using diphenylphosphoryl azide in the presence of tri-
ethylamine. After purification by FCC, -Me-N-PE-PanAm was
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obtained in a final overall yield of 45%, as a mixture of two
epimers (see the supplemental material for more details).
The antiplasmodial activity of -Me-N-PE-PanAm against the
chloroquine-sensitive P. falciparum strain 3D7 (chloroquine IC50,
11  1 nM [mean  standard error of the mean {SEM}]; n 	 3)
was determined in “aged medium” (i.e., medium in which
pantetheinase had been inactivated by incubation at 37°C for 40
h), in a manner similar to that used previously for N-PE-PanAm
(13, 20). Under these conditions, -Me-N-PE-PanAm showed ex-
cellent antiplasmodial activity, with an IC50 of 29  2 nM
(mean  SEM; n 	 3), a value that is only slightly greater than that
of N-PE-PanAm (Fig. 2a). Furthermore, -Me-N-PE-PanAm
demonstrated exceptional resistance to degradation by pantethei-
nase, compared to N-PE-PanAm, as can be seen from its antiplas-
modial activity in normal medium (i.e., with active pantethei-
nase), with an IC50 of 52  6 nM (mean  SEM; n 	 3) (Fig. 2a),
compared to the N-PE-PanAm IC50 of 6,200 nM (13, 20). Per-
forming the same test with a chloroquine-resistant strain (strain
Dd2; chloroquine IC50, 173  5 nM [mean  range/2]; n 	 2)
gave an IC50 of 129  4 nM (mean  range/2; n 	 2); based on
currently available data, it is unclear whether this difference is
related to chloroquine resistance or is merely a variation in strain
sensitivity. More importantly, resistance to pantetheinase degra-
dation did not come at a cost in target specificity, since addition of
excess extracellular pantothenate (100 M) to the medium antag-
onized the antiplasmodial activity of -Me-N-PE-PanAm against
the 3D7 strain (IC50, 860  102 nM [mean  SEM]; n 	 3; P 	
0.01) (Fig. 2a).
To confirm the stability of -Me-N-PE-PanAm, we also tested
its in vitro degradation by recombinant pantetheinase (human
VNN1) (Fig. 2b). This was done by incubating substrate (500 M
N-PE-PanAm or -Me-N-PE-PanAm; 500 M phenethylamine
was used as a reference, i.e., equivalent to 100% product forma-
tion) in 100 mM HEPES (pH 7.6) containing 500 M dithiothre-
itol (DTT) and 0.05 g/l bovine serum albumin (BSA), at 37°C.
The reaction (in a final volume of 300 l) was initiated by the
addition of pantetheinase (1.6 g/l), and the mixture was incu-
bated for 24 h. The amount of amine produced was determined by
quenching 30 l of the reaction mixture with 10 l of N-ethylma-
leimide (6 M), followed by incubation (for 10 min at 37°C) with
2 mM fluorescamine in 517 mM borate (pH 9), in a final volume
of 145 l. Fluorescence was subsequently measured using a
Thermo Varioskan multiplate spectrofluorimeter (excitation
wavelength, 395 nm; emission wavelength, 485 nm). We were able
to confirm that -Me-N-PE-PanAm was more resistant to
pantetheinase-mediated degradation than N-PE-PanAm, as it
showed only 26%  2% (mean  range/2; n 	 2) hydrolysis
(normalized to the control, which represented 100% phenethyl-
amine formed) after 24 h, compared to 96%  9% (mean 
range/2; n 	 2) for N-PE-PanAm under the same conditions.
The activity of -Me-N-PE-PanAm was tested against a hu-
man cell line (human foreskin fibroblasts [HFF]) to determine its
selectivity (21). The cells were exposed to -Me-N-PE-PanAm
FIG 1 (Left) Structure of N-PE-PanAm (compound 2), which can be de-
graded by pantetheinase (Vanin) to form pantothenate (compound 1) and
phenethylamine. (Right) Structure of -Me-N-PE-PanAm (compound 3),
which shows limited degradation by pantetheinase. The vulnerable (scissile)
amide bond is indicated by the oval on the left, while the shaded oval on the
right shows how it is modified by introduction of the methyl group to increase
stability.
FIG 2 (a) Inhibition of proliferation of P. falciparum parasites (chloroquine-sensitive strain 3D7) by -Me-N-PE-PanAm. Parasites were cultured for 96 h in
medium with (Œ) or without () pantetheinase activity; the inhibition was antagonized when the extracellular pantothenate concentration in the medium with
pantetheinase was increased from the usual 1 M to 100 M (o), consistent with the compound being on target. Values represent the mean  SEM of three
independent experiments, each performed in triplicate. (b) Pantetheinase-mediated hydrolysis of N-PE-PanAm (black bar) and -Me-N-PE-PanAm (gray bar)
in vitro after treatment with recombinant human pantetheinase for 24 h. The amount of phenethylamine released was determined by derivatization with
fluorescamine. Values represent the mean from two independent experiments, each performed in triplicate; the error bars represent range/2. **, P  0.001,
Student’s t test. (c) HFF proliferation in the presence of -Me-N-PE-PanAm after 96 h. Values represent the mean  SEM of three independent experiments, each
performed in triplicate.
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(0.781 to 100 M) for 4 days to reach confluence, and plates were
stored at 
80°C prior to exposure to SYBR Safe, as was done for
the parasite experiments. We found that -Me-N-PE-PanAm had
limited cytotoxicity for HFF cells, with a selectivity index (SI)
greater than 1,500 (Fig. 2c), rivalling the SI of chloroquine
(1,300) determined using a similar cell line (15).
With these promising findings, we unveil -Me-N-PE-PanAm
as the first pantothenate analogue with excellent potential as a new
lead compound for antimalarial drug development, based on its
potent inhibition of blood-stage parasites in the presence of serum
pantetheinase, lack of activity against human cells, and desirable
physicochemical characteristics (22) (see the supplemental mate-
rial for details). Future work will focus on determining whether
the two epimers show a difference in activity, performing tests on
other stages of the parasite’s life cycle, and determining the phar-
macokinetic properties and in vivo efficacy of -Me-N-PE-
PanAm, to establish its long-term potential for development as an
antimalarial.
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All materials used were as described before (1, 2). 
 
STATISTICAL ANALYSES 
The statistical significance for the IC50 values and the pantetheinase assay was determined using a two-
tailed Student’s t-test for paired samples.  
 
SYNTHESES 
α-Methyl pantothenic acid (mixture of epimers)  
D,L-3-Amino isobutyric acid (500 mg, 4.85 mmol) was dissolved in 1 M aqueous sodium hydroxide 
(4.80 mL, 4.85 mmol) and lyophilized, after which pantolactone (700 mg, 5.28 mmol) was added. The 
mixture was stirred under an inert atmosphere overnight at 130 °C. The resulting sticky oil was 
dissolved in water and loaded onto a prewashed Amberlite IR120 (H
+
-form) ion exchange resin. The 
free acid was eluted with water and lyophilized before purification by flash column chromatography 
(5:2:1:1 ethyl acetate: methanol: water: acetonitrile) afforded the product (0.97 g, 86%) as a white 
powder. Rf = 0.47. δH (400 MHz; D2O; 25 °C) 0.76 (3H, s, -CH3), 0.79 (3H, s, -CH3), 1.01 (3H, d, J = 
7.1 Hz, -CH3), 2.47–2.59 (1H, m, -CH-), 3.21–3.25 (2H, m, -CH2-), 3.26 (1H, d, J = 11.1 Hz, -CH-), 
3.38 (1H, d, J = 11.1 Hz, -CH-), 3.85 (1H, s, -CH-, epimer A) and 3.86 (1H, s, -CH-, epimer B). δC 





 = 234.13), [M-H]
-
 232.09 (Calculated [C10H18NO5]
-
 = 232.12). 
α-Me-N-PE-PanAm (mixture of epimers) 
Phenethylamine (163 µL, 1.29 mmol) and diphenylphosphoryl azide (278 µL, 1.29 mmol) were added 
to a solution of α-methyl pantothenic acid (250 mg, 1.07 mmol) in dimethylformamide (4 mL) at RT. 
After cooling the mixture to 0 °C, triethylamine (180 µL, 1.29 mmol) was added. The reaction mixture 
was stirred for an additional 2 h at 0 °C and left to stir overnight at RT. Dimethylformamide was 
removed in vacuo and Amberlite IR400 (OH
-
-form) resin was added. The reaction mixture was filtered 
and lyophilized before purification by flash column chromatography (10% methanol/dichloromethane) 
afforded the target compound (188 mg, 52%) as a yellow oil. Rf = 0.24. δH (600 MHz; CDCl3; 25 °C) 
0.90 (3H, s, -CH3, epimer A), 0.91 (3H, s, -CH3, epimer B), 0.99 (3H, s, -CH3, epimer A), 1.00 (3H, s, -
CH3, epimer B), 1.10 (3H, d, J = 7.1 Hz, -CH3), 2.47–2.59 (1H, m, -CH-), 2.80 (2H, t, J = 7.1 Hz, -
CH2-), 3.28–3.28 (2H, m, -CH2-), 3.42–3.49 (2H, m, -CH2-), 3.51–3.58 (2H, m, -CH2-), 3.98 (1H, 
apparent t, J = 5.1 Hz, -CH-, both epimers), 5.98 (1H, br s, -NH-), 7.17 (2H, d, J = 7.4 Hz, arom), 7.22 
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S3 
(1H, d, J = 7.3 Hz, arom), 7.25–7.27 (1H, br s, -NH-) and  7.30 (2H, dd, J = 7.3, 7.4 Hz, arom). δC (150 
MHz; CDCl3; 25 °C) 15.7, 20.4, 20.4, 35.5, 40.6, 40.7, 42.1, 48.7, 70.8, 77.5, 126.6, 126.6, 128.7, 
128.7, 128.7, 138.7, 173.7, and 175.0; (HRMS) [M+H]
+








Molecular weight: 336.42 g.mol
-1 
Calculated lipophilicity (ClogP): 0.62 
Number of H-bond donors: 4 
Number of H-bond acceptors: 2 
Polar surface area (PSA): 98.66 Å
2
 at pH = 7.40 
Distribution (logD): 0.62 at pH = 7.40 






Values of ClogP, PSA, logD and NRotB were calculated with calculator plugins in the program 
MarvinSketch 6.0.6, 2013 from ChemAxon (Budapest, Hungary). Calculations used equal weights of 






) set to 0.1 
mol.dm
-3
. Tautomerization were not considered in the calculations (see 
https://www.chemaxon.com/marvin-archive/5.11.3/marvin/help/calculations/partitioning.html).   
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